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General  introduction and outline of the thesis
Şakir Akin, MD
Department of Cardiology, Thoraxcenter and Department of Intensive Care 
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GENERAL INTRODUCTION AND OUTLINE OF THE THESIS
1INTRODUCTION
In the last decade, short- and long-term mechanical circulatory support devices have been 
increasingly used in patients with acute and chronic heart failure. Due to extreme donor 
heart shortage, long-term –durable- left ventricle assist devices (LVADs) have evolved to 
an accepted part of heart failure treatment used in severe acute or chronic heart failure 
(HF) as bridge-to-transplantation, bridge-to-candidacy and, as destination therapy.1-3 In the 
same time, more and more short-term mechanical circulatory support (MCS) have been 
implemented in the intensive care units (ICUs) as bridge to recovery, bridge to decision, or 
bridge to LVAD implantation in patients with cardiogenic shock (CS) with imminent or evolving 
multi-organ failure. 
 There are several options for short-term MCS, including intra-aortic ballon pump (IABP), 
Impella®, Levitronix®, Tandem Heart® and devices like extracorporeal membrane oxygenation 
(ECMO). Extracorporeal life support indications are expanding, and it is increasingly being 
used to support cardiopulmonary resuscitation (CPR) in children and adults. Of these, ECMO 
is the most commonly implanted for the most critically ill patients with CS and refractory 
cardiac arrest (eCPR).4 The registry contains information on 78,397 extracorporeal life support 
(ECLS/ECMO) patients, children, and adults. The report that overall, 70% of these patients 
are successfully weaned off ECMO, and 58% survived to hospital discharge. The use of 
Extracorporeal life support and centers providing ECMO support have increased worldwide. 
Though ECMO support could serve as a bridge to recovery, bridge-to-decision, and also 
as a bridge to LVAD or transplantation, its use is limited by several potential complications 
including, infections, bleeding, limp ischemia and cerebrovascular haemorragia. Preventing 
these complications is of uttermost importance in order to attempt successful weaning or 
bridging to a long-term support device. 
 Complications are also present in patients supported with a long-term LVAD, such as 
thromboembolic events, device dysfunction, infections (LVAD pump and driveline infections), 
bleeding and heart failure (due to arrhythmia, valve dysfunction, or right ventricular failure).2, 
3, 5, 6 However, the highest risk of mortality and morbidity is in the early post-LVAD implantantion 
period at the ICU / index hospital stay. Therefore, intensive clinical-, biochemical-, 
echocardiographical- and laboratory follow up, in addition to a multidisciplinary approach, 
are necessary. Given the currently used LVAD is a continuous flow pump, the classical 
hemodynamic pattern and tissue perfusion is altered. Beside global, macro-hemodynamic 
measurements, through microcirculatory assessments, have became increasingly of interest 
in the  evaluation of continuous flow related complications in these patients. 
 Despite the advances in hemodynamic monitoring techniques, complications and 
weaning from ECMO is currently still performed without comprehensive  monitoring of end-
organ function.7, 8 However, patients still die after removal of ECMO because of inadequate 
heart- or end-organ recovery. Therefore, optimal  monitoring of the  microcirculation 
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would add a novel dimension to the classical macro-hemodynamic monitoring in ICU, both 
in weaning and as a prognosti c tool for these pati ents. This pioneering approach could 
aid comprehensive pati ent monitoring with new parameters, especially when it concerns 
mechanically circulatory support, from the operati on room ti ll the living room on an e-health 
based contact (see also fi gure 1).  
Figure 1: The four pillars of Personalized Physiological Medicine required for tailor-made therapy of the individual 
criti cally ill pati ent are envisaged as consisti ng of: 1) assessment of the frailty, fi tness and physiological reserve of the 
pati ent, 2) the conti nuous and quanti tati ve functi onal assessment of the various organ systems, 3) the assessment 
of the coherence and physiological regulati on of the diff erent components of the cardiovascular systems from the 
systemic to the microcirculati on to the cellular and subcellular functi onal structures that defi nes homeostasis and 
fi nally, 4) an integrati on and feedback of the defi ning physiological variables to drive therapy and provide clinical 
control of the pati ent. Adapted from Can Ince.9 
GENERAL INTRODUCTION AND OUTLINE OF THE THESIS
1OUTLINE OF THE PRESENT THESIS
In this thesis,  the clinical aspects, novel imaging techniques and risk scores are used to 
answer the afore mentioned questions regarding short- and long-term MCS. In Chapter 2 
we describe the response of microcirculation to mechanical support of the heart in critical 
illness. In the past the monitoring possibilities from the different devices consisted of OPS and 
SDF.10 Nowadays IIDF technology is added to the monitoring possibilities during mechanical 
circulatory support. The findings in several studies in microcirculation are compared to 
macrocirculatory parameters to search for hemodynamic coherence.11 With the possibilities 
of bridging from short-term mechanical circulatory support to durable left ventricular assist 
devices. 
 Chapter 3 elaborates on the need for microcirculatory monitoring during cardiac 
surgery.12 The several devices are described in a systematic review. The use of latest 
technology in microcirculatory monitoring system, IDF during cardiac surgery are described 
together with the alterations seen in the microcirculation due to use of different solutions 
during cardiac surgery.      
 Chapter 4 summarizes the response of the cardiovascular system to extra corporeal 
membrane oxygenation with an all-round summary of the past- and current ideas.13 
Furthermore it is described how to monitor the recovery of cardiac function according to 
current global hemodynamics and echocardiography. We also describe our experience with 
microcirculatory monitoring of the cardiac function.  
 Chapter 5 describes the different abnormalities in microcirculation in critical illness and 
tissue hypoxia.14 The usefulness of direct monitoring of sublingual microcirculation has been 
described.
 In Chapters 6 and 7 we respectively investigated microcirculation as mortality risk during 
ECMO support and weaning parameter to manage weaning of cardiogenic shock patients on 
ECMO. The selection of patients to support with ECMO and later on how to wean from ECMO 
are two major issues in Extra Corporeal Support World. 
Mortality scores in patients with cardiogenic shock supported by ECMO are still controversial.15, 
16 A very accepted mortality risk score for the ICU is the SOFA score. Based on our expertise 
in mechanical circulatory support group we decided to use the right ventricle function as a 
parameter and added it to the SOFA score for better prediction of mortality in patients with 
VA-ECMO. This is described in Chapter 8.
 Short-term mechanical circulatory support (MCS) as a bridge to decision is increasingly 
used however an escape to long-term MCS is often an option.17 To investigate the optimal 
duration on short-term MCS to long-term MCS we performed this systematic review and 
meta-analysis.  After more than a decade succesfull Interagency Registry for Mechanically 
Assisted Circulatory Support Registry in the United States of America (The INTERMACS 
Regsitry),  Europe has his own register for long-term MCS, the European Registry for 
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Patients with Mechanical Circulatory Support (EUROMACS) Registry.3 We analyzed in depth 
the parameters predicting right sided heart failure (RHF) following a LVAD implantation. 
Thereafter we derivate and validate a novel RHF score after implantation of continuous flow 
left ventricular assist devices in Chapter 10. From the same population we analyzed time-
based modes of death following LVAD implantation in Chapter 11. 
 Diagnosis of cardiac tamponade post continuous-flow left ventricle assist devices 
implantation is challenging due to missing pulsatility. We describe in Chapter 12 case series 
of eleven LVAD patients with subclinical pericardial tamponade diagnosed by sublingually 
measured incident-dark-field imaging (IDF), an novel imaging tool used for diagnostic 
purposes. We sought to examine how microcirculatory alterations could be used for early 
detection of cardiac tamponade after a LVAD implantation.18
 Having implanted an LVAD the complications varies from cardiac tamponade to 
infections, pump thrombosis/thromboembolic events, ventricular arrhythmias and in longer 
term mechanical failure.19-21 In Chapters 13, we investigated the role of monitoring of 
haemolysis by measuring of lactate dehydrogenase (LDH) as a first sign of thromboembolic 
event and/or acute pump thrombosis in patients with Heart Mate II.22 
 Patients with an LVAD are challenging to evaluate using conventional imaging techniques. 
In Chapter 14 and 15 we examine novel use of conventional imaging technics in LVAD 
patients. In Chapter 14 we describe our pilot study where we evaluated the potential use 
of contrast echocardiography for the evaluation of the left ventricle wall detection. Contrast 
enhanced echocardiography is increasingly used for diagnostic and thereapeutic purposes.23 
The growing amount of patients having an LVAD, obligates us to apply new- and improve 
older techniques in cardiac imaging so that it will be useful in the clinic and lower the burden. 
We investigated the safety and feasibility of contrast enhanced echocardiography to examine 
whether the cardiac boarders are better to recognize. 
 LVAD-related infections are one of the major potiential problems on short-, and longterm 
causing significant morbidity and mortality.24-26 Unfortunately, appropriate diagnosis of 
LVAD-related and LVAD-specific infections can be very cumbersome. The differentiation 
between deep and superficial infections is crucial in clinical decision-making. Despite a 
decade of experience in using fluorodeoxyglucose positron emission tomography/computed 
tomography (18F-FDG PET/CT) to diagnose various infections, its use in LVAD patients remains 
scarce. In Chapter 15 , we reviewed the current evidence in the literature and described our 
single center experience using 18F-FDG PET/CT for the diagnosis and management of LVAD 
infections.
 LVAD support can be hampered by the occurrence of ventricular arrhythmias (VAs). 
There are limited data on the temporal evolution of VA burden during long-term follow-up.27 
We aim to in Chapter 16 to investigate the incidence, predictors, and clinical outcomes of VA 
in LVAD patients in 2 large Dutch LVAD centers. 
16
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1 Due to the extreme shortage of suitable cardiac donors and the rise of elderly patients 
ineligible for HTX, the use of cf-LVAD as DT is increasingly used. As a result, the duration of 
long-term mechanical support increases and device durability becomes extremely important 
for the long-term survival, morbidity and quality of life of patients. In the REMATCH trial 
device failure was the leading cause of death, next to sepsis.21, 24 Device failure can occur due 
to mechanical failure, driveline damage, infections or thrombosis and often requires pump 
replacement. Previous studies have reported that the incidence of device failure and device 
replacement is higher from one year of mechanical support onward.20, 28, 29 However, there 
is limited data on the long-term durability of current cf-LVADs and the distribution of device 
failure over time. Long-term durability and incidence of potential mechanical device failure 
are largely unknown. In Chapter 17, we investigated the incidence and potential predictors 
of mechanical device failure in patients with continuous flow left ventricular assist device. 
17
CHAPTER 1
REFERENCES
1. Shah P, Smith S, Haft JW, Desai SS, Burton NA, Romano MA, Aaronson KD, Pagani FD and Cowger 
JA. Clinical Outcomes of Advanced Heart Failure Patients with Cardiogenic Shock Treated with 
Temporary Circulatory Support Before Durable LVAD Implant. ASAIO J. 2016;62:20-7.
2. Kirklin JK, Pagani FD, Kormos RL, Stevenson LW, Blume ED, Myers SL, Miller MA, Baldwin JT, 
Young JB and Naftel DC. Eighth annual INTERMACS report: Special focus on framing the impact of 
adverse events. J Heart Lung Transplant. 2017;36:1080-1086.
3. de By T, Mohacsi P, Gahl B, Zittermann A, Krabatsch T, Gustafsson F, Leprince P, Meyns B, Netuka 
I, Caliskan K, Castedo E, Musumeci F, Vincentelli A, Hetzer R, Gummert J and members E. The 
European Registry for Patients with Mechanical Circulatory Support (EUROMACS) of the European 
Association for Cardio-Thoracic Surgery (EACTS): second report. Eur J Cardiothorac Surg. 2017.
4. Thiagarajan RR, Barbaro RP, Rycus PT, McMullan DM, Conrad SA, Fortenberry JD, Paden ML and 
centers Em. Extracorporeal Life Support Organization Registry International Report 2016. ASAIO J. 
2017;63:60-67.
5. Combes A. Mechanical circulatory support for end-stage heart failure. Metabolism. 
2017;69S:S30-S35.
6. Kirklin JK, Xie R, Cowger J, de By T, Nakatani T, Schueler S, Taylor R, Lannon J, Mohacsi P, Gummert 
J, Goldstein D, Caliskan K and Hannan MM. Second annual report from the ISHLT Mechanically 
Assisted Circulatory Support Registry. J Heart Lung Transplant. 2018.
7. Cavarocchi NC, Pitcher HT, Yang Q, Karbowski P, Miessau J, Hastings HM and Hirose H. Weaning 
of extracorporeal membrane oxygenation using continuous hemodynamic transesophageal 
echocardiography. J Thorac Cardiovasc Surg. 2013;146:1474-9.
8. Aissaoui N, Luyt CE, Leprince P, Trouillet JL, Leger P, Pavie A, Diebold B, Chastre J and Combes A. 
Predictors of successful extracorporeal membrane oxygenation (ECMO) weaning after assistance 
for refractory cardiogenic shock. Intensive Care Med. 2011;37:1738-45.
9. Ince C. Intensive care medicine in 2050: the ICU in vivo. Intensive Care Med. 2017;43:1700-1702.
10. Ocak I, Kara A and Ince C. Monitoring microcirculation. Best Pract Res Clin Anaesthesiol. 
2016;30:407-418.
11. Ince C. Hemodynamic coherence and the rationale for monitoring the microcirculation. Crit Care. 
2015;19 Suppl 3:S8.
12. den Uil CA, Klijn E, Brugts JJ, Lagrand WK and Spronk PE. Monitoring of the sublingual microcirculation 
in cardiac surgery using two-dimensional imaging. Anesthesiology. 2008;109:353-4; author reply 354-
5.
13. Bartlett RH. Extracorporeal life support: history and new directions. ASAIO J. 2005;51:487-9.
14. den Uil CA, Klijn E, Lagrand WK, Brugts JJ, Ince C, Spronk PE and Simoons ML. The microcirculation 
in health and critical disease. Prog Cardiovasc Dis. 2008;51:161-70.
18
GENERAL INTRODUCTION AND OUTLINE OF THE THESIS
115. Schwarz B, Mair P, Margreiter J, Pomaroli A, Hoermann C, Bonatti J and Lindner KH. Experience 
with percutaneous venoarterial cardiopulmonary bypass for emergency circulatory support. Crit 
Care Med. 2003;31:758-64.
16. Schmidt M, Burrell A, Roberts L, Bailey M, Sheldrake J, Rycus PT, Hodgson C, Scheinkestel C, 
Cooper DJ, Thiagarajan RR, Brodie D, Pellegrino V and Pilcher D. Predicting survival after ECMO 
for refractory cardiogenic shock: the survival after veno-arterial-ECMO (SAVE)-score. Eur Heart J. 
2015;36:2246-56.
17. Pagani FD, Aaronson KD, Dyke DB, Wright S, Swaniker F and Bartlett RH. Assessment of an 
extracorporeal life support to LVAD bridge to heart transplant strategy. Ann Thorac Surg. 
2000;70:1977-84; discussion 1984-5.
18. Bezemer R, Bartels SA, Bakker J and Ince C. Clinical review: Clinical imaging of the sublingual 
microcirculation in the critically ill--where do we stand? Crit Care. 2012;16:224.
19. Adesiyun TA, McLean RC, Tedford RJ, Whitman GJR, Sciortino CM, Conte JV, Shah AS and Russell 
SD. Long-term follow-up of continuous flow left ventricular assist devices: complications and 
predisposing risk factors. Int J Artif Organs. 2017;40:622-628.
20. Dembitsky WP, Tector AJ, Park S, Moskowitz AJ, Gelijns AC, Ronan NS, Piccione W, Jr., Holman WL, 
Furukawa S, Weinberg AD, Heatley G, Poirier VL, Damme L and Long JW. Left ventricular assist 
device performance with long-term circulatory support: lessons from the REMATCH trial. Ann 
Thorac Surg. 2004;78:2123-9; discussion 2129-30.
21. Rose EA, Gelijns AC, Moskowitz AJ, Heitjan DF, Stevenson LW, Dembitsky W, Long JW, Ascheim 
DD, Tierney AR, Levitan RG, Watson JT, Meier P, Ronan NS, Shapiro PA, Lazar RM, Miller LW, Gupta 
L, Frazier OH, Desvigne-Nickens P, Oz MC, Poirier VL and Randomized Evaluation of Mechanical 
Assistance for the Treatment of Congestive Heart Failure Study G. Long-term use of a left 
ventricular assist device for end-stage heart failure. N Engl J Med. 2001;345:1435-43.
22. Starling RC, Moazami N, Silvestry SC, Ewald G, Rogers JG, Milano CA, Rame JE, Acker MA, Blackstone 
EH, Ehrlinger J, Thuita L, Mountis MM, Soltesz EG, Lytle BW and Smedira NG. Unexpected abrupt 
increase in left ventricular assist device thrombosis. N Engl J Med. 2014;370:33-40.
23. Feinstein SB, Coll B, Staub D, Adam D, Schinkel AF, ten Cate FJ and Thomenius K. Contrast enhanced 
ultrasound imaging. J Nucl Cardiol. 2010;17:106-15.
24. Holman WL, Park SJ, Long JW, Weinberg A, Gupta L, Tierney AR, Adamson RM, Watson JD, Raines 
EP, Couper GS, Pagani FD, Burton NA, Miller LW, Naka Y and Investigators R. Infection in permanent 
circulatory support: experience from the REMATCH trial. J Heart Lung Transplant. 2004;23:1359-65.
25. Goldstein DJ, Naftel D, Holman W, Bellumkonda L, Pamboukian SV, Pagani FD and Kirklin J. 
Continuous-flow devices and percutaneous site infections: clinical outcomes. J Heart Lung 
Transplant. 2012;31:1151-7.
26. Hannan MM, Husain S, Mattner F, Danziger-Isakov L, Drew RJ, Corey GR, Schueler S, Holman WL, 
Lawler LP, Gordon SM, Mahon NG, Herre JM, Gould K, Montoya JG, Padera RF, Kormos RL, Conte JV, 
Mooney ML, International Society for H and Lung T. Working formulation for the standardization 
19
CHAPTER 1
of definitions of infections in patients using ventricular assist devices. J Heart Lung Transplant. 
2011;30:375-84.
27. Garan AR, Yuzefpolskaya M, Colombo PC, Morrow JP, Te-Frey R, Dano D, Takayama H, Naka Y, 
Garan H, Jorde UP and Uriel N. Ventricular arrhythmias and implantable cardioverter-defibrillator 
therapy in patients with continuous-flow left ventricular assist devices: need for primary 
prevention? J Am Coll Cardiol. 2013;61:2542-50.
28. Potapov EV, Kaufmann F, Stepanenko A, Hening E, Vierecke J, Low A, Lehmkuhl E, Dranishnikov N, 
Hetzer R and Krabatsch T. Pump exchange for cable damage in patients supported with HeartMate 
II left ventricular assist device. ASAIO J. 2012;58:578-82.
29. Holman WL, Naftel DC, Eckert CE, Kormos RL, Goldstein DJ and Kirklin JK. Durability of left 
ventricular assist devices: Interagency Registry for Mechanically Assisted Circulatory Support 
(INTERMACS) 2006 to 2011. J Thorac Cardiovasc Surg. 2013;146:437-41 e1.
20
GENERAL INTRODUCTION AND OUTLINE OF THE THESIS
1
21

Part I 
Microcirculati on in pati ents with mechanical 
circulatory support

Chapter 2
The response of the microcirculation to mechanical 
support of the heart in critical illness
Sakir Akin1,2, Ati la Kara1, Corsti aan A. den Uil1,2, and Can Ince1,3
From the 1Department of Intensive Care , 2 Department of Cardiology Erasmus MC, University Medical Center, 
Rott erdam, The Netherlands. 3 Department of Translati onal Physiology, Academic Medical Center, 
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CHAPTER 2
ABSTRACT
Critical illness associated with cardiac pump failure results in reduced tissue perfusion in all 
organs and occurs in various conditions such as sepsis, cardiogenic shock, and heart failure. 
Mechanical circulatory support (MCS) devices can be used to maintain organ perfusion in 
patients with cardiogenic shock and decompensated chronic heart failure. However, correction 
of global hemodynamic parameters by MCS does not always cause a parallel improvement in 
microcirculatory perfusion and oxygenation of the organ systems, a condition referred to as 
a loss of hemodynamic coherence between macro- and microcirculation (MC). In this paper, 
we review the literature describing hemodynamic coherence or loss occurring during MCS 
of the heart. By using Embase, Medline Cochrane, Web of Science, and Google Scholar, we 
analyzed the literature on the response of MC and macrocirculation to MCS of the heart in 
critical illness. The characteristics of patients, MCS devices, and micro- and macrocirculatory 
parameters were very heterogenic. Short-term MCS studies (78%) described the effects of 
intra-aortic balloon pumps (IABPs) on the MC and macrocirculation. Improvement in MC, 
observed by handheld microscopy (orthogonal polarization spectral (OPS), sidestream dark-
field (SDF), and Cytocam IDF imaging) in line with restored macrocirculation was found in 
44% and 40% of the studies of short- and long-term MCS, respectively. In only 6 of 14 studies, 
hemodynamic coherence was described. It is concluded that more studies using direct 
visualization of the MC in short- and long-term MCS by handheld microscopy are needed, 
preferably randomized controlled studies, to identify the presence and clinical significance 
of hemodynamic coherence. It is anticipated that these further studies can enable to better 
identify patients who will benefit from treatment by mechanical heart support to ensure 
adequate organ perfusion.
Keywords: microcirculation, hemodynamic coherence, cardiogenic shock, heart failure, 
mechanical circulatory support
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THE RESPONSE OF THE MICROCIRCULATION TO MECHANICAL SUPPORT OF THE HEART IN CRITICAL ILLNESS
2
MECHANICAL CIRCULATORY SUPPORT AND THE NEED FOR 
HEMODYNAMIC COHERENCE
Cardiogenic shock (CS) is a common disorder in critically ill patients. Several underlying 
etiologies such as myocarditis, acute myocardial infarction (AMI), peripartum cardiomyopathy, 
decompensated chronic heart failure, and postcardiotomy shock are responsible for and 
result in abnormalities in the microcirculation (MC) and tissue hypoxia [1]. In this review, 
we investigated the current state of knowledge concerning the response of MC to CS in 
patients on mechanical circulatory support (MCS) devices and descriptions of the presence 
of hemodynamic coherence between macrocirculation and MC. 
 MCS using different techniques has become a realistic and cost-effective option to 
reverse shock and prevent secondary organ failure while waiting for a permanent solution. 
With the advent of different types of devices, circulatory collapse can be treated effectively; 
however, end-organ recovery is not always achieved. When recovery is not anticipated, a 
plan for urgent heart transplantation (HT), or for a durable MCS (such as left ventricular 
assist device (LVAD) implantation as a “bridge to bridge” or “bridge to destination”), or for 
withdrawal of support (“bridge to palliative care”) needs to be made. Current knowledge is, 
however, limited and controversy exists regarding the response of the MC of patients treated 
with mechanical support devices [2].
 Understanding the functional condition of the MC may improve clinical outcomes of the 
critically ill patients [3,4]. Direct monitoring of the MC by handheld microscopy may provide 
a more physiological approach than solely monitoring the systemic circulation for clinicians to 
evaluate the efficacy of therapy and help to assess the presence of hemodynamic coherence 
between the macrocirculation and MC [4]. In this paper, we review studies that have 
documented measurement of hemodynamic variables related to the systemic circulation and 
the MC in response to MCS of the heart.
METHODS
By using Cochrane Central Register of Controlled Trials, Embase, and Medline (PubMed 
US National Library of Medicine), we performed a literature search in June 2016 using the 
following search terms:
 (1) “heart-assist devices” (MeSH Terms) AND (“heart failure” (MeSH Terms) OR “shock, 
cardiogenic” (MeSH Terms)) AND “microcirculation” (text word); and (2) extracorporeal 
membrane oxygenation (MeSH Terms) OR mechanical circulatory support (text word) OR 
intraaortic counter-pulsation (text word). From embase.com, we found 1080 items; here, we 
give an example: “microcirculation”/de OR “microvascular ischemia”/de OR microvasculature/
exp OR “microvascularization”/de OR “capillary density”/ de OR (microcirculat* OR 
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microvascu* OR microvessel* OR ((vessel* OR capillar*) NEAR/3 (densit* OR perfuse* OR 
imag* OR microscop*) OR if OR (incident* NEAR/3 (darkfield OR dark-field OR sidestream 
OR side-stream)) OR ops OR (orthogonal* NEAR/3 polari* NEAR/3 spectr*) OR SDF OR 
((darkfield OR dark-field) NEAR/3 (sidestream OR side-stream)):ab,ti) AND (“extracorporeal 
oxygenation”/de OR “extracorporeal circulation”/de OR “cardiopulmonary bypass”/de 
OR “implanted counterpulsation device”/exp OR “aorta balloon”/de OR “left ventricular 
assist device”/de OR “heart lung machine”/de OR “heart assist device”/exp OR “assisted 
circulation”/de OR (extracorpor* NEAR/3 (oxygenat* OR mechanic* OR circulat*)) OR 
(cardiopulmon* NEAR/3 bypass*) OR ecmo OR ((intraaort* OR intra-aort*) NEAR/3 balloon 
NEAR/3 pump*) OR (implant* NEAR/3 (counterpulsat* OR counter-pulsat*)) OR ((ventric* 
OR heart OR cardiac) NEAR/3 assist* NEAR/3 device*) OR CorAide OR DeBakey-Child OR 
DuraHeart OR EVAHEART OR EXCOR OR FlowMaker OR HeartMate OR HeartQuest OR Impella 
OR LP2-5 OR LP5 OR INCOR OR Left-VAD OR IABP OR Levacor OR Lion-Heart OR LionHeart 
OR LV-assist-device* OR LVAD OR MiTi-Heart OR Novacor OR TandemHeart OR VentrassistOR 
Centrimag OR Levitronix OR ((mechanical* OR device*) NEAR/3 support* NEAR/3 (heart 
ORcardiac)) OR ((heart OR cardiac) NEAR/3 (lung OR pulmonar*) NEAR/3 machine*) OR 
((assist* OR mechanical*OR artificial*) NEAR/3 (circulation* OR heart OR cardiac)) OR blood-
pump*):ab,ti) NOT ([animals]/ lim NOT [humans]/lim).
 Two investigators (S.A. and A.K.) independently retrieved potentially eligible reports 
for evaluation. Both investigators independently examined design, patient population, and 
interventions in the reports. In case of disagreement, this was resolved in consultation with 
two other reviewers (C.A.U. and C.I.).
Search machine 1st 2nd*
embase.com 1080 1061
Medline Ovid 448 89
Web-of-science  786 458
Cochrane 82 2
Google scholar 100 27
Total 2496 1637
* After deleting duplicates
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Study selection
All retrospective and prospective cohort studies with MC on adult patients receiving short-
term (hours to weeks) and long-term (weeks to years) MCS for CS and acute/chronic heart 
failure were selected (Fig. 1). We excluded reports on review articles, abstracts, animal studies, 
duplicates, pediatrics, case reports, and perioperative studies on heart-lung machines. 
Further selection was made including only reports of microcirculatory measurements in short- 
and long-term MCS. Finally, after excluding reports where both MC and macrocirculation 
parameters were not evaluated during MCS, 14 studies were left and included in this study.
Study outcomes
All studies related to mechanically supported adult hearts monitored by the measurement of 
the MC and macrocirculation were evaluated (Table 1).
Figure 1: Identification of studies comparing mic- and macrocirculation parameters in short- and long term MCS.
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Results of the literature search
Fourteen studies (N = 157 patients with varying ages (24-80 years)) met the inclusion criteria 
for this study (Fig. 1). The types of MCS used (n = 112) included intraaortic balloon pump (IABP) 
(n = 71), biventricular assist device (BiVAD, n = 15), peripheral venoarterial extracorporeal 
membrane oxygenation (VA-ECMO, n = 4), Impella 2.5 (n = 3), Tandem Heart (n = 1), and 
combination of VAECMO with IABP (n = 18), and long-term MCS (LVADs (n = 45), HeartMate 
II (HM II, n = 13), Heart Ware (HW, n = 14), MicroMed DeBakey VAD (n = 3), and HeartMate I 
(HM I, n = 15)) with support duration varying from 1 to 120 days. 
 Techniques used for microcirculatory assessments included mainly handheld video 
microscopy using sublingual sidestream dark-field (SDF) imaging (n = 8), laser Doppler 
perfusion imaging (LDPI, n = 4), tissue electron microscopy (n = 1), and beat-to-beat finger 
photoplethysmogram (PPG, n = 1) (Tables 2 and 3).
Short-term MCS and hemodynamic coherence
Monitoring the MC during restoration of the macrocirculation by MCS of the heart in the 
intensive care unit (ICU) is an increasing area of interest in hemodynamic monitoring during 
MCS [2,4]. The current literature in monitoring tissue perfusion in mechanically supported 
hearts is very heterogenic because of the variety of monitoring techniques, monitoring time, 
and diversity of operators (Tables 2 and 3). Previous studies on microcirculatory monitoring 
have reported to be of considerable heterogeneity in states of critical illness [4-12]. Several 
studies have described the subjective evaluation of sublingual MC by physicians and nurses, 
an approach that seems to be an appropriate method for identifying specific abnormalities of 
sublingual MC (e.g. [13]). These considerations lead to the question on which method is best 
suited for identifying the presence or absence of hemodynamic coherence between the MC 
and the macrocirculation in response to MCS of the heart [4,14].
 The achievement of hemodynamic coherence between the MC and macrocirculation 
must be considered as a success of MCS because these devices target mainly support of the 
systemic circulation [4]. How hemodynamic coherence by MCS device can be achieved if not 
present is a subject for future research.
 In 1992, Brittner et al. [15] investigated the effects of the Berlin Heart, a BiVAD, on the 
response of the MC in pretransplant patients. Microcirculatory forearm cutaneous blood flow 
was measured continuously and noninvasively by laser Doppler flowmetry (LDF). To examine 
microvascular responses to macrohemodynamic changes, the cardiac output (CO) was 
decreased by a 20% reduction in BiVAD pump rate. This change in CO revealed an increase 
in systemic vascular resistance (SVR) and a slight decrease in LDF, whereas systolic and 
diastolic blood pressure remained unchanged. The microvascular blood flow alterations were 
insignificant. This study was scored as negative for achievement of hemodynamic coherence 
(Table 2).
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The most studied MCS monitored by sublingual microcirculatory measurements is the IABP. 
This device was first used for the treatment of CS in 1968 [16]. Its use for a variety of clinical 
conditions requiring mechanical heart support makes it currently the most frequently used 
method of MCS in the cardiac care unit and catheterization laboratory. In this review, five 
studies on IABP [17-21] and two studies on IABP after VA-ECMO [22,23] were found. In 
57% of these studies, a loss of hemodynamic coherence was found during IABP. Handheld 
microscopy based on SDF imaging identified loss of hemodynamic coherence in 38% of 
studies.
Table 1: Overview of various short- and  long term mechanical circulatory support devices included in this review 
•  A-ECMO; Veno-Arterial Extra Corporeal Membrane Oxygenation
•  BiVAD; Biventricular assist device; Berlin Heart
•  IABP; intra-aortic balloon pump; counter pulsation device
•  RVAD; Right Ventricular Assist Device (Centrimag (on top off LVAD support))
•  TandemHeart = Percutaneous Ventricular Assist Device (pVAD)
•  Impella LP2,5 
•   LVAD; Left Ventricular Assist Device; Heart Mate I, Heart M-II, Heart Ware, MicroMed DeBakey VAD 
Not found for this review:
•  Impella LP5,0
•  PHP; Percutaneous Heart Pump
•  Heart Mate 3
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IABP has shown to improve coronary blood flow by augmenting systemic and coronary 
diastolic blood pressure and increasing cardiac index by reducing left ventricular (LV) 
work [24]. Five studies were identified where the response of sublingual MC to IABP was 
investigated during CS after AMI and high-risk percutaneous coronary interventions (PCIs) 
[17-20]. Three of these studies reported IABP induced improvement in microvascular flow, 
whereas the others did not. 
 Munsterman et al. [21] showed the presence of even negative effect of IABP in 
patients deemed ready for discontinuing IABP support. SDF imaging showed an increase in 
microcirculatory flow of small vessels after withdrawal of IABP therapy. This study seems to 
suggest that longer support using IABP may impair microvascular perfusion. In addition, this 
study found an improvement in the macrocirculation when ceasing IABP support, a condition 
not necessary for survival, however, and which was associated with an increase in perfused 
vessel density (PVD) of small vessels <20 mm. The PVD for vessels >20 mm and microvascular 
flow index (MFI) for both small and large vessels were unaltered.
 Jung et al. [20] investigated 13 patients with CS after AMI. The authors recorded SDF 
video images before and shortly after IABP support was temporarily halted. MFI of small 
and medium vessels (10-50 mm) was significantly higher in patients with IABP support. In 
contrast, den Uil et al. who studied a heterogeneous group of 13 patients suffering from CS 
of variable severity did not find any differences in perfused capillary density (PCD) and red 
blood cell velocity following cessation of IABP [17]. The MC, however, was negatively affected 
by the fact that mean arterial pressure and cardiac index were significantly lower after the 
IABP-assist ratio was switched from 1:1 to 1:8. 
 Jung et al. [19] studied six patients immediately following high-risk PCI. The MFI of 
both small and large vessels decreased significantly immediately after a short period of 
discontinuation of IABP support and returned to baseline after restarting the therapy. Once 
again, there was no correlation with changes in macrocirculation parameters indicating loss 
of hemodynamic coherence.
 Finally, most recently, Jung et al. [18] did not report any difference between patients 
treated with or without IABP in addition to early revascularization in patients with CS-
complicated myocardial infarction concerning their response of their MC. Furthermore, 
acute cessation of IABP did not influence microvascular perfusion. The responses of 
microcirculatory parameters were in line with previous findings where they were found to be 
potent predictors of outcome as reported by den Uil et al. [25].
Further studies investigating whether treatment strategies that improve sublingual MC are 
effective in improving survival of CS patients are needed. Consequently, understanding of 
improved microvascular perfusion in response to IABP support is still based on limited and 
conflicting data, although the same technique for microcirculatory measurements was used. 
 Only one study was found in the literature where both MC and macrocirculation were 
measured in response to the Impella LP2.5 after AMI complicated by shock [26]. Expelling 
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aspirated blood from the left ventricle into the ascending aorta, the Impella could provide 
flow up to 2.5 L/min. In contrast with a recent study of IABP, using Impella LP2.5 showed 
an improvement in sublingual MC also assessed by the SDF technique. In a small group of 
ST-elevation myocardial infarction (STEMI) patients (n = 3) followed for 3 days after initiation 
of Impella LP2.5 improved levels of MC as compared with the levels in healthy individuals, 
although the MC remained suboptimal after 72 h in patients without support. This was the 
first study describing a positive relationship between macrocirculation and improvement 
in sublingual MC, paralleling LV function improvement after STEMI. Randomized controlled 
trials comparing IABP and Impella monitored by sublingual MC measurements would help 
understand this difference.
 The TandemHeart in AMI complicated by cardiac shock was investigated in only one 
study by den Uil et al. [27]. This was in a heterogeneous group of mainly end-stage heart 
failure patients with the use of long-term devices implanted as a bridge to transplantation. 
After weaning from this device, multiorgan failure occurred despite initial recovery of 
macrocirculatory parameters. Microvascular perfusion decreased after removal of the 
device. In this study, the authors also investigated two patients with CS supported by VA-
ECMO with the development of multiorgan failure after unsuccessful weaning. The patients 
did not survive following removal of the device.
 Timing of weaning following “normalization” of the cardiovascular system from any 
MCS device, in particular, VA-ECMO is as important goal in the management of MCS. Too 
early or too late weaning can cause treatment failure and can lead to various complications. 
Conventionally, hemodynamic and echocardiographic parameters are used to wean from 
ECMO. However, to date, weaning strategies following VA-ECMO initiation for CS have not 
been described in the guidelines, and only a few studies have evaluated outcome predictors 
following ECMO [28-30].
 VA-ECMO is increasingly being used following CS to support the cardiovascular system 
temporarily as a bridge to recovery and transplantation or bridge to durable LVAD [22]. 
Concerns about the cardiovascular response to these MCS devices are warranted when they 
are chosen as a target treatment option for the failing heart during hypoxemic emergencies 
[2]. After VA-ECMO initiation and organ reperfusion, reperfusion damage can occur, which 
can have deleterious effects on the cardiovascular system. Even though there is a return of 
circulation, there is a high risk of thrombosis; intracardiac, intravascular, and poor cardiac 
contractility; reperfusion damage; inflammation; and stasis in and around the great vessels/
valves, in which case more advanced mechanical circulatory management may be required. 
In these cases, conventional hemodynamic monitoring may be inadequate to identify such 
complications, and modalities focusing on parenchymal perfusion and oxygenation may be 
indicated. 
 Studies on critically ill paediatric patients on VA-ECMO have shown depressed MC 
persisting during respiratory failure for >24 h [31,32]. In contrast, in adults there are no 
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significant studies concerning microcirculatory alterations in VA-ECMO in comparison to 
changes in systemic hemodynamic variables. Petroni et al. [22] showed that restoring 
pulsatility and decreasing LV afterload with IABP after VA-ECMO was associated with smaller 
LV dimensions and lower pulmonary artery pressures, although not affecting microcirculatory 
parameters in CS patients with little to no residual LV ejection. IABP might prevent severe 
hydrostatic pulmonary oedema in this context. This macrocirculatory improvement was not 
in coherence with the MC. However, because these patients had been stabilized on VAECMO-
IABP for several days, macrocirculation and MC variables had not been evaluated from the 
beginning, and thus, the effect of adding IABP for patients on VA-ECMO alone could not be 
evaluated.
 Wester et al. [23] investigated the use of IABP during VA-ECMO support in patients with 
postcardiotomy CS from endocarditis to type A aortic dissection with indication for surgery. 
The authors identified skin microvascular pathology using video microscopy (precapillary 
bleedings or haloes, micro-thrombi / capillaries with “no flow,” low functional capillary density 
(FCD) with high spatial distribution heterogeneity, or low mean flow-categorical velocity), 
which was associated with poor prognosis. There were no differences in macrocirculation 
between the survivors and non-survivors on VA-ECMO-IABP combination. This study also 
identified a loss of hemodynamic coherence whereby the MC was altered but measured 
using different techniques.
Long-term MCS and hemodynamic coherence
Continuous flow LVADs (CF-LVADs) are increasingly used following a short-term MCS in acute 
or chronic heart failure as a durable solution awaiting an HT or as a destination therapy. The 
timing of bridging to a durable LVAD from a short-term MCS remains a point of interest during 
MCS of the heart during critical illness in the ICU. In this review, five studies were identified 
(N = 45; HMII (n = 13), HMI (n = 15), HW (n = 14), and MicroMed DeBakey VAD (n = 3)) 
from 2007 to 2015 investigating microcirculatory together with macrocirculatory alterations 
during mean LVAD support varying between 1 and 120 days (Table 3).
 Drakos et al. [33] showed that pulsatile unloading of the heart by LVAD resulted in 
increased microvascular density accompanied by increased fibrosis without evidence of 
cardiomyocyte atrophy using electron microscopy of the heart muscle. This finding on tissue 
level comparing before and after LVAD implantation was in line with the improvements 
found in the macrocirculation, and could be a guide for studies of unloading-induced 
reverse remodelling of the failing human heart. By contrast, Lou et al. [34] did not find any 
alterations in microvascular endothelial function in 6 HM II patients measured by beat-to-
beat plethysmographic finger arterial pulse wave signal changes for 5 min following reactive 
hyperaemia. Although the macrocirculation in CF-LVAD patients was improved compared to 
that in end-stage heart failure patients, the reactive hyperaemic index (RHI) was unchanged 
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between the two groups of patients. The authors suggested that being on CF-LVAD support 
for 1-4 months did not negatively affect microvascular endothelial function. 
 Polska et al. [35], in their case series, showed that mean choroidal blood flow was 
maintained by changing MicroMed DeBakey VAD pump support flow within therapeutic 
values, whereas the ratio of pulsatile to non-pulsatile choroidal flow did change. Their study 
showed that in patients with durable VADs, changes in the macrocirculation could occur 
while maintaining a normal perfusion rate in the ocular MC maintained over a wide range of 
support conditions. They have suggested a concept of hemodynamic uncoupling during LVAD 
support in this relatively small interventional study. 
 Most recently, Sansone et al. [36] suggested that implantation of a CF-LVAD could also 
lead to improvements in microvascular perfusion. Macrovascular function was measured by 
flow-mediated vasodilatation (FMD) using high-resolution ultrasound of the brachial artery. 
Microvascular function was assessed in the forearm during reactive hyperaemia using LDPI 
and pulsed wave Doppler. LVAD implantation led to recovery of microvascular function, but 
not FMD. In parallel, increased free haemoglobin was observed along with red and white 
cell microparticles, and endothelial and platelet microparticles. Destruction of blood cells 
was considered as a contributor to residual endothelial dysfunction potentially caused by 
increasing NO scavenging. Direct monitoring of the MC by using currently available handheld 
microscopy can be expected to help in the understanding of the pathophysiological changes 
occurring during long-term MCS.
Sublingual MC
In this review, seven out of nine short-term MCS studies and one out of five long-term MCS 
studies were investigated by handheld SDF microscopy. After orthogonal polarization spectral 
(OPS) imaging, SDF was presently the device of choice for (sublingual) MC measurements in 
humans in real time [37-39]. However, recently, a more advanced generation of handheld 
microscopes (CytoCam, Braedius Medical, Huizen, The Netherlands) based on incident dark 
field (IDF) has been introduced that fix the persisting technical limitations of the earlier 
generation devices [40,41]. Whether IDF measurements can reproduce and confirm similar 
microcirculatory patterns in MCS of the heart seen in the studies using SDF imaging need to 
be confirmed. Initial studies comparing SDF and CytoCam-IDF imaging in healthy subjects 
and neonates [40-42] have shown that IDF imaging can detect more vessels with better 
image quality. Aykut et al. [40] observed 20-30% of more capillaries using CytoCam IDF than 
using SDF in sublingual MC obtained from healthy volunteers. By using the first-generation 
handheld video microscopes (OPS imaging), De Backer et al. [43] had shown the persistence 
of microvascular alterations in severe cardiac failure and CS, a condition which was associated 
with in-hospital mortality. There is now a growing body of evidence that microvascular flow 
alterations associated with adverse outcome may be relatively independent from global 
hemodynamics [44,4]. For example, surrogates of tissue perfusion such as central or mixed 
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venous oxygen saturation as well as arterial and venous blood pressure and CO may not 
necessarily reflect microvascular perfusion [2,9,10,14,45-48].
 This review investigated to extent to which there is hemodynamic coherence between 
the systemic circulation and MC during MCS of the heart during critical illness. It is 
concluded that for making an adequate plan for treatment, recovery or decision to long-
term MCS, microcirculatory recruitment should be optimized in parallel to macrocirculatory 
improvement, thereby achieving hemodynamic coherence. Future trials should test whether 
MC-guided therapy can better improve organ dysfunction when compared with traditional 
hemodynamic optimization strategy. In these studies, therapeutic strategies should be 
incorporated into resuscitation protocols aimed at normalizing tissue perfusion parameters 
with the aim of improving outcome in critically ill patients. 
Various techniques for microcirculatory measurements in MCS. 
The majority of IABP studies concerning MC were performed with SDF imaging and did 
not investigate bridging patients toward long-term MCS. In long-term MCS studies, there 
is only one study investigating the effects of the HM II on MC [27]. Techniques other than 
SDF imaging used for the assessment of the MC are fundus pulsation amplitude (FPA), Laser 
Doppler imaging (LDI), skin vital microscopy, electron microscopy of the heart tissue, finger 
plethysmography, and LDPI measuring microvascular reactivity during post occlusive reactive 
hyperaemia following 5 min of forearm occlusion [36]. Most of these studies, except for 
those on sublingual microcirculatory measurements and electron microscopy of the tissue 
MC, could demonstrate hemodynamic coherence (Tables 2 and 3). It must be concluded, 
however, that if achievement of hemodynamic coherence between the macrocirculation and 
MC is to be considered an important clinical target, then the quality and bedside applicability 
of microcirculatory assessments will need to be improved. The objective of this review was to 
systematically review evidence of the clinical significance of microcirculatory alterations during 
MCS and to identify correlations with the microcirculatory and macrocirculatory alterations. 
We anticipate that the further studies will explore the possibility of microcirculatory guiding of 
the MCS therapy, and to provide, based on microcirculatory assessment, an evidence-based 
recommendation on appropriate patients and MCS device selection, optimal monitoring of 
the support, and guiding the decision toward durable solutions during MCS.
38
THE RESPONSE OF THE MICROCIRCULATION TO MECHANICAL SUPPORT OF THE HEART IN CRITICAL ILLNESS
2
Limitations 
The number of eligible articles found and the number of patients investigated were very 
small. In addition, they represented a heterogeneous group of patients with acute and 
chronic heart failure, and the techniques used for measuring tissue perfusion and sublingual 
MC were varied. 
Conclusions
It can be concluded that monitoring the MC can play a pivotal role in the assessment of 
the effectiveness of short- or long-term mechanical support devices in case of CS or 
decompensated chronic heart failure. The introduction of a new generation handheld 
microscope that can evaluate and monitor MC could be a clinical option for effective 
hemodynamic coherence during mechanical support. This could possibly help in identifying 
the optimal time for bridging these patients toward a durable LVAD’s or HT. To investigate this 
more comprehensively, more robust, preferably, randomized controlled trials of well-defined 
patient categories with the use of modern MCS devices and microcirculatory monitoring 
system should be performed.
Practice points
•   Daily bedside monitoring of the MC should be considered while restoring the systemic 
circulation parameter by MCS devices in patients with CS or acute decompensated 
chronic heart failure.
•   Long-term effect of CF-LVADs on MC should be assessed periodically using third-
generation CytoCam IDF imaging handheld microscope.
Research agenda
•   There is a need for more improvement in microcirculatory monitoring techniques for 
instant evaluation of images for optimizing MCS use at the bedside.
•   Studies are needed to enable routine monitoring by nurses after initiation of MCS of the 
heart in the ICU in order to introduce daily simplified use of handheld microscopy.
•   Further work is needed to determine and identify the device-specific parameters that 
target hemodynamic coherence and microcirculatory recruitment in support of short- 
and long term MCS.
•   Well-designed trials on the effectiveness of optimizing hemodynamic coherence during 
MCS of the heart during critical illness in the ICU are needed.
•   Valid and reliable microcirculatory parameters predicting adverse outcome during short 
term MCS should be identified to optimize the time of switch to a durable solution, e.g., 
CF-LVAD or high urgency of HT when recovery is no longer an option.
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ABSTRACT 
Purpose of review
Cardiac surgery is associated with a wide range of microvascular derangements and with 
reduced tissue oxygenation. Although the macrohemodynamical targets during surgery 
may be achieved, the microcirculation may be damaged and remain dysfunctional. Direct 
observations of the microcirculation may enable more physiologically based approaches for 
diagnosis and treatment during cardiac surgery.
Recent findings
Microcirculation is the final destination of blood flow to the tissues for oxygen transport. 
Direct visualization of the microcirculation using hand-held microscopy can be considered 
the gold standard for tissue perfusion since the movement of single red blood cells can be 
observed and quantified. A new generation microcirculation monitoring device is called 
CytoCam Incident-Dark-Field imaging. This device has a high resolution imaging sensor and 
shows approximately 30% more capillaries than the devices of the previous generations. On-
pump and off-pump cardiac surgeries have induced different mechanism whose impact can be 
differentiated by observation of the sublingual microcirculation. Colloids may provide a better 
volume expansion and microcirculatory improvement than crystalloids although crystalloids 
may be more affective for hydration, and blood transfusions improves microcirculatory 
oxygenation by filling previously empty capillaries and reducing diffusion distances between 
oxygen carrying red blood cell and the parenchymal cells.
Summary
Direct visualization of the microcirculation using hand-held microscopy may provide the 
clinician the physiological feedback that is required for the early diagnosis and treatment of 
microcirculatory alterations during cardiac surgery. The coherence between the hemodynamic 
response of the macrocirculation and microcirculation during surgery seems to be essential.
Keywords
cardiac surgery, hemodynamic coherence, microcirculation
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INTRODUCTION
Cardiac surgery with or without cardiopulmonary bypass (CPB) is associated with a wide range 
of microcirculatory alterations and reduced tissue oxygenation that result from a combination 
of the surgery itself, anaesthesia, hypothermia, hemodilution, micro emboli formation, and 
inflammatory reaction [1,2]. The microcirculation is the final destination of blood flow to the 
tissues for the transport of oxygen to the parenchymal cells needed to sustain organ function, 
and its functional success defines the primary function of the cardiovascular system [3]. The 
normalization of systemic hemodynamic variables during cardiopulmonary compromise, 
however, may not always successfully improve microcirculatory failure during cardiac surgery 
[4,5]. In this review, we discuss microcirculatory alterations, the need for hemodynamic 
coherence between the macro and microcirculations and the importance of monitoring 
microcirculatory parameters during the perioperative period to monitor hemodynamic 
coherence. In conclusion, we suggest that microcirculation monitoring is important for both 
diagnosis and treatment. Introduction of a new generation of hand-held microscopes for 
evaluation of the functional activity of the microcirculation now allows clinical implementation 
of this monitoring platform.
Key points
•  the microcirculation is the final destination of blood flow to the tissues to achieve 
the transport of oxygen, which can then be used to meet the metabolic needs of the 
parenchymal cells to sustain organ function. Its success defines the primary function of 
the cardiovascular system.
•  Macrohemodynamic parameters and/or surrogates of tissue perfusion do not always 
correspond to the functional state of the microcirculation.
•  Cardiac surgery with and without CPB is associated with a wide range of microcirculatory 
alterations and reduced tissue oxygenation that results from a combination of the 
surgery itself, anaesthesia, hypothermia, hemodilution, micro emboli formation, and 
inflammatory reactions.
•  Direct visualization of the microcirculation may provide the clinician the physiological 
feedback that is required during cardiac surgery for the early diagnosis and treatment of 
microcirculatory alterations’
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Figure 1: Convective and diffusive determinants of oxygen transport from the microcirculation to the tissue cell. The 
convective flow is defined by the product of the oxygen carrying saturation of the RBCs and the rate at which RBCs 
enter the capillary and the oxygen carrying capacity of a RBC at 100% saturation (0.0362 pl O2/RBC). The diffusive 
movement of oxygen from the RBCs to the mitochondria is defined by Fick’s law of diffusion, where the flux of oxygen 
shown above is the product of the oxygen gradient from RBC to mitochondria and the diffusion distance times the 
exchange surface divided by the diffusion distance from the RBC to the mitochondria. RBCs, red blood cells.
The microcirculation and hemodynamic coherence
The microcirculation consists of a complex network of small blood vessels (<100µm 
diameter) that includes the arterioles, capillaries, and venules, and it is the final destination 
of blood flow to the tissues for oxygen transport [6]. This complex system involves different 
cell types, including endothelial cells, red blood cells (RBCs), leukocytes, and the plasma 
components of the blood [6]. All of these elements interact and are regulated by different 
complex mechanisms that control microcirculatory perfusion and oxygenation. In conditions 
of sepsis and shock, loss of (micro)vascular regulation and parenchymal cell damage causes 
heterogeneity in perfusion and oxygenation at the level of the microcirculation resulting in 
functional shunting of oxygen transport to the tissues and manifesting itself clinically as a 
reduction in oxygen extraction [7]. 
 Convective flow of RBCs and passive diffusion of oxygen to the tissue cells are the main 
mechanisms of oxygen transport from the heart to the tissue (Fig. 1) [8**]. Convective flow 
refers to the transportation of oxygen-carrying RBCs to the capillaries, and passive diffusion in 
the process by which oxygen leaves the RBCs to the oxygen sink of the respiring mitochondria 
to enable ATP production by oxidative phosphorylation. All resuscitation procedures are 
primarily aimed at enhancing convective RBC flow under the assumption that hypovolemia is 
primarily associated with inadequate flow. However, convective and diffusive flows provide 
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equal contributions to the transport of oxygen transport to the tissues [8**]. Clearly, the 
simple normalization of systemic hemodynamic variables may not always successfully 
normalize impaired convective and diffusive alterations in the microcirculation and areas of 
the microcirculation can become shunted and hypoxemic. 
 Many studies have reported that resuscitation based on the normalization of systemic 
hemodynamic variables does not always lead to parallel improvements in microcirculatory 
perfusion and cell oxygenation [9–11,12**,13,14]. Many regulatory and compensatory 
mechanisms, including hormonal, neural, biochemical, and vascular control systems, must 
be intact and be able to sense hypoxemia and regulate flow and cell metabolism to ensure 
hemodynamic coherence and adequate tissue perfusion and oxygen to the different organ 
systems. However, in states of CPB, inflammation, ischemic reperfusion, hemodilution, and 
hypothermia can damage the cellular sensing mechanisms and microcirculatory cell systems 
and microcirculatory abnormalities can persist in the presence of normalized systemic 
hemodynamics variables, such aas arterial and venous pressures, cardiac output, and 
systemic vascular resistance.
 A loss of hemodynamic coherence between the macro and microcirculation can be 
caused by primarily four types of underlying microcirculatory alterations, which can persist 
in the presence of normalized systemic hemodynamic variables. Type 1 alterations concerns 
the presence of heterogeneity in microcirculatory perfusion with obstructed capillaries next 
to capillaries with flowing RBCs can be observed in states of inflammation such as sepsis 
and reperfusion injury. Type 2 concerns hemodilution, in which dilution of blood causes a 
loss of RBC filled capillaries and results in increased diffusion distances between oxygen-
carrying RBCs and the cells of tissue cells a condition which has been described mainly in 
cardiac surgery patients. Type 3 loss of coherence occurs when vasoconstriction / tamponade 
of the microcirculation can be caused when excessive use of vasopressors are used and/or 
increased venous pressure is targeted causing microcirculatory tamponade, both conditions 
causing compromised tissue oxygenation. Type 4 losses of hemodynamic coherence is caused 
by tissue oedema because of the damage of endothelial cells, the loss of glycocalyx barriers, 
and/or the compromise of adherence and tight junctions and the overload of fluid all of 
which can be observed in both sepsis and CPB. 
 Different methods and devices can be used to visualize microcirculatory alterations. The 
sublingual microcirculation is the site most commonly used at the bedside to visualize the 
microcirculation, and the use of this site to investigate the effects of disease and therapy on 
microcirculatory function is well established [15]. Three generations of handheld microscopes 
have been developed to monitor the sublingual microcirculation over the last 2 decades [16]. 
Owing to a number of shortcomings of the first and second generation devices, including 
limited clinical applicability, and the lack of direct computer control of the imaging modality 
essential for automatic analysis of the microcirculatory images for measurement of functional 
microcirculatory parameters, a third-generation device, the CytoCam-Incident-Dark-Field 
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(IDF) device, was recently developed based on incident dark-field imaging [17,18*,19]. This 
device consists of a computer controlled, high-resolution image sensor, in combination with 
a specifically designed microscope lens, which together produces high-resolution images 
detecting 30% more sublingual capillaries than the previous generation devices [18*]. Even 
though these devices provide great detail about microcirculatory functional hemodynamics, 
they are techniques consistent under development as clinical requirements provide new 
challenges. Areas of shortcomings in the present devices in need of improvement include 
pressure artefacts, the limited focus depth and the need to stabilize the device in a single 
location to allow longer-term monitoring of single vessel hemodynamics.
Microcirculatory alterations during cardiac surgery
Cardiac surgery, including coronary artery bypass graft (CABG), cardiac valve, and aortic 
procedures, were made possible by the development of CPB in the 1950s, although surgery 
on a beating heart [off pump CABG (OPCABG)] is increasingly being used, especially for CABG 
procedures [20]. During CPB, the systemic perfusion is switched to extracorporeal circulation 
using a heart-lung machine, and the blood is exposed to nonbiocompatible polymers that 
activate blood cells and serum proteins, which trigger inflammatory reactions [21]. Other 
changes, including hypotension, hemodilution, hypothermia, cardiac arrest, and a change 
from pulsatile to nonpulsatile flow, adds to detrimental effects on the microcirculation and 
lead to tissue hypoxia and organ failure during standard CABG surgery with CPB [on-pump 
CABG (ONCABG)] [21–25]. The less invasive OPCABG reduces perioperative complications 
and can serve as an alternative to ONCABG that offers pulsatile flow without the need for 
extracorporeal circulation [26]. The OPCABG procedure has been associated with improved 
renal and pulmonary outcomes, shorter lengths of hospitalization and a reduction in 
myocardial injury compared with ONCABG [27–30]. However, few studies have investigated 
the microcirculatory advantages associated with OPCABG. De Backer et al. [1] revealed that 
OPCABG is also associated with a decrease in microcirculatory perfusion. Atasever et al. [31] 
revealed that on-pump and off-pump cardiac surgeries have different detrimental effects 
on the sublingual microcirculation. ONCABG is associated with a reduction in the functional 
capillary density and an increase in the venular blood velocity in the microcirculation induced 
by hemodilution. In contrast, cardiac positioning during OPCABG while not affecting the 
capillary density causes marked reduction in microcirculatory flow in parallel to the sudden 
decrease in cardiac output resulting from cardiac displacement [31]. These authors also 
reported that off-pump procedures are associated with severe but distinct alterations in 
microcirculatory function that are mediated by different mechanisms compared with on-
pump surgery. A recent study by Bienz et al. [26] found that OPCABG does not preserve 
postoperative microcirculatory parameters better than those in ONCABG. These authors only 
found that temperature might have a positive effect on the microcirculation [26].
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Figure 2: Conceptual framework of functional microcirculatory hemodynamics. The relation between fluid volume 
administration on the x-axis and the chances of developing clinical complication on the y-axis. The left side of 
the diagram indicates hypovolemia, where position A defines the condition where clinical indicators of organ 
hypoperfusion coincide with reduced convection indicating the need for fluid administration. Microcirculatory fluid 
responsiveness is indicated by improvement in flow (from A to B). Optimal convection and optimal diffusion define 
the optimal amount of fluid volume administration shown in position B. Indication for diffusive limitation associated 
with loss of red blood cell-filled capillaries associated with longer diffusion distances associated with a reduction in 
functional\ capillary density and signals that too much fluid has been administered.
The debate regarding the use of PP or nonpulsatile perfusion [32*] during ONCABG is ongoing. 
O’Neil et al. found that pulsatile perfusion is superior to nonpulsatile in the preservation of 
the microcirculation because of the attenuation of the inflammatory reaction during CPB 
[22]. Koning et al. observed that while they found no difference in microcirculatory perfused 
vessel density between pulsatile perfusion and nonpulsatile groups during ONCABG, whereas 
microvascular flow was better during pulsatile perfusion than nonpulsatile [33]. In contrast, 
Elbers et al. [34] observed no differences in microvascular perfusion indices between pulsatile 
perfusion and nonpulsatile groups. Grubhofer et al. [35] investigated the effect of pulsatile 
flow during CPB on cerebral microcirculation. These authors also observed no significant 
differences in regional cerebral oxygenation between pulsatile perfusion and nonpulsatile. 
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Forti et al. [36] observed no change in the microvascular response following the reduction 
of CPB flow during nonpulsatile. Voss et al. [37] performed an animal study to investigate 
the effects of physiologic flow, pulse flow and non-pulse flow on renal and intestinal blood 
flow and perfusion during extracorporeal circulation. These authors found no differences 
in microvascular renal or intestinal perfusion between groups, although the pulsatile group 
exhibited higher levels of free haemoglobin and protein leakage [37]. Consequently, there 
is limited evidence that pulsatile perfusion attenuates the deterioration of microvascular 
perfusion in response to CPB. Additionally, nonpulsatile CPB is associated with good results. 
In contrast, there are no studies that have demonstrated worse effects of pulsatile perfusion; 
studies have only reported equivalent or superior effect [32*]. 
 Hemodilution causes a loss of RBC-filled capillaries and results in increased diffusion 
distances between the oxygen-carrying RBCs and tissue cells contributing to tissue hypoxia 
during CPB (Fig. 1). From a microcirculatory perspective, hypovolemia is associated with a 
reduced convective flow and fluid therapy is advised to increase convective flow. However, 
if too much fluids are given then hemodilution causes an emptying of capillaries and 
a problem occurs with the distance that oxygen needs to diffuse to the tissue cells. Thus 
optimal fluid therapy is defined from a microcirculatory perspective as being associated with 
an adequate convective flow of RBCs with a minimum of diffusion distance between the 
oxygen carrying RBC and the respiring tissue cells (Fig. 2) [8**]. Hemodilution occurs because 
of the mixture of circulating blood with 1.5–2.0 l of pump-priming solution, and haematocrit 
values can decrease from 38–40% to 20–28% during CPB [25]. Atasever et al. [38] compared 
RBC transfusions with the use of gelatine solutions in non-resuscitation following cardiac 
surgery in terms of microvascular perfusion, vascular density, haemoglobin, and oxygen 
saturation. These authors found no differences in the changes in O2 systematic delivery, O2 
uptake, or extraction between the groups. However, RBC transfusion increased the perfused 
microcirculatory vessel density, haemoglobin content, and saturation in the microcirculation 
compared with gelatine and a control, whereas the microcirculatory blood flow remained 
unchanged [38]. Yuruk et al. [39] found that RBC transfusion recruits the microcirculation 
and leads to improved perfused vessel density and tissue oxygenation. It is hypothesized in 
these studies that the recruiting of the microcirculation is because of the increase in viscosity 
associated with RBC transfusion increase in haematocrit. 
 Despite the benefit on the microcirculation in terms of increased functional density 
and oxygen transport to tissue, there is controversy surrounding the effects of blood 
transfusion on patient outcome. There are studies showing adverse effects [40] as well as 
positive effects [41] of blood transfusion on patient outcome. On the other hand, anemia 
caused by hemodilution during cardiac surgery has also been shown to have adverse effects 
on outcome, especially with regard to renal function [42]. Choosing between tolerating 
hemodilutionally induced anemia or administering blood transfusions remains a dilemma 
in the perioperative management of cardiac surgery [43]. Various reasons underlie the 
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uncertainty and contradictions in the literature concerning the use of blood transfusion to 
treat anemia during surgery and intensive care. These include the questionable use of the 
randomized controlled trial to elucidate the effects of blood transfusion [44]. In addition, 
there is a large diversity in the quality of blood used in the various studies in terms of 
leucodepletion, age, and storage solutions used. To this background, a re-evaluation of the 
relative risks of hemodilution versus administering blood is required [45]. Based on the ideas 
expressed in this study targeting the effects of hemodilution versus blood transfusion on the 
microcirculation may provide a more physiological approach for choosing an optimal strategy 
for administration of fluids or blood [8**].
 Hypothermia reduces myocardial and cerebral oxygen consumption, may affect 
microcirculatory perfusion and lead to heterogeneous microcirculatory flow [25]. A number 
of clinical studies have investigated the effects of hypothermia on microcirculatory perfusion. 
An experimental study revealed that compared with normothermia, mild hypothermia (34°C) 
causes reductions in ventricular function, oxygen extraction, and microvascular flow and that 
the microcirculatory values recover with the correction of the temperature [46]. As previously 
mentioned, Bienz et al. found that prolonged exposure to hypothermic temperatures has 
negative effects and that the active warming of patients can elicit positive effects on the 
microcirculation during CPB [26]. 
 Hypotension can occur during CPB because of reductions in blood volume, systemic 
inflammatory reactions, hemodilution-associated reduction in viscosity and increases in 
vascular capacitance with rewarming [25]. Hypovolemia and/or systemic hypotension affects 
microcirculatory perfusion [8**]. In healthy volunteers, controlled hypovolemia was found 
to decrease the perfused vessel density, the microcirculatory flow index, and the tissue 
oxygenation [47]. Volume therapies, including passive leg raising and fluid challenge using 
crystalloids or colloids, improve cardiac output. Additionally, appropriate fluid therapy is the 
most important hemodynamic intervention in the postoperative period. Although saline 
(0.9% NaCl) has been criticized widely a fluid of choice in perioperative use it remains by far 
the most commonly used fluid for resuscitation [48]. Saline causes, however, hyperchloremic 
acidosis because of the high concentration of chloride [49]. Hyperchloremia has been shown 
to cause various adverse effects, including afferent renal arterial vasoconstriction, in animal 
models and in volunteers, and these effects have been associated with kidney dysfunction 
in perioperative and intensive care [49]. Low-chloride fluids such as present in balanced salt 
solution have been shown to be associated with less acute kidney injury [50]. In addition to 
debate about the composition of crystalloid solutions there is also much controversy about 
the use of colloids for volume expansion in states of hypovolemia. 
 Colloids elicit three to four-fold greater expansions of plasma volume compared 
with crystalloids, when volume expansion is indicated because of hypovolemia [51,52]. 
The Colloids versus Crystalloids for the Resuscitation of the Critically Ill (CRISTAL) [53] trial 
investigated the effects of colloids and crystalloids when volume expansion is required 
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because of hypovolemia associated with severe sepsis. The trial showed that although there 
was no difference in 28-day mortality, the 90-day mortality was lower among the patients 
in the colloid group where about 70% of the used colloids were starches. Additionally, the 
renal replacement therapy risk purported to be associated with starches did not increase in 
the colloid group [53]. The Crystalloid versus Hydroxyethyl Starch (HES) Trial (CHEST) [54] 
compared the use of 6% hydroxyethyl starch (130/0.4) to saline in ICU patients. The CHEST 
trial did not show a significant difference in 90-day mortality between the HES and saline 
group. Although it was not an end point of the study, the use of HES was associated with a 
slight increase in the rate of renal replacement therapy in a subset of the initially included 
patient group although the vasopressor requirements were lower among the patients with 
HES in the CHEST trial [54]. Even though starches have come into disrepute based on two 
large randomized control trials (i.e., the CHEST and 6S trial)) it must be noted that the 
patients in these trials were not truly hypovolemic in need of colloids, unlike the CRISTAL 
trial, where patients were truly hypovolemic and in need of volume expansion, the rationale 
for using colloid solutions. This is probably the reason why there was a clinical benefit for 
administrating colloids in these patients. In a microcirculation trial with septic shock patients, 
Dubin et al. compared 6% HES 130/0.4 to a saline solution for resuscitation targeting an 
improvement in mean arterial pressure. These authors found that fluid resuscitation 
with 6% HES 130/0.4 required lower volumes to normalize blood pressure and sublingual 
microcirculation with a higher capillary density being recruited and more flow achieved with 
less volume than resuscitation with saline solution [10]. For cardiac surgery patients, the 
opinions are divided too, with those against the use of starches [55] and studies showing 
there to be no deleterious effects with the use of starches in comparison to other fluids 
[56]. Indeed studies have indicated that of the colloids not only starches but also gelatins 
[57] and even albumin administration can have adverse effects on renal function [58]. An 
important point to consider when comparing studies, however, is that many studies do not 
use hemodynamic endpoints for the administration of their fluids [59]. Indeed the recent 
0.9% saline vs. Plasma-Lyte 148 for Intensive Care Fluid Therapy (SPLIT) trial comparing saline 
to a Ringer acetate-based balanced salt solution administered in a blinded manner found 
no difference between the two solutions in a large randomized controlled trial emphasizing 
the point that similar hemodynamic end points need to be targeted to allow comparisons 
between solutions and that blinding their administration is possibly not an effective design 
to investigate their effects [60]. Studies which have used hemodynamic endpoints, however, 
have also shown conflicting results, with a study targeting arterial and venous pressures 
showing starches to have deleterious effects on renal function [57] in contrast to a study by 
Magder and co-workers [61] targeting cardiac output for delivering starches showing no such 
deleterious effects and an improvement in the hemodynamic status of the patient. Taking 
these findings into consideration, it could well be that what is missing is the identification of 
a suitable physiological-based hemodynamic end point for optimizing fluid administrations 
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since studies have shown that targeting different hemodynamic endpoints require different 
volumes of fluid [62]. These considerations emphasize the need to have a clear rationale 
for choosing a type of solution based on the hemodynamic status of the patient where the 
identification of hypovolemia is a key. Visualization of the microcirculation, where capillary 
density (diffusion) and capillary flow (convection) can be measured, forms an important 
physiological measurement to establish the filling status of the patient [8**]. 
 Vasopressor agents can also be used to increase systemic perfusion pressure, and 
thereby, augment oxygen delivery to the tissues [63]. However, vasopressors can cause 
severe vasoconstriction at the microcirculatory level [64]. Therefore, the benefits of 
vasopressors depend on the coherence between the macro and microcirculation [64]. 
Jhanji et al. [65] investigated the macro and microcirculatory effects of norepinephrine 
on septic shock patients with different mean arterial pressures [mean arterial pressures 
(MAPs); from 60mmHg to 90mmHg]. These authors found that norepinephrine increased 
systemic oxygen delivery and cutaneous perfusion without changes in the pre-existent 
sublingual microcirculatory alterations. These authors did not observe any alterations in the 
microvascular density or flow parameters and concluded that high MAPs improved the global 
hemodynamics and the tissue oxygenation without worsening the microcirculation [65]. 
Nevertheless, a more careful analysis revealed that the microcirculatory parameters were 
reduced by approximately 10%, when the MAP increased from 70mmHg to 90mmHg. Dubin 
et al. [66] found that increasing the MAP from 65 to 85mmHg using norepinephrine resulted 
in reduced perfused capillary density in septic shock patients and concluded that the effects 
were highly variable but strongly dependent on the basal microcirculation. When the basal 
microcirculation was normal or high at a MAP of 65mmHg, increases in the MAP worsened 
the perfused capillary density because of vasoconstriction. In contrast, if hypotension was 
accompanied by a low-baseline microcirculatory then increasing MAP using epinephrine 
promoted microcirculatory flow properties [66]. Hypertension can also occur during cardiac 
surgery. Elbers et al. [67] investigated the effects of ketanserin, which is a serotonin and α-1 
adrenoreceptor antagonist, for the treatment of high blood pressure after extracorporeal 
circulation following CPB. These authors demonstrated clear incoherence between the macro 
and microcirculation following the administration of ketanserin for high blood pressure. 
Ketanserin effectively reduced the arterial blood pressure; however, the capillary perfusion 
was maintained at a normal value. These findings may be attributable to increased shunting 
between the macrovascular and microvascular systems [67]. Hypertension during cardiac 
surgery was also demonstrated by Atasever and co-workers who investigated the effects of 
nitroglycerine therapy to treat hypertension during cardiac surgery. By keeping the hand-held 
microscope sublingually in one and the same place during nitroglycerine therapy they were 
able to demonstrate that initially nitroglycerine caused a vasodilation in the venules resulting 
in increased microcirculatory flow. But then as blood pressure was lowered in response to 
nitroglycerine this changed into a lowering of microcirculatory flow [54]. 
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 Hyperoxia and cardiac arrest may affect microcirculation during CPB. Several studies 
have demonstrated that hyperoxemia may have deleterious effects that include a decrease 
in microvascular functional capillary density [68,69]. Cardiopulmonary arrest is considered 
to be a short period of myocardial ischemia and may cause microcirculatory deterioration. 
However, there are no studies of the microcirculatory alterations that occur during 
intraoperative cardioplegia-induced arrest [25]. Nevertheless, Elbers et al. [70] demonstrated 
that circulatory arrest in humans induces an immediate and complete shutdown of the small 
sublingual microvessels, whereas the flow in the larger microvessels persists.
CONCLUSION
Cardiac surgery is associated with a wide range of microvascular derangements and reduced 
tissue oxygenation that depend on anesthesia, hypothermia, hemodilution, and surgical 
technique. Although systemic hemodynamic variables can be monitored and successfully 
corrected, impairments of the microcirculation and tissue hypoxia are still present during the 
perioperative period. 
 Cardiac surgery without extracorporeal circulation (i.e., OPCABG) affects the 
microcirculation to a lesser extent than ONCABG because the blood is not exposed to artificial 
circulation. In contrast, changes in cardiac output and blood pressure may induce acute, 
transient microcirculatory alterations during OPCABG. ONCABG with pulsatile flow may elicit 
improved microcirculatory parameters and better patient outcomes than nonpulsatile flow. 
 Appropriate fluid therapy is the most important hemodynamic intervention 
during cardiac surgery. The main goals of ideal fluid therapy are not only to maintain 
systemic circulation but also to restore microcirculation and tissue perfusion. Despite the 
achievement of macrohemodynamic goals, the microcirculation may remain damaged and 
dysfunctional. Observations of the microcirculation in the perioperative setting may enable 
a physiologically based approach to fluid therapy by potentially preventing the unnecessary 
and inappropriate administration of large volumes of fluids. Furthermore, colloids may 
provide better volume expansion and microcirculatory improvement than crystalloids, and 
blood transfusion may improve microcirculatory parameters. Hand-held video microscopy 
can enable the visualization of sublingual microcirculatory alterations that can be used for the 
functional assessment of the hemodynamic state of the microcirculation. A new-generation 
microcirculation monitoring device, the CytoCam IDF, has a high-resolution imaging sensor 
that shows approximately 30% more capillaries than the previous generation of devices. 
 Visualization of the microcirculation may provide the clinician with the physiological 
feedback required for the early diagnosis and treatment of microcirculatory alterations during 
cardiac surgery. The observation of heterogenous flow patterns in the microcirculation signals 
the presence of shunts and manifesting itself clinically as a reduction in oxygen extraction [7]. 
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Establishing hemodynamic coherence between the macro and microcirculation and targeting 
the normalization of microcirculatory function can be considered as an important goal in the 
hemodynamic management of the cardiac surgical patient.
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ABSTRACT
Background: 
Veno-arterial extracorporeal membrane oxygenation (VA-ECMO) is an effective technique for 
providing emergency mechanical circulatory support for patients with cardiogenic shock. VA-
ECMO enables a rapid restoration of global systemic organ perfusion, but it has not been found 
to always show a parallel improvement in the microcirculation. We hypothesized in this study 
that the response of the microcirculation to the initiation of VA-ECMO might identify patients 
with increased chances of intensive care unit (ICU) survival. Methods: Twenty-four patients 
were included in this study. Sublingual microcirculation measurements were performed using 
the CytoCam-IDF (incident dark field) imaging device. Microcirculatory measurements were 
performed at baseline, after VA-ECMO insertion (T1), 48–72 h after initiation of VA-ECMO 
(T2), 5–6 days after (T3), 9–10 days after (T4), and within 24 h of VA-ECMO removal.
Results: 
Of the 24 patients included in the study population, 15 survived and 9 died while on VA-
ECMO. There was no significant difference between the systemic global hemodynamic 
variables at initiation of VA-ECMO between the survivors and non-survivors. There was, 
however, a significant difference in the microcirculatory parameters of both small and large 
vessels at all time points between the survivors and non-survivors. Perfused vessel density 
(PVD) at baseline (survivor versus non-survivor, 19.21 versus 13.78 mm/mm2, p = 0.001) was 
able to predict ICU survival on initiation of VA-ECMO; the area under the receiver operating 
characteristic curve (ROC) was 0.908 (95 % confidence interval 0.772–1.0).
Conclusion: 
PVD of the sublingual microcirculation at initiation of VA-ECMO can be used to predict ICU 
mortality in patients with cardiogenic shock.
Keywords: 
Microcirculation, VA-ECMO, Cardiogenic shock, Survival, ICU
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BACKGROUND
Cardiogenic shock (CS) has a high mortality rate and is defined as a state of tissue hypoperfusion 
induced by cardiac failure [1, 2]. Many conditions, such as acute myocardial infarction [3], end-
stage dilated cardiomyopathy [4], myocarditis [5], complications following cardiac surgery [6], 
and cardiac arrest [7], can cause CS. Veno-arterial extracorporeal membrane oxygenation (VA-
ECMO) is an effective, portable, and rapidly deployable technique for providing emergency 
mechanical circulatory support for patients in CS [8–10], and it successfully reduces the 
time required for cardiac recovery [11]. Following this bridge therapy, some patients require 
implantation of a left ventricular-assist device (LVAD) or heart transplantation for adequate 
recovery and survival. Being able to identify hemodynamic variables related to survival could 
provide an important therapeutic window for optimizing VA-ECMO support. Until recently, 
lactate values have been suggested to predict outcomes of adult and pediatric patients on 
VA-ECMO [12–14]. However, these are downstream parameters and do not provide a direct 
hemodynamic endpoint.  
 Evaluation of systemic hemodynamic parameters, such as blood pressure, cardiac 
output, and mixed venous saturation, assist in diagnosing CS. VA-ECMO can quickly restore 
global hemodynamics. However, there is no guarantee that restoring these systemic 
hemodynamic variables will also improve microcirculatory and tissue perfusion, which 
is considered the ultimate success of resuscitation. Many studies have demonstrated 
that altered microcirculatory functional parameters can be a good predictor of mortality, 
despite normalized systemic hemodynamic variables [15–18]. The use of an intra-aortic 
balloon pump (IABP) did not affect the microcirculation parameters in these patients with 
or without VA-ECMO while restoring the macrocirculation [19, 20]. However, to date, no 
study has evaluated the sublingual microcirculatory response of patients with CS on VA-
ECMO in relation to intensive care unit (ICU) outcomes after VA-ECMO. In this study, we 
tested the hypothesis that assessment of the microcirculation at initiation of VA-ECMO may 
identify patients with increased chances of ICU survival. To test this hypothesis we measured 
sublingual microcirculation in CS patients eligible for VA-ECMO therapy using hand-held 
microscopy.
METHODS 
Study setting and population
This study was conducted between September 2014 and October 2015 at the ICU of the 
Erasmus Medical Center Rotterdam, The Netherlands. All consecutive patients requiring VA-
ECMO for CS were included in the study with the exception of two patients who died within 24 
h for whom it was not possible to measure microcirculation due to continuous resuscitation 
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in an overcrowded ICU box and for four patients who did not consent to inclusion in the 
study. Survival was defined as discharge from the ICU without a need for re-admission or re-
implantation of the VA-ECMO after explantation. Additionally, bridged patients with durable 
LVADs or cardiac transplantations were documented as survivors. Non-survivors were those 
who died in the ICU during VA-ECMO support or within a couple of hours of explantation of 
VA-ECMO. 
 The following data were recorded at ICU admission: age, gender, body mass index, 
Sequential Organ Failure Assessment (SOFA) score [21], Acute Physiology and Chronic Health 
Evaluation (APACHE) II score, indications for VA-ECMO, heart rate, mean arterial pressure, 
lactate, hemoglobin (Hb), hematocrit (Htc), platelet count, lactate dehydrogenase (LDH), free 
hemoglobin (free-Hb), N-terminal of the prohormone brain natriuretic peptide (NT-proBNP), 
high sensitive troponin T (HsTnT), creatine kinase (CK), MB fraction of creatine kinase (CK-
MB), and echocardiographic parameters. 
VA-ECMO circuit and placement, and patient management under VA-ECMO  
VA-ECMO consisted of polyvinyl chloride tubing, a membrane oxygenator (Quadrox Bioline; 
Jostra-Maquet, Orleans, France), a centrifugal pump (Rotaflow; Jostra-Maquet), and either 
percutaneous arterial and venous femoral, or central right atrial and aortic cannulae 
(Biomedicus Carmeda; Medtronic, Boulogne-Billancourt, France). An oxygen-air blender 
(Sechrist Industries, Anaheim, CA, USA) ventilated the membrane oxygenator. Because of 
the percutaneous femoral VA-ECMO, an additional 7-F cannula was inserted distally into the 
femoral artery to prevent severe leg ischemia. Patients were kept on VA-ECMO for at least 
48 h. The circuit was checked daily for significant fibrin deposition or clots accumulated on 
the membrane during hemolysis, thrombocythemia, or a sharp and systematic decline after 
blood oxygenation by experienced perfusionists and changed according to protocol.
Microcirculatory measurements 
Microcirculation measurements were performed using a CytoCam imaging device (CytoCam; 
Braedius Medical, Huizen, The Netherlands), which is a third-generation hand-held 
microscope [22]. The CytoCam device has a computer-controlled, high-resolution image 
sensor. Additionally, a CytoCam-IDF (incident dark field) device has a specifically designed 
microscopic lens that produces high-resolution images, showing approximately 30 % more 
capillaries than previous-generation devices [22–24]. The newly introduced lightweight 
(140 g versus previous devices weighing approximately 450 g) Cytocam-IDF device (with 
improved optics, a computer-controlled image sensor and illumination, and a more precise 
focusing mechanism) used in the present study allows for a faster and more stable and 
precise measurement to be made. In addition to these improvements, the device also has 
a faster measurement acquisition time, requiring only 3 to 5 s to assess the quality of the 
microcirculation. The sufficiency of this time was agreed upon in the second consensus 
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conference held recently in November 2015 in Amsterdam and in March 2016 in Brussels, 
where most of the practitioners used the new Cytocam-IDF technology evaluated in the 
present study. Without applying pressure, the tip of the light guide is gently placed on 
the mucosal surface of the sublingual area. A 3- to 5-s video recording of predefined (left, 
right, and midline sublingual cavity) sites was obtained in each patient. Recordings were 
then blinded and analyzed to obtain the following microcirculatory parameters: total vessel 
density (TVD; mm/mm2), perfused vessel density (PVD; mm/mm2), proportion of perfused 
vessels (PPV; %), and microvascular flow index (MFI; arbitrary units (AU); a semiquantitative 
measure of microcirculatory flow [25]). Microcirculatory measurements were repeated 
at the following time points: baseline, after VA-ECMO insertion within 24 h (T1), 2–3 days 
after initiation of VA-ECMO (T2), 5–6 days after initiation of VA-ECMO (T3), 9–10 days after 
initiation of VA ECMO (T4), and within 24 h of explantation of VAECMO. The timing between 
VA-ECMO insertion and the first microcirculatory and echocardiography measurements are 
shown in Table 1. The first echocardiography measurement was performed after a median 
of 9 (range 1–23) h and the microcirculatory measurement was performed after a median 
of 15 (range 1–22) h. Image clips were included which confirmed a quality score defined by 
Massey et al. [26]. Thus, 154 clips of 335 were excluded, and 181 clips were analyzed. Details 
of the excluded and included clips and the number of patients at each time point are shown 
in Additional file 1: Table S5. The most important reason for the poor quality of the clips was 
patient-related clinical conditions (such as bleedings, saliva, difficulty opening the mouth, 
difficulty inserting the device appropriately due to an endotracheal or gastric tube, and the 
lack of patient cooperation), especially in explanted patients. In addition, device-related 
conditions such as difficulties with focusing, brightness, and pressure artefacts resulted in 
poor-quality clips. Image clips were randomized and blinded to the three investigators (AK, 
SA, WdW) who performed the analysis using software to calculate the various functional 
microcirculatory parameters [27]. Microcirculatory parameters were divided into two 
categories: small vessels, defined as having a diameter of 25 μm or less (for example, TVD 
small vessel, PVD small vessel); and all vessels, defined as having small vessels and large 
vessels (>25–100 μm diameter; TVD all vessel, PVD all vessel) according to the consensus on 
microcirculatory assessment by De Backer et al. [25]. 
Statistical analyses
Categorical variables are presented as frequencies and percentages. Continuous variables 
are presented as medians and range. Continuous variables were compared using a Mann–
Whitney U test. For comparisons of microcirculatory parameters of patients in the same 
group at consecutive time points, a Friedman test was used. Baseline PVDs of all vessels, 
lactate HsTnT, and left ventricular ejection fraction (LVEF) were assessed as prognostic tests 
of survival using receiver operating characteristic curves (ROC) and their corresponding 
area under the curve. Cut-off points were calculated by obtaining the best Youden index 
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(sensitivity + specificity – 1). Sensitivity, specificity, and positive and negative predictive values 
were calculated and compared to each other. With the cut-off values, an association between 
microcirculatory impairment and survival was explored. Statistical significance was defined as 
p < 0.05. Statistical analyses were performed using SPSS version 21.0.0.1 (SPSS, IBM, Armonk, 
NY, USA). 
RESULTS
Thirty consecutive patients requiring VA-ECMO for CS were recruited to the study. Six 
patients were excluded: two patients who died within 24 h for whom it was not possible to 
measure microcirculation due to continuous resuscitation in an overcrowded ICU box, and 
four patients who did not consent to inclusion in the study. In total, 24 patients were included 
in the study. 
 Of the 24 patients who comprised the study population, 15 survived and 9 died on VA-
ECMO. Eight patients were also inserted with an IABP in addition to VA-ECMO (two patients 
in the survival group (IABP was placed before ECMO), and six patients in the non-survival 
group received IABP (4 patients before ECMO and 2 patients during ECMO support)). The 
baseline characteristics, baseline global hemodynamics, and microcirculatory parameters are 
shown in Table 1. The median ages of the patients in the survivor and non-survivor groups 
were 51 (range 23–70) and 51 (20–67), respectively. The number of males was higher in 
the survivor group (n = 12; 80 %) compared to the non-survivor group (n = 4; 44 %). The 
APACHE II scores (31 (19–45) and 34 (29–44), respectively), SOFA scores (10 (4–20) and 12 
(2–15), respectively), and systemic hemodynamics were not significantly different between 
the groups. The use of vasopressors and inotropic drug doses and blood transfusions did not 
statistically differ between groups on the first day of VA-ECMO or during VA-ECMO (Additional 
file 2: Table S6). Systemic hemodynamic variables, such as the lactate and hemoglobin values 
at the microcirculatory measurement time points, did not differ between survivors and non-
survivors (Additional file 2: Table S6 and Additional file 3: cardiac output ROC, curve 5). While 
the cardiac output at baseline was statistically significantly different between the groups, the 
predictive value for ICU survival is less significant than the PVD measured sublingually. The 
cardiac function assessed by echocardiography was comparable between the groups, except 
for the LVEF 20 (8–55) and 10 (7–20); p = 0.010). The heart function biomarkers also showed 
no differences between the survivors and non-survivors. However, the baseline troponin 
levels at the initiation of VA-ECMO (1683 (45–42,813) ng/L and 13,369 (215–89,641) ng/L; 
p = 0.030) were significantly higher in the non-survivors. The ICU and hospital durations of 
stay were significantly different between the groups (18 (6–65) and 5 (2–36); and 22 (6–72) 
and 5 (2–36) days for survivors and non-survivors, respectively). The total number of days on 
VA-ECMO was similar for the survivor and non-survivor groups. 
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As shown in Fig. 1, the microcirculatory parameters at the initiation of VA-ECMO were 
significantly lower in the patients who subsequently did not survive compared to those who 
survived. The comparisons of measured microcirculatory parameters are shown for all time 
points in Additional file 4: Table S2. The microcirculatory parameters at T1 (i.e., the TVD, PVD, 
and PPV values) were significantly different between the survivor and non-survivor groups 
(all vessels p = 0.008, p = 0.001, and p = 0.044, respectively; small vessels p = 0.009, p = 
0.003, and p = 0.038, respectively). The microcirculatory values decreased in both groups 3 
days after the initiation of VA-ECMO at T2 in parallel with a reduction in arterial Hb, which 
is associated with hemodilution. Although the microcirculatory parameters of the non-
survivor group somewhat recovered at day 6 (T3), they remained significantly lower than 
those in the survivor group (Fig. 2; Additional file 5: Table S3). All the non-survivors passed 
away while on VA-ECMO, whereas additional microcirculation was observed in the survivors 
following weaning from VA-ECMO. The microcirculatory parameters of the survivors then 
became slightly lower upon removal of VA-ECMO compared to their values while still on VA-
ECMO (Fig. 2). Notably, the microcirculatory parameter values did not significantly change in 
time when on VA-ECMO. This effect was observed in both the survivors and non-survivors 
(Additional file 5: Table S3) and is shown in Fig. 3, where no difference in the VA-ECMO blood 
flow was observed between the initiation of VA-ECMO and all the other time points between 
the both groups. None of the surviving patients were bridged to a cardiac transplantation or 
LVAD in this period. 
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To compare the sensitivity and specificity of the microcirculatory parameters for PVD in all 
vessels, LVEF, HsTnT, and lactate at the moment of initiation of VA-ECMO and at T1 were 
evaluated with ROC curve analysis to differentiate these values between the survivors and 
non-survivors (Fig. 4). The areas under the ROC curves (and the 95 % confidence interval) 
were 0.908 (0.772–1.0), 0.847 (0.672–1.0), 0.755 (0.524–0.986), and 0.556 (0.300–0.813) 
in the survivors and non-survivors, respectively. According to the ROC curve analysis, the 
threshold value of PVD for all the vessels was 15.2 (mm/mm2) and was found to predict 
ICU survival (sensitivity 88.9 %, specificity 86.7 %, positive predictive value 80 %, negative 
predictive value 92.9 %, and Youden index 0.75; Additional file 6: Table S4, Additional file 7, 
Additional file 8).
DISCUSSION
This prospective, observational, single-center study on patients with cardiogenic shock 
requiring VA-ECMO circulatory support showed that ICU survival could be predicted by 
observation of poor microcirculatory function at the initiation of VA-ECMO. Our study 
furthermore showed that VA-ECMO in itself did not change the physiological condition of the 
microcirculation throughout the course of VA-ECMO. These results suggest that assessment 
of sublingual microcirculation at initiation of VA-ECMO can be used to predict survival. While 
most of the differences are observed at baseline, changes over time seem less relevant. This 
seems to reflect more what occurred before, rather than during, ECMO. It also characterizes 
VA-ECMO as a bridge-to-treat procedure not contributing to resolving cardiac dysfunction 
following CS. From these considerations it could be argued that our results lay the foundation 
for introducing new adjunct therapeutic modalities aimed at improving microcirculatory 
function during the course of VA-ECMO, which may improve the chances of successful weaning 
from VAECMO and survival. Finally, our study suggests that microcirculatory monitoring could 
provide an easy tool to help the intensivist make the clinical decision to initiate or escalate 
further treatment options in patients with cardiogenic shock. 
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Figure 1a: Microcirculatory measurements showing the median and interquartile range between the survivors (S) 
and non-survivors (NS) for  all vessels [AU arbitrary units, MFI microvascular flow index, PPV proportion of perfused 
vessels, PVD perfused vessel density, TVD total vessel density]
To date, several studies have evaluated predictors of outcome at the time of VA-ECMO 
initiation for CS. Schmidt et al. [28] described the value of pre-VAECMO implantation factors 
for predicting survival in cardiogenic shock patients receiving VA-ECMO on which they 
formulated a survival after VA-ECMO (SAVE) score. They found that this SAVE score could predict 
survival in these patients. Van Genderen et al.[29] investigated sublingual microcirculatory 
and peripheral tissue perfusion parameters in relation to systemic hemodynamics during 
and after therapeutic hypothermia following out-of-hospital cardiac arrest. They found that 
microcirculatory parameters were significantly lower in non-survivors at hospital admission 
and after rewarming than survivors. Microcirculatory alterations were also associated with 
organ failure and death, independent of changes in systemic hemodynamic parameters [29]. 
Aissaoui et al. [30] investigated predictors of successful VA-ECMO weaning after assistance 
for refractory CS. They described a number of echo criteria predictive for successful weaning. 
However, their study did not describe any predictors for patient survival. In this study, we 
found that baseline perfused vessel density is the best microcirculatory parameter predictive 
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of ICU survival. Observation of low PVD measurements at initiation of VA-ECMO could lead to 
earlier initiation of advanced therapies such as LVAD or heart transplantations. 
Figure 1 b: small vessels at the initiation of the VA-ECMO insertion (T1), 48–72 h after VA-ECMO initiation (T2), and 
5–6 days after VA-ECMO initiation (T3).
Another study we performed in pediatric ECMO patients [31] showed that patients who 
responded to ECMO with improved microcirculation went on to survive, whereas those that 
did not failed to survive. A surrogate biomarker for left ventricular function was measured 
in our study. HsTnT was also found to be a good predictor for survival in the ROC analysis 
we performed. The study by Luyt et al. [32] assessed the predicative value of biomarkers for 
the prediction of cardiac recovery in patients on VA-ECMO who had not been investigated 
for HsTnT. However, their study investigated troponin Ic, which may have been the reason 
why they had found no relationship between cardiac biomarkers and cardiac recovery in VA-
ECMO. Apart from HsTnT, LVEF was found to be the second best predictor for survival in 
the ROC analysis we performed. However, after initiating VA-ECMO, the heart is artificially 
bypassed and the cardiac output and ejection fraction are influenced by VA-ECMO. Thus, 
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the echocardiography is affected by several factors such as aortic valve regurgitation, the 
aortic valve opening ratio, afterload change, and the VA-ECMO flow. In addition, transthoracic 
echocardiography is poor in quality, and transesophageal echocardiography is a less reliable 
ejection fraction measurement during VA-ECMO, which affects the measurement of the 
LVEF. However, even though the above parameters were related to the outcome to various 
degrees, our ROC analysis identified microcirculatory alterations measured on day 1 as having 
the highest specificity and sensitivity of all parameters measured for predicting mortality in 
the ICU. 
Figure 2: Example of change in the perfused vessel density (PVD) parameters in the survivor (S) and non-survivor 
(NS) groups at the following time points: initiation of the VA-ECMO insertion (T1), 48–72 h after VA-ECMO initiation 
(T2), 5–6 days after VA-ECMO initiation (T3), and after VA-ECMO explantation (Texp). The medians are depicted.
In our observational study, volume status was mainly assessed by echocardiography and 
general hemodynamic parameters, such as the central venous pressure (CVP). We found 
no statistical significance between the two groups regarding the associations between fluid 
balance and CVP in the first 24 h and the outcome. It is worth pointing out, however, that 
even though the assessment of volume in non-VA-ECMO critically ill patients has extensively 
been studied and included in guidelines, accurate assessments of volume status in patients 
on ECMO with altered circulatory conditions (e.g., the presence of extracorporeal circulation 
and bypassing different parts of the endogenous circulation) is a subject in need of further 
investigation. 
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Figure 3: VA-ECMO blood flow showing the median and interquartile range between the survivors (S) and non-
survivors (NS) at the initiation of the VA-ECMO insertion (T1), 48–72 h after VA-ECMO initiation (T2), and 5–6 days 
after VA-ECMO initiation (T3). ECMO extracorporeal membrane oxygenation
Our findings highlight the fact that ECMO is not a therapy that improves patient outcomes 
but rather it is a bridge to treatment. Our findings therefore identify a mean of 5 days as 
a window for treatment. It also means that additional therapeutic modalities targeting the 
microcirculation need to be developed for inclusion in the ECMO procedure, which may then 
elevate ECMO from the therapeutic modality status as a bridge to a treatment. 
 In the course of VA-ECMO, systemic perfusion is switched to an extracorporeal 
circulation, the blood is exposed to non-biocompatible polymers that can activate blood cells 
and the coagulation system, and it changes from a pulsatile to a non-pulsatile flow [33, 34]. 
While IABP may provide a pulsatile flow, many studies have shown that this was of no benefit 
to the microcirculation [20, 35, 36]. All of these factors might have detrimental effects on 
the microcirculation and may explain why the microcirculatory parameters decreased from 
T1 to T2 in both groups. At the same time, even though the VA-ECMO flows were similar in 
both groups, microcirculatory parameters were absolutely different at all time points. This 
means that there was no hemodynamic coherence between macrohemodynamics and the 
microcirculation and that microcirculatory alterations manifest themselves independently of 
systemic hemodynamics [37]. Furthermore, differences in microcirculatory measurements 
between the groups were observed at all time points, while persistent microcirculatory 
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derangement was observed in the non-survivor group. In addition, our study showed that 
microcirculation remains high after VA-ECMO explantation in the survivor group. 
Figure 4: Receiver operating characteristics (ROC) curves showing the relationship between sensitivity and 1 – 
specificity in determining the perfused vessel density (PVD) all vessels, high sensitive troponin T (HsTnT), lactate, and 
left ventricular ejection fraction (LVEF) to predict ICU survival
Our study, however, has some limitations. First, it was single-center study and concerned 
a relatively small number of patients. However, to the best of our knowledge, this is the 
largest series of patients investigated on this topic to date. Second, we included patients who 
presented with different kinds of VA-ECMO cardiac injury. Therefore, these patients may have 
had different microcirculation properties prior to presentation. Another limitation was the 
exclusion of patients dying within 24 h. Fourth, apart from global hemodynamics, VA-ECMO 
can adversely affect the microcirculation for many reasons such as hemodilution, hemolysis, 
coagulopathy, non-pulsatile flow, and hypothermia [38]. T1 measurements were performed 
within 24 h after the initiation of VA-ECMO, which can be considered a long time period.
 The last, but still controversial, limitation is the length of recording sequences used in 
our study. The use of a new generation hand-held microscopy device may have advantages, 
but also may have disadvantages. The advantage of the Cytocam IDF camera used in this 
study is that images are able to observe more capillaries (30 %) than the previous-generation 
sidestream dark field (SDF) cameras due to improved optics [22, 24]. In combination with 
a larger field of view (1.55 × 1.16 mm = about three times larger than the field of view of 
previous devices) of the new generation camera, it could be argued that this camera provides 
more accurate information concerning microcirculation alterations then previous-generation 
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SDF camera. On the other hand, default Cytocam measurements take between 3- and 5-s 
recordings which have been found to be of sufficient length in a large number of recent 
studies [22, 39–42]. A recent review on microcirculation measurements by Massey and 
Shapiro [43] also recommended that lengths of between 3 and 5 s are sufficient. However, 
this length may be considered too short when comparing it to video sequences of 20 s 
recommended for SDF devices in the consensus of 2006 [25], although this recommendation 
was based on opinion and has never been validated in the literature. Even for SDF images, it 
has suggested in a recent experimental study by Kildal et al. [44] in pigs that measurements 
up to 10 min provide extra information. The only way to establish the sufficient length of the 
video sequences is to demonstrate statistical significance between the groups, which we did 
for this study. Whether such a length is sufficient for other applications, however, has to be 
investigated.
CONCLUSION
In our study, altered baseline perfused sublingual microcirculatory vessel density was found 
to be related to ICU survival in cardiogenic shock patients treated with VAECMO. To our 
knowledge, this is the first study to describe such an application in this group of patients. We 
conclude that monitoring sublingual microcirculation could be used for earlier identification 
of patients who will survive, as well as for exploring the usefulness of earlier consideration 
of the utilization of advanced therapies. Our expectation is that such assessment may be of 
value in the early identification of patients at a high risk of death, or those with poor recovery, 
and to potentially develop microcirculatory-targeted recovery strategies. Further studies with 
a larger number of patients and the same etiology of CS are needed.
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ABSTRACT
Background: 
Veno-arterial extracorporeal membrane oxygenation (VA-ECMO) is increasingly adopted for 
the treatment of cardiogenic shock (CS). However, a marker of successful weaning remains 
largely unknown. Our hypothesis was that successful weaning is associated with sustained 
microcirculatory function during ECMO flow reduction. Therefore, we sought to test the 
usefulness of microcirculatory imaging in the same sublingual spot, using incident dark field 
(IDF) imaging in assessing successful weaning from VA-ECMO and compare IDF imaging with 
echocardiographic parameters.
Methods: 
Weaning was performed by decreasing the VA-ECMO flow to 50% (F50) from the baseline. The 
endpoint of the study was successful VA-ECMO explantation within 48 hours after weaning. The 
response of sublingual microcirculation to a weaning attempt (WA) was evaluated. Microcirculation 
was measured in one sublingual area (single spot (ss)) using CytoCam IDF imaging during WA. 
Total vessel density (TVDss) and perfused vessel density (PVDss) of the sublingual area were 
evaluated before and during 50% flow reduction (TVDssF50, PVDssF50) after a WA and compared 
to conventional echocardiographic parameters as indicators of the success or failure of the WA.
Results: 
Patients (n = 13) aged 49 ± 18 years, who received VA-ECMO for the treatment of refractory 
CS due to pulmonary embolism (n = 5), post cardiotomy (n = 3), acute coronary syndrome (n 
= 2), myocarditis (n = 2) and drug intoxication (n = 1), were included. TVDssF50 (21.9 vs 12.9 
mm/mm2, p = 0.001), PVDssF50 (19.7 vs 12.4 mm/mm2,p = 0.01) and aortic velocity–time 
integral (VTI) at 50% flow reduction (VTIF50) were higher in patients successfully weaned 
vs not successfully weaned. The area under the curve (AUC) was 0.99 vs 0.93 vs 0.85 for 
TVDssF50 (small vessels) >12.2 mm/mm2, left ventricular ejection fraction (LVEF) >15% and 
aortic VTI >11 cm. Likewise, the AUC was 0.91 vs 0.93 vs 0.85 for the PVDssF50 (all vessels) 
>14.8 mm/mm2, LVEF >15% and aortic VTI >11 cm.
Conclusion: 
This study identified sublingual microcirculation as a novel potential marker for identifying 
successful weaning from VA-ECMO. Sustained values of TVDssF50 and PVDssF50 were found 
to be specific and sensitive indicators of successful weaning from VA-ECMO as compared to 
echocardiographic parameters.
Keywords: Cardiogenic shock, VA-ECMO, Microcirculation, Incident dark field imaging, 
Sublingual, CytoCam, Weaning, Cardiac recovery
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BACKGROUND
Cardiogenic shock (CS) associated with cardiac pump failure results in a state of inadequate 
tissue perfusion, which leads to organ failure with a mortality rate between 50 and 80% [1]. 
Veno-arterial extracorporeal membrane oxygenation (VA-ECMO) is considered a lifesaving 
treatment that is increasingly used for the treatment of critically ill patients that have 
experienced CS [2–4]. However, mortality rates remain high, with  reports of up to 44% 
mortality despite the use of VA-ECMO [1, 5].
 Current strategies for weaning from VA-ECMO are ongoing, largely unknown and based 
on empirical evidence [6–8]. Most of the current markers of  weaning from VA-ECMO are 
based on echocardiography, such as aortic velocity–time integral (VTI), left ventricular 
ejection fraction (LVEF), and tissue Doppler lateral mitral annulus peak systolic velocity (TDSa) 
[9]. However, performing high-quality echocardiography in critically ill patients requires 
specialized training and is relatively costly [10].
 In a recent study, we found that the initial inability of VA-ECMO to recruit the 
microcirculatory alteration associated with CS predicts adverse outcomes following VA-
ECMO treatment irrespective of improved systemic hemodynamic parameters [11]. This is 
based on the concept that the success of resuscitation from states of circulatory shock is the 
normalization of microcirculatory and tissue perfusion [12, 13].
 It is known that there is possibly a loss of coherence between the systemic and 
microcirculation, which can occur in states of shock and resuscitation [14]. Previous studies 
measuring sublingual microcirculation using hand-held video microscopy have shown 
impairment of sublingual microcirculation to be associated  with  CS [12, 13, 15]. In addition, 
studies have found that sustained microcirculatory perfusion by VA-ECMO as detected by 
handheld video microscopes is associated with lower morbidity and even mortality [12, 14].
 Our hypothesis was that successful weaning is associated with sustained microcirculatory 
function during ECMO  flow reduction. Therefore, we sought to test the usefulness of 
microcirculatory imaging in the same sublingual spot, using incident dark field (IDF) 
imaging in assessing successful weaning from VA-ECMO and to compare IDF imaging with 
echocardiographic parameters [7].
METHODS
Study population
The institutional medical ethics board of the Erasmus Medical Center approved this study 
under protocol number NL45915.078.13, and informed consent was obtained from all patients 
and/or legal representatives. Between October 2014 and January 2016, our prospective 
observational study included all eligible patients under VA-ECMO support admitted to the 
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Intensive Care Unit of our center, a terti ary and nati onal referral center for end-stage heart 
failure, heart transplantati on and left  ventricular assist devices. Inclusion criteria were > 18 
years old and need for VA-ECMO due to any form of refractory cardiogenic shock. Exclusion 
criteria were being moribund and refusal to parti cipate in the study (Fig. 1).
Echocardiography
Acquisiti on
Transthoracic echocardiography (TTE) and/or transesophageal (TEE) echocardiography was 
performed during weaning att empts using the CX50 ultrasound system (Philips Medical 
System, Best, The Netherlands). Pulsed-wave and conti nuous-wave Doppler signals were 
recorded at a sweep speed of 50–100 mm/s. Color Doppler recordings were opti mized for 
display with the color velocity scale at ± 60 (50–70 cm/s) during the enti re study.
Analysis
All echocardiograms were analyzed by two experienced echo cardiologists (OS and SA), in 
accordance with published guidelines [16], using the QLAB quanti fi cati on soft ware (Philips 
Healthcare, Best, The Netherlands). Aorti c VTI was measured by manually tracing the spectral 
envelope of conti nuous-wave Doppler in the apical 5-chamber or 3-chamber view. The LVEF 
was visually esti mated from apical views. The right ventricular functi on was assessed by 
measuring the tricuspid annular planer systolic excursion (TAPSE) from the M-mode images 
in the apical 4-chamber view. Tissue Doppler lateral mitral annulus peak systolic velocity 
(TDSa) was also measured when feasible.
Weaning strategy
Weaning from VA-ECMO was initi ated in pati ents with persistently stable hemodynamics 
(mean arterial pressure > 60 mmHg, lactate < 2 mmol/L and mixed venous saturati on values > 
65%) and with persisti ng arterial pulsati lity wave on the monitor under low doses of inotropic 
support (Fig. 1). Weaning was performed by lowering the blood fl ow to 50% of the baseline 
value under hemodynamic and echocardiographic surveillance. Persisti ng hemodynamic 
stability was defi ned as aorti c VTI > 10 cm and esti mated LVEF > 20–25% [7, 9]. Pati ents who 
recovered from severe cardiac  dysfuncti on and who tolerated the weaning att empt were 
considered for device removal [7].
Microcirculatory imaging
Acquisiti on Sublingual microcirculati on was measured independently of echocardiography 
data during the same weaning att empt, just before or aft er echocardiography, at baseline 
(100%) VA-ECMO fl ow (F100), and aft er reducing VA-ECMO fl ow to 50% of the baseline fl ow 
(F50) and at returning VA-ECMO fl ow to baseline aft er 2 minutes (F100). We performed these 
measurements  just before or aft er the classical weaning att empt using echocardiography. 
These microcirculatory data were not used to drive ECMO management.
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Figure 1: Flow chart for inclusion for weaning att empts and their outcomes (n = 13). VA-ECMO, veno-arterial 
extracorporeal membrane oxygenati on; VTI, velocity − ti me integral; LVEF, left  ventricular ejecti on fracti on; HD, 
Hemodynamic; RVF, Right ventricular functi on
Such a weaning att empt was followed by microcirculatory measurements during a weaning 
att empt,  which took a maximum of 10 minutes in total. All aspects of microcirculatory 
measurements were performed as stable video recordings with a durati on of 3–5 seconds   by 
placing the CytoCam IDF imaging camera (Braedius Medical, Huizen, The Netherlands) [17] 
in the same sublingual area during the enti re procedure, with total vessel density measured 
at a single spot (TVDSS).
 The IDF device consists of a computer-controlled, high-resoluti on image sensor in 
combinati on with a specifi cally designed microscope lens at the end of an image guide, 
covered by a disposable sterile cap. Placing the ti p of the guide to the sublingual ti ssue 
surface provides high-resoluti on images of the  microcirculati on  where red blood cells can 
be clearly visualized fl owing through the microvessels.
 This device is based on IDF imaging technique as described by Sherman et al. [18]. 
Sidestream dark fi eld (SDF) technique opti cally isolates the incoming light from the refl ected 
while IDF illuminates the fi eld in a non-homogeneous fashion according to dark  fi eld.  In 
this CytoCam device, there are prominent technical improvements such as digital signal, 
lower weight, and higher opti cal resoluti ons, compared to previous devices. In Fig. 2 and 
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Additi onal fi le 1: Table S1 we show the visual and characteristi c diff erences between SDF and 
IDF technique as adapted. from van Elteren et al. [19].
 This new iterati on of the device with improved opti cs detects 30% more sublingual 
vessels than the previous generati on microscope [17, 19, 20]. Microcirculatory parameters are 
quanti fi ed by analyzing the movies using specialized image processing soft ware (Automated 
Vascular Analysis (AVA)) [21].
Analysis
Two microcirculati on experts (SA and GG) independently analyzed all microcirculati on 
parameters based on internati onal consensus on the quanti fi cati on of sublingual 
microcirculatory alterati ons [22]. The images were analyzed to determine the functi onal 
parameters of large microvessels (> 25 μm) and small vessels (≤ 25 μm). These parameters 
consisted of the TVD (mm/mm2); perfused vessel density (PVD (mm/mm2)); and proporti on 
of perfused vessels (PPV (%)) in accordance with internati onal consensus guidelines related 
to the quanti fi cati on of such microcirculatory images [22]. Microcirculatory measurements 
were compared with echocardiography parameters (LVEF, aorti c VTI and TDSa, if available) 
and used to evaluate the last weaning procedure as described by Aissaoui et al. [7].
Stati sti cs
Categorical variables are presented as frequencies and percentages. Conti nuous variables 
are presented as the mean ± standard deviati on (SD). Conti nuous variables were compared 
with the Mann-Whitney U test. For comparisons within the same group, the microcirculatory 
parameters of pati ents at diff erent ti me points were analyzed using the Friedman and 
Wilcoxon test. To compare the microcirculatory parameters of pati ents successfully weaned 
(SW) and not successfully weaned (NSW) at diff erent ti me points, the generalized linear 
model repeated measurements test was used. Spearman’s correlati on analysis was used to 
compare the correlati on between echocardiographic and microcirculatory parameters in 
SW and NSW pati ents. Stati sti cal signifi cance was defi ned by a p value <0.05. Analyses were 
performed using SPSS version 21.0.0.1 (SPSS, IBM, Armonk, NY, USA) and MedCalc (MedCalc, 
Ostend, Belgium) soft ware.
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Figure 2: Technical diff erences between sidestream dark fi eld (SDF) and incident dark fi eld (IDF) technique adapted 
with permission from reference [19]. LED, light-emitti  ng diode
RESULTS
The study populati on consisted of 13 pati ents with cardiogenic shock, 49 ± 18 years old, 
11 of whom (85%) were male. Of the 13 pati ents, 10 were SW from VA-ECMO (Fig. 1). The 
causes of admission were pulmonary embolism (n = 5, 38%), post cardiotomy (n = 3, 23%), 
acute coronary syndrome (n = 2, 15%), myocarditi s (n = 2, 15%) and drug intoxicati on (n = 
1, 8%) (Table 1). In total, 19 weaning att empts were performed in 13 pati ents, of which 10 
were successful and led to cardiac recovery (CR): 8 out of 10 were SW aft er the fi rst att empt. 
Five pati ents need more than one weaning att empt (Fig. 1). In the nine unsuccessful weaning 
att empts, three pati ents died (non-cardiac recovery; NCR) aft er six unsuccessful weaning 
att empts and two pati ents were SW aft er two and three att empts, respecti vely.
 The global hemodynamics were not signifi cantly diff erent between SW and NSW 
pati ents during weaning att empts (Additi onal fi le 2: Figure S1A and S1B). Successful and 
unsuccessful weaning was classifi ed according to echocardiographic assessment as described 
previously. The results from the microcirculati on measurements showed that in SW pati ents, 
TVDss, PVDss and PPVss measured in the same sublingual area maintained their values prior 
to the weaning att empt, whereas these values decreased in  the pati ents  who were NSW 
(Additi onal fi le 3: Figure S2A through Additi onal fi le 4: Figure S2F).
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Table 1: Baseline characteristics of the microcirculation of 13 patients observed during weaning attempts
Baseline characteristics Successful weaning 
(n = 10)
Non-successful 
weaning (n = 3)
Total p value
Number of patients in each group 10 3 13 0.02
Weaning attempts 13 6 19 0.32
Age 56 ± 17 41 ± 16 49 ± 18 0.43
Male gender 9 2 11 0.11
Etiology
PE 5 0 5 0.03
Post cardiotomy 2 1 3 1.0
ACS 1 1 2 1.0
Myocarditis 1 1 2 1.0
Intoxication 1 0 1 1.0
Days on ICU 15 (6–65) 30 (3–36) 20 (3–65) 0.72
Days of ECMO 5 (2–21) 21 (3–36) 13 (2–36) 0.02
WA p.p. 1.3 ± 0.7 2.0 ± 1.7 1.5 ± 0.5 0.21
Abbreviations: ACS acute coronary syndrome, ICU intensive care unit, PE pulmonary embolism, VA-ECMO veno-arterial 
extracorporeal membrane oxygenation,per patient, WA weaning attempts
p values in italics are statistically significant
TVDss, PVDss and PPVss were statistically significantly reduced following a flow reduction 
(from F100 to F50) in patients who were not NSW (TVDss all vessels p = 0.001; PVDss all 
vessels p = 0.01; PPVss all vessels p = 0.04; TVD small vessels p = 0.001; PVDss small vessels p 
= 0.01; PPV small vessels p = 0.03). The images acquired from the same sublingual area during 
VA-ECMO 100% and 50% flow, were evaluated visually and then quantified side by side by 
comparing total small and large vessel densities (Fig. 3a and b see also Additional file 5: Clip 
1 and Additional file 6: Clip 2). In SW patients, no or minimal alterations in microcirculation 
were seen during VA-ECMO 100% and 50% flow. In contrast, patients who were not SW 
had clear deterioration in total small and large vessel densities during VA-ECMO 50% flow 
(Additional file 7: Table S2A, B and C). Figure 3c shows an example of successful and not 
successful weaning attempts in the same patient.
 TVD of all vessels and TVD of small vessels were statistically reduced in the NSW patients 
during 50% VA-ECMO flow compared to no change or even increased values in SW patients. 
Examples of the recorded moving images of the sublingual microcirculation of the two 
categories of patients can be found in Additional file 8.
 A comparison of the microcirculatory parameters with echocardiographic parameters 
values according to the published Aissaoui criteria for weaning from VA-ECMO [9] showed 
good correlation, especially with LVEF (r = 0.6214 and p = 0.01) (Additional file 7: Table S3).
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Receiver operating characteristic (ROC) curves showed the area under the curve (AUC) was 
0.99 vs 0.93 vs 0.85 for the TVDssF50 (small vessels) >12.2 mm/mm2, LVEF > 15% and aortic 
VTI > 11 cm (Additional file 9: Figure S3). Likewise, the AUC was 0.91 vs 0.93 vs 0.85 for the 
PVDssF50 (all vessels) > 14.8 mm/mm2,  LVEF  > 15% and aortic VTI > 11 cm.
 After reanalyzing the data using the individual outcome of weaning attempts as an 
endpoint, TVD was highly predictive of a successful weaning attempt from ECMO (Additional 
file 7: Table S4A and S4B). In three weaning attempts, the outcome of SW and NSW patients 
did not match with the TVD changes in the microcirculation, with false negative (n = 2) and 
false positive (n = 1) values seen. The positive predictive value of sustained microcirculation 
for successful weaning is 89%. Two of these three attempts were in the same patient. All 
unsuccessful weaning attempts were  during 50% ECMO flow below the 14.3 mm/mm2 
cutoff point   of TVDssF50 predicting successful weaning, when pooled to determine the 
success of each weaning attempt separately (Fig. 4a and b).
DISCUSSION
The main finding in this study is that sustained sublingual microcirculation during VA-
ECMO flow  reduction in a convenient cohort sample  of patients supported with VA-ECMO 
during cardiogenic shock, can provide a marker for the success of weaning from VA-ECMO. 
Cardiogenic shock affects all organs and compromises central hemodynamic cardiovascular 
function and consequently tissue perfusion. Currently used strategies for weaning from 
VA-ECMO are largely based on echocardiographic parameters. However, performing 
echocardiography in the ICU is challenging [10]. The results of    the present study show 
that functional parameters of microcirculation, including TVDss and PVDss, reflect recovery 
from cardiogenic shock and predict successful weaning from VA-ECMO. Patients who were 
success- fully weaned had significantly higher baseline  TVDss and PVDss compared to 
those of patients who were not successfully weaned. Even though global hemodynamics 
were comparable between patients with and without successful weaning, microcirculatory 
parameters were significantly different. The occurrence of such disassociation between 
macrocirculation and microcirculation, referred to as a loss of hemodynamic coherence,  has 
been described before in other conditions of cardiovascular compromise [11, 23–28].
 The microcirculatory approach presented in this study could provide an alternative 
approach for the rapid assessment of cardiac recovery from cardiogenic shock during 
weaning attempts and/or in addition to echocardiographic evaluation. This approach could 
also be useful for the echocardiographic assessment of the left ventricular systolic function, 
especially in ICU patients with poor echo windows. Cavarocchi et al. [8] used a 4-stage 
strategy to evaluate 50% VA-ECMO blood flow, volume challenge and inotropic challenge 
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during at least 1 hour of the conti nual monitoring of heart rate, blood pressure, and right 
ventricle (RV) and left  ventricle (LV) functi on under transesophageal echocardiography. 
 Weaning was considered successful when both LV and RV functi ons tolerated volume 
challenge and demonstrated inotropic reserve. However, this strategy required intravenous 
sedati on to tolerate transesophageal echocardiography and an increased physical load 
in non-intubated pati ents throughout the weaning att empt with need for conti nuous 
therapeuti c anti coagulati on. A diff erent approach involves the use of biomarkers as indicators 
of the success of weaning; however, such markers appear very late and seem inconclusive for 
determining the success of weaning from VA-ECMO. The usefulness of biomarkers in weaning 
from VA-ECMO, therefore, remains controversial. In line with this limitati on, Luyt et al. [29] 
reported that in pati ents with refractory cardiogenic shock receiving VA-ECMO support, early 
measurements of cardiac biomarkers are not useful for identi fying those who would recover.
 In a VA ECMO weaning study, Aissaoui et al. measured left  ventricular functi onal 
parameters (e.g., LVEF, VTI, TDSa) and found these to be good predictors of successful 
weaning. However, such echocardiographic assessment is limited to the evaluati on of the 
left  heart functi on under the conditi on that there are suffi  cient windows for analysis [9]. 
The echocardiography parameters used in these weaning att empts, however, do not provide 
informati on about the right heart functi on, systemic hemodynamics or ti ssue perfusion, 
which also deteriorate as a consequence of cardiogenic shock. Our study shows that during 
weaning att empts,  recovery from cardiogenic shock is revealed in the microcirculati on, 
which agrees with total cardiac recovery upon echocardiography.
 Monitoring the microcirculati on using direct vital imaging with handheld microscopy has 
the potenti al  to be the technique of choice to assess ti ssue perfusion in diff erent phases of 
shock [27, 30]. The study described  in this paper illustrated that the assessment of sublingual 
microcirculati on and the echocardiographic evaluati on of cardiac functi on was acceptably 
matched in discriminati ng between pati ents who were and were not successfully weaned. 
Microcirculatory evaluati on was rapid since alterati ons were observed within 2 minutes 
following a lowering of ECMO fl ow.
 Physiologically, this fast-adapti ng mechanism can also be evaluated from fracti onal fl ow 
reserve (FFR) measurements in coronary angiography. In these measurements, the hyperemic 
phase aft er the resoluti on of stenosis also occurs within 2 minutes [31]. Several studies have 
been performed on microcirculatory alterati ons during ECMO [32, 33] with diff ering results 
concerning the relati onship between global hemodynamics to the microcirculati on [23, 34–
38]. In a recent study, however, we found a signifi cant predicti ve value of sublingual measured 
perfused vessel density in VA-ECMO pati ents for survival in the ICU [11]. However, to date, 
sublingual measurements have not been employed to guide weaning from VA-ECMO.
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Figure 3: a Microcirculatory alterati ons in successfully weaned (SW) vs not successfully weaned (NSW) pati ents 
during weaning att empts with baseline fl ow (F100) and 50% of the baseline fl ow (F50). Examples are shown of 
microcirculati on in the same sublingual area in two pati ents during F100 and F50. Images were taken from a 
51-year-old man, there was cardiac recovery 3 days aft er tentamen suicidii with 900 mg of amlodipine and 1600 
mg of hydrochlorothiazide in the same sublingual area during a weaning att empt on day 3, with no alterati ons in 
microcirculati on (F100, veno-arterial extracorporeal membrane oxygenati on (VA-ECMO) fl ow 6.1 L/min; mean arterial 
pressure (MAP) 77 mmHg and F50, VA-ECMO fl ow 3 L/min; MAP 74 mmHg). b Images were taken from a 26-year-old 
woman with stable human immunodefi ciency virus infecti on (HIV) developed myocarditi s and biventricular heart 
failure. Aft er 4 weeks, there was no improvement in cardiac functi on. The microcirculatory images were documented 
during four weaning att empts without improvement. The same sublingual area was also used during the last weaning 
att empt, which showed obvious persisti ng deteriorati on in microcirculati on (blue zones) (F100, VA-ECMO fl ow 4.7 
L/min; MAP 75 mmHg and F50, VA-ECMO fl ow 2.7 L/min; MAP 67 mmHg). c Changes in total vessel density (TVD) 
in small vessels during non-successful (day 2, red) and successful (day 4, green) weaning att empts in pati ent 7. This 
65-year-old man suff ered from cardiogenic shock aft er coronary artery bypass graft  (CABG) surgery.
101
CHAPTER 5
Figure 4: a Data from individual successful weaning att empts (n = 10), in which 8 demonstrated sustained or 
increased total vessel density (TVD) independently from extracorporeal membrane oxygenati on (ECMO) fl ow. 
Two weaning att empts showed decreased TVD aft er reducing the ECMO fl ow. b Data from individual unsuccessful 
weaning att empts (n = 9), in which 8 demonstrated non-sustained or declining TVD during 50% ECMO fl ow. One 
weaning att empt showed sustained TVD aft er reducing the ECMO fl ow in contrast to clinical judgment. However, the 
TVD was lower than the cutoff 14.3 mm/mm2
Limitati ons
The authors acknowledge the following limitati ons. First, this was a single-center observati onal 
study with a small populati on of pati ents with various underlying diseases causing cardiogenic 
shock. Furthermore, analyses of echocardiography and global hemodynamics, together with 
microcirculatory parameters measured in the same sublingual area, were performed only in 
pati ents deemed eligible to wean. This meant that we could not perform microcirculatory 
measurements without echocardiography for weaning att empts in pati ents under VA-ECMO 
support because of the observati onal nature.
 The methods of measurement and evaluati on of the microcirculati on remain sensiti ve 
to arti facts and technical limitati ons. The strength of our study from a methodological 
perspecti ve, however, lies in the fact that all measurements were performed in the same 
area (single spot). This methodology allowed us to assess the  response of single microvessels 
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to changes in pump setti  ngs as against comparing the mean value of microcirculati on 
parameters of images at diff erent locati ons  and at diff erent ti me points.
CONCLUSION
We found that the functi onal microcirculatory parameters measured sublingually using IDF 
imaging (TVDssF50 and PVDssF50) during weaning att empts  for  pati ents from VA-ECMO 
showed essenti al alterati ons within 2 minutes and predicti on of cardiac recovery aft er cardio- 
genic shock. Future clinical and possible crossover studies should be designed in larger 
study populati ons undergoing VA-ECMO for monitoring  microcirculati on to guide weaning 
att empts.
Key messages
•  Veno-arterial extracorporeal membrane oxygenati on (VA-ECMO) use is a last opti on for 
survival in many types of cardiogenic shock (CS).
•  Conventi onal weaning from VA-ECMO is guided by echocardiographic parameters such 
as the aorti c velocity − ti me integral on conti nuous wave Doppler recordings from left  
ventricular outf low tract and by assessing improvement in left  ventricular ejecti on 
fracti on. Echocardiographic measurements are not easily obtained in the ICU setti  ngs. 
On the other hand, a novel imaging technique, dark fi eld imaging of the microcirculati on, 
is quite feasible in almost all pati ents in the ICU.
•  Identi fi ed sublingual microcirculati on is a novel potenti al marker for identi fying successful 
weaning from VA-ECMO. Sustained values of single-spot measurements of total 
vessel density during 50% fl ow reducti on (TVDssF50) and single-spot  measurements 
of perfused vessel density during 50% fl ow reducti on (PVDssF50) were found to be 
specifi c and sensiti ve indicators of successful weaning from VA-ECMO as compared to 
echocardiographic parameters. Therefore, weaning from VA-ECMO could be performed 
by imaging of the microcirculati on using simple markers of ti ssue perfusion during 
weaning att empts.
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CHAPTER 6
Purpose of review:
Critical illness includes a wide range of conditions from sepsis to high-risk surgery. All these 
diseases are characterized by reduced tissue oxygenation. Macrohemodynamic parameters 
may be corrected by fluids and/or vasoactive compounds; however, the microcirculation and 
its tissues may be damaged and remain hypoperfused. An evaluation of microcirculation 
may enable more physiologically based approaches for understanding the pathogenesis, 
diagnosis, and treatment of critically ill patients.
Recent findings:
Microcirculation plays a pivotal role in delivering oxygen to the cells and maintains tissue 
perfusion. Negative results of several studies, based on conventional hemodynamic 
resuscitation procedures to achieve organ perfusion and decrease morbidity and mortality 
following conditions of septic shock and other cardiovascular compromise, have highlighted 
the need to monitor microcirculation. The loss of hemodynamic coherence between the 
macrocirculation and microcirculation, wherein improvement of hemodynamic variables of 
the systemic circulation does not cause a parallel improvement of microcirculatory perfusion 
and oxygenation of the essential organ systems, may explain why these studies have failed.
Summary:
Critical illness is usually accompanied by abnormalities in microcirculation and tissue hypoxia. 
Direct monitoring of sublingual microcirculation using hand-held microscopy may provide 
a more physiological approach. Evaluating the coherence between macrocirculation and 
microcirculation in response to therapy seems to be essential in evaluating the efficacy of 
therapeutic interventions.
Keywords: 
critical illness, hemodynamic coherence, microcirculation, sepsis
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KEY POINTS
•   Microcirculation plays a pivotal role in delivering oxygen to the tissue cells by maintaining 
tissue perfusion, and it involves the final branches of the cardiovascular system, a 
complex network of small blood vessels with diameters less than 100µm.
•   Critical illness is usually accompanied by abnormalities in microcirculation and causes 
regional tissue hypoxia. Sepsis in particular but also different states of shock, cardiac 
arrest, and high-risk surgery are the main reasons for deterioration in the microcirculation 
of critically ill patients. 
•   The normalization of global hemodynamics does not always lead to a parallel 
improvement in microcirculation because of a loss of hemodynamic coherence as a 
result of a loss in vascular regulation caused by inflammatory mediators and hypoxia.
•   Direct monitoring of sublingual microcirculation using hand-held microscopy helps 
achieve a more physiological approach to the diagnosis and treatment in states of 
critical illness.
INTRODUCTION
Critical illness includes a wide range of disease states such as sepsis, high-risk surgery, 
cardiac arrest, and respiratory failure, and is associated with reduced tissue oxygenation 
related to a compromise in the cardiovascular system (CVS).     Microcirculation involves 
the smallest branches of the  CVS  and plays an essential role in the transport of oxygen 
to the parenchymal cells needed to sustain organ function [1]. It is generally accepted that 
resuscitation procedures should aim to correct macrohemodynamic variables during critical 
illness, with the goal of improving tissue perfusion. However, although macrohemodynamic 
targets may be reached, it is often uncertain whether these procedures lead to a parallel 
improvement in the microcirculation [2]. In this review, we discuss the microcirculatory 
alterations in critical illness and the importance of hemodynamic coherence between the 
macrocirculation and microcirculation that occurs in response to resuscitation. In conclusion, 
we suggest that monitoring the microcirculation is important for determining hemodynamic 
coherence as a response to therapy and can provide the feedback needed to ensure good 
clinical outcomes. The introduction of a new generation of computer-controlled hand-held 
microscopes for monitoring the microcirculation now provides a new clinical approach to 
monitoring the determinants of tissue oxygenation.
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THE MICROCIRCULATION AND HEMODYNAMIC COHERENCE
Microcirculation consists of a branching network  of small blood vessels (<100 mm diameter) 
that includes the arterioles, capillaries, and venules,  and plays a pivotal role in the delivery 
of oxygen  to tissue cells [3]. The main mechanisms of oxygen transport are the convective 
flow of red blood cells (RBCs) and the passive diffusion of oxygen from the RBCs to the 
tissue cells [4]. As convective flow refers to the transport of oxygen-carrying RBCs to the 
capillaries, passive diffusion refers to the transport of oxygen from  the RBCs  in the capillaries 
to the tissue cells. Resuscitation procedures primarily target the correction of convective 
RBC flow under the assumption that hypovolemia is primarily associated with inadequate 
blood flow. However, convective and diffusive flows have an equal contributory effect on the 
transport of oxygen [4]. Thus, the normalization of systemic hemodynamic variables alone 
may increase convective flow but may not necessarily mean that adequate oxygen is being 
delivered to the tissues, especially if non oxygen carrying resuscitation fluids are used and 
if areas of the microcirculation are obstructed [5**]. This led us to introduce the term of 
hemodynamic coherence  [5**]  to  describe  the  condition  where  resuscitation is successful 
if macrocirculatory resuscitation causes a parallel improvement in the perfusion and oxygen 
of the microcirculation. Loss of hemodynamic coherence between the macrocirculation 
and the microcirculation can occur under various conditions of microcirculatory alterations 
(see Fig. 1), where correction of systemic hemodynamic variables does not cause a parallel 
improvement  in  the  condition  of  the  microcirculation  resulting  in a lack of tissue perfusion 
despite apparently normalized systemic hemodynamic. Because loss of hemodynamic 
coherence does not improve surrogates of hypovolemia, such as lactate, oliguria, and strong 
ion difference, which are either related to microcirculatory dysfunction not being improved 
by targeting macrocirculatory parameters or are being caused by other factors not related to 
conventional resuscitation procedures, clinicians at the bedside will continue administrating 
inappropriate amounts of fluids and vasoactive drugs potentially causing harm. To identify 
this  condition  and assess the presence or absence of hemodynamic coherence,  monitoring 
of   the   microcirculation  is essential.
 The microcirculation is controlled by many regulatory and compensatory systems 
including hormonal, neural, biochemical, and vascular control systems that all must be intact 
to respond adequately to systemic hemodynamic changes [6]. However, these regulatory 
systems are often damaged in critically ill patients because of infection, inflammation, 
and regional ischemia or hypoxia, resulting in a loss of hemodynamic coherence between 
macrocirculation and microcirculation, and vulnerable microcirculatory units in organ beds 
that become shunted and hypoxic, manifesting clinically as a reduction in oxygen extraction 
[5**,7*]. Several studies have shown that the normalization of systemic hemodynamic 
variables does not always lead to parallel improvements in microcirculation and cell 
oxygenation, especially under specific conditions [8–13].
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Figure 1:  Microcirculatory alterations underlying the loss of hemodynamic coherence, resulting in tissue hypoxia 
(blue cells). Type 1: heterogeneous perfusion of the microcirculation, as seen in septic patients, with obstructed 
capillaries next to perfused capillaries, resulting in a heterogeneous oxygenation of the tissue cells. Type 2: 
hemodilution with the dilution of microcirculatory blood, resulting in the loss of RBC-filled capillaries and increasing 
diffusion distance between RBCs in the capillaries and the tissue cells. Type 3: stasis of microcirculatory RBC flow 
induced by altered systemic variables [e.g., increased arterial vascular resistance (R)] and/or increased venous 
pressure causing tamponade. Type 4: alterations involving edema caused by capillary leak syndrome, which results 
in an increased diffusive distance and reduced ability of the oxygen to reach the tissue cells. Red, well oxygenated 
RBC and tissue cells; purple, RBC with reduced oxygenation; blue, reduced tissue cell oxygenation. RBC, red blood 
cell. Reproduced with permission [5**].
Four types of microcirculatory alteration are associated with a loss of hemodynamic coherence 
between the macrocirculation and microcirculation (Fig.1)   [5**].   Type   1   alterations 
are   associated with heterogeneity in the perfusion of the microcirculation, in which some 
capillaries are obstructed next to capillaries with flowing RBCs, and can be observed in states 
of inflammation, especially sepsis and reperfusion injury. Type 2 represents conditions of 
hemodilution, in which dilution of the blood causes a decrease in capillary hematocrit, 
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resulting in increased diffusion distances between the oxygen-carrying RBCs and the tissue 
cells; this situation occurs mainly in cardiac surgery and also in sepsis when excessive non 
oxygen carrying resuscitation fluids are given. Type 3 microcirculatory alterations occur 
when there is a vasoconstriction/tamponade of the microcirculation caused by the excessive 
use of vasopressors and/or increased venous pressure. Type 4 microcirculatory alteration 
is associated with tissue edema caused by damage to the endothelial cells and the loss of 
glycocalyx, capillary leakage because of compromised vascular barriers and fluid overload, all 
of which can be observed in sepsis, reperfusion injury, and surgery.
 Various methods can be used to visualize microcirculation. Sublingual microcirculation 
is the  most commonly used area to visualize the microcirculation, and the use of this site to 
investigate  the clinical effects of disease and therapy on the microcirculation is well established 
[14]. Three generations of hand-held microscopes have been developed to monitor the 
sublingual microcirculation [15]. Orthogonal polarization spectral (OPS) and sidestream dark 
field (SDF) imaging methods are, respectively, the first-generation and second-generation 
microcirculation-monitoring devices. These earlier devices had some limitations such as 
suboptimal optics and the lack of a direct computer control in the imaging modality, which is 
needed for direct bedside evaluation of the images. Recently, a third-generation lightweight 
device, the CytoCam-IDF device, was developed based on incident dark field imaging [16–18]. 
The CytoCam-IDF device consists of a computer-controlled, high resolution  image  sensor  in 
combination  with  a specifically designed microscope lens that provides better image quality, 
enabling the detection of more capillaries than previous generation devices [17,19,20]. 
Although this device visualizes microcirculatory changes better than previous devices, it is 
a technique under continuous development, as clinical requirements provide new technical 
specification challenges. Pressure artifacts, the     limited focus depth, the need to stabilize 
the microscope lens on the tissue surface and improved automatic image analysis are still 
limitations in need of technical development.
MICROCIRCULATORY ALTERATIONS IN SEPSIS
Sepsis is one of the most common syndromes suffered by critically ill patients. It has recently 
been redefined as a life threatening form of organ dysfunction caused by a dysregulated 
host response to infection [21**]. Infections associated with sepsis trigger inflammation, 
and a resultant cytokine storm can lead to cardiovascular depression, which together causes 
cellular dysfunction that results in organ failure [22]. Hemodynamic normalization can be 
achieved by the rapid administration of fluids and vasoactive drugs. Rivers’ study showed that 
early goal-directed therapy (EGDT) can improve survival rates in specific types of septic shock 
patients, which led to EGDT being recommended by Surviving Sepsis guidelines [23,24]. 
However, recent multicenter trials were conducted in the United States [Protocolized Care for 
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Early Septic Shock (ProCESS)] [25], Australasia [Australasian Resuscitation in Sepsis Evaluation 
(ARISE) trial] [26], and in the United Kingdom [Protocolized Management in Sepsis (ProMISe)] 
[27] that showed that this approach showed no clear benefits in terms of survival. Another 
large randomized trial, SEPSISPAM (Assessment of two levels of arterial pressure on survival 
in patients with septic shock study), included 776 septic shock patients and showed that 
higher mean arterial pressure (MAP) targets (80–85 mmHg) in comparison with conventional 
targets (65–70 mmHg) did not improve survival [28]. The Transfusion Requirement in Septic 
Shock (TRISS) study compared lower versus higher hemoglobin levels in septic shock [29]. 
They found that mortality at 90 days and the rates of ischemic events and use of life support 
were similar in both groups. The therapeutic end points of these studies were aimed at 
correcting macrohemodynamic variables such as blood pressure, heart rate, and cardiac 
output, but they did not evaluate whether correcting these systemic variables resulted in 
improved parenchymal perfusion, oxygenation, and microcirculation. It can be concluded 
that these large negative randomized control trial studies provide little insight into effective 
therapeutic strategies for sepsis from a hemodynamic perspective, indicating the need for 
information regarding the microcirculatory system and tissue perfusion.
 The pathogenesis of sepsis is defined at the level of the microcirculation and parenchymal 
cells. Sepsis causes multifactorial microcirculatory alterations including endothelial cell 
dysfunction associated with the expression of adhesion molecules, increased leukocyte 
adhesion, glycocalyx degradation, connexin uncoupling, vascular leakage, micro-thrombi 
formation, altered local perfusion pressures, and functional shunting of oxygen transport [6]. 
Although various types of microcirculatory alterations have been observed in septic patients, 
from a hemodynamic perspective, the heterogeneity in microvascular perfusion (type 1 
microcirculatory alteration) is characteristic, as it explains the origin of oxygen transport 
dysfunction in sepsis [7*]. Even if the total blood flow to the organs is preserved, hypoxic 
zones can occur  because of heterogeneity  in  microvascular  blood  flow  [7*,9].  Thus, 
recruiting microcirculation is more complex than simply increasing the total blood flow to an 
organ. De Backer et al. [13] investigated microcirculatory alterations in 252 sepsis patients 
and found that early microcirculatory deteriorations (first 24 h) were the strongest predictor 
of outcomes, more sensitive and specific than macrohemodynamic variable. Hernandez et 
al. [30] and Edul et al. [9] also showed that severe abnormalities in microcirculatory perfused 
vessel density were associated with organ dysfunction and mortality in septic shock patients. 
 A current source of debate is the relationship between heart rate and sepsis. In a 
multicenter international observational trial with 530 mixed intensive care patients, Vellinga 
et al. [31] showed that tachycardia was the single most sensitive parameter for predicting 
outcomes but that if tachycardia was associated with microcirculatory altera- tions, an even 
worse outcome was the result. Recently, Morelli et al. [32] reported that the fast acting 
beta-blocker, esmolol, reduced heart rate and improved survival in septic patients. They 
explained that the expected increase in stroke volume in patients with beta-blocker-treated 
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sepsis was associated with a decreasing heart rate. Aboab et al. [33] found that esmolol 
increased stroke volume by reducing heart rate in a porcine model of hypodynamic sepsis. 
Jacquet-Lagreze et al. [34] investigated the beneficial effects of the fast acting beta-blocker 
in improving microcirculation in a porcine model of hyperdynamic sepsis. They found that 
beta-blockers provided maintenance of sublingual and gut microcirculation during sepsis; 
however, they were not able to show that a reduction in heart rate was accompanied by 
an increase in stroke volume. Therefore, the hemodynamic role of beta-blockers in the 
treatment of sepsis remains unclear, as the microcirculatory findings are not explained by 
their macrohemodynamic changes [35].
MICROCIRCULATORY ALTERATIONS IN SURGERY
High-risk surgery associated with cardiac surgery, trauma, and hemorrhagic shock is another 
common cause of critical illness. Yu Chang and colleagues investigated the associations 
between surgical stress and microcirculatory dysfunction in patients post general and 
thoracic surgery. They concluded that early (first 24 h) microcirculatory parameters (total and 
perfused vessel density) might be used as a predictor of surgical complications and outcomes 
in critically ill surgical patients. Maddison et al. [36] investigated sublingual microcirculatory 
alterations in patients with intraabdominal  hypertension.  They found that grades I and 
II intraabdominal hypertension (intraabdominal pressure from 12 to 18 mmHg) was not 
associated with microcirculatory alterations. 
 Cardiac surgery is characterized by a wide range of microcirculatory changes and 
reduced tissue oxygenation [37]. Microcirculatory alterations occur not only as a result of 
underlying cardiac disease or cardiogenic shock but can also occur as  a result of anesthesia, 
hypothermia, and hemodilution as well as the surgery itself [38,39]. The hemodynamic 
effects of the nature of the cardiac surgery (e.g., off-pump or on-pump cardiac surgery) are 
still a source of controversy [40]. De Backer et al. [39] showed that off-pump cardiac surgery 
was associated with a decrease in microcirculatory perfusion, whereas Atasever et al. [41] 
found that on-pump and off-pump cardiac surgeries caused specific and different types of 
sublingual microcirculation alterations. A recent study showed that off-pump surgery does 
not preserve postoperative microcirculatory parameters better than on-pump cardiac surgery 
[42]. A consistent finding in cardiac surgery, however, is that hemodilution causes a reduction 
in functional capillary density, which can be corrected by blood transfusion [43–45]. 
 Microcirculatory dysfunction in patients with hemorrhagic shock has  a similarly poor 
outcome  as sepsis patients. In traumatic hemorrhagic shock patients, Tachon et al. [11] found 
that despite the successful restoration of systemic hemodynamic variables within hours, the 
restoration of sublingual microcirculation took up to 4 days. They found that the length of 
recovery of the microcirculation correlated with the severity of organ dysfunction. Stens et 
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al. [46] investigated whether the hemodynamic optimization of systemic perfusion based 
on pulse pressure variation (PPV) and cardiac index (CI) improved the microcirculation in 
patients with abdominal surgery when compared with a MAP-based strategy. They found that 
PPV and CI-based therapy was not associated with an improved microcirculatory perfusion 
compared with MAP-guided therapy. The outcomes may improve, however, when goal-
directed therapy is aimed at correcting the microcirculation after major surgery [5**].
MICROCIRCULATORY ALTERATIONS IN VARIOUS CLINICAL 
CONDITIONS IN CRITICALLY ILL PATIENTS
Cardiac arrest is one of the leading causes of death in critically ill patients and can 
cause microcirculatory deterioration. After cardiopulmonary resuscitation,  therapeutic 
hypothermia  is   recommended to improve neurological outcomes [47]. However, the optimal 
target therapeutic hypothermia level remains unknown. In an international trial, Nielsen et 
al. [48] investigated targeting the temperature management at 33 versus 368C after cardiac 
arrest. The authors found that hypothermia at a targeted temperature of 338C was not 
more beneficial than a targeted temperature of 36oC. From a microcirculatory perspective, 
Koopmans et al. [49] investigated the potential differences in microcirculatory alterations 
and vascular reactivity in comatose patients after cardiac arrest who were treated with a 
target temperature management of 338C in comparison to patients treated with 368C. They 
found that microcirculatory blood flow and vascular reactivity did not differ between the 
groups. Resuscitation guidelines also recommend keeping patients’ oxygen saturation levels 
at approximately 94% because of the side-effects of hyperoxia [50]. Concerning the types of 
microcirculatory changes, hyperoxia falls into the type 3 microcirculatory alterations category 
[5**],  in  which  hyperoxia  causes  vasoconstriction and reductions in microvascular flow,  as 
shown by Orbegozo Cortes et al. [51] in healthy volunteers. 
 Critically ill patients often have more than one chronic disease such as diabetes, cirrhosis, 
and chronic kidney disease. The microcirculatory effects of these comorbidities and age are 
important in hemodynamically stable patients. Reynolds et al. [52] investigated the effects of 
age, diabetes mellitus, cirrhosis, and chronic kidney disease on sublingual microcirculatory 
flow. They showed that sublingual microcirculatory parameters did not significantly differ 
between healthy young volunteers, healthy older adults, and patients with diabetes, cirrhosis, 
and chronic renal failure. Kanoore Edul et al. [53] evaluated sublingual microcirculation in 
patients with\ and without chronic arterial hypertension. They found that chronic arterial 
hypertension decreased vascular density but that the microcirculatory variables remained 
unchanged over a large age range. Dababneh et al. [54] compared microcirculatory alterations 
in patients with and without pulmonary hypertension. They found a lower microcirculatory 
flow index (MFI) in patients with pulmonary  hypertension.  Interestingly,  George   et al. 
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[55] compared sublingual microcirculation between pregnant and nonpregnant women and 
observed that pregnant women had a higher MFI compared with nonpregnant women.
MICROCIRCULATORY EFFECTS OF RESUSCITATION THERAPIES IN 
CRITICAL ILLNESS
Fluid therapy is the initial approach when hypovolemia is suspected in critically ill patients. 
The aforementioned early  fluid  resuscitation  is  important in restoring microcirculation [4]. 
However, fluid volume and fluid composition form are crucial aspects of effective volume 
therapy. Regarding their impact on the microcirculation from a physiological perspective, fluid 
therapy increases the convective flow in hypovolemia [56]. Pranskunas et al. [57] assessed 
the changes in sublingual microcirculatory flow in patients with impaired organ perfusion 
based on clinical surrogates such as hyperlactate, tachycardia, hypotension, and oliguria 
because of fluid overload. They measured the MFI before and after fluid challenge, and they 
found that fluid administration only increased the MFI in patients with a low baseline MFI 
(<2.3). The correction of MFI caused a parallel response in the surrogates.
 However, in patients with surrogates but not with normal MFI, fluid was ineffective in 
correcting either variable. In all the conditions, however, fluids increased the stroke volume 
and were effective in correcting the surrogates. They concluded that MFI could be used 
to predict fluid response. Pottecher et al. [56] showed that increasing the intravascular 
volume by passive leg raising and intravenous volume administration improved sublingual 
microcirculatory perfusion in severe sepsis and septic shock patients.
 Ospina-Tascon et al. [58] explored the importance of the timing of fluid administration 
in septic patients and the authors found that early but not  late fluid challenge can improve 
perfusion to the microcirculation. However, if too much fluid is given, hemodilution, capillary 
leakage, and tissue edema cause problems in oxygen transport. Sepsis guidelines recommend 
increasing central venous pressure up to 12 mmHg for adequate volume therapy [24]. 
However, elevated central venous pressure may cause different adverse effects, in particular 
acute renal failure. From a microcirculatory perspective, elevated venous pressure can cause 
a type 3 microcirculatory alteration associated with tamponade of the microcirculation. 
Vellinga et al. [59] showed this effect when they compared critically ill patients with a central 
venous pressure higher than 12 mmHg to those with a venous pressure lower than 12 mmHg; 
they found that there was a significant reduction in microcirculatory flow in the high venous 
pressure group. Fluid therapy guided by optimizing stroke volume determined by the PiCCO 
technique was used in the PRISM (PiCCO-guided Resuscitation in Severe Malaria) trial in 
patients with malaria [60]. PiCCO-guided resuscitation caused fluid overload and severe tissue 
edema. The normalized systemic hemodynamics but with altered type 4 microcirculation in 
this example shows the loss of hemodynamic coherence. This generalized peripheral edema 
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did not resolve tissue hypovolemia or metabolic acidosis and increased acute renal failure, 
highlighting the importance of demonstrating hemodynamic coherence. Hanson et al. [61] 
evaluated rectal microcirculation in malaria patients who were resuscitated by stroke volume-
guided fluid therapy. They found that although fluids were successful in correcting systemic 
hemodynamic variables, they had little effect on malaria-associated RBC sequestration,  the 
primary pathology underlying malaria. Therefore, fluid administration targeting systemic 
hemodynamic parameters in this patient group was not successful in correcting for metabolic 
acidosis and resulted in adverse severe edema in the kidney, abdomen, and lungs.
 Types of fluids and their composition are also a highly controversial issue in resuscitation 
medicine. In a microcirculation study, Dubin et al. [62] compared 6% hydroxyethyl starch 
130/0.4 to an isotonic saline solution for resuscitation in septic shock patients, targeting 
an improvement in MAP. They showed that fluid resuscitation with 6% hydroxyethyl starch 
130/0.4 required lower volumes to reach targeted blood pressures and caused a higher 
capillary density of flowing RBCs in sublingual microcirculation, with a higher flow being 
achieved with less volume than with the isotonic saline solution [9]. In addition to resuscitation 
fluids, blood transfusions can have a positive as well as negative effect on patient outcomes 
[63,64]. However, when applied physiologically, studies have shown that blood transfusions 
can lead to improved microcirculatory functional capillary density [44,45]. In evaluating the 
effects of blood transfusion on critically ill patients, there is a large variability in the quality of 
blood, leucodepletion, and age and storage solutions used. Therefore, a reevaluation of the 
relative risks of hemodilution, anemia versus blood transfusion, is required [65].
 The effects of vasoactive compounds on the microcirculation have been extensively 
investigated in critically ill patients. Vasopressor agents are administered to achieve targeted 
systemic hemodynamic values with the expectation that this will augment oxygen delivery 
to the tissues [66]. However, excessive vasopressor therapy can cause microcirculatory 
stasis (type 3) by severe vasoconstriction [67]. For example, Boerma et al. [68] showed 
that the vasopressin analog terlipressin impaired sublingual microcirculation in a patient 
with catecholamine-resistant septic shock. They also concluded in a review of the literature 
over the past 15 years that there were no beneficial effects of increasing MAP above 65 
on microcirculatory perfusion [69].  Xu  et al. [70] evaluated the impact of increasing MAP 
levels to approximately 70 mmHg through norepinephrine administration in patients with 
chronic hypertension. They concluded that increasing the arterial blood pressure improved 
sublingual microcirculation independent of other tissue perfusion indicators such as lactate 
and urinary  output. Dubin et al. [71] found that increases in MAP from 65 to 85 mmHg 
in septic shock patients resulted    in decreased perfusion of the microcirculation, strongly 
dependent on the basal microcirculation. When basal microcirculation was normal at a MAP 
of 65 mmHg, increases in MAP worsened the microcirculation because of    vasoconstriction 
(type 3 microcirculatory alteration). If, however, there was a slow flow in the baseline 
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microcirculation, increases in MAP improved microcirculatory flow parameters [71]. Similar 
results were found by Jhanji et al. [72].
 The vasoactive therapy most effective in promoting regional perfusion is vasodilatory 
therapy. Spronk et al. [73] showed that nitroglycerin administration improved sublingual 
microcirculatory perfusion in pressure-resuscitated septic shock patients. Boerma and 
Ince [69],  however, were not able to reproduce this effect in fluid-resuscitated septic 
patients. Groeneveld and Lima [74], on the other hand, showed that increasing the doses of 
nitroglycerin was able to recruit microvascular perfusion in circulatory shock patients.
 In addition to vasoactive and fluid therapy, anti-inflammatory therapy can also have 
positive effects on the microcirculation. Recombinant human activated protein C, which has 
an anti-inflammatory effect, was used in septic shock patients [75]. Another anti-inflammatory 
drug, cortisol, was recommended in vasopressor refractory septic shock patients [24]. 
Recently, an interesting study by Povoa et al. [76] investigated the effects of stress dose 
steroids with or without recombinant activated protein C therapy in septic shock patients. 
They found that there were no beneficial effects. From a microcirculatory perspective, Donati 
et al. [77] showed that activated protein C treatment improved microcirculation in severe 
sepsis and septic shock patients. Bushels et al. [78] evaluated the effects of hydrocortisone 
on microcirculation  in patients with septic shock. They found that hydrocortisone improved 
capillary perfusion.
CONCLUSION
Critical illness is associated with a wide range of diseases such as sepsis, high-risk surgery, 
cardiac arrest, and respiratory failure and is characterized by reduced tissue oxygenation 
caused by microcirculatory dysfunction. Optimal fluid therapy is the most important 
hemodynamic intervention in critically ill patients. The main goals of fluid therapy are 
not only to maintain macrocirculation but also to recruit microcirculation. The loss of 
hemodynamic coherence between macrocirculation and microcirculation should always be 
kept in mind, and all therapeutic approach should aim to correct hemodynamic incoherence. 
This requires microcirculatory directed therapy to be considered. Direct observations of the 
microcirculation are essential  to monitor hemodynamic coherence. By doing so,  a  more 
physiological  approach  could  prevent  the unnecessary and inappropriate  administration of 
large volumes of fluids. In the state of hypovolemia, colloid solutions are approximately three 
times more effective in volume expansion than crystalloids and improve the microcirculation 
more effectively than crystalloids. Apart from fluids, blood transfusions may improve 
microcirculatory parameters and, more importantly,  transport oxygen more effectively than 
nonoxygen carrying fluids. The new generation microcirculation-monitoring device, the 
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CytoCam-IDF, enables the clinical monitoring of sublingual microcirculation, and it can be 
easily used for the functional assessment of the hemodynamic state of the microcirculation.
 Direct visualization of  the  microcirculation at the bedside should be integrated with 
monitoring systemic hemodynamic variables for the early diagnosis and treatment of critical 
illness. Establishing and monitoring hemodynamic coherence and targeting not only the 
normalization of the macrocirculation but also that of microcirculation can be considered an 
essential component in the hemodynamic management of critically ill patients.
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INTRODUCTION
The principles of extracorporeal life support started with the first experimental efforts of Jean 
Baptiste Denis who circa 1693 performed a cross-transfusion of the blood of a human with the 
“gentle humors of a lamb” to determine whether living blood could be transmitted between 
two creatures [1]. However, clinical efforts to provide extracorporeal support began around 
1930 with the work of John and Mary Gibbon. They developed a freestanding roller pump 
device for extracorporeal support after the death of a patient from a pulmonary embolus. 
Sixteen years later, the first human use of the device was performed in the operating room to 
assist during repair of an atrial septal defect in 1953. After some years, the use of the silicone 
membrane oxygenator, which was developed to allow recovery outside the operating room, 
led to the use of the term extracorporeal membrane oxygenation (ECMO). In the 1960s, 
with the development of gas-exchange devices, a silicone rubber membrane was interposed 
between the blood and the oxygen. This modification (and others) allowed the use of a heart-
lung machine for days or weeks [3] reducing the threshold for their use. In 1972, Dr Bartlett 
successfully provided ECMO support to a two-year old boy following a Mustard procedure for 
correction of transposition of the great vessels with subsequent cardiac failure. The patient 
underwent ECMO support for 36 h until recovery. In 1975, the first neonate (Esperanza) with 
respiratory  failure underwent ECMO support for 72 h and was successfully decannulated.
 Advances in management and monitoring of extracorporeal support therapy on the ICU 
are continuing. ECMO has increasingly become a part of the arsenal in the treatment of acute 
cardiopulmonary failure and resuscitation. Mechanical circulatory support (MCS) devices to 
temporarily (days to months) support heart and/or lung function (partially or totally) during 
cardiopulmonary failure, are functioning as a bridge to recovery or transplantation. Different 
varieties have been developed for specific cardiac or respiratory failure and veno-venous 
ECMO (VV-ECMO) for respiratory failure and veno-arterial ECMO (VA-ECMO) in cardiogenic 
shock, as well as during cardiopulmonary resuscitation (CPR), are growing in use.
 Concerns about cardiovascular responses to different types of ECMO are inherent to the 
target treatment option for the failing organ. In VV-ECMO, the main issue is oxygenation of 
the severe hypoxic patient. VV-ECMO is used in pediatric applications, in severe respiratory 
distress syndrome and, since the H1N1 pandemic, use has been expanded to include severe 
pulmonary hypertension, hyperinflated lungs and in all conventional difficult-to-ventilate 
lungs. 
 The H1N1 flu pandemic led to a wider use of VV-ECMO, proving its power in hypoxemic 
emergencies and acute respiratory failure. The indications for VVECMO are supplemented 
by respiratory support as a bridge to lung transplantation, correction of lung hyperinflation 
during chronic obstructive pulmonary disease (COPD) exacerbation and respiratory support 
in patients with the acute respiratory distress syndrome (ARDS), possibly also without 
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mechanical ventilation. In these patients, there is usually no cardiac dysfunction in need of 
support. 
 Acute severe heart failure/cardiogenic shock with a high mortality risk despite optimal 
conventional therapy needs VA-ECMO support. The purpose of this treatment consists 
primarily of recovery of the heart, bridge to a permanent support (e.g., left ventricular assist 
device [LVAD]) or a bridge to heart transplant. When there is acute cardiogenic shock or 
cardiac arrest there is an urgent need for cardiovascular blood flow indicating the need for 
VA-ECMO. 
 In VA-ECMO, oxygen rich blood is given via the artery. In VV-ECMO, venous drained blood 
is oxygenated and given back venously. The conventional access site is the groin although 
there is interest in upper body cannulation for the early mobilization of the patient. By 
drainage of the oxygen-poor blood from the right side of the heart to the external membrane 
oxygenator and back, the oxygenated blood through the arterial tube bypasses the complete 
cardiopulmonary system. This is comparable with cardiac surgery on cardiopulmonary bypass 
(CPB) except that it is for long-term support. In a cardiogenic shock patient there is severe 
circulatory compromise together with low cardiac output, low mean arterial pressure (MAP), 
tachycardia and signs of other organ failure. To achieve sufficient flow to these organs, a more 
or less acceptable blood pressure, tissue perfusion and coronary flow need to be achieved. 
 As familiarity and experience with ECMO have grown, new indications have evolved, 
including emergent resuscitation. This utilization has been termed extracorporeal CPR (ECPR). 
The literature supporting emergent cardiopulmonary support is mounting [2]. Reasonable 
survival rates have been achieved after initiation of support during active compressions of the 
chest following in-hospital cardiac arrest although there are still limitations in practice. For 
example, due to limitations in conventional circuits for ECMO, some centers have developed 
novel systems for rapid cardiopulmonary support [2]. In contrast to deteriorating heart failure 
or cardiogenic shock, in CPR there is no heart activity and the blood pressure (e.g. MAP, RR) 
is totally dependent on ECMO. This device can be implanted during resuscitation in a matter 
of a couple of minutes when there is insufficient flow and severe hypoxia. 
 After initiation of ECMO and end-organ reperfusion, reperfusion damage can occur, 
which has deleterious effects on the heart and blood vessels. Even though there is return of 
circulation, artificial usually for a couple of days, there is a high risk of thrombosis – intracardiac 
and intravascular – and poor cardiac contractility, reperfusion damage, inflammation and 
stasis in and around the great vessels/valves can persist. Conventional hemodynamic 
monitoring may be inadequate to identify such conditions and more sensitive monitoring 
modalities focusing on parenchymal perfusion and oxygenation are needed. 
 This chapter reviews the cardiovascular response to ECMO, with focus on (micro) 
circulatory alterations during ECMO support, potential consequences thereof for daily 
patient care and weaning of ECMO. The different influences of the daily intensive care unit 
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(ICU) practices with different types of fluid infusion, blood transfusion and effects of ECMO 
on cardiopulmonary recovery and end-organ perfusion are also discussed.
MICROCIRCULATORY ALTERATIONS DURING ECMO
VA-ECMO, ECPR and VV-ECMO are used commonly in acute or acute-on-chronic heart or 
lung failure. Until now, macrocirculatory parameters have been used for clinical assessment 
of these patients. Tools for monitoring end-organ recovery at the end of the extracorporeal 
course are lacking. Measured parameters, such as lactate and mixed venous oxygen saturation 
(SvO2) are still surrogates of end-organ perfusion. 
 Long-term ECMO support with continuous flow in the setting of the ICU is somewhat 
comparable to short-term CPB during cardiac surgery. Here too the systemic circulation enters 
the extracorporeal circulation of the heart-lung machine and the blood is exposed to non-
biocompatible polymers, activating blood cells and serum proteins to cause inflammatory 
reactions. Other changes, including hypotension, hemodilution, hypothermia, cardiac 
arrest and a change from pulsatile to non-pulsatile flow, cause a detrimental effect on the 
parenchymal perfusion and microcirculation and can lead to tissue hypoxia and organ failure 
during standard coronary artery bypass graft (CABG) surgery with CPB [4–7]. Off-pump CABG 
can reduce the perioperative complications related to CPB. This less-invasive off-pump CABG 
alternative to on-pump CABG, offers pulsatile flow without the need for an extracorporeal 
circulation. Off-pump CABG has been associated with improved renal and pulmonary 
outcomes, shorter length of hospitalization and a reduction in myocardial injury compared to 
on-pump CABG [8–11]. Some studies have investigated the microcirculatory response to off-
pump CABG. De Backer et al. for example showed that off-pump CABG was also associated 
with a decrease in microcirculatory perfusion [12]. Recently Bienz et al. reported that off 
pump CABG did not preserve postoperative microcirculatory parameters better than on-
pump CABG [13]. They showed that temperature might act as a confounding factor, because 
active warming of patients under CPB could have a positive effect on the microcirculation 
[13]. Several studies have investigated the effects of pulsatility and have generally found no 
advantage between pulsatile and non-pulsatile flow for end-organ perfusion [6, 14–16]. Forti 
et al. showed no differences in microvascular response on reduction of the CPB flow during 
non-pulsatile flow [17]. Consequently, there is limited evidence that pulsatility attenuates 
the deterioration in microvascular perfusion and there are no studies showing adverse 
effects of pulsatility, only studies showing an equal or better effect. Nevertheless when using 
pulsatile flow patterns, which mimic closely the physiological waveforms, there seems to be 
no advantage in terms of organ perfusion or inflammatory response. Moreover, the extent of 
hemolysis and capillary leak is higher compared to non-pulsatile perfusion. Efforts to optimize 
pulsatility therefore seem not to be justified [18]. 
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FLUID MANAGEMENT IN VA-ECMO 
VA-ECMO patients are commonly fluid overloaded due to frequent blood transfusions and 
fluid infusions. The slightest form of hypovolemia results in collapse of the drainage cannula, 
which impairs ECMO blood flow. Usually, patients receive volume to overcome this problem. 
However, current evidence has shown that a positive fluid balance in the early course is highly 
predictive of 90-day mortality [19]. Hypotension can occur due to the reduction in blood 
volume, systemic inflammatory reactions, and increased vascular capacitance with warming 
specifically after ECPR when the patient has rewarmed after therapeutic hypothermia. 
Hypovolemia and/or systemic hypotension affect microcirculatory perfusion [20]. In healthy 
volunteers, controlled hypovolemia decreased the perfused vessel density (PVD) and 
microcirculatory flow index (MFI), and reduced tissue oxygenation [21]. Volume therapy 
using crystalloids or colloids improves cardiac output and tissue perfusion in most cases, 
which is why fluid therapy is considered the most important hemodynamic intervention in 
the postoperative period. 
 Whatever the fluid therapy of choice for VA-ECMO patients, fluid overload is present 
and is associated with increased mortality. In the setting of acute kidney injury (AKI) there will 
be more and earlier need for continuous renal replacement therapy (CRRT). Fluid restriction 
seems to be the trend in the treatment of VAECMO patients although transfusion restriction 
would be inacceptable for patients with bleeding complications. In addition, it must be kept in 
mind that a positive fluid balance causes hemodilution and a reduction in tissue oxygenation. 
 Hemodilution causes a loss of red blood cell (RBC)-filled capillaries and results in 
increased diffusion distances between the oxygen carrying RBCs and tissue cells. Atasever et 
al. compared RBC transfusion to gelatin solutions and no infusion after cardiac surgery and 
studied the effects on microvascular perfusion, vascular density, hemoglobin, and oxygen 
saturation. They found no differences in changes in systemic oxygen delivery, oxygen uptake 
or oxygen extraction between the groups. RBC transfusion however, compared to gelatin 
or no-infusion, increased perfused microcirculatory vessel density, hemoglobin content, and 
saturation in the microcirculation, while microcirculatory blood flow remained unchanged [22]. 
Yuruk et al. showed that RBC transfusion during cardiac surgery recruited the microcirculation 
and led to improve PVD and tissue oxygenation [23]. A recent study by Mukaida et al. showed 
the presence of a compensatory mechanism in patients on CPB in which increased blood 
flow of the microcirculation compensated for the lack of oxyhemoglobin delivery caused by 
hemodilution [24]. Experiences regarding RBC function and behavior in the microcirculation 
in the hemodiluted cardiovascular system make it important to carefully monitor end-organ 
function in VA-ECMO patients and avoid the risks associated with fluid overload. 
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REPERFUSION DAMAGE
Experimental studies and investigations in patients with congenital heart disease have shown 
the usefulness of ECMO for reduction of ischemia and ischemia-induced reperfusion damage 
[25, 26]. The effects of cardiac arrest care on post cardiac arrest reperfusion injury are not well 
known [27]. However, recent data have shown that for refractory cardiac arrest, which includes 
mechanical CPR, peri-arrest therapeutic hypothermia and ECMO are feasible and associated 
with a relatively high survival rate [28]. Several studies have shown that hyperoxemia may 
have deleterious effects, including a decrease in microvascular functional capillary density 
[29–30]. Cardiopulmonary arrest is considered as a short period of myocardial ischemia, 
which may cause microcirculatory deterioration. There are no studies on the microcirculatory 
alterations during intraoperative cardioplegia-induced arrest. Nevertheless, Elbers et al. 
showed that circulatory arrest in humans induced an immediate shutdown of complete 
sublingual small microvessels while flow in larger microvessels persisted [14]. There is also a 
need for studies on the microcirculation that compare ischemia and reperfusion damage in 
patients undergoing ECPR. 
WEANING FROM VA-ECMO
The use of MCS devices should be anticipated, and every attempt made to initiate support 
before the presence of dysfunction of end organs or circulatory collapse. In an emergency, 
these patients can be resuscitated with ECMO and subsequently transitioned to a long-term 
ventricular assist device after a period of stability. But the continuing question should be how 
and when we can remove this MCS device. Removal of MCS devices is challenging. Despite 
improvements in hemodynamic monitoring some patients still die after removal of MCS 
devices. 
 Weaning from VA-ECMO is an important decision-making point in the management of 
these patients and should be guided by both clinical and echocardiography parameters. Echo 
provides the best assessment of native ventricular and valvular function in this setting. Either 
transthoracic echocardiography (TTE) or transesophageal echocardiography (TEE) can be 
used. A baseline echo is performed and any contraindications to weaning should be noted. 
Anticoagulation is optimized to ensure therapeutic anticoagulation unless contraindicated. A 
formalized weaning process should be used so that weaning evaluations can be compared. 
 To evaluate the success of weaning, VA-ECMO flows are reduced in a stepwise fashion. 
Some centers describe weaning by a set percentage of flow. Expected findings on echo to 
support a successful wean include evidence of recruitment of left ventricular and/or right 
ventricular function (qualitatively or quantitatively) and a recruitment of stroke volume 
demonstrated on echo by an increase in left ventricular outflow velocity time interval (VTI) 
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[31]. In an observational study looking at the echocardiography parameters associated with 
successful ECMO weaning, aortic VTI ≥ 10 cm, left ventricular ejection fraction (LVEF) > 
20–25% and lateral mitral annulus peak systolic velocity (TDSa) ≥ 6 cm/sec when the ECMO 
flow was reduced to < 1.5 l/min were predictive of successful weaning from VA-ECMO [32]. 
However, the main limitations in these studies are that only hemodynamically stable patients 
were considered eligible for such a weaning trial. 
 Various methods are being introduced to more effectively guide the weaning process. 
Recently, ECMO weaning guided by miniaturized TEE probes has been described. Tokita et 
al. described the usefulness of N-terminal pro-brain natriuretic peptide (NT-pro-BNP) for 
weaning from intra-aortic balloon pumps (IABPs) [33]. However, the usefulness of biomarkers 
in weaning from ECMO is very controversial. Luyt et al. reported, in contrast to previous 
reports, no additive value of cardiac biomarkers for weaning [34]. 
MICROCIRCULATORY GUIDED WEANING FROM ECMO
Current knowledge about what happens to the microcirculation during support with MCS 
devices is limited. Reis Miranda et al. showed that the mean pulmonary artery pressure 
decreased very fast after initiation of VV-ECMO in patients with respiratory distress syndrome 
[35]. This prompts the question as to what kind of alterations would be seen in such 
circumstances in the microcirculation? 
 In pediatric studies of VA-ECMO, there is evidence of a depressed microcirculation 
persisting over 24 h [36, 37]. In adults there is little literature concerning microcirculatory 
alterations in VV-ECMO and controversial data in VA-ECMO. ECPR is a totally new paradigm 
and there are no studies looking at microcirculatory alterations in ECPR patients. In our 
center, we are testing the hypothesis that the microcirculatory alterations measured using 
new-generation, handheld microscopes, called Cytocam Incident Dark Field (IDF) imaging, in 
response to flow reduction during ECMO can predict the likely success of weaning [38–40] 
(Fig. 1). 
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Figure 1: The conceptual differences between sidestream dark field (SDF) and incident dark field (IDF) imaging. 
Previous generation SDF imaging uses light-emitting diodes (LED) optically isolated from the center reflecting light 
guide and images are captured by a conventional video camera. The new generation Cytocam IDF imaging device 
has a wider field of illumination, a specially designed magnification lens and a computer controlled high-resolution 
image sensor resulting in 30% more capillaries being observed than previous generation hand held microscopy 
devices. Adapted from [40]
Cardiogenic shock is one of the most common causes of death with several underlying 
etiologies, including acute myocarditis, myocardial infarction, and deterioration of chronic 
cardiomyopathy. In these patients, ECMO provides circulatory support while awaiting cardiac 
recovery and allows time to consider other therapies such as heart transplantation or a long-
term LVAD. The timing of weaning a ‘normalized’ cardiovascular system from ECMO is as 
important as management during ECMO, because early or late weaning can cause treatment 
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failure and associated complications. Hemodynamic and echocardiography parameters are 
used to wean from ECMO. However, to date, weaning strategies following ECMO initiation for 
cardiogenic shock have not been reported, and only a few studies have evaluated outcome 
predictors following ECMO institution (e.g., [41]) (Fig. 2).
Figure 2: Recommendations for successful weaning from ECMO. Adapted from [41] with permission. MAP: mean 
arterial pressure; LVEF: Left ventricular ejection fraction; VTI: Velocity time interval; TDSa: tissue Doppler lateral 
mitral annulus peak systolic velocity
CONCLUSION
In this chapter, we have briefly reviewed the cardiovascular response to ECMO, paying 
particular attention to the microcirculatory alterations. With the advent of ECMO, circulatory 
collapse can be treated effectively; however, end-organ recovery is not always successful. 
The appropriate timing of initiating and weaning from ECMO warrant clinical studies. The 
microcirculatory alterations/responsiveness to ECMO may help in these very complex clinical 
issues in this growing mechanical circulatory support population.
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SUMMARY
Short-term mechanical circulatory support (MCS) is increasingly used as a bridge to decision 
in patients with refractory cardiogenic shock. Subsequently, these patients might be bridged 
to durable MCS either as a bridge to candidacy/transplantation, or as destination therapy. 
The aim of this study was to review support duration and clinical outcome of short-term MCS 
in cardiogenic shock, and to analyse application of this technology as a bridge to long-term 
cardiac support (left ventricular assist device, LVAD) from 2006 till June 2016. Using Cochrane 
Register of Trials, Embase and Medline, a systematic review was performed on patients with 
cardiogenic shock from acute myocardial infarction, end-stage cardiomyopathy, or acute 
myocarditis, receiving short-term MCS. Studies on periprocedural, postcardiotomy and 
cardiopulmonary resuscitation support were excluded. Thirty-nine studies, mainly registries 
of heterogeneous patient populations (n = 4151 patients), were identified. Depending on the 
device used (intra-aortic balloon pump, Tandem Heart, Impella 2.5, Impella 5.0, CentriMag 
and peripheral veno-arterial extracorporeal membrane oxygenation), mean support duration 
was (range) 1.6–25 days and the mean proportion of short-term MCS patients discharged was 
(range) 45–66%. The mean proportion of bridge to durable LVAD was (range) 3–30%. Bridge 
to durable LVAD was most frequently performed in patients with end-stage cardiomyopathy 
(22 [12–35]%). We conclude that temporary MCS can be used to bridge patients with 
cardiogenic shock towards durable LVAD. Clinicians are encouraged to share their results in a 
large multicenter registry in order to investigate optimal device selection and best duration 
of support.
Keywords: 
Mechanical circulatory support • Left ventricular assist device • Cardiogenic shock • Heart 
failure
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INTRODUCTION
Refractory cardiogenic shock is a deadly complication of acute myocardial infarction (AMI), 
fulminant myocarditis, and end-stage cardiomyopathy (CMP). Short-term mechanical 
circulatory support (MCS) using different techniques (Supplementary Material, Table S1) has 
become a realistic and cost-effective option to reverse shock [1]. In this way, time can be 
taken to assess and ameliorate secondary organ failures and to predict the chance of cardiac 
recovery (‘bridge to recovery and decision’) [2]. When recovery cannot be expected, a 
multidisciplinary decision has to be made to subsequently bridge the patient either to urgent 
heart transplantation (HTX), or to durable MCS (mainly left ventricular assist device (LVAD) 
implantation as ‘bridge to bridge’ or ‘bridge to destination’) or to withdrawal of support 
(‘bridge to palliative care’)[3]. Due to extremely limited suitable donor hearts and good long 
term function of second generation LVADs, selected severe heart failure patients around the 
world are increasingly being bridged to durable MCS, either as destination therapy or as a 
bridge to candidacy or transplantation [4]. However, the extent and optimal timing of bridging 
towards recovery or long-term MCS in patients with cardiogenic shock being supported with 
short-term MCS is currently unclear. We aimed at reviewing (i) support duration,(ii) outcome 
including feasibility of bridging towards durable LVAD stratified to device and diagnosis, and 
(iii) providing a real life algorithm on the selection of patients receiving short-term support 
who can be bridged successfully to long-term support using optimal timing for changing the 
device.
METHODS
We created this manuscript according to the PRISMA guidelines (see Supplementary Material, 
data for checklist) [5]. 
 Using Cochrane Central Register of Controlled Trials, Embase and Medline, we 
performed a literature search in June 2016 using the following search terms: (i) ‘heart-assist 
devices’ [MeSH Terms] AND(‘heart failure’ [MeSH Terms] OR ‘shock, cardiogenic’ [MeSH 
Terms])AND ‘bridge’ [text word]; and (ii) extracorporeal membrane oxygenation[MeSH 
Terms] OR mechanical circulatory support [text word].Two investigators (C.A.U. and S.A.) 
then independently retrieved potentially eligible reports for evaluation. Both investigators 
independently examined design, patient population and interventions in the reports. A 
methodological filter was used to limit the results to adult humans, published in the last 10 
years (back to the year 2006),in English. We restricted results to the last 10 years given the 
introduction of durable, truly long-term LVADs in the year 2006. In addition, we performed 
hand searching of reference lists of obtained(review) articles, www.clinicaltrials.gov was 
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searched, and conference proceedings were checked. We had contact with several expert 
colleagues to ensure that no potentially eligible studies were missed.
 We selected all retrospective and prospective cohort studies on adult cardiogenic 
shock patients receiving short-term (hours to weeks) MCS for pump failure (i.e. severe 
left or biventricular(Biv) cardiac dysfunction). We excluded reports on patients (primarily)
undergoing high risk (coronary) intervention, with postcardiotomy heart failure, cardiac 
allograft failure or refractory cardiac arrest and case reports. To exclude severely under 
powered, low quality studies, we made (arbitrary) cut-offs for study size (intra-aortic balloon 
pump (IABP) in cardiogenic shock from AMI: at least 100 patients; IABP in end-stage CMP, 
Tandem Heart, Impella and central extracorporeal membrane oxygenation(ECMO): at least 
10 patients; peripheral veno-arterial (VA)-ECMO: at least 50 patients). Studies that included 
a lower number of patients than these cut-offs were excluded.
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Figure 1: Identification of studies.
We evaluated the mode and duration of MCS, the proportion of patients bridged to the 
next therapy or condition (bridge to transplant versus bridge to durable MCS versus bridge 
to recovery versus bridge to palliation), and hospital discharge. Outcomes were stratified 
according to the device that was used. Additional meta-analysis was performed of studies 
stratified to diagnosis in which only studies investigating isolated patients with AMI, acute 
myocarditis, or end-stage CMP/heart failure (ESHF) were included.
Statistical analysis
All data were analysed with SPSS 22.0 (SPSS Inc., Chicago, IL,USA), and MedCalc (MedCalc 
Software, Ostend, Belgium) software. Categorical variables were presented in numbers and 
in percentages. Continuous variables were presented as mean± standard deviation (SD). For 
continuous variables reported as median and interquartile range (IQR), the mean and SD 
were estimated. The mean was estimated by the formula x = (a + 2m+ b)/4 using the values 
of the median (m), P25 and P75 (a and b, respectively) [6]. The estimator SD = interquartile 
range/1.35was used to estimate SD from the interquartile range [7]. For continuous variables 
reported as median and range, we calculated mean ± SD by using the appropriate formulas 
according to the size of the sample as proposed by Hozo et al. [6].
 The final results were presented as mean ± SD or as proportions with the associated 95% 
confidence interval (CI). Heterogeneity between trials, defined as variation among the results 
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of individual trials beyond that expected from chance, was assessed with Cochran’s Q-statistic 
(Phetero) and I2 statistic. As a result of general heterogeneity of patient populations, a 
random effects model was consistently used to calculate averages. Differences between 
groups concerning a binary outcome were tested with a chi-square test. Differences between 
groups concerning a continuous outcome were tested with a t-test (2 groups) or analysis of 
variance(ANOVA, more than 2 groups).
RESULTS
Thirty-nine studies (n = 4151 patients) met our inclusion criteria(Fig. 1). Patients were 
supported with IABP (n = 2527),Tandem Heart (n = 272), Impella 2.5 (n = 343), Impella 5.0 (n 
= 123), CentriMag (n = 128) or VA-ECMO (n = 758). 
We identified 8 studies of patients with AMI complicated by shock (Table 1): 7 were 
registries [8–14] and 1 was a randomized controlled trial (RCT) (IABP-SHOCK II trial: IABP 
versus conventional care) [15]. Most patients had anterior myocardial infarction, where 
the rate of Biv failure was not reported in any study. Support time was reported in only 3 
studies [12, 14, 15]; means ranged from 3.0 to 5.9 days. One study found an association of 
support time and long-term survival: patients being assisted for 6 days or more had worse 
outcome [14]. Patients were bridged to either recovery or palliative care (30%, reported in 
1 study [14]). Most studies presented cohorts from the pre-LVAD era. Thiele et al. reported 
that 3.7% of patients who received an IABP were bridged to durable MCS with good long-
term outcome [15]. More than 55% of patients could be discharged from the hospital. Four 
studies investigated INTERMACS profile type I-II patients receiving prolonged IABP support 
via surgical subclavian (through a graft) [16], percutaneous axillary [17], or femoral access 
[18, 19] (Table 1). Tanaka et al. [16] and Estep et al. [17] succeeded to bridge most patients 
to transplantation. Ntalianis et al. [19] were able to reverse right ventricular dysfunction in 
some patients who had a former contraindication for LVAD implantation. Bridge to LVAD was 
possible in 23 [12–37]% (I2 = 82%, P for heterogeneity <0.001) with 30-day survival greater 
than 80%. Survival rate at discharge was not reported in most studies.
The TandemHeart was investigated in 5 studies: 4 cohort studies [20–23] and 1 RCT (Table 
2) [24]. Occurrence of prior IABP/Impella support was 44–82% [20, 22, 24]. Median support 
time was 5.1 ± 4.8 days. One study provided the protocol for weaning [22]. Bridging to 
durable MCS was performed in 19 [13–27]%. Thirty-day survival in patients bridged to LVAD 
was 60–100%. About half of the patients survived until discharge.
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Six studies reported Impella 2.5 support, predominantly in patients with cardiogenic shock 
from AMI (Table 3) [25–30]. Most patients had anterior myocardial infarction, the rate of Biv 
failure was not reported in any study. Occurrence of prior IABP support was 29–49% [25, 
26]. Support time was short, 1.6 ± 2.7 days. Bridging to LVAD was performed in few patients. 
Forty-seven [35–59]% of patients were discharged alive (P for heterogeneity <0.01). Four 
studies evaluated the use of Impella 5.0 in mixed populations of cardiogenic shock (Table 
3) [31–34]. Occurrence of prior IABP support was 0–52%. Mean support time was 6.1 ± 3.9 
days. Thirty [22–38]% of patients could be bridged to durable MCS with good 30-day survival 
(63–100%). Two studies provided weaning protocols [32, 33]. A relative high proportion of 
patients were discharged alive (64 [55– 72]%).
Four studies investigated central ECMO, mainly in Biv support mode (Table 4) [35–38]. 
Occurrence of prior IABP support was 59–85%. Based on our inclusion criteria we excluded 
cases from two studies and performed the analysis on the remaining patients [35, 36]. 
Support times were relatively long (20 ± 20 days). The weaning protocol was described in 1 
study [35]. Several patients (25 [18–33]%) were bridged towards implantable VAD and 83– 
100% of them were discharged. Survival until discharge was relatively good: 66 [58–74]%. 
We identified 5 cohorts of patients who received peripheral ECMO in cardiogenic shock 
of mixed etiology (Table 5) [39–43]. Prior IABP/Impella support occurred in 31–55% of the 
cases. Support time was longer in patients who survived at least until the next therapy than 
in patients who died [7.1 ± 6.1 vs 5.0 ± 6.9 days, standardized mean difference 0.4 [0.2–0.6], 
P < 0.001, I2 = 0%, Phetero = not significant (NS)]. Cannulation was changed to the subclavian 
or directly central position in 4–18%. Weaning protocols were provided by the groups from 
Padua and Paris [40, 42, 43]. A minority of patients was bridged to transplantation or LVAD. 
Carroll et al. reported that 24% of patients were bridged from ECMO to another form of 
MCS: 53% received durable LVAD, 23% received right ventricle assist device, 13% needed 
short-term biventricular assist device, 7% had right ventricle assist device + durable LVAD, 
and 3% received IABP. Fifty-nine percent of the patients who were bridged to any type of VAD 
survived to discharge, whereas 67% who were bridged to durable LVAD survived to discharge 
[41]. Tarzia et al. [40] demonstrated that recovery of cardiac function was achieved only in 
patients with de novo heart failure. Forty-five [39–51]% of patients survived until hospital 
discharge (P for heterogeneity NS). Three registries were found on peripheral VA-ECMO in 
isolated myocarditis (Table 5) [44–46]. Prior IABP support occurred in 31–65%. Support time 
was 7.0 ± 9.1 days. Hsu et al. [46] provided the protocol for weaning. Most patients (69 
[64–75]%) were weaned and a minority (7 [3–11]%) was bridged towards durable mechanical 
support. Survival until hospital discharge was 64 [58–70]% (P for heterogeneity NS).
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Additional analysis was performed of studies on isolated AMI, myocarditis or end-stage CMP/
heart failure (Table 6).  AMI  (n = 2752): Patients receiving Impella or (central/peripheral) 
ECMO were younger than patients receiving IABP support  (P = 0.04, P < 0.001, respectively). 
Patients receiving ECMO had higher creatinine levels than IABP or Impella patients (both  P < 
0.001). Lactate levels were lower in ECMO patients than in Impella patients (P < 0.05). Impella 
patients underwent cardiopulmonary resuscitation more frequently  than  IABP  patients  (P 
< 0.001). Impella and ECMO patients were more frequently mechanically ventilated than 
IABP patients (both P < 0.001). Support time was highest in ECMO patients and lowest in 
Impella patients (P < 0.001). Bridge to LVAD occurred most frequently in ECMO patients. 
Hospital discharge was greatest in IABP patients and lowest in Impella patients (P < 0.001). 
Myocarditis (n = 279): Isolated myocarditis was only investigated in peripheral ECMO studies. 
End-stage  CMP/heart failure (n = 258): Preoperative cardiopulmonary resuscitation was 
more likely in combined TandemHeart/Impella 5.0 patients than in IABP assisted patients 
(P < 0.001). Support times were greater in patients treated with IABP than in patients who 
received TandemHeart or Impella 5.0 (P < 0.001). TandemHeart/Impella 5.0 patients were 
more  frequently  bridged  towards LVAD (P < 0.01) but heterogeneity among studies was 
high.
DISCUSSION
We provide an overview of recent reports on short-term MCS (IABP, TandemHeart, Impella and 
ECMO) in cardiogenic shock from AMI, end-stage CMP, and myocarditis. Mortality was high 
in all studies. Bridge to durable MCS occurred in all device groups, but was more frequently 
performed in patients with end-stage CMP than in patients with AMI or myocarditis.
 We present a variety of MCS techniques. Pros and cons of these techniques are 
presented in the Supplementary Material, Table S1. For years, the IABP has been first-line 
mechanical support in patients with severe heart failure and cardiogenic shock. However, 
IABP-SHOCK II reported no general benefit in patients with cardiogenic shock from AMI [15]. 
In this trial, the median time needed until haemodynamic stabilization was 3.0 days [15]. The 
IABP is still widely used in clinical practice with hospital discharge rates >50% [47]. However, 
registries did not include patients who did not survive before IABP placement. IABP-SHOCK II 
excluded patients without an intrinsic heart action [15], but these patients were included in 
TandemHeart and ECMO registries. Therefore, the reported outcomes in IABP studies might 
well be biased as a result of not selecting the sickest or dying patients. 
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Figure 2: Current application of short-term mechanical circulatory support and possible timing towards durable left 
ventricular assist device in patients with refractory cardiogenic shock. § Bridge to recovery is only realistic in case of 
de novo heart failure or in acute on chronic heart failure when a clear cause for exacerbation exists.
The majority of IABP studies did not bridge patients towards long-term MCS. Only recently 
have studies been done in patients with end-stage CMP demonstrating promising rates of 
bridge to transplant or long-term MCS. However, most investigators did not report survival 
rate until discharge (Table 1). Patients treated with TandemHeart, Impella 5.0 and peripheral 
ECMO had median support times of 5–6 days. This time was used to stabilize the patient, 
to reverse other organ failure, and to bridge them towards the next therapy. Using these 
3 devices, a bridge to recovery or successful weaning was possible in at least one quarter 
of the patients. A minority of these patients finally did not survive until hospital discharge. 
Patients supported with TandemHeart or Impella 5.0 could be bridged to long-term MCS in 
>25% of the cases, with good long-term outcome. Only a minority of patients treated with 
a peripheral ECMO were bridged to long-term MCS, possibly because more ECMO patients 
were bridged to recovery. Impella 2.5 supported patients had a median support duration 
<2 days, that might be too limited to bridge patients until haemodynamic stabilization. 
Bridging until durable MCS only occurred in few patients in these AMI studies. Most patients 
supported with central ECMO (CentriMag) had Biv failure and long support times and could 
be bridged to implantable VAD in a quarter of patients.
 Complication rates of the IABP are very low and were in fact not different from controls 
in IABP-SHOCK II [15]. All larger bore percutaneous and surgical MCS carry a relatively high 
160
BRIDGE TO BRIDGE IN REFRACTORY CARDIOGENIC SHOCK
9
risk of bleeding [35, 48]. ECMO by femoral approach requires placement of a cannula in the 
superficial femoral artery to ensure antegrade leg perfusion. Mortality was high in all studies. 
Survival until hospital discharge was heterogeneous, however, this was probably primarily 
caused by the fact that the studies included different patient populations (Table 6).
 Although baseline characteristics were lacking in several studies, clear differences across 
device groups were present. In general, patients receiving low-level support (IABP) were less 
sick as compared to patients receiving higher level support. We believe these differences 
may, at least in part, explain the observed differences in outcome.
 Timing and the possibility of durable LVAD implantation depends primarily on the 
severity of other organ failure as well as on possible recovery of ventricular function, and 
consequently determined by the underlying diagnosis of cardiogenic shock (Table 6). Due to 
heterogeneous patient populations, the use of different devices, and the lack of controlled 
studies, it is currently impossible to provide evidence-based recommendations on best timing 
to durable LVAD. We therefore present a broad overview of current application of short-term 
MCS and suggest possible timing (Fig. 2) but individualized decisions taken by a dedicated 
multidisciplinary MCS-team are important.
Limitations
Limitations of our study include the fact that 95% of the studies were uncontrolled registries 
resembling heterogeneous patient populations, treatments and outcomes, as also reflected 
by the multiple significant tests for heterogeneity.
CONCLUSION
We conclude that temporary MCS, with differential support duration according to diagnosis 
and device, can be used to bridge patients towards durable LVAD. To investigate this more 
thoroughly, clinicians are encouraged to share their results in a large multicentre registry 
where at least patient characteristics, diagnosis, the nature of cardiac failure and device and 
timing aspects should be well recorded.
SUPPLEMENTARY MATERIAL
Supplementary material is available at EJCTS online.
Conflict of interest: none declared
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ABSTRACT 
Background:
The aim of the study was to derive and validate a novel risk score for early right-sided heart 
failure (RHF) after left ventricular assist device implantation.
Methods:
The European Registry for Patients with Mechanical Circulatory Support (EUROMACS) was used 
to identify adult patients undergoing continuous-flow left ventricular assist device implantation 
with mainstream devices. Eligible patients (n=2988) were randomly divided into derivation 
(n=2000) and validation (n=988) cohorts. The primary outcome was early (<30 days) severe 
postoperative RHF, defined as receiving short- or long-term right-sided circulatory support, 
continuous inotropic support for ≥14 days, or nitric oxide ventilation for ≥48 hours. The secondary 
outcome was all-cause mortality and length of stay in the intensive care unit. Covariates found 
to be associated with RHF (exploratory univariate P<0.10) were entered into a multivariable 
logistic regression model. A risk score was then generated using the relative magnitude of 
the exponential regression model coefficients of independent predictors at the last step after 
checking for collinearity, likelihood ratio test, c index, and clinical weight at each step.
Results: 
A 9.5-point risk score incorporating 5 variables (Interagency Registry for Mechanically Assisted 
Circulatory Support class, use of multiple inotropes, severe right ventricular dysfunction on 
echocardiography, ratio of right atrial/ pulmonary capillary wedge pressure, hemoglobin) was 
created. The mean scores in the derivation and validation cohorts were 2.7±1.9 and 2.6±2.0, 
respectively (P=0.32). RHF in the derivation cohort occurred in 433 patients (21.7%) after left 
ventricular assist device implantation and was associated with a lower 1-year (53% versus 
71%; P<0.001) and 2-year (45% versus 58%; P<0.001) survival compared with patients without 
RHF. RHF risk ranged from 11% (low risk score 0–2) to 43.1% (high risk score >4; P<0.0001). 
Median intensive care unit stay was 7 days (interquartile range, 4–15 days) versus 24 days 
(interquartile range, 14–38 days) in patients without versus with RHF, respectively (P<0.001). 
The c index of the composite score was 0.70 in the derivation and 0.67 in the validation 
cohort. The EUROMACS-RHF risk score outperformed (P<0.0001) previously published scores 
and known individual echocardiographic and hemodynamic markers of RHF.
Conclusions:
This  novel  EUROMACS-RHF  risk  score  outperformed  currently known risk scores and 
clinical predictors of early postoperative RHF. This novel score may be useful for tailored 
risk-based clinical assessment and management of patients with advanced HF evaluated for 
ventricular assist device therapy.
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CLINICAL PERSPECTIVE
What Is New?
•  This project provides a novel and simple risk score for right-sided heart failure in adults 
undergoing left ventricular assist device implantation with current mainstream devices.
•  Using 2988 adults (age >18 years) who underwent continuous-flow left ventricular 
assist device implantation across the European Union in the largest EU Registry of 
mechanical circulatory support devices, we derived and validated a right-sided heart 
failure prediction model that outperformed several published scores and well-known 
hemodynamic and echocardiographic individual markers of right-sided heart failure.
•  The right-sided heart failure prediction model included the following risk factors: need 
of ≥3 inotropic agents, Interagency Registry for Mechanically Assisted Circulatory 
Support class 1 through 3, severe right ventricular dysfunction on semi-quantitative 
echocardiography, ratio of right atrial to pulmonary capillary wedge pressure >0.54, and 
hemoglobin ≤10 g/dL.
What Are the Clinical Implications?
•  Our findings offer a step toward improving prediction of the risk of right-sided heart 
failure among patients undergoing left ventricular assist device implantation.
•  This score may help to target future optimal strategies aiming at early and intensive right-
sided heart failure management for the highest-risk subgroups of the left ventricular 
assist device population.
•  Future studies should determine whether early right ventricular assist device 
implantation or intensive right-sided heart failure medication can improve survival and 
reduce intensive care unit stay among left ventricular assist device candidates at high 
risk for right-sided heart failure.
173
CHAPTER 10
INTRODUCTION
Continuous-flow left ventricular (LV) assist devices (LVADs) are increasingly used in patients 
with end-stage heart failure (HF) as a bridge to transplantation, a bridge to candidacy, or 
destination therapy (DT). The 1-year survival reported for patients treated with continuous-
flow LVAD was ≈80% and 73% in the Interagency Registry for Mechanically Assisted 
Circulatory Support (INTERMACS) and the European Registry for Patients with Mechanical 
Circulatory Support (EUROMACS), respectively.1,2 Early post-LVAD mortality is due partly to 
the development of right-sided HF (RHF) in the early post-LVAD phase.3 The pathophysiology 
of RHF, however, is not well known.4,5 Post-LVAD RHF has been reported to be between 
4% and 50%,6–10 and RHF-associated 6-month mortality was seen in up to 29% of patients 
receiving an LVAD.11 Moreover, RHF has a greater impact in patients who receive LVAD as DT, 
for whom there is no opportunity for bailout with heart transplantation.
 Management of RHF depends primarily  on  the  timing and severity of the condition. 
Patients with severe preoperative RHF are usually considered for biventricular support. In 
primary LVAD operations, post-LVAD patients with RHF often require prolonged inotropic 
support, nitric oxide (NO) ventilation, prolonged intensive care unit (ICU) stay, or temporarily 
a right ventricular (RV) assist device.
 Prediction and early recognition of RHF could help in timely intervention and thus 
improvement of patients’ outcome. Several prediction scores of RHF in patients with LVAD 
have been proposed.9,11–13 Those prediction scores have mostly been based on earlier-
generation LVADs and were derived from rather small populations or heterogeneous LVADs.
 The objective of this study was to develop and validate a new simple score to predict 
early post-LVAD RHF in a large population with continuous-flow LVADs from the EUROMACS 
Registry.
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METHODS
The Euromacs Registry
The EUROMACS is a registry of the European Association for Cardio-Thoracic Surgery. The 
registry gathers data for scientific analyses, aimed at improving care of patients with end-
stage HF who require mechanical circulatory support.2 All relevant clinical, echocardiographic, 
hemodynamic, and laboratory parameters were prospectively collected by participating sites 
in the EUROMACS Registry and entered into an electronic database (see Appendix I in the 
online-only Data Supplement for the list of the EUROMACS sites and investigators [alphabetic 
according to country]). The EUROMACS Registry began officially in January 1, 2011, but sites 
were also allowed to collect data retrospectively from patients who were already implanted 
before that date. A protocol for data collection and data entry, including all relevant data for 
the registry, was provided to all participating centers before data entry was allowed. Details 
of the registry and data collection are described elsewhere.2 This study was approved by the 
institutional review committee of all respective participating centers, and all subjects gave 
informed consent.
Study Design
The present study was approved by the EUROMACS Committee. All patients (n=3897) 
undergoing LVAD implantation between January 2006 and May 2017 were identified. We 
excluded patients <18 years of age (n=171) and patients with primary devices (total artificial 
heart, single-ventricle assist device) other than LVAD (n=97). Devices other than mainstream 
(n=641) were also excluded (Figure 1).
Study outcome 
The primary outcome was early (<30 days) severe postoperative RHF, defined as receiving 
short- or long-term right-sided circulatory  support,  continuous  inotropic  support  for  ≥14 
days, or NO ventilation for ≥48 hours.14 The secondary outcome was all-cause mortality and 
length of stay in the ICU. We used a hierarchy selection of the components of RHF definition 
in which the need for RV assist device has the strongest weight, the prolonged use of 
inotropes comes next, and the use of inhaled NO comes last. Of note, only a small minority 
were defined on the basis of the last outcome component.
Potential Predictors of RHF
We examined 82 potential preoperative predictors and cardiopulmonary bypass (CPB) time 
for the association with RHF. Preoperative clinical data included age, sex, body surface area, 
body mass index, ethnic origin and blood group type, HF etiology, New York Heart Association 
functional class, and INTERMACS  class.15   Comorbidity  factors  included  diabetes mellitus, 
history  of  neurological  events,  carotid  artery  disease, history of cardiac arrest, use of 
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mechanical ventilation, use of feeding tube,  implantable cardioverter-defibrillator, history 
of major myocardial infarction, previous cardiac  surgery, renal dialysis, ultrafiltration, and 
positive blood culture. Furthermore, LVAD strategies such as DT, use of an intra-aortic balloon 
pump, and use of extracorporeal membrane oxygenator were also included. 
 The preoperative use of HF medication included individual medications such as milrinone, 
dobutamine, dopamine, levosimendan, vasopressors, norepinephrine, and  epinephrine, as 
well as the use of ≥3 intravenous inotropes. Amiodarone, angiotensin-converting enzyme 
inhibitors, β-blockers, aldosterone antagonists, loop diuretics, and anticoagulants were also 
examined.
 Preoperative echocardiographic parameters were recorded and analyzed in accordance 
with published guidelines,16,17 including tricuspid annular plane systolic excursion, RV 
dysfunction on visual score, LV diastolic and systolic dimensions and volumes, LV ejection 
fraction, and mitral, aortic, and tricuspid valvular regurgitation. Median duration of 
echocardiographic  data  collection  before  LVAD  surgery  was  6 days. Severity of valvular 
regurgitation was graded as none, trivial,  mild,  moderate,  or  severe  according  to  published 
guidelines.18,19
 Hemodynamic predictors included cardiac rhythm, heart rate, systolic and diastolic blood 
pressures, and Swan-Ganz recordings. The Swan-Ganz recordings included systolic, diastolic, 
and mean pulmonary artery (PA) pressure; right atrial (RA) pressure; transpulmonary gradient; 
pulmonary  vascular resistance; pulmonary capillary wedge pressure (PCWP); pulmonary and 
systemic vascular resistance; stroke  index; and cardiac index. The transpulmonary gradient 
was calculated as the difference between the PA mean pressure and PCWP, which has a 
normal value of ≤12 mm Hg. Pulmonary vascular resistance is calculated as transpulmonary 
gradient divided by cardiac output, which has a normal value of <3 Wood units (or 240 
dynes·s·cm−5). The ratio of RA to PCWP and the PA pulsatility index were also calculated. The 
RV systolic work index was calculated as follows: RV stroke volume index×(mean PA pressure−
central venous pressure)×0.0136 expressed in grams per square meter per beat. The factor 
0.0136 was used to covert pressure (millimeters of mercury) into work (grams per square 
meter). Normal values are 5 to 10 g/m2 per beat.
 Candidate laboratory variables included serum sodium and potassium levels; renal 
function parameters, including blood urea nitrogen; serum creatinine levels; and liver function 
parameters, including alanine transaminase, aspartate transaminase, lactate dehydrogenase, 
total bilirubin, and serum albumin levels. In addition, white blood count, platelets count, 
hemoglobin level, and serum C-reactive protein were evaluated.
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Figure 1:  Flowchart  of  the  study  population. EUROMACS indicates European Registry for Patients With Mechanical 
Circulatory Support; LVAD, left ventricular assist device; SVAD, single-ventricle assist device; and TAH, total artificial 
heart. 
Statistical Analysis
Patient characteristics are described as means (SD) or medians (interquartile range [IQR]) 
for continuous variables and frequency (percentage) for categorical variables. Differences 
between patient groups were evaluated for continuous variables by the Student t tests 
(gaussian distribution) or nonparametric Mann-Whitney-U tests (nongaussian distribution) 
and for categorical variables with the χ2 test. 
 Univariate logistic regression analysis was applied to relate a broad range of preoperative 
parameters to the study outcome, including demographics, clinical values, comorbidities, 
medications, and echocardiographic, hemodynamic, and laboratory parameters. Variables 
with a value of P<0.10 entered the multivariate stage, and a logistic regression model was 
constructed to predict early post-LVAD RHF, applying the stepwise forward method, with 
a value of P=0.05 a modelentry criterion. All variables were checked for multicollinearity 
assumption using correlations, tolerance, and variable inflation factor to avoid redundancy in 
the prediction model. Casewise diagnostics were done, as well as a check for the Mahalonobis 
and Cook distances for outliers. Outliers outside 3 SD were omitted.
 Dichotomization of all relevant continuous variables was performed at the 25th 
percentile (systolic blood pressure, diastolic blood pressure, cardiac index, PA pulsatility 
index, RV stroke work index, serum albumin, serum hemoglobin, and platelets), at the 50th 
percentile (body surface area, tricuspid annular plane systolic excursion, LV end-diastolic 
diameter, LV end-diastolic volume, systolic PA pressure, diastolic PA pressure, transpulmonary 
gradient,  RA pressure,  systemic vascular resistance, and RA/PCWP ratio), or at the 75th 
percentile (heart rate, CPB time, serum creatinine, serum alanine transaminase, serum 
aspartate transaminase, lactate dehydrogenase, total bilirubin, white cell count, and serum 
C-reactive protein). Dichotomization was based mainly on clinical relevance such as using the 
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25th percentile for a variable with a known association of its lower value and worse outcome 
and vice versa. In some cases such as the RA/PCWP ratio, we used the  receiver-operating 
characteristic  (ROC)  curve  area  under the curve (AUC) analysis to calculate the best cutoff 
point for its association with RHF.
 The relative magnitude of the model regression coefficients from statistically significant 
variables in the final multivariable model was used to calculate an individual patient’s risk score 
for the development of post-LVAD RHF. The model discrimination abilities were evaluated by 
the c index of the final multivariate model. ROC curve analysis of the EUROMACS-RHF risk 
score was compared with published risk scores and with individual known markers of RHF. 
Finally, we validated the risk model in the validation cohort. The optimal cutoff value for the 
EUROMACS-RHF risk score was calculated through the ROC curve and the respective Youden 
index.
 We handled the missing data by performing multiple imputations of all relevant 
parameters in the entire popu lation. SPSS version 24 was used for multiple imputations 
using the automated function. After analyzing the patterns of missing values in the data set, 
we used the built-in automatic method that perform imputations based on data scanning. 
The automatic method scans the data and uses the monotone method if the data show a 
monotone pattern of missing values; otherwise, fully conditional specification is used. A 50% 
limit for the missing data was set to exclude variables with excessive missing data. No relevant 
parameter had >10% missing data. Furthermore, the vast majority of variables that were 
included in the final multivariable regression model had <5% missing data. 
 The incidence rate of post-LVAD RHF was calculated over the follow-up period. We 
plotted Kaplan-Meier curves for the occurrence of up to 2-year all-cause mortality according 
to the presence or absence of post-LVAD RHF and stratified by the EUROMACS-RHF risk score 
categories. The log-rank test was used to examine time to mortality differences in the Kaplan-
Meier analyses. A 2-tailed value of P<0.05 was considered statistically significant, and all 
statistics were undertaken with SPSS statistics version 24 (IBM Corp, Armonk, NY) and the 
R-statistical package.
RESULTS
Patient Population
The final study population comprised 2988 patients with a mean age of 53±13 years and 523 
women (18%). The majority were white (68%, n=2022). The main type of HF was nonischemic 
(66%,  n=1985). The main indication for LVAD was bridge to candidacy (37%, n=1102), 
followed by bridge to transplantation (24.5%, n=731). HeartWare HVAD was the most used 
LVAD brand (50.5%, n=1509), followed by HeartMate II (40.3%, n=1204), and the minority 
received HeartMate 3 (8%, n=240). 
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Derivation and Validation Cohorts
The final study patients were randomly divided into derivation (67%, n=2000) and validation 
(33%, n=988) cohorts. Both cohorts were well matched in key baseline and operative 
characteristics (Tables 1 and 2). Mainstream device brands were HeartMate II (40% [n=800] 
versus 41% [n=404]), HeartMate 3 (9% [n=169] versus 7% [n=71]) (both manufactured by 
Thoratec Corp, now Abbott Laboratory, Pleasanton, CA), and HeartWare HVAD  System 
(50%  [n=1007]  versus  51%  [n=502]) (manufactured by HeartWare Corp, now Medtronic, 
Framingham, MA) in the derivation and validation cohorts, respectively (P=NS). The 3 main 
indications for LVAD were as bridge to transplantation (25% [n=490] versus 24% [n=241]), 
bridge to candidacy (38% [n=754]  versus  35%  [n=348]),  and  DT  (17%  [n=333] versus 17% 
[n=170]) in the derivation and validation cohorts, respectively (P=NS; Table 2).
Table 1: Baseline Characteristics of Patients Undergoing Left Ventricular Assist Device 
Variables Derivation Cohort 
(n=2000)
Validation Cohort  
(n=988)
P Value
Demographics
Age, y 53±13 53±12 0.71
Female sex, n (%) 344 (17) 179 (18) 0.54
Body surface area, m2 1.96±0.23 1.97±0.23 0.11
Body mass index, kg/m2 26.0±5.1 26.3±4.9 0.18
White race, n (%) 1347 (67) 675 (68) 0.36
Nonischemic origin, n (%) 1335 (67) 650 (66) 0.60
Blood type O, n (%) 733 (37) 359 (36) 0.60
NYHA functional class, n (%) 0.93
III 635 (32) 299 (30)
IV 805 (40) 404 (41)
INTERMACS class, n (%) 0.57
1 222 (11) 111 (11)
2 630 (32) 297 (30)
3 513 (26) 263 (27)
≥4 559 (28) 275 (28)
IABP, n (%) 198 (10) 76 (8) 0.06
VA-ECMO, n (%) 178 (9) 95 (10) 0.52
Intravenous medication, n (%)
Use of vasopressors 410 (21) 208 (21) 0.71
Use of ≥3 inotropes 239 (12) 119 (12) 0.93
Laboratory values
Serum creatinine, mg/dL 1.20 (0.95–1.60) 1.20 (0.92–1.60) 0.69
AST, U/L 32 (22–63) 32 (22–77) 0.54
Total bilirubin, mg/dL 1.30 (0.82–2.09) 1.30 (0.79–2.10) 0.46
Albumin, g/dL 3.6 (3.0–4.2) 3.6 (2.9–4.2) 0.75
Hemoglobin, g/dL 12.2 (10.5–13.9) 11.7 (10.1–13.6) 0.78
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Table 1, continued
Hemodynamic
RA pressure, mm Hg 11 (7–15) 9 (6–15) 0.11
PCWP, mm Hg 25 (16–30) 22 (17–28) 0.91
PAPI 2.55 (1.50–3.75) 2.88 (1.65–4.25) 0.29
PAP, mean, mm Hg 35 (29–43) 34 (27–44) 0.58
RVSWI, g/m2  per beat 6.7 (4.1–10.2) 6.8 (4.5–9.6) 0.91
RA/PCWP 0.48 (0.31–0.78) 0.42 (0.29–0.67) 0.12
Echocardiographic
Severe RV dysfunction, n (%) 192 (10) 91 (9) 0.83
TAPSE, mm 14 (12–16) 15 (13–17) 0.59
Severe tricuspid regurgitation, n (%) 278 (14) 113 (11) 0.29
Severe mitral regurgitation, n (%) 218 (11) 134 (14) 0.97
LVEF grade <20%, n (%) 718 (36) 405 (41) 0.80
All continuous values are presented in mean±SD unless stated otherwise or presented as median (IQR).AST 
indicates serum aspartate transaminase; IABP, intra-aortic balloon pump; INTERMACS, Interagency Registry for 
Mechanically Assisted Circulatory Support (for INTERMACS classes, see text for details); LV, left ventricular; LVAD, 
left ventricular assist device; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; PAP, 
pulmonary artery pressure; PAPI, pulmonary artery pulsatility index; PCWP, pulmonary capillary wedge pressure; 
PVR, pulmonary vascular resistance; RA, right atrial; RV, right ventricular; RVSWI, right ventricular stroke work 
index; TAPSE, tricuspid annular plane systolic excursion; and VA-ECMO, veno-arterial extracorporeal membrane  
oxygenator..
Early Post-LVAD RHF
LVAD implantation was complicated by RHF in 433 patients (21.7%) in the early 30-day post-
LVAD period. Diagnosis of RHF was based on the need for postoperative mechanical RV 
support in 141 patients (7.1%), the need for prolonged postoperative inotropic support in 
327 (16.4%), and the need for prolonged NO ventilation in 17 (1%). Median time to RV assist 
device implantation was 1 day (IQR, 0–5 days). Components of RHF definition are shown on 
Figure I in the online-only Data Supplement.
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Table 2: Operative Characteristics of Patients Undergoing Left Ventricular Assist Device Implantation
Operative characteristics Derivation Cohort 
(n=2000)
Validation Cohort  
(n=988)
P Value
Main LVAD strategy, n (%) 0.20
BTT (on the list) 490 (25) 241 (24)
BTC (possible BTT) 754 (38) 348 (35)
DT 333 (17) 170 (17)
LVAD device brand, n (%) 0.68
HeartMate II 800 (40) 404 (41)
HeartMate 3 169 (9) 71 (7)
Heart Ware HVAD 1007 (50) 502 (51)
Surgical duration
CPB time, min 85 (65–115) 85 (63–115) 0.89
Surgery time, min 212 (175–298) 220 (180–286) 0.55
BTC indicates bridge to candidacy; BTT, bridge to transplantation; CPB, cardiopulmonary bypass; DT, destination 
therapy; and LVAD, left ventricular
Logistic Regression Analysis for Early Post-LVAD RHF
Exploratory  univariate  logistic  regression  analysis for early post-LVAD RHF yielded 58 
potential covariates (P<10) of 83 tested variables, which are listed in Tables 3 and 4, as clinical, 
medication, laboratory, echocardiographic, hemodynamic, and operative co-variates (Table 
5). Covariates were eliminated because of reasons mentioned above such as collinearity, 
resulting in 21 variables in the multivariable model. Significant predictors of early post-
LVAD RHF in the derivation cohort included INTERMACS class, need for multiple intravenous 
inotropes, severe RV dysfunction, RA/PCWP ratio, and hemoglobin. The final model has a c 
index of 0.70 in the derivation cohort.
 Patients in INTERMACS class 1 through 3 had a 27% risk of RHF versus 12% risk for those 
in INTERMACS class 4 through 7 (P<0.001). Additionally, patients on ≥3 inotropic agents in 
the preoperative period had 42% risk of RHF versus 22% risk for those on ≤2 inotropic agents 
(P<0.001). In terms of semi-quantitative echocardiographic assessment, patients with severe 
RV dysfunction on visual score had 50% risk of RHF versus 23% for those with better RV 
function. Furthermore, patients with an RA/PCWP ratio >0.54  had  27.1% risk of RHF versus 
16.1% for those with lower ratio (P<0.001). Finally, patients with hemoglobin ≤10 g/dL had 
35% risk of RHF versus 23% risk for those with hemoglobin >10 g/dL (P<0.001).
EUROMACS-RHF Risk Score
With the use of the relative magnitude of the coefficient of regression in the multivariable 
model in the derivation cohort, points were assigned to the 5 covariates (Table 6). Values 
were rounded to the nearest integer to simplify the calculation of the composite risk score in 
routine clinical practice. A total 9.5-point score was generated. 
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Table 3: Exploratory Unadjusted Univariable Analysis for Outcome of Early Postoperative Right-Sided Heart Failure 
After Left Ventricular Assist Device Implantation in the Derivation Cohort
Covariate Univariable Analysis OR (95% CI) P Value
Demographic and clinical characteristics
Age (per 1-y increase) 1.005 (0.996–1.013) 0.27
Female sex 1.032 (0.780–1.366) 0.83
Body surface area (per 1-m2 unit increase) 1.501 (0.933–2.414) 0.09
Body mass index (per 1-kg/m2 unit increase) 1.018 (0.997–1.039) 0.10
Race (white vs others) 3.785 (2.829- 5.064) <0.001
Heart failure origin (nonischemic vs ischemic) 0.986 (0.787–1.236) 0.91
NYHA functional class (IV vs III) 1.677 (1.354–2.078) <0.001
INTERMACS (1–3 vs 4–7) 2.969 (2.218–3.974) <0.001
Blood type O (yes vs no) 1.153 (0.926–1.435) 0.20
Diabetes mellitus (yes vs no) 1.142 (0.505–3.055) 0.64
History of CVA (yes vs no) 0.966 (0.665–1.404) 0.86
Symptomatic PVD (yes vs no) 1.173 (0.742–1.856) 0.50
History of cardiac arrest (yes vs no) 2.240 (1.494–3.357) <0.001
Use of mechanical ventilation (yes vs no) 2.457 (1.803–3.348) <0.001
Use of feeding tube (yes vs no) 3.485 (2.382–5.099) <0.001
ICD implantation (yes vs no) 1.054 (0.848–1.310) 0.63
COPD (yes vs no) 0.757 (0.529–1.083) 0.13
Prior major MI (yes vs no) 1.536 (1.536- 2.076) 0.005
Prior cardiac surgery (yes vs no) 1.501 (1.102- 2.045) 0.01
Renal replacement therapy (yes vs no) 4.191 (2.427–7.237) <0.001
Ultrafiltration (yes vs no) 2.332 (1.497–3.635) <0.001
Intra-aortic balloon pump (yes vs no) 1.983 (1.450–2.712) <0.001
VA-ECMO (yes vs no) 3.565 (2.596–4.896) <0.001
Medication use
Use of vasopressors 3.026 (2.373–3.858) <0.001
≥3 Intravenous inotropes 2.601 (1.953–3.466) <0.001
Amiodarone 1.787 (1.415–2.257) <0.001
ACE inhibitors 0.772 (0.611–0.975) 0.03
β-Blockers 0.521 (0.410–0.662) <0.001
Aldosterone antagonists 0.611 (0.477–0.783) <0.001
Loop diuretics 1.529 (1.067–2.193) 0.02
Anticoagulant therapy 3.040 (2.284–4.045) <0.001
ACE  indicates  angiotensin-converting  enzyme;  CI,  confident interval; COPD, chronic obstructive pulmonary disease; 
CVA, cerebral vascular accident; ICD, implantable cardioverter-defibrillator; INTERMACS, Interagency Registry for 
Mechanically Assisted Circulatory Support; MI, myocardial infarction; NYHA, New York Heart Association; OR, odds 
ratio; PVD, peripheral vascular disease; and VA-ECMO, veno-arterial extracorporeal membrane oxygenator
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Predictive Power of the EUROMACS-RHF Risk Score in the Derivation Cohort
The mean score in the derivation cohort was 2.7±1.9, ranging from 0 to 9.5 (Figure 2A). 
Likewise, data on the operative EUROMACS-RHF risk score are shown in Figure 2B. The 
predicted rate of RHF was significant (P for linear trend <0.001) increased from 11% for a score 
of 0 to 2 to 43.1% for a score of >4 (Figure 3A). Sensitivity, specificity , positive likelihood ratio, 
negative likelihood ratio, positive predictive value, and negative predictive value according to 
the EUROMACS-RHF risk score are presented in Table I in the online only Data Supplement, 
and those of the operative EUROMACS-RHF risk score are presented in Table II in the online-
only Data Supplement.
Validation of the EUROMACS-RHF Risk Sore
The mean score in the validation cohort was 2.6±2.0, ranging from 0 to 8.5 (Figure 2A). The 
predicted rate of RHF was similar and significant (P<0.001 for linear trend) increased from 
12.5% for a score of 0 to 2 to a 42.4% for a score of >4 (Figure 3B). The c index was 0.70 in the 
derivation versus 0.67 in the validation cohort (Figure II in the online-only Data Supplement).
 The Hosmer-Lemeshow goodness-of fit P value was 0.61 in the validation cohort, which 
reflects an appropriate fit for the data in this cohort. A comparison of the ROC curve of 
the EUROMACSRHF risk score with a modified score that includes CPB time >100 minutes 
and 2 previously published RHF scores derived from continuous-flow LVAD populations 
demonstrated higher AUC for the EUROMACS-RHF risk score compared with the Kormos et 
al11 (P<0.001) score and the Central Venous Pressure >15 mmHg, Severe RV Dysfunction, 
Preoperative Intubation, Severe Tricuspid Tegurgitation, Tachycardia21 (P<0.001) score (Table 
7). AUC was similar for the EUROMACS-RHF and modified postoperative EUROMACS-RHF 
scores (P=0.41). ROC curve comparison with other individual known hemodynamic and 
echocardiographic markers of RV failure demonstrated the highest AUC for the EUROMACS-
RHF score (all P<0.001).
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Table 4: Exploratory Unadjusted Univariable Analysis for Outcome of Early Postoperative Right- Sided Heart Failure 
After Left Ventricular Assist Device Implantation in the Derivation Cohort Using Laboratory, Echocardiographic, and 
Hemodynamic Characteristics
Covariate Univariable Analysis OR (95%CI) P value
Laboratory characteristics
Sodium 1.010 (1.002–1.018) 0.01
Potassium 1.237 (1.075–1.425) 0.003
BUN 1.004 (1.002–1.007) 0.001
Creatinine (per 1-unit increase) 1.407 (1.213–1.632) <0.001
Creatinine >2.3 mg/dL (75%) 2.373 (1.662–3.389) <0.001
AST >37 U/L 2.091 (1.661–2.633) <0.001
ALT >72 IU/L 2.400 (1.736–3.319) <0.001
LDH (>445 vs ≤445 U/L) 1.554 (1.173–2.058) 0.002
Total bilirubin >2 mg/dL 1.620 (1.260–2.082) <0.001
Albumin (<3.3 vs ≥3.3 g/dL) 1.107 (0.809–1.515) 0.52
WBCs 1.050 (1.026–1.074) <0.001
Hemoglobin ≤10 g/dL 1.628 (1.281–2.070) <0.001
Platelets 0.996 (0.996–0.998) <0.001
HCO3 (per 1-mEq/dL increase) 0.996 (0.963–1.030) 0.80
Echocardiographic characteristics
Severe RV dysfunction 3.535 (2.578–4.848) <0.001
LV end-diastolic diameter (per 1-mm increase) 1.003 (1.000–1.006) 0.04
LV end-systolic diameter (per 1-mm increase) 1.004 (1.000–1.009) 0.05
LV end-diastolic volume (per 1-mL increase) 0.998 (0.995–1.001) 0.11
LV end-systolic volume (per 1-mL increase) 0.998 (0.994–1.002) 0.36
TAPSE (≤14 vs >14 mm) 1.241 (0.847–1.817) 0.27
LV ejection fraction (<20% vs >20%) 1.780 (1.391–2.278) <0.001
Severe vs less severe mitral regurgitation 0.550 (0.389–0.777) 0.001
Severe vs less severe tricuspid regurgitation 0.917 (0.666–1.262) 0.59
Severe vs less severe aortic regurgitation 4.888 (1.483–16.114) 0.009
Hemodynamic characteristics
Nonsinus vs sinus rhythm 1.202 (0.957–1.508) 0.11
Heart rate (≥96 vs <96 bpm) 1.445 (1.141–1.832) 0.002
Systolic blood pressure (≤85 vs >85 mm Hg) 1.623 (1.202–2.190) 0.002
Diastolic blood pressure (≤52 vs >52 mm Hg) 1.629 (1.199–2.213) 0.002
Cardiac index (≤1.2 vs >1.2 L/min) 0.817 (0.482–1.387) 0.46
PAP, systolic (≥53 vs <53 mm Hg) 1.220 (0.919–1.620) 0.17
PAP, diastolic (≥27 vs <27 mm Hg) 0.818 (0.617–1.085) 0.16
PAP, mean (≥35 vs <35 mm Hg) 0.967 (0.730–1.282) 0.82
RA pressure (≥11 vs <11 mm Hg) 1.729 (1.279–2.338) 0.001
PCWP (≥12 vs <12 mm Hg) 1.086 (0.649–1.819) 0.75
SVR (≥1488 vs <1488 mm Hg) 0.712 (0.479–1.059) 0.09
TPG (≥12 vs <12 mm Hg) 1.043 (0.758–1.436) 0.80
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PVR (≥3.3 vs <3.3 mm Hg) 0.163 (0.027–0.983) 0.05
PAPI (≤1.6 vs >1.6) 2.175 (1.584–2.988) <0.001
RVSWI (≤4.6 vs >4.6 g/m2 per beat) 1.481 (1.051–2.086) 0.03
RA/PCWP (>0.54 vs ≤0.54) 2.075 (1.383–3.112) <0.001
ALT indicates alanine transaminase; AST, serum aspartate transaminase; BUN, blood urea nitrogen; CI, confidence 
interval; HCO, bicarbonates; LDH, lactate dehydrogenase; LV, left ventricular; OR, odds ratio; PAP, pulmonary artery 
pressure; PAPI, pulmonary artery pulsatility index; PCWP, pulmonary capillary wedge pressure; PVR, pulmonary 
vascular resistance; RA, right atrial; RV, right ventricular; RVSWI, right ventricular stroke work index; SVR, systemic 
vascular resistance; TAPSE, tricuspid annular plane systolic excursion; TPG, transpulmonary gradient; and WBC, 
white blood cell.
EUROMACS-RHF Risk Score and All-Cause Mortality
Cumulative survival in the postoperative 24 months was higher in patients without RHF at 
the 6-month (79% versus 61%), 12-month (71% versus 53%), 18-month (65% versus 49%), 
and 24-month (58% versus 45%) follow-up compared with patients with RHF (log-rank test, 
P<0.001; Figure 4A). Likewise, cumulative survival in the postoperative 24 months was at the 
6-month (80% versus 66% versus 56%), 12-month (73% versus 60% versus 48%), 18-month 
(66% versus 54% versus 46%), and 24-month (61% versus 46% versus 43%) follow-up patients 
with low, intermediate, and high EUROMACS-RHF risk score, respectively (log-rank test, 
P<0.001; Figure 4B). Multiorgan failure and sepsis were the most frequent primary causes of 
death, in particular in patients with RHF. Other common causes of death were cerebrovascular 
accidents, bleeding, and cardiopulmonary failure (Figure 5). Multiorgan failure was seen in 
50% of patients who died with sepsis ast he primary cause of death.
Table 5:  Exploratory Unadjusted Univariable Analysis of Operative Characteristics for Outcome of Early Postoperative 
Right-Sided Heart Failure After Left Ventricular Assist Device Implantation in the Derivation Cohort
Covariate Univariable Analysis OR (95%CI) P Value
LVAD strategy
BTT vs other 0.441 (0.334–0.583) <0.001
LVAD device brand
HeartMate II 1 (Reference)
HeartMate III 1.734 (1.364–2.204) <0.001
HeartWare HVAD 1.803 (1.211–2.684) 0.004
Surgical duration
CPB time (per 10-min increase) 1.041 (1.020–1.062) <0.001
CPB time >100 min (yes vs no) 1.544 (1.235–1.929) <0.001
Surgery time (per 10-min increase) 1.020 (1.010–1.030) <0.001
Surgery time >215 min (yes vs no) 1.377 (1.098–1.726) 0.006
BTT indicates bridge to transplantation; CI, confidence interval; CPB, cardiopulmonary bypass; LVAD, left ventricular 
assist device; and OR, odds ratio. For manufacturers of the LVADs, see text.
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EUROMACS-RHF Risk Score and ICU Stay Duration
Median ICU stay was 7 days (IQR, 4–15 days) versus 24 days (IQR, 14–38 days) in patients 
without versus with RHF (P<0.001). Likewise, the ICU stay was linearly increased from 6 
days (IQR, 4–13 days) versus 13 days (IQR, 6–25 days) versus 19 days (IQR, 9–31 days) in the 
EUROMACS-RHF score low, intermediate, and high risk category, respectively (P<0.001 for 
trend; Figure 6A and 6B).
Subgroup Analysis
We performed subgroup analysis to test the predictive value of the EUROMACS-RHF risk 
score in patient populations treated with different LVADs. The incidence of RHF was 15.5% 
versus 24.1% versus 24.9% for patients treated with HeartMate II, HeartWare, and Heart-
Mate 3, respectively (P<0.001 for trend; Table III in the online-only Data Supplement). In the 
derivation cohort, the AUC of the EUROMACS-RHF risk score was 0.75, 0.66, and 0.60 in the 
HeartMate II, HeartWare, and HeartMate 3 populations, respectively (Table IV in the online-
only Data Supplement). Sensitivity, specificity, positive likelihood ratio, negative likelihood 
ratio, positive predictive value, and negative predictive value according to the EUROMACS-
RHF risk score in the device brand subgroups are presented on Tables V–VII in the online-only 
Data Supplement.
Table 6: European Registry for Patients with Mechanical Circulatory Support Multivariable Model for Right- Sided 
Heart Failure Derived From the Derivation Cohort
Variables OR Lower 
95% CI
Upper 
95% CI
χ2 Value 
(χ2=56.9)
Coefficients Score
Preoperative model
RA/PCWP >0.54 2.075 1.383 3.112 12.441 0.730 2
Hemoglobin ≤10 g/dL 1.611 1.037 2.502 4.506 0.477 1
Multiple intravenous inotropes 3.197 1.851 5.524 17.355 1.162 2.5
INTERMACS class 1–3 2.903 1.723 4.893 16.014 1.066 2
Severe RV dysfunction* 2.055 1.183 3.57 6.534 0.720 2
Postoperative RHF model after adding CPB time
RA/PCWP >0.54 2.151 1.412 3.278 12.699 0.766 1
Hemoglobin ≤10 g/dL 2.609 1.544 4.409 12.839 0.959 1.5
Multiple intravenous inotropes 3.013 1.712 5.302 14.635 1.103 2
INTERMACS Class 1–3 3.393 1.946 5.915 18.561 1.222 2
Severe RV dysfunction* 2.099 1.193 3.694 6.618 0.742 1
CPB time >100 min 2.032 1.296 3.184 9.562 0.709 1
CI indicates confidence interval; CPB, cardiopulmonary bypass; INTERMACS, Interagency Registry for Mechanically 
Assisted Circulatory Support; OR, odds ratio; PCWP, pulmonary capillary wedge pressure; RA, right atrial; RHF, right-
sided heart failure; and RV, right ventricular. See Appendix I in the online-only Data Supplement for an explanation 
of how to use this table to predict an individual patient’s risk of RHF. Examples of risk score calculation using the 
model presented in Table 6. The following example illustrates the use of Table 6 to calculate the European Registry 
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for Patients with Mechanical Circulatory Support (EUROMACS) RHF risk score of early postoperative RHF after LVAD 
implantation in individual patients: Consider a patient who was referred to left ventricular assist device implantation 
who has INTERMACS class 3, has severe RV dysfunction on echocardiography, has an RA/PCWP ratio of 0.55 on 
Swan-Ganz catheter, is on 3 inotropic support, and has a hemoglobin of 10 g/dL. Using the EUROMACS-RHF risk 
score of RHF model coefficients in Table 6, this patient’s preoperative risk score for RHF is the highest because he 
scored all points (2+1+2.5+2+2=9.5) according to the prediction model. Furthermore, if this patient had CPB time 
>100 min, this patient’s postoperative risk score for RHF with a similar formula will be 8.5 points. *Semiquantitative 
assessment of RV systolic function on echocardiography.
Figure 2: Distribution of the EUROMACS (European Registry for Patients With Mechanical Circulatory Support) right-
sided heart failure (RHF) risk score (A) and the postoperative EUROMACS-RHF risk score (B) in the derivation cohort 
(DC) and the validation cohort (VC). 
CPB indicates cardiopulmonary bypass; IQR, interquartile range; and RS, risk score.
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Figure 3: Frequency of early right-sided heart failure (RHF) stratified by (A) the European Registry for Patients With 
Mechanical Circulatory Support (EUROMACS) RHF risk score and (B) the postoperative EUROMACS-RHF risk score 
categories.
CPB indicates cardiopulmonary bypass
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DISCUSSION
This study is a multicenter study that includes the largest European population of patients 
who received currently used continuous-flow LVADs, evaluating the risk for RHF. Early severe 
RHF occurs in one fifth of patients with LVAD in this study and is associated with high mor 
tality, up to 29% in some series.11 We developed and validated a novel EUROMACS-RHF risk 
score using a simple 5-item scoring system for the prediction of early RHF after continuous-
flow LVAD implantation.
 RHF is an important and frequent complication in the early postoperative period after 
LVAD implantation.3 In prior studies, rates of post-LVAD RHF have ranged between 4% and 
50%.6–10 This wide range of reported RHF incidence is due partly to the lack of a universal 
definition of post-LVAD RHF across the literature. In primary LVAD implantation, severe RHF 
requires either mechanical RV support via RV assist device or extracorporeal membrane 
oxygenator, pharmacological support via the use of continuous intravenous inotropic 
support, or pulmonary vasodilators such as inhaled NO. Those 3 components are used in the 
RHF definition in this study, which is in line with the INTERMACS definition of severe RHF.14 
 Risk stratification of patients undergoing LVAD implantation is important to identify 
candidates for RV support, to provide timely pharmacological intervention, and thus to 
improve patients’ outcome. This could be important in the decision process, preoperative 
preparation, and timing of surgery. This should be reflected also in the informed consent of the 
patients and the family, especially in patients receiving DT in whom there is no opportunity for 
bailout with heart transplantation. Few risk-scoring systems have been described to predict 
post-LVAD RHF. However, those studies are limited by small sample size, single centers, and 
the heterogeneous nature of LVADs. Kormos et al11 and Atluri et al21 investigated multivariate 
predictors of RHF in 484 and 167 patients, respectively, who received continuous-flow LVAD. 
However, the studies included only HeartMate II devices, disregarding other currently used 
mainstream LVADs such as HeartWare or the new HeartMate 3. In our study, the EUROMACS-
RHF risk score was derived from a population of 2000 patients treated with mainstream 
LVADs.  
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Table 7: Performance Characteristics of Clinical Risk Prediction Scores and Individual Predictors for Right- Sided Heart 
Failure in the Derivation Cohort
C Index (95% CI) P Value
Risk scores
EUROMACS-RHF risk score* 0.70 (0.67–0.73) 1 (Reference)
Postoperative EUROMACS-RHF risk score† 0.71 (0.68–0.74) 0.41
Kormos et al11 score 0.58 (0.54–0.61) <0.0001
CRITT score21 0.63 (0.60–0.66) <0.0001
Individual hemodynamic parameters
RA pressure, mm Hg 0.60 (0.55–0.65) <0.0001
TPG, mm Hg 0.55 (0.50–0.61) <0.0001
PVR, woods unit 0.56 (0.51–0.61) <0.0001
RVSWI, g/m2 per beat 0.52 (0.47–0.56) <0.0001
Severe RV dysfunction 0.57 (0.52–0.61) <0.0001
CI indicates confidence interval; EUROMACS, European Registry for Patients with Mechanical Circulatory Support; 
CI, confidence interval; CRITT, Central Venous Pressure >15 mmHg, Severe RV Dysfunction, Preoperative Intubation, 
Severe Tricuspid Tegurgitation, Tachycardia; PVR, pulmonary vascular resistance; RA, right atrial; RHF, right-sided 
heart failure; RV, right ventricular; RVSWI, right ventricular stroke work index; and TPG, transpulmonary gradient.  *P 
value is EUROMACS-RHF risk score versus other scores or individual parameters.
     The preoperative score includes need of ≥3 inotropic agents, Interagency Registry for Mechanically Assisted 
Circulatory Support class 1 through 3, severe RV dysfunction on semiquantitative echocardiography, RA/pulmonary 
capillary wedge pressure ratio >0.54, and hemoglobin ≤10 g/dL.
     †The modifi postoperative score includes cardiopulmonary bypass time >100 minutes and the 5 preoperative 
components of the EUROMACS-RHF risk score.
Risk Score Components
The EUROMACS-RHF risk score is composed of severe RV dysfunction (2 points), ratio of 
RA/PCWP ≥0.54 (2 points), advanced INTERMACS class 1 through 3 (2 points), need for ≥3 
intravenous inotropes (2.5 points), and hemoglobin ≤10 g/dL (1 point).
 Because of the multifactorial nature of RHF after LVAD,4,5 83 parameters of clinical 
relevance are  examined in this study for possible association with early post-LVAD  RHF.
 Patients with preoperative severe RV dysfunction on echocardiography have an ≈2-
fold increase in the incidence of evident RHF in the early post-LVAD period compared with 
those without severe RV dysfunction. Echocardiographic assessment of RV function is readily 
available to assess RV contractility at bedside. Of note, there is a potential high variability in 
visual scoring of RV function on a scale from normal to severe; therefore, a quantitative marker 
such as RV fractional area change or the recently introduced iRotate echocardiography22 can 
accurately quantify RV function. Nevertheless, visual assessment of a severe RV dysfunction 
on echocardiography in daily practice is, in our expert opinion, simple but robust.
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Likewise, an elevated RA pressure in relation to pulmonary capillary wedge pressure shows 
a similar association with clinically evident early post-LVAD RHF. On the one hand, high RA 
pressure is a sign of RV failure; on the other hand, it could be a sign of volume overload. 
Aggressive diuresis, usually with inotropic support, and sometimes ultrafiltration, in case 
of ineffective diuresis, should be tried in patients with volume overload to achieve optimal 
euvolemic state.
Figure 4: Two-year Kaplan-Meier estimates of death resulting  from any cause stratified by (A) right-sided heart 
failure (RHF) and (B) the European Registry for Patients With Mechanical Circulatory Support (EUROMACS) RHF risk 
score strata.
In the EUROMACS database, as well as in other published data, most patients who are 
receiving an LVAD have some degree of RV dysfunction. In this study, 88% of patients have 
mild or more impairment of RV systolic function. However, RV dysfunction could remain silent 
as a result of a limited RV preload. RV preload has to increase immediately after LVAD to match 
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increased LVAD workload. Furthermore, LV unloading tends to cause a leftward shift of the 
interventricular septum, therefore compromising effective RV contractility and aggravating 
the already impaired RV systolic function. The interventricular septum contributes to at least 
one third of the RV contractility.23 Therefore, it is important to optimize LVAD flow to prevent 
excessive LV suction to avoid a vicious circle of RV function impairment.
Figure 5: Five main known causes of death in the derivation cohort.
The need for multiple inotropes in the preoperative period in this study was seen in 12% of 
patients and is associated with an ≈2-fold higher risk of RHF than in patients with ≤2 inotropes. 
The use of multiple inotropes has the greatest weight in predicting post-LVAD RHF among all 
5 predictors. This might reflect in fact, the biventricular origin of hemodynamic instability. 
Despite the dire need for inotropic support in those patients, excess or prolonged use of 
intravenous inotropic agents could have a detrimental effect on the myocardial energetics 
and metabolism.24 In this study, an average of 1.5 inotropes were used per patient. Moreover, 
dobutamine was the most (53%) used inotropic agent (Figure III in the online-only Data 
Supplement). On the other hand, 12% of patients received levosimendan. Levosimendan is 
currently available in the European Union and various countries but remains investigational 
in the United States.25 Levosimendan could prevents the development of RHF and improves 
contractility in established pressure overload–induced RV failure in the preclinical setting.26 
However, the short- and long-term outcomes of those inotropic agents have not been 
demonstrated in randomized clinical trials. Further studies are needed to test their role in 
early intensive management of RHF. As a potential example, a randomized study could be 
designed to test a temporary RV circulatory support in patients who are on or require >2 
inotropes before LVAD implantation. In this proposed trial, patients could be randomized to 
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an early temporary mechanical circulatory support or to escalating the number or doses of 
inotropic or vasopressor support.
 An advanced INTERMACS score is found in this study to be associated with an ≈5-fold 
increase in the incidence of evident RHF in the early post-LVAD period compared with those 
with less advanced INTERMACS class before LVAD. This finding is in line with published data 
from the INTERMACS database.27 We categorized patients according to the modifiers of the 
INTERMACS profile definition into a group of hospitalized patients on intravenous inotropes 
or temporary circulatory support (class 1 through 3) and a second group including “frequent 
flyers” (class 4) and less sick (class 5 through 7) patients.28 The fi group represents sicker 
and decompensating patients who suffer severe hemodynamic derangement, threatening 
secondary organ (renal, hepatic) failure, compared with ambulatory, less sick, or relatively 
stable patients in the second group.
 Finally,  anemia  as  demonstrated  with  hemoglobin ≤10 g/dL was associated with 
1.5-fold increase in post- LVAD RHF. Anemia is found in about one third of patients with 
chronic HF. The most common causes are chronic renal failure and iron deficiency. It could be 
speculated that anemia could play a role in triggering RHF in the setting of already vulnerable 
RV, and multiple blood transfusions in the early postoperative period could play a role in 
the pathophysiology of RHF in those patients. Blood transfusion–associated circulatory 
overload has been associated with an increased risk of RHF.29,30 Furthermore, the already 
vulnerable RV is very likely to be challenged by borderline perfusion and thus impaired oxygen 
delivery resulting from anemia. On the other hand, anemia might reflect the severity of the 
underlying multiorgan failure. Impaired nutrition, malabsorption (resulting from congestion 
and abnormal production of hepcidin), and reduced intracellular uptake of iron have been 
reported as causes of anemia in patients with HF.31,32
 In this study, we examined CPB time and LVAD surgery time in the prediction model of 
early post-LVAD RHF. Both parameters are significantly associated with the incidence of early 
post-LVAD RHF; however, a CPB time >100 minutes remained significant in the final model. 
It is associated with a 2-fold increase in the incidence of early post-LVAD RHF, but it did not 
improve much the AUC of the composite score.
Clinical Implications
In this study,  RHF  was  associated  with  increased  early and late mortality. Most common 
causes of death were multiorgan failure, sepsis and cerebrovascular accidents. Patients with 
RHF died more often as a result of multiorgan failure and sepsis. Those patients have severe 
systemic congestion and tissue hypoperfusion from under filling of the LVAD. Moreover, 
patients with RHF had a longer ICU stay. It has been reported  that≈50% of ICU patients had a 
nosocomial  infection  and are  therefore  at  a  high  risk  for  sepsis.33   Furthermore, intestinal 
source of infection is a known source of sepsis  in patients with multiorgan failure in the ICU 
as a result of translocation of gut flora into bloodstream. 
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Figure 6: Median intensive care unit (ICU) stay in days stratified by (A) right-sided heart failure (RHF) and (B) the 
European Registry for Patients With Mechanical Circulatory Support (EUROMACS) RHF risk score strata.
In this study, the composite 5-point score predicts early post-LVAD RHF, with graded risk for 
both RHF and death seen with higher scores. The score is simple, validated, and composed of 
widely available and clinically relevant variables derived from a multivariate logistic regression 
analysis.  In  contrast, the  more  complex recently published machine prediction bayesian 
models34 from the INTERMACS database consisted of 33 to 34 preoperative variables.
 Our model variable selection was based on biological plausibility and knowledge 
of experts in the field to avoid redundancy in the model and unexplained or unexpected 
predictors. This risk score includes intuitive predictors that are known to be relevant in the 
pathophysiology of early post-LVAD RHF and its associated mortality. Furthermore, the final 
model of the EUROMACS-RHF risk score was validated in a separate validation cohort.
 This novel scoring system may provide clinicians with opportunity for tailored risk 
decision making before, during, or early after LVAD surgery. A patient with a high risk score 
may require perioperative optimization of RV support, biventricular assist device, or total heart 
support. Optimization of RV support could be achieved via reduction of preload, afterload, 
and RV contractility support. Aggressive diuresis, early use of pulmonary vasodilators such as 
NO, phosphodiesterase type 5 inhibitors, or early RV mechanical support may be indicated. 
Furthermore, measures such as tricuspid valve repair could be considered. Those patients 
would benefit from early recognition in terms of not only less need for prolonged ICU stay but 
also, more important, better survival. However, those corrective measures remain speculative 
and should be tested in some prospective randomized trials to prove their usefulness.
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Limitations
Caution should be taken in general against using solely a risk model for clinical decision making 
without prospective validation in randomized clinical trials. There are several limitations that 
should be acknowledged in this study. First, a validation ROC of 0.67 of this risk score is not 
ideal. It could be due to the fact that onlyvery few patients were assigned to some high 
scores. The score could perform better in a larger population in which more patients are 
represented in all score levels. Another limitation is the semiquantitative assessment of RV 
function on echocardiography. A quantitative and preferably advanced RV assessment such 
strain analysis could improve the score performance. On the other hand, the widely used 
scores, also simple, such as CHADS2-VASC35 and even Pooled Cohort equations36 are not 
different from this score. Furthermore, it may not be appropriate to generalize our findings 
to other types of VAD not included in the present analysis. However, the 3 LVADs in this study 
represent the mainstream LVADs used worldwide. An important limitation of this study is 
the retrospective analysis of the EUROMACS database. However, data on MCS devices are 
derived largely from registry databases. A prospective randomized study such as in patients 
with cardiogenic shock on multiple inotropes, which had the highest weight among RHF 
predictors, is warranted to prove the predictive value of this risk score. 
 Furthermore, there are potential confounders that might not be accounted for here. In 
addition, potential mechanisms of RHF that take place exclusively after LVAD surgery such as 
an immediate increase in RV work to match the increase in LVAD flow are not considered. 
Missing data were present for many of our variables. However, we addressed this issue by 
using multiple imputations, and no variables were missing in >90% of cases. Medication 
dosages were not considered in the present model. Pharmacological interventions could 
alter many biological markers such as hepatic and renal functional biomarkers, thus affecting 
the meaning of those markers in a prediction model. Of note, only hemoglobin appeared in 
the final step of the EUROMACSRHF risk model.
CONCLUSIONS
We developed and validated the EUROMACS-RHF risk score, a simple 5-item scoring system 
for the prediction of early RHF and RHF-associated mortality after continuous-flow LVAD 
implantation. The score identified high-risk patients in whom timely optimization or mechanical 
RV support may be considered to reduce RHF-related mortality and morbidity. 
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Supplementary Table III: Subgroup analysis (LVAD brand)
Incidence of right heart failure score stratified according to left ventricular assist device brand
HeartMate II 
LVAS
HeartWare 
HVAD
Thoratec - 
HeartMate 3
Derivation Cohort 
(n=2000)
Early Post- 
LVAD RHF
No 676 (84.5%) 764 (75.9%) 127 (75.1%) 1567 (79.3%)
Yes 124 (15.5%) 243 (24.1%) 42 (24.9%) 433 (21.6%)
*Validation Cohort 
(n=988) Early Post- 
LVAD RHF
No 340 (84.2%) 380 (75.7%) 45 (63.4%) 765 (78.3%)
Yes 64 (15.8%) 122 (24.3%) 26 (36.6%) 212 (22.6%)
*Missing device type (n=24)
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Supplementary Table IV: Performance characteristics of EUROMACS-RHF score for risk prediction of RHF stratified 
by brand of left ventricular assist device in the derivation cohort.
Cohort Device Brand LVAD Area Std. Errora p-valueb 95% Confidence Interval
Lower Bound Upper Bound
Derivation Cohort HeartMate II LVAS 0.75 0.03 0.00 0.70 0.81
HeartWare HVAD 0.67 0.02 0.00 0.63 0.71
Thoratec - HeartMate 3 0.61 0.05 0.04 0.50 0.71
Validation Cohort HeartMate II LVAS 0.70 0.04 0.00 0.62 0.77
HeartWare HVAD 0.66 0.03 0.00 0.61 0.71
Thoratec - HeartMate 3 0.56 0.08 0.38 0.42 0.71
a. Under the nonparametric assumption
b. Null hypothesis: true area = 0.5
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SUPPLEMENTAL FIGURES
Supplementary Figure I: Components of Right Heart Failure Definition in the derivation (left) versus validation 
(Right) cohort. Of note, total patients who had right heart failure = 433; some patients were already on inotropic 
support >14 days and received later an RVAD.
Right Heart Failure DefinitionRight Heart Failure Definition
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Supplementary Figure II: ROC Curve analysis derived from the derivation cohort (DC) and validation cohort (VC). 
ROC Curve of the EUROMACS RHF-Risk Score, postoperative modified (plus CPB time) EUROMACS RHF-Risk Score are 
compared with two published RHF risk scores derived from patients with continuous flow LVAD as well as the areas 
under the receiver operating characteristic (ROC) curve for the individual scores.
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Supplementary Figure III: Percentage of Patients Receiving Inotropic Support in derivation cohort
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APPENDIX I. LIST OF EUROMACS SITES AND INVESTIGATORS 
(alphabetical according to country)
Name City: Country: Representative
Universitätskliniken Innsbruck Innsbruck Austria Prof. Herwig Antretter
Central Clinic Hospital Baku Azerbaijan Prof. Kamran Musayev
National Institute “Cardiology” Minsk Belarus Dr. Valeriya Krachak
Onze Lieve Vrouwenziekenhuis Aalst Belgium Dr. Marc Vanderheyden
Universitair Ziekenhuis Gent Gent Belgium Prof. Yves van Belleghem
Katholieke Universiteit Leuven Leuven Belgium Prof. Bart Meyns
IKEM (Institute for Experimental Cardiac Surgery) Prague Czech Republic Prof. Ivan Netuka
Center for Cardiovascular and Transplant Surgery Brno Czech Republic Prof. Petr Nemec
Rigshospitalet Copenhagen Copenhagen Denmark Prof. Finn Gustafsson
Centre Chirurgical Marie Lannelongue
Le Plessis- 
Robinson
France Prof. Julien Guihaire
Deutsches Herzzentrum Berlin Berlin Germany Prof. Thomas Krabatsch
Universitätsklinikum Schleswig Holstein Lübeck Germany Prof. Stefan Klotz
Herz- und Diabeteszentrum Nordrhein- Westfalen Bad Oeynhausen Germany Prof. Jan Gummert
Universitätsklinikum Eppendorf Hamburg Germany Prof. Hermann Reichenspurner
Universitäts Herzzentrum Freiburg - Bad Krozingen Freiburg Germany Prof. Friedhelm Beyersdorf
Klinikum Karlsburg Karlsburg Germany Dr. Lutz Hilker
Aristotle University of Thessaloniki Thessaloniki Greece Prof. Kyriakos Anastasiadis
Onassis Cardiac Surgery Center Athens Greece Prof. George Stavridis
Heart Center of the Semmelweis 
University
Budapest Hungary Prof. Béla Merkely
Gottsegen Gy. Hungarian Institute of 
Cardiology
Budapest Hungary Dr. Gabor Bodor
Osepdale S. Orsola Bologna Italy Prof. Roberto Di Bartolomeo
Ospedale San Camillo Rome Italy Prof. Francesco Musumeci
Ospedale Niguarda Ca’Granda Milan Italy Prof. Claudio Russo
Ospedale Papa Giovanni XXIII Bergamo Italy Dr. Attilio Iacovoni
Ospedale dei Colli Naples Italy Dr. Cristiano Amarelli
ISMETT (Mediterranean Institute for 
Transplantation and Advanced Specialised 
Therapies)
Palermo Italy Prof. Sergio Sciacca
Regina Margherita Children’s Hospital Torino Italy Prof. Carlo Pace Napoleone
National Research Cardiac Surgery Center 
- Kazakhstan
Astana Kazakhstan Prof. Yuri Pya
Erasmus Medisch Centrum Rotterdam Netherlands Dr. Kadir Caliskan
Universitair Medisch Centrum Utrecht (UMCU) Utrecht Netherlands Dr. Faiz Ramjankhan
Universitair Medisch Centrum Groningen (UMCG) Groningen Netherlands Dr. Kevin Damman
Rikshospitalet Oslo Norway Prof. Arnt Fiane
Childrens Memorial Hospital Warsaw Poland Prof. Bodan Maruszewski
Silesian Center for Heart Diseases Zabrze Poland Prof. Marian Zembala
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Clínica Universidad de Navarra Pamplona Spain Prof. Gregorio Rábago
Inselspital Bern Bern Switzerland Prof. Paul Mohacsi
Kinderspital Zürich Zürich Switzerland Prof. Michael Hübler
Ege University School of Medicine Izmir Türkiye Prof. Mustafa Özbaran
Florence Nightingale Hospital Istanbul Türkiye Dr. Erman Pektok
Başkent University Hospital Ankara Türkiye Prof. Atilla Sezgin
Yüksek Ihtisas Hospital Ankara Türkiye Prof. Ümit Kervan
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ABSTRACT
Background: 
Despite advances in pump technology, thromboembolic events/acute pump thrombosis 
remain potentially life-threatening complications in patients with continuous-flow left 
ventricular assist devices (CF-LVAD). We sought to determine early signs of thromboembolic 
event/ pump thrombosis in patients with CF-LVAD, which could lead to earlier intervention.
Methods: 
We analysed all HeartMate II recipients (n = 40) in our centre between December 2006 and 
July 2013. Thromboembolic event/pump thrombosis was defined as a transient ischaemic 
attack (TIA), ischaemic cerebrovascular accident (CVA), or pump thrombosis.
Results: 
During median LVAD support of 336 days [IQR: 182–808], 8 (20 %) patients developed a 
thromboembolic event/pump thrombosis (six TIA/CVA, two pump thromboses). At the time 
of the thromboembolic event/pump thrombosis, significantly higher pump power was seen 
compared with the no-thrombosis  group  (8.2 ± 3.0  vs.  6.4 ± 1.4 W, p = 0.02), as well as a 
trend towards a lower pulse index (4.1 ± 1.5 vs. 5.0 ± 1.0, p = 0.05) and a trend towards higher 
pump flow (5.7 ± 1.0 vs. 4.9 ± 1.9 L m, p = 0.06). The thrombosis group had a more than 
fourfold higher lactate dehydrogenase (LDH) median 1548 [IQR: 754– 2379] vs. 363 [IQR: 
325–443] U/L, p = 0.0001). Bacterial (n = 4) or viral (n = 1) infection was present in 5 out of 8 
patients. LDH > 735 U/L predicted thromboembolic events/ pump thrombosis with a positive 
predictive value of 88 %. 
Conclusions:
In patients with a CF-LVAD (HeartMate II), thromboembolic events and/or pump thrombosis 
are associated with symptoms and signs of acute haemolysis as manifested by a high LDH, 
elevated pump power and decreased pulse index, especially in the context of an infection. 
Keywords: 
Thromboembolic event · Pump thrombosis · Haemolysis · Left ventricular assist device (LVAD) 
· HeartMate II
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INTRODUCTION
Left ventricular assist devices (LVADs) have increasingly become part of the arsenal in 
the treatment of end-stage heart failure [1–3]. Despite advances in pump technology, 
thromboembolic events and acute pump thrombosis remain potentially life-threatening 
complications [4–6]. The clinical presentation varies from acute malfunction of the pump 
with heart failure, arrhythmias and/or to systemic thromboembolic events. The exact 
prevalence and aetiology of pump thrombosis is uncertain [7]. Rates of thromboembolic 
events, including ischaemic stroke and acute pump thrombosis, vary between 1 and 14 % 
among different studies of continuous flow (CF) LVADs with either axial or centrifugal flow 
[6, 8–15].
 Recently, Starling et al. reported an increasing rate of Thoratec HeartMate II pump 
thrombosis, which was preceded by increasing lactate dehydrogenase (LDH), and was 
associated with substantial morbidity and mortality [16]. Other reports showed a strong 
association of haemolysis with increased pump power and with partial or complete 
LVAD thrombosis [17, 18]. The current guidelines of the International Society for Heart 
and Lung  Transplantation (ISHLT) advise to follow up haemolysis as a sign of thrombosis 
[7]. Haemolysis in the presence of altered pump function should prompt admission for 
optimisation of anticoagulation and antiplatelet management and possible pump exchange 
[4]. However, there is no advice in the guidelines about detection of thrombosis. Clinically 
obvious haemolysis could be seen as dark urine, anaemia, jaundice, and/or as elevated LDH. 
Early detection of a thromboembolic event/ pump thrombosis could help in the proper 
management of these LVAD patients.
 As thromboembolic events and pump thrombosis are part of the same disease spectrum, 
we sought to analyse the determinants of thromboembolic events and/or pump thrombosis 
in the cohort of patients with a CF-LVAD implanted at our institution.
METHODS
Forty consecutive patients implanted with axial type continuous-flow HeartMate II LVADs 
(Thoratec Corporation, Pleasanton, California) in our institution, a tertiary referral centre for 
end-stage heart failure and heart transplantation, between December 2006 and July 2013, 
were included in this study.
Data collection
All data from LVAD recipients were stored electronically in the hospital electronic patient 
records. According to Dutch law, informed consent was not required, since study-specific 
actions were not implemented. All data were readily available in the medical records of the 
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patients and were obtained during routine treatment. Subsequently, data were processed 
anonymously. Data were retrospectively analysed for demographic, clinical and LVAD pump 
parameters. Clinical events such as signs of haemolysis, heart failure or infections were 
examined and confirmed independently by two cardiologists (SA, KC).
 
Clinical and laboratory investigation
Clinical data, ECG, laboratory and echocardiography were collected every 2–3 months or 
more frequently according to the clinical need. Likewise, LVAD interrogation was performed 
regularly at every outpatient clinic visit by an LVAD technician. The last 12-lead ECGs before 
LVAD implantation and at follow-up/events were analysed including rhythm, QRS width and 
QTc interval. Blood samples were collected serially to assess parameters of haemolysis, kidney 
and liver function as well as inflammation (Table 1). The treating cardiologist made the choice 
of and changes  in medications including heart failure and antiarrhythmic drugs. Twenty-five 
of 40 patients (63 %) already had an implantable cardioverter defibrillator according to the 
current guidelines [19].
Antithrombotic therapy
According to the ISHLT guidelines, postoperative anticoagulation started after LVAD 
implantation and completed postoperative haemostasis [7]. On postoperative day 1–2, 
intravenous heparin was started if there was no evidence of bleeding. On day 2–5, after 
removal of the chest tubes, aspirin 80 mg daily and vitamin K antagonists were started with a 
target international normalised ratio (INR) of 2.0–2.5. In case of a suspected thromboembolic 
event/pump thrombosis, intravenous heparin was started along with clopidogrel 75 mg/day. 
The target INR was increased to 2.5–3.5 or 3.0–4.0 in case of asymptomatic (laboratory only) 
signs of haemolysis versus thromboembolic event/pump thrombosis, respectively. In case of 
acute pump thrombosis, thrombolytic therapy (alteplase: bolus 15 mg in 1–2 min, followed 
by 0.75 mg/kg (max. 50 mg) continuous infusion in 90 min, and 0.5 mg/kg (max. 35 mg) 
continuous infusion in the second 90 min) was given.
Outcome definitions
Pump thrombosis was defined as signs and symptoms of otherwise unexplained heart failure 
with signs of LVAD dysfunction and haemolysis, thromboembolic events as cerebrovascular 
accident (CVA) or transient ischaemic attack (TIA), as confirmed by a neurologist. 
Haemolysis was diagnosed according to the ISHLT guidelines and the Interagency Registry of 
Mechanically Assisted Circulatory Support (INTERMACS) on analysis of pump throm- bosis [7, 
20]. Laboratory and clinical diagnosis of LVAD haemolysis and thrombosis were considered 
according to these ISHLT guidelines and the INTERMACS registry. In the ISHLT guidelines, 
screening for haemolysis is indicated in the setting of an unexpected drop in the haemoglobin 
or haematocrit level along with other clinical signs of hae molysis, such as haematuria. 
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Screening for haemolysis with serum LDH, plasma free haemoglobin in addition to the 
haemoglobin or haematocrit level is recommended [7]. The INTERMACS recently specified 
a new definition, accepted by the US Food and Drug Administration and industry, indicating 
a lower threshold of biochemical markers of haemolysis. They used a cut-off value of serum 
free haemoglobin >40 mg/dl in association with clinical signs of haemolysis beyond 72 h post-
implantation to define haemolysis [7].
Statistical analysis
Categorical variables are presented as frequencies and percentages. Continuous variables 
are presented as mean ± standard deviation or median (interquartile range 25th, 75th 
percentile). Continuous variables were compared using paired or independent t-test, Mann–
Whitney U-test or Wilcoxon’s test when appropriate. When comparing frequencies, the Chi-
square or Fisher’s exact test was used, where applicable. Cumulative Kaplan–Meier survival 
curves were constructed for each outcome variable. All tests were two-tailed and p-values 
less than 0.05 were considered statistically significant. All p-values between 0.05 and 0.10 
were considered to be a statistical trend. Multivariate analysis was not done due to the too 
low number of events and small population.
RESULTS
In our single-centre LVAD cohort of bridge-to-transplant patients, we found clinical features 
and other factors associated with thromboembolic events and acute pump thrombosis in 
8 of the 40 patients. One out of 5 patients on LVAD support with HeartMate II developed 
this catastrophic complication during a median follow-up of approximately 18 months. 
Thromboembolic events/pump thrombosis occurred at a minimum of 34 days and a maximal 
of 649 days after implantation. Demographic, clinical, laboratory, pump and echocardiography 
characteristics of the thrombosis and no-thrombosis groups at baseline and at follow-up are 
listed in Table 1 and 2, respectively. The patients were divided into two groups with and 
without a thromboembolic event and/ or pump thrombosis. The baseline data are from the 
pre-implant period, the laboratory values from the day before the operation. In all patients, 
the LVAD  was implanted as  a bridge to transplant. However, in three patients LVAD support 
ended in destination therapy (severe CVAs in two and malignancy in one). In one patient, the 
LVAD  could  be explanted due to cardiac recovery. All patients were followed for a median of 
336 (IQR 182–808) days. No patients were lost to follow-up. 
 At baseline, an intra-aortic balloon pump was used significantly more often in the 
thrombosis group, and this group had a higher blood urea nitrogen. Furthermore, the 
thrombosis group showed a trend towards INTERMACS class IV (p = 0.05) and less inotropic 
use (p = 0.05). At the last follow-up (July 2013), eight (20 %) patients had one  or more 
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thromboembolic events or pump thrombosis at median follow-up of 549 [269–856] days: TIA 
in 4 patients, ischaemic CVA in 3 patients and acute pump thrombosis in 2 patients. There 
was no difference in survival between the groups censored for heart transplantation or LVAD 
explan tation (p = 0.13, Fig. 1). One patient with pump thrombosis was treated with acute 
pump replacement (Table 3 and Fig. 2a) and one patient underwent successful thrombolysis 
(Fig. 2b). Four patients in the no-thrombosis group had a non-ischaemic CVA, one due to an air 
embolism and three due to intracerebral bleeding. In these patients, a neurologist ruled out 
an ischaemic stroke by CT scan. At the time of the thromboembolic event/pump thrombosis, 
higher pump power was seen in thrombosis group compared with the no-thrombosis group 
(8.2 ± 3.0 vs. 6.4 ± 1.4 W, p = 0.02), as well as a trend towards a lower pulse index (4.1 ± 1.5 
vs. 5.0 ± 1.0 p = 0.05) and a trend towards higher pump flow (5.7 ± 1.0 vs. 4.9± 1.9 L m p = 
0.06) Macroscopic haemoglobinuria was seen in 4 of 8 patients of the thrombosis group and 
3 of 32 patients of no-thrombosis group (50 vs. 9 %, p = 0.02). The patients in the thrombosis 
group with macroscopic haemoglobinuria had concomitant infections; at that time they had 
a therapeutic INR or activated partial thromboplastin time. They were all empirically treated 
with intravenous heparin and clopidogrel. None developed a thromboembolic event or pump 
thrombosis. The presence of a thrombus in the pump was confirmed at explantation by the 
thoracic surgeon and manufacturer in 4 of the 8 patients.
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Table 1: Baseline characteristics of all patients with or without thromboembolic events
Total population  
(n = 40)
Thromboembolic 
event or pump 
thrombosis  
(n = 8)
No thromboembolic 
event or pump 
thrombosis  
(n = 32)
p-value
Demographics
Age at implantation, years 46 [41–57] 56 [48–58] 45 [39–55] 0.12
Male gender 26 (65) 6 (75) 20 (63) 0.69
Weight, kg 71 ± 13 75 ± 12 70 ± 13 0.41
BSA, m2 1.87 ± 0.22 1.92 ± 0.19 1.86 ± 0.22 0.44
BMI, kg/m2 22.5 ± 3.0 23.3 ± 2.9 22.3 ± 3.0 0.44
Aetiology
Non-ischaemic cardiomyopathy 23 (57) 4 (50) 19 (59) 0.70
Ischaemic cardiomyopathy 17 (43) 4 (50) 13 (41) 0.70
Comorbidity
Diabetes mellitus 3 (8) 0 3 (9) 1.0
Hypertension 4 (10) 1 (13) 3 (9) 1.0
Previous cardiac surgery 3 (8) 2 (25) 1 (3) 0.10
Previous PCI 15 (38) 2 (25) 13 (41) 0.69
Previous TIA/CVA 2 (5) 0 2 (6) 1.0
INTERMACS class 2.4 ± 1.0 2.8 ± 1.3 2.3 ± 0.9 0.28
I 10 (25) 2 (25) 8 (25) 1.0
II 9 (23) 1 (12.5) 8 (25) 0.66
III 16 (40) 2 (25) 14 (44) 0.44
IV 5 (13) 3 (38) 2 (6) 0.05
Inotropic support 35 (87.5) 5 (63) 30 (94) 0.05
Extra-corporal circulatory support 9 (23) 2 (25) 7 (22) 1.0
Intra-aortic balloon pump 13 (33) 0 13 (41) 0.04
LVAD parameters at discharge
Pump speed, rpm 9325 ± 516 9375 ± 225 9313 ± 568 0.76
Pump flow, L/m 4.9 ± 1.2 4.8 ± 1.0 5.0 ± 1.2 0.67
Pulse index 4.8 ± 0.9 4.9 ± 0.7 4.8 ± 0.9 0.92
Pump power, Watts 6.0 ± 1.3 6.0 ± 1.0 6.0 ± 1.3 0.94
Electrocardiography
Atrial fibrillation 3 (8) 0 3 (9) 1.0
QRS duration, ms 146 ± 71 160 ± 54 143 ± 75 0.56
QTc, ms 462 ± 49 506 ± 35 451 ± 46 0.003
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Table 1, continued
Echocardiography
Left atrial dimensions, mm 48 ± 12 51 ± 9 47 ± 12 0.51
LV end-diastolic dimension, mm 67 ± 16 63 ± 14 66 ± 17 0.46
LV end-systolic dimension, mm 61 ± 16 63 ± 14 61 ± 17 0.76
Baseline laboratory values
Lactate dehydrogenase, U/L 407 [321–849] 361 [277–455] 433 [333–1101] 0.21
NT-proBNP, pmol/L 1136 ± 1112 800 ± 471 1222 ± 1216 0.35
Total bilirubin, umol/L 24 ± 21 20 ± 14 25 ± 23 0.52
BUN, mmol/L 16 ± 10 23 ± 17 14 ± 7 0.03
Creatinine, umol/L 147 ± 89 143 ± 65 148 ± 95 0.89
CRP mg/L 56 ± 71 44 ± 54 59 ± 75 0.56
ALAT, U/L 314 ± 684 126 ± 227 361 ± 752 0.39
ASAT, U/L 297 ± 636 149 ± 268 334 ± 696 0.47
Albumin, g/L 30 ± 6 29 ± 4 30 ± 7 0.66
Haemoglobin, mmol/L 7.1 ± 1.2 7.5 ± 1.4 7.0 ± 1.1 0.26
Haematocrit l/l 0.35 ± 0.06 0.38 ± 0.08 0.34 ± 0.06 0.19
WBC count, 1000/mm3 10.1 ± 5.4 9.3 ± 2.7 10.3 ± 5.9 0.63
Platelet count, 1000/mm3 207 ± 89 250 ± 97 196 ± 85 0.13
Categorical variables are presented as frequencies and percentages. Continuous variables are presented as mean 
± standard deviation or median [IQR (interquartile range 25th, 75th percentile)]. IQR interquartile range, BSA body 
surface area, BMI body mass index, PCI percutaneous coronary intervention, TIA transient ischaemic attack, CVA 
ischaemic cerebrovascular accident, Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS), 
LVAD left ventricular assist device, rpm revolutions per minute, NT-pro-BNP N-terminal of the prohormone brain 
natriuretic peptide, BUN blood urea nitrogen, CRP C-reactive protein, ALT alanine aminotransferase, AST aspartate 
aminotransferase, WBC white blood cell.
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Table 2: Comparison of outcome in patients with and without acute pump thrombosis/thromboembolic events at 
the time of the event or last follow-up 
Total population  
(n = 40)
Thromboembolic 
event or pump 
thrombosis  
(n = 8)
No thromboembolic 
event or pump 
thrombosis  
(n = 32)
p-value
Follow-up, days 336 [182–808] 549 [269–856] 297 [152–806] 0.39
Death 8 (20) 0 (0) 8 (25) 0.17
Heart transplantation 18 (45) 4 (38) 14 (44) 1.0
On-going support 12 (30) 3 (38) 9 (28) 0.68
LVAD explantation 1 (3) 1 (13) 0 (0) 0.20
LVAD parametersa
Pump speed, rpm 9245 ± 364 9200 ± 283 9256 ± 384 0.70
Pump flow, L/m 5.1 ± 1.0 5.7 ± 1.0 4.9 ± 0.9 0.06
Pulse index 4.8 ± 1.2 4.1 ± 1.5 5.0 ± 1.0 0.05
Pump power, Watts 6.8 ± 1.9 8.2 ± 3.0 6.4 ± 1.4 0.02
Clinical haemolysis parameters
Macroscopic hemoglobinuria 7 (18) 4 (50) 3 (9) 0.02
LDH levels >735 U/L 20 (50) 7 (88) 13 (41) 0.04
Free Hb (<6 indicates
haemolysis) 15 ± 34 33 ± 58 10 ± 22 0.31
Infection at the time of TE/PT 15 (38) 5 (63) 10 (31) 0.13
Viral 5 (13) 1 (13) 4 (13) 1.0
Bacterial 10 (25) 4 (50) 6 (19) 0.07
Readmissions
Surgery for driveline fracture 6 (15) 1 (13) 5 (16) 1.0
Re-admission due to HF 8 (20) 2 (25) 6 (19) 0.65
Medications at TE/PT or latest follow-up
Vitamin K antagonist 33 (83) 8 (100) 25 (78) 0.31
Aspirin 30 (75) 7 (88) 23 (72) 0.65
Clopidogrel 4 (10) 2 (25) 2 (6) 0.17
Electrocardiography
Atrial fibrillation 6 (15) 1 (13) 5 (16) 0.82
QRS duration, ms at event 148 ± 47 161 ± 45 145 ± 48 0.40
QTc, ms at event 463 ± 75 535 ± 79 445 ± 63 0.001
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Table 2, continued
Echocardiography
Grade aortic regurgitation 1.0 ± 0.9 1.1 ± 1.0 1.0 ± 0,9 0.66
Grade mitral regurgitation 1.2 ± 1.1 1.3 ± 0.9 1.2 ± 1.2 0.89
LV end-diastolic dimension, mm 57 ± 15 61 ± 14 56 ± 16 0.42
LV end-systolic dimension, mm 50 ± 14 52 ± 13 50 ± 15 0.73
Left atrial dimensions, mm 38 ± 11 38 ± 9 38 ± 11 1.0
Laboratory findings
LDH, U/L 382 [331–591] 1548 [754–2379] 363 [325–443] <0.0001
NT-proBNP, pmol/L 473 ± 890 915 ± 1551 342 ± 558 0.11
Total bilirubin, umol/L 38 ± 79 24 ± 13 41 ± 88 0.60
BUN, mmol/L 10 ± 7 12 ± 9 10 ± 7 0.56
Creatinine, umol/L 136 ± 166 152 ± 148 132 ± 172 0.77
CRP, mg/L 70 ± 91 84 ± 92 67 ± 91 0.64
ALAT, U/L 82 ± 159 162 ± 226 62 ± 135 0.11
ASAT, U/L 121 ± 203 185 ± 156 106 ± 212 0.33
Albumin, g/L 39 ± 9 40 ± 8 39 ± 10 0.77
INR 2.3 ± 1.1 2.4 ± 0.9 2.3 ± 1.1 0.89
Haemoglobin, mmol/L 6.7 ± 1.8 6.0 ± 1.7 6.9 ± 1.8 0.19
Haematocrit, l/L 0.33 ± 0.09 0.31 ± 0.07 0.34 ± 0.09 0.41
WBC count, 1000/mm3
10 ± 6 10 ± 6 10 ± 6 0.99
Platelet count, 1000/mm3 198 ± 84 237 ± 71 188 ± 84 0.14
Categorical variables are presented as frequencies and percentages. Continuous variables are presented as mean ± 
standard deviation or median [IQR (interquartile range 25th, 75th percentile)].
p value < 0.05 is significant. p value 0.05–0.10 is called tendency.
IQR Interquartile range. LVAD left ventricular assist device, rpm revolutions per minute, LDH lactate dehydrogenase, 
free Hb free haemoglobin, TE thromboembolic event, PT pump thrombosis, HF heart failure, LV left ventricle, NT-
pro BNP N-terminal of the prohormone  brain natriuretic peptide, BUN blood urea nitrogen, CRP C-reactive protein, 
ALAT alanine aminotransferase, ASAT aspartate aminotransferase, INR international normalised ratio, WBC white 
blood cell.
aLVAD parameters at event or latest follow-up; Values presented as mean (SD), median (interquartile range), or n (%).
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Figure 1: Kaplan-Meyer curve for survival during LVAD support for the thrombosis group (TE/PT+) and the no-
thrombosis group (TE/PT−). Patients are censored at heart transplantation and LVAD explantation
Furthermore, the thrombosis group had more than four-fold higher lactate dehydrogenase levels (median LDH: 1548 
[IQR: 754–2379] vs. 363 [IQR: 325–443] U/L, p < 0.0001). In the thrombosis group, infection was associated with 
a more than threefold increase of LDH with or without clinical signs of TIA/CVA or pump thrombosis. In 63 % (vs. 
31 % in the no-thrombosis group, p = 0.13) of the patients presenting with thromboembolism/pump thrombosis, 
an infection (bacterial in 4 and viral in 1 of the 8 patients) was confirmed. At baseline and at follow-up, there was a 
significantly longer corrected-QT interval in the thrombosis group.
The sensitivity and specificity of LDH as a marker of haemolysis (cut-off value three times the upper limit of normal 
(LDH > 735 U/L) were 88 and 97 %, respectively, with the positive and negative predictive value being 88 vs. 97 %, 
respectively.
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Figure 2: a Explanted pump inlet rotor in a 54-year-old male (patient no. 8 in Table 3) with acute pump thrombosis. 
Due to acute pump thrombosis, the patient had acute left- and right-sided heart failure with signs of severe haemolysis 
and acute renal failure. Macroscopic fresh white and red old thrombus is shown on the rotor, as confirmed by the 
manufacturer. b LDH course of the 57-year-old male (patient no. 7 in Table 3) presenting with acute pump thrombosis 
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successfully treated with recombinant tissue-plas- minogen activator (rt-PA). This patient had several episodes 
of an abrupt peak of LDH during therapeutic INRs associated with relapsing urinary tract infections (Citrobacter 
freundii). At the highest LDH peak he developed acute pump thrombosis, which was treated with thrombolytic 
therapy (alteplase). Dashed line = upper limit of normal value LDH. c Time course of serum LDH (U/L) in a 37-year-old 
woman (patient no. 5 in Table 3),  6 months on LVAD support, admitted with a ischaemic cerebrovascular event and 
response to various therapeutic interventions. CVA cerebrovascular accident, INR international normalised ratio, ASA 
acetylsalicylic acid, iv intravenous. Dashed line = upper limit of normal value LDH
DISCUSSION
In  our  single-centre  LVAD  cohort  of bridge-to-transplant patients, we studied the clinical 
features and associated fac tors in patients with thromboembolic events and acute pump 
thrombosis. One out of 5 patients on LVAD  support with   a HeartMate II developed a 
thromboembolic event/pump thrombosis during a median follow-up of approximately 18 
months. Infection was confirmed at the time of the event  in two-thirds of these patients. 
Elevated pump power and macroscopic haemoglobinuria predicted thromboembolic 
events/pump thrombosis, but LDH more than three times the upper level of normal was 
the best biochemical parameter in predicting and guiding the management of LVAD-related 
thromboembolic events and/or acute pump thrombosis, with a sensitivity of 88 % and 
specificity of 97 %.
Thromboembolic events in continuous-flow LVADs
CF-LVADs have been increasingly used in the last decade as a bridge to transplantation 
[21]. Thromboembolic events/ pump thrombosis remain one the most feared common 
complications in CF-LVAD patients, although bleeding results in the most morbidity and 
mortality [22–23]. The anticoagulation strategy of Whitson et al. [6] has been nuanced 
because it requires a delicate balance of adequate anticoagulation  to minimise thrombotic 
complications but not so excessive that it will cause bleeding complications (e.g., 
gastrointestinal or neurological bleeding). What further complicates the clinical picture is the 
inherent haematological effects of CF-LVADs [24–25]. In our cohort there were 23/40 cases 
of early post-implantation bleeding, 21 of which resulted in early cardiac tamponade. In their 
analysis in 2008, John et al. [12] found a low thromboembolic risk (4.4 %) in HeartMate II 
patients even with less stringent requirements for anticoagulation, which was confirmed by 
Menon et al. in 2012 [13]. From 2013, there has been an increase in thromboembolic events/
pump thrombosis in HeartMate II patients to 13.4 %, according to Whitson et al. [6]. In our 
report, 5 of the 40 patients (12.5 %) had a CVA or pump thrombosis, if TIAs were excluded 
due their mild clinical sequelae.
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Acute pump thrombosis
Acute pump thrombosis is a life-threatening condition and its optimal management requires 
early intervention. Detection of the earliest signs of pump thrombosis could lead to successful 
thrombolysis of a soft developing thrombus [26]. Uriel et al. examined 177 LVAD patients of 
whom 19 (11 %) developed acute pump thrombosis, whereby all underwent pump exchange; 
the recurrence rate was 1 %. In one-third of the patients, inadequate anticoagulation was 
found due to withholding or cessation of anticoagulation [15]. Thrombolysis could also be 
used with varying effect, as in our cases in Fig. 2a, b and c [11, 27]. In our experience, the use 
of clopidogrel on top of aspirin and coumarins in optimising anticoagulation seems effective 
and safe, but the efficacy of antiplatelet therapy using clopidogrel in one study was not 
sufficient in more than 50 % of the patients [28].
Haemolysis
In a multicentre analysis it was recently demonstrated that haemolysis causes long-term 
negative effects in the long-term course of LVAD support [29]. In 7 % of their 115 patients 
with a HeartMate II, Hasin et al. found signs of haemolysis presenting with very high LDHs 
(more than six times normal) which after intensifying the anticoagulation therapy decreased 
to baseline within 2 weeks [11]. However, recurrent haemolysis was very common: 75 % over 
1–7 months [11]. A recent analysis of the INTERMACS Registry of 4850 patients frequently 
found a mean time to event of 7.4 months and a cumulative incidence of 9 % at 2 years 
[29]. In another cohort of 20 consecutive cases of pump thrombosis, haematological 
markers, including LDH, plasma free haemoglobin and creatinine, were the only reliable 
sign of LVAD thrombosis, as opposed to echocardiographic or pump parameters.[30] Along 
with the emerging association of LDH with thrombo-embolism in patients with HeartMate 
II, there is also a growing association with acute infections [31], probably due to increased 
hypercoagulability [15, 31]. We can confirm this in our cohort, where there seems to be a 
correlation between infection and thrombosis in LVAD. LDH seems to be a very powerful 
parameter in predicting serious thromboembolic adverse events in  HeartMate II patients.
 Interestingly, the QTc was longer in the thrombosis group compared with the no-
thrombosis group both at baseline and at latest follow-up. It is known that QTc is a very 
crucial prognostic parameter in end-stage heart failure and we see here an association with 
the development of thrombosis [32]. To our knowledge there are no reports on LVAD studies 
that have described this before. Further studies are needed to analyse these novel findings.
Study limitations
This study has several limitations, which should be taken into account in the final interpretation 
of the data. The design is a retrospective study, the number of cases is very limited, and there 
was no routine follow-up and analysis of eventual hypercoagulability and/or antiplatelet 
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drugs resistance. Also, our findings were restricted to HeartMate II and may not be applicable 
to patients supported with other types of CF-LVADs.
CONCLUSION
In patients with CF-LVAD (HeartMate II), thromboembolic events and/or pump thrombosis 
are associated with symptoms and signs of acute haemolysis as manifested by high LDH, 
elevated pump power and decreased pulse index, especially in the context of an infection. 
These symptoms and signs could help in the early diagnosis and timely intensification 
of antithrombotic and/or antiplatelet therapy to prevent acute pump thrombosis and 
thromboembolic events or the need for pump replacement.
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ABSTRACT
Aims: 
Patients with a left ventricular assist device (LVAD) are challenging to evaluate using 
conventional imaging techniques, such as standard echocardiography (SE). The aim of this 
pilot study was to evaluate the potential of contrast echocardiography (CE) for the evaluation 
of the left ventricle (LV).
Methods and results: 
This prospective study included 14 ambulatory patients (mean age 58 ± 9 years, 79% male) 
with a LVAD (all HeartMate 3, Abbott Laboratories, Chicago, IL, USA). Nine (64%) patients had 
an ischaemic cardiomyopathy, and 5 (36%) had a non-ischaemic cardiomyopathy. All patients 
underwent SE and CE using intravenous administration of Sonovue contrast agent (Bracco, 
Milan, Italy). The echocardiograms were assessed by three observers, using a standard 
17-segment model of the LV. Left ventricular end-diastolic volume (LVEDV) was assessed using 
the biplane Simpson method. The contrast agent was well tolerated by all patients, without 
any side effects. Overall, SE allowed visualization of 57% of LV segments (135/238) and CE 
allowed visualization of 79% of LV segments (187/238), P < 0.001. Per patient, SE resulted 
in visualization of 9.6 ± 5.2 segments and CE was able to visualize 13.4 ± 5.8 segments (P 
< 0.001). Administration of contrast agent significantly improved the assessment of LVEDV 
(feasibility SE: 36% vs. CE: 79%, P < 0.05).
Conclusion:
Routine use of a contrast agent appears safe when used in patients having a new third 
generation LVAD and may enhance the diagnostic accuracy of transthoracic echocardiography 
in these patients. LV size determination can be obtained more often due to improved LV 
visualization using contrast agent.
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INTRODUCTION
Left ventricular assist devices (LVADs) are an increasingly used treatment option for patients 
with advanced heart failure refractory to optimal medical therapy, either as a bridge 
to cardiac transplantation or destination therapy.1–3 The introduction of the LVAD has 
resulted in a good long-term survival with substantial improvement in the patient’s quality 
of life.3 Non-invasive imaging plays an important role in the follow-up of patients with a 
LVAD, for the evaluation of LV function, monitoring of treatment response, and screening 
for potential complications.4,5 However, a substantial number of these patients exhibit an 
impaired image quality or may even deemed unsuitable for conventional imaging techniques 
including standard echocardiography (SE). Multiple studies have demonstrated that contrast 
echocardiography (CE) may substantially improve the endocardial border delineation and the 
evaluation of the LV function.6,7 CE was recently proposed as an imaging modality for the 
evaluation of the LV in patients with a LVAD, particularly to overcome the limitations of SE.8,9 
The aim of the current pilot study was to evaluate the safety, feasibility and potential of CE 
in patients with a novel continuous-flow LVAD, type HeartMate 3. This a third generation 
LVAD, with a magnetically levitated impellor, which is a potential source of destruction of 
echocardiography contrast agents. 
 The hypothesis of this study was that CE use was safe and feasible in patients with 
HeartMate 3 LVAD to improve visualization of the LV cavity and facilitates the determination 
of LV size. 
METHODS
Patient population and study protocol
This prospective study included all patients with a LVAD that underwent CE. The study protocol 
was approved by the Medical Ethics Committee of the Erasmus Medical Center, Rotterdam, 
The Netherlands. All patients provided informed consent. Consecutive ambulatory patients 
with a LVAD (all patients had a HeartMate 3, Abbott Laboratories, Chicago, IL, USA) because 
of advanced heart failure due to ischaemic or non-ischaemic cardiomyopathy were asked 
to participate in this prospective pilot study. All patients underwent a SE examination in 
conjunction with CE. Exclusion criteria were  contraindications for the use of ultrasound 
contrast agent, such as unstable angina, acute cardiac failure, acute endocarditis, known 
right-to-left shunts, and known allergy for microbubble contrast agents. 
Echocardiographic acquisition
The SE and CE examinations were performed using a Philips EPIQ 7C ultrasound system (Philips 
Medical Systems, Bothell, USA), with an X5-1 transducer. For SE and CE, a standardized image 
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acquisition protocol based on the American Society of  echocardiography guideline was 
used.10 In short, parasternal long-axis and short axis views, and apical 4-, 2- and 3-chamber 
views were obtained using B-mode ultrasound and colour Doppler imaging. For the CE 
examination, the ultrasound system was switched to its contrast mode. The contrast mode 
was using amplitude modulation techniques and a mechanical index of 0.1–0.5 to optimize 
the CE images. CE was performed using intravenous administration of SonoVueTM ultrasound 
contrast agent (sulphur hexafluoride microbubble suspension, Bracco S.p.A., Milan, Italy). 
The ultrasound contrast agent was injected in boluses of 0.5mL, the bolus administration 
was repeated when necessary up to a total dose of 5.0mL. During and after contrast 
administration, the patients were observed for potential side effects or complications and 
LVAD function parameters were monitored. For both SE and CE, cineclips were digitally stored 
and reviewed offline. 
Echocardiographic analysis
The SE and CE studies were reviewed offline by three independent observers unaware of the 
clinical data. A 17-segment model of the LV was used to analyse the LV in three standard views: 
parasternal long-axis, apical 4- and 2-chamber view. The image quality of each LV segment 
on the SE and CE clips was independently scored as (i) interpretable or (ii) uninterpretable. If 
there was a discrepancy in the scores of the independent readers, a consensus was reached. 
LV end-diastolic dimension (LVEDD) and LV end-diastolic volume (LVEDV) were assessed 
on the SE and CE datasets using TomTec Arena software (TomTec Imaging Systems GmbH, 
Unterschleissheim, Germany). The LVEDD was measured from leading edge to leading edge 
on the parasternal long-axis view. The LVEDV was assessed with the biplane Simpson method 
using the 4- and 2-chamber apical view.
Statistical analyses 
Statistical analyses were performed using SPSS for Windows (version 17.0, SPSS, Chicago, IL, 
USA) and Excel (Excel 2003, Microsoft, Redmont, USA). Continuous variables are reported as 
mean± standard deviation. Categorical variables are expressed as number (%). The v2 test 
was used to evaluate differences between proportions. A P-value <0.05 was considered to 
indicate a statistically significant difference. 
RESULTS
Patient characteristics
The patient characteristics (mean age 58±9 years, range 43–75 years, 11 (79%) men and 3 
(21%) women) are summarized in Table 1. The majority of the patients had received a LVAD 
because of an ischaemic cardiomyopathy (9, 64%), whereas the remaining 5 (36%) patients 
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had a non-ischaemic cardiomyopathy. LVAD implantation was considered as a bridge to 
transplantation in 8 (57%) patients and a destination therapy in 6 (43%). 
Safety and feasibility 
All CE studies were performed without adverse reactions and were well tolerated. None 
of the patients had signs of an allergic reaction and no known or unknown side effects 
occurred during or after intravenous administration of the contrast agent. No changes in 
LVAD function parameters were observed during or after CE. The dose of the contrast agent 
that was necessary for an adequate CE examination in these patients with an LVAD was not 
different from the dose that is regularly used in our centre for CE in patients without an LVAD. 
Hence, there were no signs that the HeartMate 3 LVAD caused a substantial destruction of 
the contrast agent. 
Table 1: Clinical characteristics of the study population
Characteristic Data
Age (y) 58 ± 9
Men 11 (79)
Height (cm) 179 ± 9
Weight (kg) 80 ± 14
BMI (kg/m2) 25 ± 4
Intermacs class 1-3 8 (57)
Intermacs class 4-7 6 (43)
NYHA class 3 7 (50)
NYHA class 4 7 (50)
Ischemic cardiomyopathy 9 (64)
Nonischemic cardiomyopathy 5 (36)
Paroxysmal atrial fibrillation 6 (43)
Ventricular tachycardia 11 (79)
Percutaneous coronary intervention 7 (50)
Coronary bypass surgery 2 (14)
Image quality
SE resulted in an interpretable visualization of all 17 segments in 2 (14%) patients. In the 
remaining 12 (86%) patients, visualization of the LV segments was impaired (range 0–16 
interpretable segments). Using SE, visualization of 57% (135/238) of LV segments was possible. 
Per patient, SE leads to interpretable image quality in on average 9.6± 5.2 LV segments. CE led 
to an improvement in the number of interpretable LV segments in 10 (71%) patients. Figure 
1 demonstrates an improved visualization of the LV endocardial borders using CE. In 4 (29%) 
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patients, CE did not change the image interpretation. Overall, CE resulted in a significant 
improvement of image quality, and visualization of 79% (187/238) LV segments was possible 
(P< 0.001). Per patient, CE yielded visualization of on average 13.4± 5.8 LV segments, an 
improvement of 3.8± 2.7 segments as compared to SE. 
Figure 1: Standard echocardiography (SE) and corresponding contrast echocardiography (CE) images in a patient 
with advanced heart failure and a HeartMate 3 LVAD. SE resulted in a poor visualization of the LV, in both 4-chamber 
(A) and 2 chamber (C) apical views. After intravenous administration of the ultrasound contrast agent, CE yielded an 
improved visualization of the LV endocardial borders, in both 4-chamber (B) and 2 chamber (D) apical views. Videos 
of this example are available online.
Assessment of LVEDD was possible in all patients, both on SE (LVEDD 66± 14mm) and CE 
(LVEDD 64± 11 mm). Using SE, assessment of LVEDV using the biplane Simpson method was 
possible in 5/14 (36%) patients on SE, with an average LVEDV of 177± 55mL. In four remaining 
patients assessment of LVEDV on SE was possible only in the 4-chamber apical view, and in 
five patients assessment of LVEDV was not possible at all. Administration of contrast agent 
significantly improved the assessment of LVEDV (feasibility SE: 36% vs. CE: 79%, P< 0.05). 
Using CE, assessment of LVEDV was possible in 11/14 (79%) of patients with a LVAD (LVEDV 
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229± 68mL). In two remaining patients assessment of LVEDV on CE was possible only in the 
4-chamber apical view, and in one patient assessment of LVEDV was not possible. 
DISCUSSION
The main findings of the present study are: (I) that CE in patients with an LVAD is safe and 
feasible and (II) CE significantly improves the visualization of the endocardial borders of the 
LV. Imaging of the LV and evaluation of LVEDV is clinically relevant to monitor changes in LV 
function and size in response to therapy and to detect potential complications, such as intra-
cardiac thrombi and blood flow stasis. 
 Continuous-flow LVADs are increasingly being used in patients with advanced heart 
failure, as a bridge to LV recovery, cardiac transplantation, or as destination therapy.1–3 
The evaluation of LV shape, function and intra-cardiac blood flow in patients with a LVAD 
may be challenging. SE is currently used as the main imaging method in the evaluation of 
these patients. The current study demonstrates that SE in these patients is associated with a 
significantly impaired image quality. Several factors may explain the impaired image quality. 
First, the LVAD and the inflow and outflow cannulas limit the acoustic window. Second, the 
device may cause artefacts. Third, patients with a LVAD cannot always be optimally positioned 
for echocardiography. Finally, additional factors like bandages and concomitant lung disease 
hinder accurate visualization of segmental and global LV function. Computed tomography has 
been used in the evaluation of these patients, but this technique is also limited by artefacts 
caused by the LVAD. Additionally the use of iodinated contrast agent is a limitation of that 
technique, particularly in those with an impaired renal function. Cardiac magnetic resonance 
imaging cannot be used because of the metal components of the LVAD. 
 The American Society of Echocardiography and the European Association of 
Echocardiography have recognized the clinical value of CE and issued position papers 
providing guidelines.10–12 It has become clear that CE is a safe imaging modality13,14 
that may provide improved image quality or information that cannot be obtained by SE 
in stable and critically ill patients.15,16 Clinical applications of CE include: improvement 
of LV endocardial border delineation, reduction of variability in assessment of LV volumes 
and function, increase reader confidence, and assessment of LV structural abnormalities: 
apical variant of hypertrophic cardiomyopathy, ventricular noncompaction, apical thrombus, 
aneurysm, pseudo aneurysm, myocardial rupture and intracardiac masses (tumours and 
thrombi).6,7,10–12 
 Recently, CE has been proposed, in a case-report8 and a retrospective case series,9 
as a potentially useful imagingmodality in the evaluation of patients with a LVAD. Moser 
et al.8 reported the case of a 25-yearold woman with a non-ischaemic cardiomyopathy 
and a LVAD (HeartMate II). Echocardiography revealed an apical pseudo aneurysm on SE, 
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additional CE demonstrated a bidirectional flow between the LV and the pseudo-aneurysm 
evident by contrast enhancement. This case demonstrates the critical role of SE and CE in the 
follow-up of patients with a LVAD to confirm circulatory function and exclude device-related 
complications. Fine et al.9 retrospectively reviewed the records of 251 patients with a LVAD 
implantation who received a clinically indicated echocardiogram. Of them, 10 (4%) patients 
with a LVAD (HeartMate II in 9, Heartmate XVE in 1 patient) underwent a CE study, of whom 
2 patients had a repeat CE study. No adverse events or known side-effects occurred during 
or after CE. These patients underwent a CE because of a suboptimal endocardial border 
delineation during SE. The use of contrast agent (Definity in 9 and Optison in 3 patients) aided 
image interpretation in 10 (83%) CE examinations. 
 The current prospective study confirms that CE in patients with a LVAD (all patients had a 
HeartMate 3) is safe, and can be performed with a regular dose of contrast agent (Sonovue). 
There were no signs that the LVAD caused a substantial destruction of the contrast agent. This 
study has clinically relevant implications. This study shows that the SE allowed visualization of 
57% of LV segments. After safe and easy intravenous administration of the ultrasound contrast 
agent, CE resulted in visualization of 79% of LV segments. Moreover, LV size determination 
could be obtained more often due to improved LV visualization using CE. Clearly, segmental 
and global LV function and LVEDV are important parameters in patients with a LVAD to 
monitor alterations in response to therapy and to diagnose potential complications. 
 This study has several limitations. First, because this was a pilot study, the number of 
patients that was considered was small. Second, potential destruction of the contrast agent 
by the LVAD was visually assessed and could not be quantitatively assessed. Third, this study 
was performed with Sonovue contrast agent, and it is not clear whether the results can be 
extrapolated to CE using other agents. Fourth, all of the patients had a HeartMate 3 LVAD, 
and it is not sure whether the current results can be extrapolated to patients with other LVAD 
systems. Fifth, the mentioned contraindications were considered at the time of the study 
conception and design, recently the contraindications have been removed by the US Food 
and Drug Administration 
CONCLUSION
Routine use of a contrast agent appears safe when used in patients having a new third 
generation LVAD and may enhance the diagnostic accuracy of transthoracic echocardiography 
in these patients. LV size determination can be obtained more often due to improved LV 
visualization using contrast agent.
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ABSTRACT 
Implantable continuous flow left ventricular assist devices (LVADs) are increasingly used in 
end-stage heart failure treatment as a bridge-to-transplant and destination therapy (DT). 
However, LVADs still have major drawbacks, such as infections that can cause morbidity and 
mortality. Unfortunately, appropriate diagnosis of LVAD-related and LVAD-specific infections 
can be very cumbersome. The differentiation between deep and superficial infections is 
crucial in clinical decision-making. Despite a decade of experience in using fluorodeoxyglucose 
positron emission tomography/computed tomography (18F-FDG PET/CT) to diagnose various 
infections, its use in LVAD patients remains scarce. In this case series, we review the current 
evidence in literature and describe our single center experience using 18F-FDG PET/CT for the 
diagnosis and management of LVAD infections. 
 
248
18F-FDG PET/CT IN THE DIAGNOSIS AND MANAGEMENT OF CF-LVAD INFECTIONS
15
INTRODUCTION 
Continuous flow left ventricular assist devices (LVADs) are increasingly used as bridge-to-
transplantation or destination therapy (DT).1 However, driveline and pump infections remain 
a major point of concern, resulting in significant morbidity and mortality. The consequences 
of a LVAD infection depend on the location, depth, and the severity of the infection. There is 
currently no gold standard test available for the detection of the exact site of infection or to 
monitor the response to treatment of LVAD infections.2 The International Society for Heart and 
Lung Transplantation (ISHLT) has proposed standard criteria for the clinical, microbiologic, and 
radiologic diagnosis of infection in LVAD patients.2 These definitions allow for comparative analysis 
of time course, incidence, outcome, and risk factors for infection in ventricular assist device 
(VAD) recipients. However, data regarding the optimal imaging technique to detect infection and 
monitor the response to treatment in these patients is lacking. In this regard, ultrasound imaging 
and computed tomography (CT) angiography can be helpful in detecting fluid collections around 
drivelines, cannulas, and pump. Historically, nuclear imaging modalities described in case series 
about LVAD infections, are 99mTc-leucocyte and 67 Gallium scintigraphy.3,4 However, nowadays 
18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/
CT) is increasingly used in the diagnostic work-up of infectious endocarditis, especially in the 
detection of metastatic and primary extra-cardiac infections.5 Despite a decade of experience in 
using 18F-FDG PET/CT to diagnose various infections, its use in LVAD remains scarce.6–8 
 In this case series, we describe our single center experience using 18F-FDG PET/CT in the 
diagnosis and management of LVAD infections. Additionally, we have conducted a literature 
review on LVAD-related and -specific infections and the use of diagnostic nuclear imaging 
with 18F-FDG PET/CT scans. 
METHODS
Patients
All consecutive HeartMate II (HMII) implantations performed between January 2011 (PET-CT 
camera installed in the hospital) and May 2016 in our tertiary referral center were reviewed. 
These data were extracted from the ongoing EuroMacs Registry (European Registry for Patients 
with Mechanical Circulatory Support) database.9 Patients have agreed with the registry and 
signed the informed consent. The patients who had 18F-FDG PET/CT scintigraphy to investigate 
suspected LVAD-related or LVAD-specific infections were included in this case series. Their 
clinical courses were reviewed, including medical history, comorbidities, microbiologic and 
laboratory investigation, and imaging results (Table 1). We categorized these patients into three 
groups based on their clinical, microbiologic, and nuclear imaging characteristics: 1) persistent 
LVAD-specific infection with positive blood cultures, 2) persistent LVADspecific infection with 
negative blood cultures, and 3) fever of unknown origin with negative blood cultures and swab. 
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CHAPTER 15
18F-FDG PET/CT Imaging 
All 18F-FDG PET/CT images were acquired using a Siemens Biograph mCT (Siemens Medical 
Solutions USA Inc., Malvern, PA). Data were iteratively reconstructed (3 iterations, 21 subsets, 
and 5 mm Gaussian filter) using time-of-flight information and resolution recovery. Low-dose 
CT was used for attenuation correction. The protocol of patient preparation and scanning was 
according to the guidelines of Society of Nuclear Medicine and Molecular Imaging (SNMMI) 
and the European Association of Nuclear Medicine (EANM). As we were interested in imaging 
of infection near the myocardium, it was important to avoid physiologic uptake of glucose by 
normal myocardium cells. Therefore a low carbohydrate diet for 24 h before the PET/CT study 
was recommended to switch the myocardium from using glucose as an energy source to using 
fatty acids, this is one of the options to reduce physiologic myocardial uptake as suggested in 
the mentioned guidelines.10,11 In short, patients had a low carbohydrate diet 1 day before the 
regular fast of 6 h. A total of 2.3 MBq/kg body weight 18F-FDG was administered after which 
patients were resting in a quiet and warm waiting room (to avoid uptake in muscles, brown 
fat, etc.). Imaging started 60 min after administration. Low-dose CT was directly followed by 
PET imaging: the latter for 3 min/bed position for patients <70 kg and for 4 min/bed position 
for patients >70 kg. This meant total imaging time of about 30 min for scintigraphy from 
skull to groin. Interpretation of scans was performed on both for attenuation corrected and 
noncorrected images to avoid false positive judgment caused by artifacts introduced by 
attenuation correction.
Literature Search
Additionally, we performed a PubMed/Medline search by using MeSH terms focusing 
on articles on LVAD-related and LVAD-specific infections and on use of diagnostic nuclear 
imaging with 18F-FDG PET/CT scans. Basic information collected included journal, author, year 
published, number of patients, and types of LVAD. Specific data collected included the clinical 
problem, method(s) of (nuclear) imaging, and outcome.  
RESULTS
Fifty-one HMII implantations were performed in 48 patients between January 2011 and May 
2016. In 9 patients (7 males; mean age 54 ± 15 years) with suspected LVAD-related infections, 
a total of 10 18F-FDG PET/CTs were performed. The primary indications for LVAD implantation 
were bridge-to-transplant (8/9) and DT (1/9). 
 The median duration of LVAD support from implantation or exchange to 18F-FDG PET/CT 
was 134 days (range 24–645 days). The long-term mortality rate was 11%. A (semi-)urgent 
listing for heart transplantation (HTx) caused by infectious complications was needed in 4 
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patients (44%), after a median of 59 days (range 49–200) after the first PET/CT. The detailed 
clinical characteristics of all patients are summarized in Table 1.
 Overall, we describe 9 patients with suspected LVAD infection, either pump or driveline; 
in 33% blood cultures were positive and in 44% wound cultures were positive. 18F-FDG PET/CT 
was performed to establish and determine the extent of LVAD-related or -specific infections. 
In 3 patients we performed the 18F-FDG PET/CT within 90 days postoperative (= short term) 
and in 6 patients the 18F-FDG PET/CT was performed at longer term follow-up. Sixty-seven 
percent of the patients had unexpected extensive deep infections. In 2/9 patients, 18FFDG 
PET/CT was able to rule out any LVAD-related or -specific infections, both very early (24 and 
29 days, respectively) in the postoperative phase. In only one patient there was an isolated 
pump inflow cannula infection (see Table 1, Supplemental Digital Content, http://links.lww.
com/ASAIO/A138). 
A. Persistent LVAD-specific infection with positive blood cultures: This type of infection was 
observed in 3 patients (see Table 1; cases AI–AIII), in which 18F-FDG PET/CT scans were 
performed because of recurrent positive blood cultures despite antibiotics (AB) therapy for 
3–6 weeks. In case I (AI in Table 1), the connection between the inflow cannula and the pump 
body was detected as the source of LVAD infection (Figure 1A). Unfortunately, replacing the 
LVAD would have been a very high risk operation because of a previous LVAD replacement 
caused by driveline fracture. The patient was placed on the high urgency list for HTx, and 
was transplanted 49 days later under AB treatment. After explantation of the LVAD, debris 
was found in the connection between inflow cannula and the pump housing (Figure 1B). 
Microscopy showed the same monoculture of Staphylococcus epidermidis as in patient’s 
previous cultures. The patient is currently doing well and has not experienced any severe 
infections 3 years after HTx. 
 In case AII, this 67 year old male LVAD patient was admitted 175 days after LVAD exchange 
by sternal infection with coagulase negative Staphylococcus epidermidis (CNS) bacteremia. 
Ongoing deep infection despite AB therapy proved by 18F-FDG PET/CT led to semi-urgent 
HTx. The interval after LVAD removal and HTx was complicated by infection, and bacteremia 
with Enterobacter aerogenes detected in fluid aspirated from the substernal region and in 
the explanted driveline. A reoperation to address a possible mediastinitis was considered 
and planned. At day 17 post-HTx, a newly performed 18F-FDG PET/CT showed a hot spot just 
caudal to the sternum, which was a nonencapsulated fluid collection from which the same 
Enterobacter species was cultured after an ultrasound-guided puncture. The former driveline 
route was no longer considered as infected and the planned operation for a mediastinitis was 
cancelled. The patient has had no infectious problems at 31 months of follow-up periode 
(FUP) post-HTx. 
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Figure 1A:  Case AI: 18F-FDG PET/CT  images of a high FDG ring around the inflow cannula of the LVAD. Banded ring 
with high degree of accumulation in the connection part of the inflow cannula with the housing.
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Figure 1B: Case AI: Picture of the debris we found in the connection between inflow cannula and pump housing 
(hands of APWMM).
In one patient (case AIII; Figure 2), osteomyelitis was detected at the level of the 5th lumbar vertebra (L5), in addition 
to a LVAD and driveline infection. Unfortunately, because of severe infection, he became a DT patient and died after 
acute LVAD failure 1,219 days after implantation. Large bacterial growths were found at the insertion opening of the 
driveline, and around the LVAD on autopsy. The treatment of the rest of this group of patients varied according to 
the 18F-FDG PET/CT findings from placement on urgent transplantation list, to continued AB therapy with or without 
vacuum-assisted closure (VAC) therapy.
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Figure 2: Case AIII; 59-years-old man with inflammation of driveline, subcutaneous part as well as intra-abdominal 
portion close to pump housing. Beside this there is a strongly suspected osteomyelitis of Lumbar vertebra L5.
B. Persistent LVAD-specific infection with negative blood cultures: As shown in Figure 3, three 
patients were found in this group (cases BI–BIII; Table 1). In this group of three patients, 
clinical symptoms of infection that progressed during AB therapy, despite negative blood 
cultures, the clinical signs and symptoms of infection were progressive during AB. Figure 3 is 
an example from this group of patients. These patients (Table 1) were all admitted or unable 
to be discharged after LVAD implantation because of fever with negative blood cultures. The 
time between implantation of LVAD and 18F-FDG PET/CT varied from 37 days to 371 days. 
18F-FDG PET/CT showed infection of different parts of the LVAD or deep driveline infection 
despite negative blood cultures, patients had persistent fever.
 Ongoing AB therapy was accepted in case BI because of extended LVAD-specific infection 
37 days after HMII concomitant with aortic valve replacement (AVR). This patient had no 
deterioration of chronic infection at follow-up of 831 days on continuing LVAD support. In 
case BII, there was persisting driveline infection with Staphylococcus aureus 40 days after 
implantation until HTx and despite several AB regimens and surgical interventions. The abscess 
around the driveline exit was drained and treatment with intravenous (i.v.) flucloxacillin was 
started. However, the patient developed recurring cellulitis and the cultures taken from the 
driveline entrance remained positive despite of AB treatment. The 18F-FDG PET/CT showed 
high intensity in the abdominal segment because of FDG accumulation along the driveline 
route. Two hundred days after LVAD implantation she underwent HTx and is still doing well. 
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In case BIII (Figure 3A), a 61 year old male with LVAD was admitted with a suspected driveline 
infection caused by cellulites of the abdominal skin at the driveline exit. The cultures showed 
S. aureus in the driveline exit, but blood cultures were negative. An abdominal ultrasound was 
performed which showed an infiltrated aspect of the skin. After 16 days of AB therapy, the 
fluid collection around the driveline decreased. The 18F-FDG PET/CT showed subcutaneous 
fat infiltration along the driveline with abnormal FDG accumulation. There was no other 
suspicion of infection beside this deep driveline infection on 18F-FDG PET/CT. The patient 
was listed for urgent HTx. Despite AB therapy, a control 18F-FDG PET/CT showed extension of 
increased uptake in the infected region; from the driveline exit to the outflow cannula (Figure 
3B). He was transplanted 5 days after the 18F-FDG PET/CT scan. Postoperative cultures of the 
LVAD showed S. aureus and Candida species.  
Figure 3A: Case BIII, 61-years-old male with example of a deep driveline infection; Driveline in situ with subcutaneous 
fat infiltration visible around the course of the line in the abdominal wall (dotted green arrows).  3B. In case B III, the 
second  18F-FDG PET/CT  showed 54 days later persisting and increased metabolic activity around the subcutaneous 
driveline in abdominal wall. Furthermore appearance of increased metabolic activity around the outflow cannula  of 
the LVAD near to ascending aortae (green arrows) .
C. LVAD patients with fever of unknown origin and negative culture. In these three patients, 
18F-FDG PET/CT was used after negative blood and swab cultures to either detect or excluded 
LVAD-specific or -related infection and detect other causes for fever. The first patient (CI in Table 
1) is a 75 year old female who received a LVAD as DT. The patient was previously admitted with 
superficial sternum infection and was treated with empirical AB therapy, however the patient 
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was re-admitted with fever and progression of the sternal wound infection. The 18F-FDG PET/
CT showed an infected system and mediastinitis because of migration of the infection. The 
patient was treated with VAC therapy and AB because of a diffuse infected pump, driveline 
and mediastinum. There was no other infection unrelated to LVAD, particularly not around 
the implantable cardioverter defibrillator (ICD). At an optimal moment after VAC therapy, a 
rectus abdominis muscle flap reconstruction was performed 82 days after initiation of AB 
and VAC therapy to reconstruct the sternal wound. Figure 4 shows this case as an example of 
the worst case scenario for persisting progressive sternum infections with negative cultures 
during AB therapy. 
Figure 4: Case CI: 74-years-old female with mediastinitis in diffuse LVAD infection after re-admission due to 
progressive clinical signs of sternal wound infection during antibiotic treatment.
 The second patient (CII in Table 1) is a 54 year old man (Figure 5) with LVAD and 
concomitant AVR who was admitted to cardiac ICU because of driveline fracture with recurrent 
LVAD alarms more than two years post LVAD implantation. Because of driveline dysfunction, 
the LVAD device was exchanged. Three days after surgery because of fever and increased 
infection parameters, diagnostic CT thorax was performed which showed signs of empyema 
of the left pleural space. It was treated by thoracic drainage and vancomycin, cefuroxim, 
clindamycin, and rifampicin for 2 weeks (blood cultures showed growth of Micrococcus 
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luteus and S. aureus). After discontinuation of i.v. AB, oral clindamycin was continued for 
1 month. The 18F-FDG PET/CT was performed 24 days after LVAD exchange to monitor the 
infection and the effect of treatment. There were no signs of an infected LVAD or active 
infections elsewhere. He is currently alive on LVAD support for more than 3 years.
 The last patient (CIII; 40 year old male) with LVAD and AVR was admitted for recurrent 
cardiac tamponade. Because of persisting fever on day 19 post LVAD implantation a thoracic 
CT scan was done, showing air bubbles in the pericardium which was concluded to be a 
normal postoperative effect. Ten days later, after initiation of broad spectrum AB for 2 weeks, 
the 18F-FDG PET/CT was performed which ruled out LVAD infections or prosthetic valve 
endocarditis. After 410 days on LVAD support, he has no signs of infection at the outpatient 
clinic. 
Figure 5: Case CII; 54-years-old male 24 days after LVAD exchange (678 days on support) PET/CT guided exclusion of 
active infection. Mild increased activity around the pleural fluid in the right lung, as well as slightly increased activity 
in multiple mediastinal and hilar lymph nodes bilaterally as well as in pleural nodular; all possible still reactive. There 
is no focus of infection. Other finding is subcutaneous emphysema with pneumothorax right sided.
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DISCUSSION
In this paper, we present nine different LVAD patients who suffered from clinically suspected 
or proven infections in which 18F-FDG PET/CT imaging supported clinical decision making in 
LVAD-specific and -related infection. To our best knowledge, our case series contains yet the 
largest population of HMII patients ever managed by 18F-FDG PET/CT. However, limited data 
exist regarding the management and outcomes of LVAD infections. In the current literature, 
we found only 4 studies with case reports and series with a total of 47 cases: 2 case reports 
and 2 case series with 18F-FDG PET/CT were published between 2013 and 2016. The findings 
of these four studies are summarized in Table 2. 
 One of the major drawbacks for long-term LVAD support are LVAD-specific and LVAD-
related infections resulting in high risk of morbidity and mortality.12 Prompt diagnosis of 
LVAD-related infections can be particularly challenging in cases involving pump of cannula 
infections, pocket infections or deep sternal wound or mediastinal infections. Innovations 
in cardiovascular imaging strategies have emerged to resolve these issues such as: multi-
slice CT, 3D echocardiography, 18F-FDG PET scan, molecular imaging, and cardiac magnetic 
resonance. 
 18F-FDG PET/CT appeared to be a useful nuclear imaging diagnostic tool to assess LVAD 
infections. In a clinical study of 31 LVAD patients, 18F-FDG PET/CT had a sensitivity of 100% and 
a specificity of 80% of 18F-FDG PET/CT in detecting infections of LVAD components, both in 
patients with and without obvious infection.13 In our current case series we found a sensitivity 
and specificity of 100% in nine HMII patients including early and very early performed 18F-FDG 
PET/CT in contrast to previous studies and recommendations. Additionally, the timing when 
to perform the 18F-FDG PET/CT varies greatly in the current literature (Table 2). Although 
our sample size is small, 18F-FDG PET/CT was able to evaluate and rule out LVAD infections 
as early as 3 weeks post-implantation, in contrast to the current paradigm of waiting 3–6 
months after LVAD implantation. This was in line with the first paper on nuclear imaging in 8 
HMII patients with suspected infection (mean durations after implantation 54 days) without 
any false positive result.3 In our case series 18F-FDG PET/CT was used to detect the site and 
extent of infection and to guide duration of AB treatment in 7/9 patients (Table 1). The study 
accurately ruled out infection in 2/9 patients. Therefore, given the clinical experience in the 
current literature and our paper, we believe that 18F-FDG PET/CT is a crucial imaging tool in 
the diagnosis and management in infection specific and related to LVAD patients. However, 
some issues remain unresolved and require further investigation. 
 The optimal conditions for 18F-FDG PET/CT acquisition that allows us to improve the image 
contrast and to better discriminate between positive and negative scans, have to be further 
determined. 18F-FDG PET/CT could have a widespread use based on practical reasons, however it 
is limited by meticulous test preparation with low-carbohydrate diet. In the latter circumstance, 
physiologic myocardial uptake can be seen, reducing the specificity of scan findings. 
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It is therefore unfortunate that among all of the studies reported so far, only two included a 
high-fat, low-carbohydrate diet in addition to the fasting period in the patients’ preparation. 
Furthermore, image analysis should be standardized regarding both the pattern and the 
quantification of the uptake. Additionally, the impact of factors such as AB treatment and 
the type of infective agent needs to be evaluated more precisely. The initiation of AB therapy 
and, if present, its duration before imaging is likely to alter the inflammatory response of 
the host and thus FDG uptake.5 Also, it is acknowledged that some bacteria strains may 
escape immune response either by producing a biofilm on prosthetic material, or by using an 
intracellular cycle, allowing them to be hardly detectable by immune cells.7 
 The timing of 18F-FDG PET/CT remains controversial because of recent surgery.13 
Nevertheless, in our small cohort there is a promising use of this imaging technique to rule out 
function even in an early postoperative period (3–6 weeks). Larger studies and comparisons 
are needed to optimize timing of 18F-FDG PET/CT when there is an ongoing suspicion of LVAD-
specific infections without source control in both in the outpatient and inpatient setting. In 
particular, it is important to define who are the patients that would benefit the most from 
this test according to their probability of infection based on clinical evaluation, echo(cardio)
graphy results and risk factors for development of infection during LVAD support. 
CONCLUSION
In this case series of nine patients with continuous flow LVAD type HMII, 18F-FDG PET/CT 
imaging provided accurate information on the localization and extent for LVAD-specific or 
-related infections as early as 3 weeks post-implantation. Review of the current literature 
with 2 case reports and 2 case series with a total of 47 cases, confirms the promising role of 
this novel imaging modality.
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Continuous-flow left ventricular assist devices (CF-LVADs) are increasingly used in the 
management of patients with end-stage heart failure; however, CF-LVAD support can be 
hampered by the occurrence of ventricular arrhythmias (VAs) (1–5). There are limited data 
on the temporal evolution of VA burden during long-term follow-up. The aim of the present 
study was to investigate the incidence, predictors, and clinical outcomes of VA in CF-LVAD 
patients. We reviewed all adult patients receiving a CFLVAD between March 2006 and April 
2015 in 2 large Dutch LVAD centers. The primary outcome was the occurrence of VA, defined 
as VA that was sustained for >30 s or was treated by an implantable cardioverter-defibrillator 
(ICD). Multivariate Cox regression analysis was performed to investigate predictors of late 
(>30 days) post-LVAD VA. Overall, 204 patients underwent CF-LVAD implantation (mean age 
at implantation 49.2 ± 12.5 years, 70.6% male, 70.6% nonischemic cardiomyopathy, 58.3% 
ICD). The majority of patients (93.6%) received an LVAD as a bridge to heart transplantation 
(HTX). Eighty-five patients (41.7%) had a history of VA before LVAD implantation. During 
a median follow-up of 17.3 months (interquartile range: 8.1 to 29.5 months), 62 patients 
(30.4%) experienced post-LVAD VA. The burden of VA followed a U-shaped curve, with the 
highest incidence in the first postoperative month, a nadir at 15 to 18 months, and a rise after 
that time (Figure 1A). Pre-LVAD VA, the presence of an ICD, the use of beta blockers, and atrial 
fibrillation were univariate predictors of late post-LVAD VA. In a multivariate Cox regression 
model, only pre-LVAD VA remained as an independent predictor of late post-LVAD VA 
(adjusted hazard ratio [HR]:2.13; 95% confidence interval [CI]: 1.06 to 4.27; p = 0.03) (Figure 
1B). During follow-up, 88 patients (43.1%) underwent HTX and 57 patients (27.9%) died. 
The 1-year mortality and HTX rates were 11.8% and 18.6%, respectively. The most common 
mode of death was noncardiac death (52.6%), followed by cardiac death (28.1%) and death 
of indeterminate causes (19.3%). Post-LVAD VA was not associated with increased mortality 
(HR: 1.10; 95% CI: 0.63 to 1.95; p = 0.73), HTX (HR: 0.99; 95% CI: 0.63 to 1.55; p = 0.96), or 
the combined endpoint of HTX or death (HR: 0.98; 95% CI: 0.69 to 1.41; p = 0.93). However, 3 
of 62 patients (4.8%) with post-LVAD VA had difficult to control VA that required urgent HTX. 
The incidence of post-LVAD VA was 30.4% in the present study, which is in agreement with 
previous studies (1–5). A high early post-operative burden of VA was followed by a relatively 
low VA burden after hospital discharge. However, at long-term follow-up, there appears 
to be increased vulnerability to VA, which could reflect incipient hemodynamic failure of 
appropriate LVAD support. Pre-LVAD VA was an independent predictor of late post-LVAD VA. 
This is not surprising, because it reflects the presence of an arrhythmogenic substrate that 
is not abolished by the implantation of an LVAD. The effect of post-LVAD VA on survival rates 
is ambiguous in the literature (2–4). In a small study comprising 61 patients with CF-LVAD 
and ICDs, post-LVAD VA was an independent predictor of mortality (3). We did not find an 
association between post-LVAD VA and increased mortality, albeit a minority of patients with 
therapy-resistant VA required urgent HTX as a bail-out procedure. Our study is hampered by 
its retrospective design. 
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The incidence of VA might be underestimated when VA episodes are not documented 
properly, especially in patients without an ICD. In summary, the incidence of post-LVAD VA 
followed a U-shaped curve with an increase in incidence at long-term follow-up. Patients 
with pre-LVAD VA were more prone to develop late post-LVAD VA. Post-LVAD VA did not 
appear to impact survival or HTX rates; however, urgent HTX was needed in some patients 
with therapy-resistant VA. It is important to realize that in destination-therapy patients with 
therapy-resistant VA, urgent HTX will probably not be a good option.
Figure 1: Post –LVAD VA
(A) Incidence of post-LVAD VA depicted as the percentage of patients with VA 
per time interval. (B) Kaplan-Meier event curves for late (>30 days) post-LVAD 
VA stratiﬁed by pre-LVAD VA. LVAD = left ventricular assist device;  
VA = ventricular arrhythmia. 
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Figure 1. Post –LVAD VA 
(A) Incidence of post-LVAD VA depicted as the percentage of patients with VA per time interval. (B) Kaplan-Meier 
event curves for late (>30 days) post-LVAD VA stratified by pre-LVAD VA. LVAD = left ventricular assist device; 
VA = ventricular arrhythmia.
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ABSTRACT
Background:
Long-term durability and incidence of potential mechanical device failure are largely 
unknown. In this study, we investigated the incidence and potential predictors of mechanical 
device failure (MDF) in continuous flow left ventricular assist device (cf-LVAD) patients.
Methods: 
We conducted a retrospective study of all cf-LVADs (type HeartMate II) implanted in our 
center. MDF was defined as a failure of driveline, inflow-outflow graft, electrical power, drive 
unit or motor failure, excluding device failure due to a biologic complication (ea. device 
thrombosis, hemolysis or infections).
Results:
A total of 69 cf-LVADs were implanted in 59 patients (median support time 344 days [IQR 
149-712days], mean age 50.1±10.7 years, 75% male). MDF occurred in 9 (13%) cf-LVAD 
patients at a median follow-up time of 846 [IQR:708-1337] days after implantation. Freedom 
of MDF through the 1st, 2nd, and 3rd year after LVAD implantation was 100%, 85%, and 
64%, respectively. Patients who experienced MDF, were significantly longer supported by 
their LVAD (median 846 [IQR: 708-1337] vs. 268 [IQR:103-481] days, p = 0.001), were more 
frequently re-admitted due to LVAD related technical problems (p=0.002), including a higher 
rate of LVAD controllers exchange (44% vs. 12%, respectively p=0.03). The main reason for 
MDF was a damaged or fractured driveline (n=8, 89%).  In 2 patients, sudden death was 
related to MDF.  
Conclusion:
Patients needing extended cf-LVAD-support are at increasing risk for MDF. Various technical 
problems precede the onset of a MDF event. Periodical extensive assessment of the technical 
integrity of the device is indicated during long-term LVAD support.
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BACKGROUND
Continuous flow left ventricular assist devices (CF-LVADs) are increasingly used in the 
treatment of end-stage heart failure patients in the form of bridge-to-transplantation (BTT), 
bridge-to-recovery, and as destination therapy (DT).(1-5) Although the use of LVAD as BTT 
has improved the quality of life and the survival of patients awaiting heart transplantation 
(HTX),  HTX still remains the most successful treatment option for patients with refractory 
heart failure with a mean survival beyond 13-14 years.(6) Due to the extreme shortage of 
suitable cardiac donors and the rise of elderly patients ineligible for HTX, the use of cf-LVAD as 
DT is increasingly used in recent years.(1, 2) As a result, the duration of long-term mechanical 
support increases and device durability becomes extremely important for the long-term 
survival, morbidity and quality of life of patients, in particular for DT patients.(7, 8) In the 
REMATCH trial device failure was the leading cause of death, next to sepsis (9). Device failure 
can occur due to mechanical failure, driveline damage, infections or thrombosis and often 
requires pump replacement, which is associated with increased healthcare costs, morbidity 
and mortality.(8, 10-12) Previous studies have reported that the incidence of device failure 
and device replacement is higher from one year of mechanical support onward.(9, 11, 
12) However, there is limited data on the long-term durability of current cf-LVADs and the 
distribution of device failure over time. In this study, we investigated the incidence, predictors 
and clinical outcome of device failure in HeartMate II (formerly Thoratec Inc., currently 
Abbott, Chicago, IL) cf-LVAD patients beyond one year of implantation.  
METHODS
Study design and patient population
We conducted a retrospective review of all patients (age ≥16 years) between December 2006 
and August 2015, receiving an axial type continuous-flow HeartMate II LVAD at the Erasmus 
MC, Rotterdam, a tertiary referral center. Each cf-LVAD implant (primary or secondary) was 
separately entered into the study. The cohort of patients used in this study is derived from 
the local input of the EUROMACS Registry.(5) The study was approved by the institutional 
review board of the Erasmus MC and informed consent was signed by the patients. 
Outcome definitions
The primary outcome was the occurrence of mechanical device failure (MDF). For the 
definition of MDF, the criteria given by Fries et al. was utilized and defined as: a mechanical 
problem resulting from a driveline, inflow / outflow graft damage or as a drive unit or 
motor failure of an implanted ventricular assist device.(13) Device failure due to a biologic 
complication (device thrombosis, hemolysis or infections) was excluded and is reported 
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separately.(14) Deaths were classified as “cardiac” when a definitive cause of death related 
to a cardiovascular event or LVAD failure, and as “non-cardiac” when the cause of death did 
not relate to the cardiovascular system. Secondary outcomes were all-cause mortality, heart 
transplantation, LVAD replacement or explantation. 
Data collection 
Relevant baseline characteristics, demographics, postoperative and clinical data were 
collected, primarily for the EUROMACS Registry. Eventual missing data were easily retrieved 
from the medical records of the patients, which were stored electronically in the hospital 
electronic patient records. The data was obtained from reports from routine clinic visits and 
written correspondence from local physicians. Date of onset was recorded for all major LVAD 
alarms, device failure and adverse events such as, re-thoracotomy and pump thrombosis. 
LVAD alarms were collected by the LVAD technician (CvdH) for clinical purposes during 
regular clinical visits. The device failure was confirmed independently by the cardiologists 
(KC, SA). Subsequently, data were processed anonymously. All cases of device failure were 
extensively revised to determine the characteristics of the patient, onset, diagnostic tests 
used, treatment and treatment outcome. 
Statistical analysis
Categorical variables are represented by frequencies and percentages. Continuous data are 
presented as mean ± standard deviation or as median and interquartile range [25th to 75th 
percentile]. Continuous variables were compared using paired or independent t-test, Mann-
Whitney U-test or Wilcoxon’s test when appropriate. When comparing frequencies between 
groups, the Chi-square or Fisher’s exact test was used, where appropriate. Statistical analyses 
were performed using SPPS version 21(IBM corporation, Armonk, NY). All test were two-
tailed. All p-values between 0.05 and 0.10 were considered to be a statistical trend and a 
p-value <0.05 was considered statistically significant. 
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Table 1: Baseline Characteristics of Study Population at LVAD Implantation
Total 
Population 
(n=69)
Mechanical 
Device Failures 
(n=9)
Nonmechanical 
Device Failures 
(n=60)
p Value
Demographics
Age at implantation (years) 50.1 ± 10.7 47.4 ± 14.2 50.5 ± 10.2 NS
Male gender 52 (75) 7 (78) 45 (75) NS
BSA (m2) 1.9 ± 0.21 1.9 ± 0.18 1.9 ± 0.21 NS
BMI (kg/m2) 23.0 ± 3.7 22.9 ± 3.4 22.6 ± 3.8 NS
Non-ischemic CMP 37 (54) 3 (33) 34 (57) NS
Ischemic CMP 32 (46) 6 (67) 26 (43)
Comorbidities at baseline
Myocardial infarct 30 (44) 6 (67) 24 (40) NS
PCI 26 (38) 4 (44) 22 (37) NS
CABG 4 (6) 2 (22) 2 (3) 0.08
ICD 42 (61) 4 (44) 38 (63) NS
Hypertension 12 (17) 1 (11) 11 (18) NS
Diabetes mellitus 4 (6) 1 (11) 3 (5) NS
TIA/CVA 6 (9) — 6 (10) NS
COPD 3 (4) — 3 (5) NS
Preoperative status
INTERMACS class NS
I 14 (20) 2 (22) 12 (20)
II 15 (22) 4 (44) 11 (18)
III 19 (28) 3 (33) 16 (27)
IV 12 (17) — 12 (20)
V–VII 9 (13) — 9 (15)
Inotropic support 54 (78) 9 (100) 45 (75) NS
IABP 27 (39) 5 (56) 22 (37) NS
ECMO 13 (19) 2 (22) 11 (18) NS
Categorical variables are presented as frequencies and percentages. Continuous variables are presented as mean 
± standard; ns, not significant (p>0.05); BSA, body surface area; BMI, body mass index; CMP, cardiomyopathy; 
PCI, percutaneous coronary intervention; CABG, Coronary artery bypass graft; TIA, transient ischemic attack; 
CVA, ischemic cerebrovascular accident; COPD, Chronic Obstructive Pulmonary Disease;  Interagency Registry for 
Mechanically Assisted Circulatory Support (INTERMACS); IABP, Intra-aortic balloon pump; ECMO, Extracorporeal 
Membrane Oxygenation.
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RESULTS
Baseline characteristics 
A total of 69 CF-LVADs were implanted in our center between December 2006 and August 
2015 in 59 patients (mean age at implantation 50.1±10.7 years, 75% male, 54% non-ischemic 
cardiomyopathy).  All patients received their LVAD initially as a BTT. Seventy-eight percent of 
the patients required intravenous inotropic agents, 39% had an intra-aortic balloon pump 
and 19% were supported by an ECMO, pre-implantation. MDF occurred in 9 patients, of 
whom 7 had lead fractures. Their baseline characteristics did not differ significantly when 
grouped into MDF and Non-MDF groups (Table 1). 
Clinical outcomes and the epidemiology of mechanical device failure
During a median follow-up (FU) duration of 344 days [IQR 149-712 days], 9 (13%) patients 
reached the endpoint MDF. Overall, 12 (17%) patients died and 26 (38%) patients underwent 
heart transplantation during the follow-up period (Table 2). MDF accounted for 17% of the 
deaths. Outcomes stratified by groups are presented in Figure 1. Three (4%) patients had 
their LVAD exchanged because of pump thrombosis, and one patient experienced cardiac 
recovery and subsequently the LVAD was explanted (Figure 2.) Competing endpoints up to 60 
months after LVAD implantation are presented in Figure 3. 
Figure 1: Flow-chart. LVAD, left ventricular assist device.
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Figure 2: The rise of mechanical failure. HTX, heart transplantation; LVAD, left ventricular assist device. 
Figure 3: Competing endpoints after continuous flow left ventricular assist device (CF-LVAD) implantation. 
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MDF occurred at a minimum of 649 days with a median time of 846 days [IQR 708-1337 
days] after implantation. In addition, patients who experienced MDF were significantly longer 
supported by their LVAD compared to the Non-MDF group, median 846 days [IQR 708-1337 
days] versus 268 days [IQR 103-481 days], p = 0.001, respectively (Table 2). The incidence 
in the first, second and third year was 0%, 13% and 38%, respectively. Event-free survival 
through the 1st, 2nd, and 3rd year after LVAD implantation for MDF was 100%, 85%, and 
64%, respectively. The total incidence rate (IR) was 0,11 MDF per patient year. In Figure 4 the 
cumulative percentage of patients free from technical problems preceding the onset of MDF 
is presented, censored for death and HTX. 
 
Table 2: Follow-up after LVAD implantation.
Total Population 
(n=69)
Mechanical Failures 
(n=9)
Nonmechanical Device 
Failures (n=60)
p Value
Follow-up, days 344 [149–712] 846 [708–1337] 268 [103–481] 0.001
BMI difference at last FU* +2.0 ± 3.0 +2.0 ± 2.5 +2.1 ± 3.2 NS
NYHA class at last FU* NS
I 30 (51) 8 (89) 22 (44)
II 19 (32) 1 (11) 18 (36)
III 8 (14) — 8 (16)
IV
Clinical outcome 2 (3) — 2 (4)
Death 12 (17) 2 (22) 10 (17) NS
Heart transplantation 26 (38) 5 (56) 21 (35) NS
LVAD explantation 1 (1) — 1 (2) NS
Rethoracotomy 34 (49) 5 (56) 29 (48) NS
Early (<30 days) 28 (41) 3 (33) 25 (42) NS
Readmission reason
Cardiac deterioration 5 (7) 2 (22) 3 (5) NS
LVAD related 36 (52) 9 (100) 27 (45) 0.002
*Only patients included who were discharged. Categorical variables are presented as frequencies and percentages. 
Continuous variables are presented as mean ± standard deviation or median [IQR (interquartile range 25th, 75th 
percentile)]. BMI, body mass index; FU, follow-up; LVAD, left ventricular assist device; NS, not significant (p > 0.05); 
NYHA, New York Heart Association.
Onset of MDF, Diagnosis and Treatment
The number of patients with any cf-LVAD alarms was higher in the MDF group, mainly 
due internal driveline damages. Seventy-eight percent of the patients in the MDF group 
experienced a red LVAD alarm versus 3% in the Non-MDF group (p<0.001, Table 3). Likewise, 
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more patients had their LVAD controllers exchanged (p=0.03) and had a damaged or fractured 
driveline in the MDF group compared to the Non-MDF group (p<0,001). There was no 
difference in the re-admission frequency due to progression of heart failure. In addition, the 
frequency of any or early (<30 days) re-thoracotomy after LVAD implantation did not differ 
significantly between the two groups. 
Table 3: Overview of technical problems in advance of mechanical device failure.
Total Population 
(n=69)   
Mechanical Device 
Failures (n=9)   
Nonmechanical Device 
Failures (n=60)
p Value
LVAD parameters at last FU*
Pump speed (rpm) 9058 (319) 9155 (240) 9040 (331) NS
Pump flow (L/m) 5.0 (1.0) 5.0 (0.73) 4.9 (1.0) NS
Pulse index 5.7 (1.0) 5.6 (0.68) 5.7 (1.1) NS
Pump power (Watts) 5.7 (0.9) 6.0 (0.65) 5.6 (0.9) NS
Any LVAD alarm 23 (33) 9 (100) 14 (23) 0.001
Red alarm 9 (13) 7 (78) 2 (3) 0.001
Yellow alarm 4 (6) 1 (11) 3 (5) NS
Other 10 (15) 1 (11) 9 (15) NS
Driveline damage 12 (17) 8 (89) 4 (7) <0.001
Internal damage 7 7 —
External damage 5 1 4
Battery lead damage 14 (20) 3 (33) 11 (18) NS
Battery defect 3 (4) 2 (22) 1 (2) NS
LVAD controller exchange 11 (16) 4 (44) 7 (12) 0.03
LVAD exchange 10 (15) 7 (78) 3 (5) 0.001
Due to mechanical failure 7 (10) 7 (78) —
Due to pump thrombosis 3 (4) — 3 (5)
*Only patients included who were discharged. Categorical variables are presented as frequencies and percentages. 
Continuous variables are presented as mean ± standard deviation. FU, follow-up; LVAD, left ventricular assist 
device; ns, not significant (p > 0.05).
An overview of the 9 patients with MDF (age at implantation 47.4±14.2, 78% male, 67% 
Ischemic cardiomyopathy) is given in table 4. Furthermore, three out of nine MDF patients (2 
pre-MDF and one post-MDF) were treated with benzodiazepines during their LVAD-support. 
Two (22%) of these patients died suddenly outside the hospital, one at home and one in a 
nursing home. The primary reason for MDF was a driveline fracture. In three (33%) patients 
the LVAD alarms or pump speed drops were position-dependent. In all patients, a history of 
technical problems before the occurrence of MDF was present. No traumatic event could be 
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recalled in all the MDF patients. All the patients except for one, presented themselves with 
red alarms, low-flow alarms, temporary pump stop or a combination of the aforementioned.
 In four patients, the driveline fracture was detected with abdomen x-ray (Figure 5). LVAD 
replacement was necessary in 6 patients (86%) and one patient had his external driveline 
repaired by the manufacturer. All patients that were re-admitted to the hospital due to the 
occurrence of MDF survived until discharge. Two (22%) of these patients are still on LVAD 
support after LVAD replacement, and 5 (56%) patients underwent heart transplantation 109, 
166, 244, 660, and 985 days after experiencing MDF. 
Figure 4: Percentage of patients free from mechanical failure or technical problems.
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Figure 5: A X-ray of internal part of the driveline of a 54-year-old male (Patient no. 7 in table 3), who received 
a LVAD because of progressive heart failure, which originated from a myocarditis. Twenty-six months after LVAD 
implantation he experienced low voltages. Initially it was thought to be a software problem and his controller was 
exchanged. However, he presented himself, 29 months after LVAD implantation, with a pump stop during the night, 
which was position dependent. X-ray of the internal part of the driveline showed irregularities in the C-shape section. 
Because of the pump stop and the irregularities of the driveline, his LVAD and driveline was exchanged. B Driveline 
damage externally observed.
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DISCUSSION
In this study we describe the rate, associated factors, clinical presentation and outcome of 
MDF in CF-LVAD patients. MDF is a serious complication seen at mid-term follow-up of cf-
LVAD patients, jeopardizing the long-term outcome. Patients with apparently futile, however 
cumulative technical problems over time were more prone to experience MDF, which often 
requires invasive surgery and LVAD replacement. The incidence of technical problems rises 
over time, comparatively like the incidence of MDF. MDF occurred at a median FU time of 
846 [708-1337] days after implantation. The majority of the patients with MDF presented 
with red LVAD alarms and concomitant temporary pump stop.  Seventeen percent of the 
deaths was due to MDF. However, if patients reached the hospital on time, then they could 
be treated successfully. Through timely connection to an ungrounded cable or staying on 
batteries, further electrical shortcut could be prevented and semi-urgent LVAD exchange or 
external repair of de driveline could be conducted. 
Current developments and the rise of Mechanical Device Failure 
Studies have reported an increase in survival of patients on mechanical circulatory support 
(MSC) since the use of cf-LVADs.(15) The two-year survival in the HeartMate II DT trial 
improved from 58% in the early trial experience to 63% for the midtrial group.(16) Also, 
the INTERMACS analysis of 2011 showed that cf-LVADs are superior to pulsatile pumps for 
DT and with the approval of the HeartMate II cf-LVAD for DT, the number and proportion 
of devices implanted as DT progressively increased. The DT already represent nearly half of 
the long-term MCS device strategy in the USA.(1) These developments lead to an increase 
of patients who are supported by a cf-LVAD for longer than 2 years. However, due to the 
fact that these patients are not eligible for transplantation, they have no other treatment 
options in the case of cardiac deterioration or severe adverse events, in contrast to the BTT 
patients.  Therefore, device durability is extremely important for this group of patients. Up to 
now, the most common cause of device failure was pump thrombosis (10, 11, 17). However, 
we report a cohort with a higher incidence of device failures requiring LVAD replacement 
originating from a mechanical problem (13%) in contrast to a biological problem (4%). This 
is supported by the major clinical trial; HeartMate II Destination Therapy.(18) Eight percent 
of the pump replacements in the CF-LVAD patients was in this trial due to mechanical device 
failure and 2% due to biological problems. In a recent study, Stulak and colleagues reported 
on driveline damages (incidence 3.9%) and durability of driveline repair.(19) In contrast to 
our study with mainly internal driveline fractures requiring device exchange, they reported 
on damages to the external portion of the driveline, which could be managed in the majority 
of the patients through driveline repair with good durability.(19)  An explanation for the 
overall higher incidence of MDF in our cohort could be the fact that most studies describe the 
survival of patient up to two years. However, in our study the majority (67%) of MDF occurred 
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after two years and 33% occurred even three years after LVAD implantation. Furthermore, a 
relatively high percentage of patients (17%) had a damaged driveline in our study, which is an 
important cause for MDF. 
Factors associated with device durability 
It has been reported that the durability and functionality of LVADs is influenced by multiple 
factors, including anatomical constraints, patient complications, device design and 
manufacturer.(17) The most common cause of MDF in our study was due to a damaged 
driveline, which is also described elsewhere.(8, 12) In addition, factors as support time, LVAD 
alarms and controller exchanges seem to be associated with device durability and  predict 
MDF. On the other hand, an uncontrolled level of anxiety could lead to inadvertent damages 
to the DL. In our cohort limited data was available on anxiety levels in order to further 
quantify this. All the patients in the MDF group had improved functional status at time of 
event and had gained some weight. Increased body size has been mentioned as a risk factor 
for driveline fractures because of the constant pulling of the cable.(12) In combination with 
improved functionality, it could be hypothesized that an increased weight and activity has an 
additive effect on the risk of developing driveline damage and eventually mechanical device 
failure. Further research has yet to prove these hypotheses.   
Survival
In the REMATCH trial, LVAD failure was the second most frequent cause of death (17%) 
among device-supported patients and they reported a device failure probability of 35% at 
24 months.(4) Our study is in line with the reported frequency of LVAD failure as cause of 
death (17%). However, contrary to the REMATCH trial, in our study only 6 patients (9%) had a 
device failure due to any problem at 24 months. Kirklin et al, already reported that patients, 
who undergo transplantation, potentially avoid an unfavorable LVAD outcome.(15) This 
“censoring” of patients at time of transplantation introduces considerable uncertainty about 
long-term device complications and device failure. This uncertainty affects mostly the DT 
patients, due to the fact that they do not have transplantation as a rescue option. Therefore, 
further research is needed, which addresses only the DT patients and investigates the long-
term device complications and true survival of these patients. 
Analogy
As history repeats itself, it has proven multiple times, the use of any medical device is 
accompanied by the risk of failure. Examples include the Bjork-Shiley valves or the Riata ICD 
leadsIn a study conducted by de Mol et al., 7 of the 24 electively explanted Bjork-shiley valves 
showed a defect in at least one strut, while there were no indications for a valve defect 
before explanting the valve.(20) Their findings supported the hypothesis that because of the 
devastating consequences of  a strut fracture the true incidence of fractures can remain 
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undetected. This also applies to mechanical circulatory support devices, with regard to the 
driveline.  Although, the follow-up of cf-LVAD patients are very strict. It has to be emphasized 
that MCS devices are designed to only last for a limited amount of time. Unawareness of 
the state (internal or external) of the driveline may therefore lead to fatal cases that could 
have been prevented. Both, device characteristics as human errors can increase the risk of 
malfunctioning. (17, 20) Luckily, manufacturers keep modifying their devices over time, which 
has led to a significantly decline in the incidence of lead failures (21). These two lead revisions 
included; changes to the external connector bend relief at the controller (June 2007), and 
changes to the internal pump-end bend relief (December 2010) (21). The HeartMate II is 
worldwide the most implanted LVAD, it has been of paramount importance for the treatment 
of end-stage heart failure and a stepping stone for the success of MCS. However, the journey 
toward the ideal LVAD is still long and therefore, careful assessments of technical integrity of 
the device during follow-up is needed to ensure patients’ safety.
Clinical implications: an urgent call for periodical technical inspections of the device. 
Although the introduction of the CF-LVAD had an positive impact on the survival of end-stage 
heart failure patients, neglecting it limitations can lead to devastating events. Mechanical 
device failure is an arising problem for patients who are surpassing the boundaries of 
mechanical circulatory support. Consequently, device durability has become extremely 
important to patients living with mechanical circulatory devices. We report MDF as main 
reason for death after the second year of LVAD-support and a MDF incidence of 38% during 
the third year after implantation. Therefore, periodical and intensive examination of the LVADs 
driveline and its technical integrity is indicated. Pamboukian and colleagues reported that 
through a formalized long-term management strategy, an intensive surveillance protocol and 
better patient selection leads to an improved two-year survival.(22) We add to this that there 
should be more emphasis on controlling the driveline on the long-term. It is reported that 
often the damage on the driveline occurs at a “weak” place, the feed through of the driveline 
to the pump body.(12) We observed also driveline damages mainly in the internal part of 
the driveline, especially the C-shape part (see Figure 5A). The duration of LVAD-support, 
history of technical problems and the presence of driveline damage should be considered to 
determine if the performance of regular x-ray is justified. Especially in patients with increased 
weight and physical activity, a low-threshold should be taken in to account. 
Limitations of the study
This study has several limitations, which should be taken into account in the final interpretation 
of the data. This is a single-center study and is partly confined by its retrospective design. 
The data was collected from the hospitals electronic medical records. Therefore, the data 
depends on documented events. Also, the number of cases and patients with LVAD-support 
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duration larger than 3 years were limited. Finally, our findings were restricted to HeartMate II 
and may not be applicable to patients supported with other types of cf-LVADs. 
CONCLUSION
In conclusion, the incidence of mechanical device failure increases with time and CF-
LVAD recipients with an extended LVAD-support time, a history of technical problems or 
damaged driveline are more prone to experience mechanical device failure. Mechanical 
device failure can be managed successfully if patients reach the hospital in time. We expect 
improvements that will increase the durability of devices and the survival of patients. 
New technical improvements are used in the driveline of the HeartMate III to improve its 
longevity. Further research has to show if this adds to the reliability and durability of the 
cf-LVAD.
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Worldwide, patients with acute on chronic heart failure or with a cardiogenic shock are still 
dying in the ICU despite increasing possibilities to keep them alive and to gain time through 
short-term and long-term mechanical circulatory support devices (MCS). Luckily, national 
and International data shows increasingly use of short- and long-term MCS devices. MCS for 
short- and long-term sought to replace the failing heart to maintain the circulation and tissue 
perfusion. In our center, the most likely fastest growing population in the short-term are 
patients with cardiogenic shock needing veno-arterial extracorporeal membrane oxygenation 
(VA-ECMO). For permanent or long-term support, as bridge to transplant or as a destination, 
are those patients bridged from short-term support to continuous flow left ventricular assist 
devices (LVAD). Usually these are patients with cardiogenic shock belonging to INTERMACS I 
to II after supported by short-term MCS or INTERMACS III to IV due to deteriorating chronic 
heart failure or ongoing severe chronic heart failure. Monitoring the adequacy of circulation 
in these patients before and after MCS is based on surrogate markers of tissue perfusion 
e.g. lactate, mixed venous saturation and global hemodynamics e.g. mean arterial pressure 
and heart rate. In this thesis, we sought to examine microcirculatory monitoring during 
mechanical circulatory support.
 The aim of this thesis was to investigate clinical features of short-and long-term mechanical 
circulatory support devices and the potential application of microcirculatory monitoring for 
a timely detection and prediction of potential complications. Therefore, this thesis is in five 
parts as follows: part 1 (microcirculation in patients with mechanical circulatory support), 
part 2 (Short-term mechanical circulatory support: veno-arterial extra corporeal membrane 
oxygenation for cardiogenic shock), part 3 (Long-term mechanical support: left ventricular 
assist devices for long-term mechanical circulatory support in patients with end-stage heart 
failure), part 4 (Summary, Conclusions and Future Perspectives), and part 5 (Appendices).         
The Introduction presented in chapter 1 of this thesis provides an overview regarding the 
current position of VA-ECMO and LVAD therapy as short- and long-term mechanical circulatory 
support for the treatment of acute or chronic heart failure, respectively. Monitoring of the 
circulation could be cumbersome in these patients. In many studies this tool outperformed 
the known global hemodynamic parameters in accuracy. VA-ECMO as a short-term mechanical 
circulatory support is enabling the heart to win time to recover, time for an intervention, 
transplantation or implantation of a long-term mechanical circulatory support device like a 
continuous flow LVAD. Once the heart is recovered, the question “when do we wean this 
patients from the ECMO?” arises. The challenge of weaning from VA-ECMO and the timing 
of this moment is a very debated topic. The answer for this question could be found by 
directly monitoring the tissue perfusion. The accurate assessment of the peripheral tissue 
oxygenation, by measuring the microcirculation, could be a novel method for the monitoring 
of these artificial circulations. 
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Once a patient is not able to wean from VA-ECMO and eligible for LVAD implantation, an 
critical period arises which has to be taken seriously by caregivers. Hence, the patients 
are dying on VA-ECMO the timing of bridging from VA-ECMO to a long-term LVAD is very 
important. Having known this the diagnosis and prediction on VA-ECMO could be performed 
by directly measurement of the microcirculation. Therefore, we sought to examine the value 
of microcirculatory monitoring from the literature in the precursor of the VA-ECMO, the 
heart Lung-machine. This brought us to the experimental use of microcirculatory monitoring 
in VA-ECMO patients, for prognostic and diagnostic use, beside the discussion of different 
clinical aspects of short-term MCS. Cardiovascular effects of ECMO on the circulation and 
the prognosis of ECMO support are explained in the further chapters (part 1). Thereafter, we 
extensively analysed patients with long-term MCS e.g. continuous flow LVAD for there clinical 
features, and especially diagnostic predictors for the associated life threatening complications 
(part 2). These fields are the main topics of this thesis. In all aspects of long-term follow-up, 
with a personalized physiological medicine in our mind for tailored therapy, in patients before 
or after short- and long-term mechanical circulatory support devices an effort has to be made 
in order to optimize the circulatory guiding and survival in this very complex population. By 
integrating the microcirculation into the assessment of end-organ function, it could help us to 
better understand and optimize all treatment modalities. The development of proper hard- 
and software for daily use at home should be investigated in the near future. 
PART 2 MICROCIRCULATION IN PATIENTS WITH MECHANICAL 
CIRCULATORY SUPPORT.
In part 2, microcirculation studies on heart lung machine, short- and long-term mechanical 
circulatory support devices have been extensively analysed. In Chapter 2, we reported that 
the response of microcirculation to MCS during critical illness is associated with cardiac pump 
failure and reduced tissue perfusion in all organs. MCS, having pivotal roll in maintaining 
the tissue oxygenation during cardiogenic shock and decompensated chronic heart failure, 
are missing dedicated monitoring parameter. Correction of global hemodynamic parameters 
by MCS does not always cause a parallel improvement in microcirculatory perfusion and 
oxygenation of the organ systems, a condition referred to as a loss of hemodynamic coherence 
between macro- and microcirculation (MC). More studies using direct visualization of the MC 
in short- and long-term MCS by handheld microscopy are needed, preferably randomized 
controlled studies, to identify the presence and clinical significance of hemodynamic 
coherence. It is anticipated that these further studies can enable to better identify patients 
who will benefit from treatment by mechanical heart support to ensure adequate organ 
perfusion.
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In Chapter 3, a comprehensive review of the studies regarding the use of microcirculation 
during cardiac surgery are presented. Cardiac surgery, associated with a wide range of 
microvascular derangements and with reduced tissue oxygenation, has been the main 
focus. Although the macro-hemodynamic targets during cardiac surgery may be achieved, 
the microcirculation may be damaged and even remain dysfunctional. Direct visualization of 
the microcirculation using hand-held microscopy may provide the clinician the physiological 
feedback that is required for the early diagnosis and treatment of microcirculatory alterations 
during cardiac surgery. The coherence between the hemodynamic response of the macro-
circulation and microcirculation during surgery seems to be essential.
 In Chapter 4, microcirculatory and systemic global hemodynamic parameters were 
investigated in 24 patients with cardiogenic shock under VA-ECMO. 15 patients survived and 
9 died while on VA-ECMO. There was no significant difference between the systemic global 
hemodynamic variables at initiation of VA-ECMO between the survivors and non-survivors. 
There was, however, a significant difference in the microcirculatory parameters of both small 
and large vessels at all time points between the survivors and non-survivors. Perfused vessel 
density (PVD) at baseline (survivor versus non-survivor, 19.21 versus 13.78 mm/mm2, p = 
0.001) was able to predict ICU survival on initiation of VA-ECMO; the area under the receiver 
operating characteristic curve (ROC) was 0.908 (95 % confidence interval 0.772–1.0). The 
results show that PVD of the sublingual microcirculation at initiation of VA-ECMO can be 
used to predict ICU mortality in patients with cardiogenic shock. However, larger studies are 
needed to confirm our observations.
 In Chapter 5, the potential value of microcirculatory alterations during weaning 
attempts from VA-ECMO was evaluated. A marker of successful weaning from VA-ECMO 
remains largely unknown. Our hypothesis was that successful weaning is associated with 
sustained microcirculatory function during ECMO flow reduction. Therefore, we sought to 
test the usefulness of microcirculatory imaging, in the same sublingual spot using incident 
dark field (IDF) imaging, in assessing successful weaning from VA-ECMO, and we compared 
the performance of IDF imaging with echocardiographic parameters. We found that the 
functional microcirculatory parameters, measured sublingually using IDF imaging (TVDssF50 
and PVDssF50) during weaning attempts for patients from VA-ECMO, showed essential 
alterations within 2 minutes and that it was a predictor of cardiac recovery after cardio- genic 
shock. VA-ECMO in 13 patients was included. TVDssF50 (21.9 vs 12.9 mm/mm2, p = 0.001), 
PVDssF50 (19.7 vs 12.4 mm/mm2,p = 0.01) and aortic velocity–time integral (VTI) at 50% flow 
reduction (VTIF50) were higher in patients successfully weaned vs not successfully weaned. 
The area under the curve (AUC) was 0.99 vs 0.93 vs 0.85 for TVDssF50 (small vessels) >12.2 
mm/mm2, left ventricular ejection fraction (LVEF) >15% and aortic VTI >11 cm. Likewise, the 
AUC was 0.91 vs 0.93 vs 0.85 for the PVDssF50 (all vessels) >14.8 mm/mm2, LVEF >15% and 
aortic VTI >11 cm. The results emphasize the role of same sublingual spot microcirculation as 
a novel potential marker for identifying successful weaning from VA-ECMO.  
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In Chapter 6, we investigated effects of critical illness including sepsis, high-risk surgery, 
cardiac arrest, and respiratory failure which is characterized by reduced tissue oxygenation 
caused by microcirculatory dysfunction. Every field with impaired tissue oxygenation 
which monitored inadequately due to loss of hemodynamic coherence was investigated. 
Direct monitoring of sublingual microcirculation using hand-held microscopy may provide 
a more physiological approach. Evaluating the coherence between macro-circulation and 
microcirculation in response to therapy seems to be essential in evaluating the efficacy of 
therapeutic interventions. The loss of hemodynamic coherence between macro-circulation 
and microcirculation should always be kept in mind, and all therapeutic approach should aim 
to correct hemodynamic incoherence. 
PART 3 SHORT-TERM MECHANICAL CIRCULATORY SUPPORT: VENO-
ARTERIAL EXTRA CORPOREAL MEMBRANE OXYGENATION (VA-ECMO) 
FOR CARDIOVASCULAR SUPPORT FOLLOWING CARDIOGENIC SHOCK 
In part 3, the focus of short-term mechanical circulatory support (MCS) is mostly towards VA-
ECMO, which is increasingly used in our center for in patients with heart failure, during heart 
transplantation and as mechanical circulatory support. Cardiogenic shock (CS) has a high 
mortality rate and is defined as a state of tissue hypoperfusion induced by cardiac failure. 
Many conditions, such as acute myocardial infarction, end-stage dilated cardiomyopathy, 
myocarditis, complications following cardiac surgery, and cardiac arrest, can cause CS. Veno-
arterial extracorporeal membrane oxygenation (VA-ECMO) is an effective, portable, and 
rapidly deployable technique for providing emergency mechanical circulatory support for 
patients in CS, and it successfully reduces the time required for cardiac recovery. Following 
this bridge therapy, some patients require implantation of a left ventricular-assist device 
(LVAD) or heart transplantation for adequate recovery and survival. Being able to identify 
hemodynamic variables related to survival could provide an important therapeutic window 
for optimizing VA-ECMO support. Currently VA-ECMO is also increasingly used as indicated 
for cardiopulmonary resuscitation (eCPR). All patients included were on VA-ECMO with or 
without IABP as bridge to recovery, bridge to transplantation or continuous flow LVAD.  
 In Chapter 7, we outlined the cardiovascular response to extra corporeal membrane 
oxygenation from development until now and different fields of its use. (Clinical use of) 
tools for dedicated monitoring end-organ recovery during ECMO are still lacking. Surrogates 
of tissue perfusion e.g. mixed venous oxygen saturation and lactate are still used. Direct 
visualization of the microcirculation using hand-held microscopy can be considered the gold 
standard for tissue perfusion since the movement of single red blood cells can be observed 
and quantified. A new generation microcirculation-monitoring device is called CytoCam-
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Incident-Dark-Field imaging. The microcirculatory alterations/responsiveness to ECMO may 
help in very complex clinical issues in this growing mechanical circulatory support population.
 In Chapter 8, a novel mortality risk score was developed to predict ICU mortality, 
in patients with cardiogenic shock under VA-ECMO, comprehensively by adding the 
right ventricular (RV) function to the existing SOFA score. Mortality after veno-arterial 
extracorporeal membrane oxygenation (VA-ECMO) implantation remains high in patients 
with cardiogenic shock. RV failure causes suboptimal left ventricular (LV) filling, frequently 
resulting in biventricular failure requiring VA-ECMO support. In our center from 2004 until 
2016 only 103 patients received a VA-ECMO therapy, 37 (36%) died in the ICU. The median 
duration of VA-ECMO support was 7 days [IQR 4-11] with mean age 49 ± 16 years, and 54% 
male. By adding RV function to the existing SOFA score, the performance of the SOFA score 
improved significantly. SOFA-RV has an AUC of the ROC curve of 0.70, and was significantly 
better than SOFA alone (AUC of 0.57). In addition, SAVE and MELD scores were not able 
to predict ICU mortality. None of the existing mortality prediction scores account for right 
ventricular dysfunction. Adding RV function to the existing SOFA score improves significantly 
the prediction of ICU mortality in patients with VA-ECMO. Dedicated evaluation of the right 
ventricular function in patients with VA-ECMO is therefore highly recommended. In this study 
we showed that adding RV function to the existing SOFA score improves significantly the 
prediction of ICU mortality in patients with VA-ECMO. Therefore, dedicated evaluation of the 
right ventricular function in patients with VA-ECMO is highly recommended. 
 In Chapter 9, we systematically reviewed the literature and performed a meta-analysis 
to support duration and the rate of bridging from short-term to durable mechanical 
circulatory support devices between 2006 and 2016. Thirty-nine studies, mainly registries 
of heterogeneous patient populations (n = 4151 patients), were identified. Depending on 
the device used mean support duration was (range) 1.6–25 days and the mean proportion 
of short-term MCS patients discharged was (range) 45–66%. The mean proportion of bridge 
to durable LVAD was (range) 3–30%. Bridge to durable LVAD was most frequently performed 
in patients with end-stage cardiomyopathy (22 [12–35]%). We conclude that temporary MCS 
can be used to bridge patients with cardiogenic shock towards durable LVAD. Clinicians are 
encouraged to share their results in a large multicenter registry in order to investigate optimal 
device selection and best duration of support.
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PART 4 LONG-TERM MECHANICAL SUPPORT: LEFT VENTRICULAR 
ASSIST DEVICES FOR LONG-TERM MECHANICAL CIRCULATORY 
SUPPORT IN PATIENTS WITH END-STAGE HEART FAILURE 
In part 4, we investigated the most frequent problems after continuous-flow left ventricular 
(LV) assist devices (LVADs) implantation. The increasing use of these devices in patients with 
end- stage heart failure (HF) as a bridge to transplantation, a bridge to candidacy, or destination 
therapy (DT) force us to search for solutions improving survival. The 1-year survival reported 
for patients treated with continuous-flow LVAD was ≈80% and 73% in the Interagency Registry 
for Mechanically Assisted Circulatory Support (INTERMACS) and the European Registry for 
Patients with Mechanical Circulatory Support (EUROMACS), respectively.
 In Chapter 10, we derivate and validate a novel right-sided heart failure (RHF) model 
following LVAD implantation within the largest European registry, The EUROMACS right-sided 
heart failure risk score. Post-LVAD RHF has been reported to be between 4% and 50%, and 
RHF-associated 6-month mortality was seen in up to 29% of patients receiving an LVAD. 
Moreover, RHF has a greater impact in patients who receive LVAD as DT, for whom there is 
no opportunity for bailout with heart transplantation. A 9.5-point risk score incorporating 5 
variables (Interagency Registry for Mechanically Assisted Circulatory Support class, use of 
multiple inotropes, severe right ventricular dysfunction on echocardiography, ratio of right 
atrial/ pulmonary capillary wedge pressure, hemoglobin) was created. The mean scores in 
the derivation and validation cohorts were 2.7±1.9 and 2.6±2.0, respectively (P=0.32). RHF 
in the derivation cohort occurred in 433 patients (21.7%) after left ventricular assist device 
implantation and was associated with a lower 1-year (53% versus 71%; P<0.001) and 2-year 
(45% versus 58%; P<0.001) survival compared with patients without RHF. RHF risk ranged 
from 11% (low risk score 0–2) to 43.1% (high risk score >4; P<0.0001). Median intensive 
care unit stay was 7 days (interquartile range, 4–15 days) versus 24 days (interquartile range, 
14–38 days) in patients without versus with RHF, respectively (P<0.001). The c index of the 
composite score was 0.70 in the derivation and 0.67 in the validation cohort. The EUROMACS-
RHF risk score outperformed (P<0.0001) previously published scores and known individual 
echocardiographic and hemodynamic markers of RHF. This novel scoring system may provide 
clinicians with opportunity for tailored risk decision making before, during, or early after LVAD 
surgery. Those patients would benefit from early recognition in terms of not only less need 
for prolonged ICU stay but also, more important, better survival. However, those corrective 
measures remain speculative and should be tested in some prospective randomized trials 
to prove their usefulness. This novel  EUROMACS-RHF  risk  score  outperformed  currently 
known risk scores and clinical predictors of early postoperative RHF. This novel score may be 
useful for tailored risk-based clinical assessment and management of patients with advanced 
HF evaluated for ventricular assist device therapy.
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In Chapter 11, we analysed the modes of death following LVAD implantation in the largest 
European registry. In 2689 European patients with LVAD, 1062 (39%) died during a median 
follow-up duration of 320 [IQR 88-661] days, of whom, 487(46%) of the deaths occurred 
within 90 days. Independent predictors of early death were INTERMACS class 1 to 3, 
destination therapy, RA to PCWP>0.54, pulmonary vascular resistance (PVR)>4.5 Woods 
unit and hemoglobin ≤10 g/dL. The main modes known of early death were MOF (36%), 
sepsis (28%), CPF (10%), CVA (9%), and right-sided heart failure (RHF, 8%). Sepsis (28%), 
CVA (23%), MOF (14%), bleeding (10%) and CPF (8%) were the main modes of late death. 
Bleeding caused 19% of death in day 1, and reappear after 90 days as an important mode 
(10%) of death. Likewise, CVA start on the day of LVAD implantation (11%) and reappear 
after 90 days as an important mode of death (23%). Device failure (5%) as a mode of death 
was seen only after 90 days after LVAD implantation. This study presents the highly urgent 
need for improvement of pre- and postoperative care to increase survival early after LVAD 
implantation. Of those modes of death are modifiable targets such as RHF and anemia as 
well as potentially modifiable determinants of early death in the high INTERMACS class and 
destination therapy. Early death is mainly driven by MOF in contrast to CVA in the late period. 
These finding could help caretakers to improve patients’ survival via appropriate and timely 
management of drivers of death such as RHF and anemia before LVAD implantation. 
 In Chapter 12, the microcirculation before and after LVAD implantation was evaluated 
sublingually by a novel technique using incident-dark-field imaging (IDF). We included eleven 
patients with subclinical pericardial tamponade. Mean duration from the microcirculatory 
measurement until the clinical diagnosis of cardiac tamponade was 24 [IQR 0.6-73] hours. 
Imaging of the sublingual microcirculation adds a new dimension in the clinical monitoring 
of post-cardiac surgery patients, including continuous flow –LVAD’s, as a patient friendly 
monitoring tool and could possibly be extremely useful in early detecting of cardiac 
tamponade, an otherwise missed life threatening cardiac complication. Daily assessment of 
the sublingual microcirculation following LVAD implantation up to two weeks could trigger 
the clinician to early use of advanced imaging tools e.g. echocardiography and/or CT scan 
for in time detection of cardiac tamponade. Microvascular flow index and portion of the 
perfused vessels are promising microcirculatory parameters which require further validation 
in larger LVAD populations.
 Chapter 13, emphasize the problem of thromboembolic events/acute pump thrombosis 
as potentially life-threatening complications in patients with continuous-flow left ventricular 
assist devices (CF-LVAD). We sought to determine early signs of thromboembolic event/ pump 
thrombosis in patients with CF-LVAD, which could lead to earlier intervention. In patients with 
a CF-LVAD (HeartMate II), thromboembolic events and/or pump thrombosis are associated 
with symptoms and signs of acute haemolysis as manifested by a high LDH, elevated pump 
power and decreased pulse index, especially in the context of an infection.
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In patients with CF-LVAD (HeartMate II), thromboembolic events and/or pump thrombosis 
are associated with symptoms and signs of acute haemolysis as manifested by high LDH, 
elevated pump power and decreased pulse index, especially in the context of an infection. 
These symptoms and signs could help in the early diagnosis and timely intensification 
of antithrombotic and/or antiplatelet therapy to prevent acute pump thrombosis and 
thromboembolic events or the need for pump replacement.
 In Chapter 14, presents our prospective study with 14 ambulatory patients with 
HeartMate 3 who underwent standard (SE) and contrast enhanced (CE) echocardiography. 
The aim of this pilot study was to evaluate the potential CE for the evaluation of the left 
ventricle (LV). Overall, SE allowed visualization of 57% of LV segments (135/238) and CE 
allowed visualization of 79% of LV segments (187/238), P < 0.001. Routine use of a contrast 
agent appears safe when used in patients having a new third generation LVAD and may 
enhance the diagnostic accuracy of transthoracic echocardiography in these patients. LV size 
determination can be obtained more often due to improved LV visualization using contrast 
agent.
 In Chapter 15, infections in patients with LVAD are investigated especially diagnosis 
of LVAD-related and LVAD-specific infections are extensively analysed. The differentiation 
between deep and superficial infections is crucial in clinical decision-making. We used 
fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/
CT) to diagnose various infections. In this chapter, we reviewed the current evidence in 
literature and describe our single Center experience using 18F-FDG PET/CT for the diagnosis 
and management of LVAD infections.  This study presents nine different LVAD patients who 
suffered from clinically suspected or proven infections in which 18F-FDG PET/CT imaging 
supported clinical decision making in LVAD-specific and -related infection. This study is the 
largest population of HMII patients ever managed by 18F-FDG PET/CT. In the current literature, 
we found only 4 studies with case reports and series with a total of 47 cases: 2 case reports 
and 2 case series with 18F-FDG PET/CT were published between 2013 and 2016. 18F-FDG PET/
CT imaging provided accurate information on the localization and extent for LVAD-specific 
or -related infections as early as 3 weeks post-implantation. Review of the current literature 
with 2 case reports and 2 case series with a total of 47 cases, confirms the promising role of 
this novel imaging modality.
 In Chapter 16, was the search for pre- and post-implantation occurrence of ventricular 
arrhythmias (VAs). We reviewed all adult patients receiving an LVAD between March 2006 
and April 2015 in 2 large Dutch LVAD centers. The primary outcome was the occurrence of 
VA, defined as VA that was sustained for >30 s or was treated by an implantable cardioverter-
defibrillator (ICD). Multivariate Cox regression analysis was performed to investigate predictors 
of late (>30 days) post-LVAD VA. Overall, 204 patients underwent LVAD implantation. Eighty-
five patients (41.7%) had a history of VA before LVAD implantation. During a median follow-up 
of 17.3 months (interquartile range: 8.1 to 29.5 months), 62 patients (30.4%) experienced 
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post-LVAD VA. The burden of VA followed a U-shaped curve, with the highest incidence 
in the first postoperative month, a nadir at 15 to 18 months, and a rise after that time. 
Pre-LVAD VA, the presence of an ICD, the use of beta blockers, and atrial fibrillation were 
univariate predictors of late post-LVAD VA. In a multivariate Cox regression model, only pre-
LVAD VA remained as an independent predictor of late post-LVAD VA (adjusted hazard ratio 
[HR]:2.13; 95% confidence interval [CI]: 1.06 to 4.27; p = 0.03). The incidence of VA might 
be underestimated when VA episodes are not documented properly, especially in patients 
without an ICD. In summary, the incidence of post-LVAD VA followed a U-shaped curve with 
an increase in incidence at long-term follow-up. Patients with pre-LVAD VA were more prone 
to develop late post-LVAD VA. Post-LVAD VA did not appear to impact survival or HTX rates; 
however, urgent HTX was needed in some patients with therapy-resistant VA. It is important 
to realize that in destination-therapy patients with therapy-resistant VA, urgent HTX will 
probably not be a good option.
 In Chapter 17, we included 69 patients with LVAD retrospectively to investigate the 
incidence and potential predictors of mechanical device failure (MDF) in continuous flow 
left ventricular assist device patients. This study shows the rate, associated factors, clinical 
presentation and outcome of mechanical device failure in continuous-flow left ventricle assist 
device patients. MDF is a serious complication seen at mid-term follow-up of cf-LVAD patients, 
jeopardizing the long-term outcome. Patients with apparently futile, however cumulative 
technical problems over time were more prone to experience MDF, which often requires 
invasive surgery and LVAD replacement. The incidence of technical problems rises over time, 
comparatively like the incidence of MDF. MDF occurred at a median FU time of 846 [708-
1337] days after implantation. The majority of the patients with MDF presented with red 
LVAD alarms and concomitant temporary pump stop.  Seventeen percent of the deaths was 
due to MDF. However, if patients reached the hospital on time, then they could be treated 
successfully. Through timely connection to an ungrounded cable or staying on batteries, 
further electrical shortcut could be prevented and semi-urgent LVAD exchange or external 
repair of de driveline could be conducted. In conclusion, the incidence of mechanical device 
failure increases with time and CF-LVAD recipients with an extended LVAD-support time, a 
history of technical problems or damaged driveline are more prone to experience mechanical 
device failure. Mechanical device failure can be managed successfully if patients reach the 
hospital in time. We expect improvements that will increase the durability of devices and the 
survival of patients. New technical improvements are used in the driveline of the HeartMate 
III to improve its longevity. 
305
CHAPTER 18
FUTURE PERSPECTIVES
Mechanical circulatory support (MCS) is a very rapidly evolving field in acute and chronic 
heart failure treatment. Due to yet young field, many clinical aspect are yet being elucidated 
and improved. From the early ’70s short-term / temporary MCS devices to long-term/durable 
circulatory support, in the last one to two decades, there is true revolution in the treatment 
of severe acute heart failure and end-stage chronic heart failure treatment, which is still 
rapidly evolving. 
 Twenty years ago, helping an end-stage heart failure patient live for more than a year 
without a donor heart, was considered a medical feat. Today the majority of patients live an 
average of two years with an LVAD as they await transplantation. Despite the growing survival 
after long-term support with improved quality of life, these patients will sustain in frequently 
admissions to the hospital. 
 In this thesis we investigated many of the current challenges in the clinical, patho-
physiological, logistic challenges in short- and long-term MCS. Newer indications needing 
short- and long-term MCS for example ECMO supported cardiopulmonary resuscitation 
is a growing and well-known phenomena. In this and furthered fields on MCS we expect 
to distribute the collaboration of academic centers with non-academic heart centers for 
improvement of the expertise and patient’s outcome. The non-academic MCS centers could 
serve as peripheral hubs where specialized cardiac intensivists and intensive cares which 
could be a part of national cardiogenic shock program guided by academic shock centers 
with specialized shock teams for mobile services between the hub and the peripheral hubs. 
Hence, there is a need for an in hospital and remote organised clinical and hemodynamic 
monitoring system for these artificial circulations. 
 New temporary devices for RV and LV failure will play more and more a role in treatment 
of the severely ill patients with cardiogenic shock needing circulatory support as a bridge to 
recovery or implantation of long-term MCS device. Highly skilled teams can be used anywhere 
and forward deployed the MCS devices like ECMO, Impella and IABP continues to be the hope 
for survival for many critically ill patients. Currently, ECMO is used for severe heart and lung 
failure in all ages. Further research are needed with focus on improving anticoagulation and 
devices, defining indications, and new applications like septic shock, ECPR for cardiac arrest, 
and to salvage organs for transplantation. 
The future of temporary MCS devices depends largely on the emergence of new technology, 
much of which has already been developed or is in the initial stages of development. Newer 
MCS circuits could likely include a further simplification of circuits, increased portability, and 
automation, potentially allowing for increased use in austere environments. These types of 
improvements would likely be associated with further reduction in required anticoagulation 
parameters, decreased inflammatory response, and reduced monitoring requirements at a 
higher cost.
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Improvements in designing the LVADs of the future
For long-term, durable MCS / VAD devices, is  the future of miniaturization, from complete to 
partly hemodynamic support, minimal invasive to percutaneous instead of open sternotomy 
and smaller and more adaptable for individual patients. Engineers are taking the next 
major step forward by creating a smaller pump that requires less wattage – allowing for 
total battery implantation and safer recharging, less-invasive implantation procedures and 
greater patient freedom – and that’s more compatible with a heart recovering from failure. 
Furthermore, development of device that’s more invisible to the patient and adaptable to 
the unique physiologic demands of each person will be more forgettable. Therefore, next-
generation LVADs (and RVAD’s) would be fully implantable (to reduce infection risk) on both 
the left and right sides of the heart, with multiple feedback mechanisms to automatically 
regulate pump functions. But currently in the nearer future in the acute decompensated 
chronic heart failure setting, the more central question is not partial versus full support but 
rather immediate permanent device versus temporary device as a bridge to either recovery 
or permanent device. More and more partial support devices early in the heart failure 
treatment would be an option. These devices would be easier to implant and in general in 
patients with lower NYHA class to prevent from deteriorating heart failure. Furthermore, 
debating the need of univentricular versus biventricular MCS, the concept of partial versus 
total circulatory support is quite intriguing. Experience with bridging patients to transplant 
successfully with axillary intra-aortic balloon pumps shows the utility of partial mechanical 
support for the failing heart.
 Risk factors and management strategies to limit right ventricular failure following LVAD 
implantation have been extensively described in the literature over the past five years. We 
performed a right sided heart failure risk score within EUROMACS which will help us in the 
near future in selecting the best patients for an LVAD implantation. However, appropriate 
selection and prediction of the RV prior to LVAD implementation remains a diagnostic enigma. 
Many centers including ours, utilize a variety of intra-operative manoeuvres to reduce the 
strain on the right ventricle. This has to be uniformized for comparable patients worldwide. 
In patients with life-threatening right sided heart failure on the way to LVAD implantation, 
prophylactic  novel percutaneous RVADs could be an answer which was safe, easy to deploy, 
and reliably for immediate macrohemodynamic recovery post LVAD, preventing acute kidney 
injury, sepsis, and multi-organ failure in many recent studies. This device will also help by its 
probable benefits in these severely ill patients to bridge in better condition to the operation 
room for an LVAD and there afterwards.
Improvements in monitoring the matters in circulation
Further studies on the microcirculation in patients with cardiogenic shock and chronic 
heart failure should improve the use of this unique method to literally see what happens 
to the microcirculation by modifying the macrocirculation. Probably, even by the patient 
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at his own environment, when patient self-care proved this tool could be used as remote 
monitoring. Nowadays there are invasive monitoring tool used to prevent decompensated 
heart failure before and after LVAD implantation which are still use surrogate endpoints of 
circulation. These invasively collected data could add to microcirculatory alterations to better 
understand the micro physiology of the artificial circulations. This way of monitoring of the 
microcirculation could also been considered for monitoring the recovery of the systemic 
circulatory parameters in cardiogenic shock patients, in addition to conventional imaging 
tools.
 In our focus, MCS devices like VA-ECMO as bridge-to-bridge therapy, is still underused 
or initiated too late, potentially leading to preventable deterioration of the patient. Research 
should focus on developing new, less invasive, left or right ventricular support devices for 
short- and also long-term MCS. Short- and long-term mechanical circulatory support devices 
have revolutionized the treatment options for patients suffering from acute and chronic heart 
failure. As we simultaneously expand the patient population that can benefit from these 
technologies as well as the morbidity of implantation, we will take significant strides in the 
treatment of very severe critically ill patients. We have already gained considerable gains in 
the therapy and monitoring for these patients over the past thirty to fifty years and the future 
is understandably bright for mechanical circulatory support.
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Nederlandse samenvatting
“Clinical features of short- and long-term 
mechanical circulatory support”
“Klinische aspecten van tijdelijke en permanente 
mechanische circulatieondersteuning”
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SAMENVATTING EN CONCLUSIES VOOR LEKEN
Wereldwijd sterven nog steeds patiënten met acuut en chronisch hartfalen aan de gevolgen 
van pompfalen van het hart (cardiogene shock) op de intensive care, ondanks medische en 
technische vooruitgang om ze in leven te houden en tijd te winnen door middel van tijdelijke 
of permanente mechanische bloedsomloop ondersteunende apparaten (Mechanical 
Circulatory Support = MCS). 
 Nationaal en internationaal neemt het gebruik van deze apparaten toe. Mechanische 
bloedsomloop pompen voor tijdelijke en permanente ondersteuning dienen ertoe om het 
falende hart te vervangen en handhaving van de bloedsomloop en weefseldoorbloeding 
te realiseren. In ons centrum is er ook een duidelijk groeiende populatie van met name 
patiënten met een cardiogene shock die een verfijnde vorm van hart-longmachine (veno-
arteriële extracorporale membraanoxygenatie = VA-ECMO) nodig hebben. MCS worden 
gebruikt voor langdurige ondersteuning als een brug naar harttransplantatie of als 
bestemmingstherapie (destination therapy). Indien er sprake is van bestemmingstherapie 
worden die patiënten overbrugd van tijdelijke ondersteuning naar apparaten voor permanente 
linkerhartkamerondersteuning met een steunhart (Left Ventricular Assist Device = LVAD). Deze 
patiënten met een cardiogene shock behoren tot de hoogste klassen van het register voor 
mechanische ondersteuning van de circulatie (Interagency Registry for Mechanically Assisted 
Circulatory Support = INTERMACS) van klasse I tot II na ondersteuning van tijdelijke steun van 
bloedsomloop of INTERMACS III tot IV als gevolg van progressief hartfalen of aanhoudend 
ernstig chronisch hartfalen. 
 Het monitoren van de bloedsomloop bij deze patiënten, voor en na starten 
van mechanische bloedsomloop, is vaak gebaseerd op surrogaateindpunten van 
weefseldoorbloeding, b.v. melkzuur (lactaat), gemengde zuurstofverzadiging van aderlijk 
bloed en globale bloeddrukken, zoals gemiddelde slagaderlijke bloeddruk en hartslag. In dit 
proefschrift onderzochten we de bloedsomloop in de kleinste (haar)vaten (microcirculatie) 
als bewaking van de bloedsomloop tijdens mechanische circulatieondersteuning. Verder 
was het doel van dit proefschrift: het onderzoeken van klinische kenmerken van tijdelijke 
en lange termijn mechanische circulatiehulpmiddelen en de mogelijke toepassing van 
microcirculatiemetingen voor een tijdige detectie en voorspelling van mogelijke complicaties. 
 De 17 hoofdstukken van dit proefschrift zijn gegroepeerd in 5 delen: deel 1 
Microcirculatie bij patiënten met mechanische circulatiesteun, deel 2; Tijdelijke mechanische 
bloedsomloop-ondersteuning: VA-ECMO na cardiogene shock, deel 3; Kunstharten op lange 
termijn: uitrusting voor ondersteuning van de linker hartkamer voor langdurige mechanische 
ondersteuning van de bloedsomloop bij patiënten met terminaal hartfalen, deel 4; Algemene 
discussie, samenvatting, conclusies en toekomstperspectieven en deel 5; Bijlagen.
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In Hoofdstuk 1 wordt een overzicht gegeven van behandelingen met respectievelijk VA-ECMO 
en LVAD als mechanische ondersteuning voor tijdelijke en permanente ondersteuning van 
het falend hart, waarbij de beoordeling van microcirculatie centraal staat. Het goed kunnen 
meten van de bloedsomloop is bij deze patiënten niet makkelijk  door het onnatuurlijke (niet 
pulsatiele) karakter van de bloeddoorstroming. Daarom is de microcirculatiemeting onder de 
tong een makkelijke, toegankelijke en efficiënte controle van de kunstmatige bloedsomloop. 
In veel onderzoeken bleek de meting van de microcirculatie beter dan de bekende globale 
hemodynamische parameters VA-ECMO als tijdelijke mechanische ondersteuning van de 
bloedsomloop stelt het hart in staat om tijd te winnen voor herstel, interventie, transplantatie 
of implantatie van een permanente mechanische ondersteuning voor lange termijn, zoals 
een LVAD. Zodra het hart voldoende is hersteld om de bloedsomloop te behouden, is de 
uitdaging het ontwennen van VA-ECMO. De voorspelling van dit herstelmoment is een nog 
veel bediscussieerd onderwerp. Het antwoord op deze vraag kan worden gegeven door de 
weefseldoorbloeding rechtstreeks in beeld te brengen. Een nauwkeurige beoordeling van 
de zuurstofverzadiging in de weefsels door het meten van de microcirculatie zou een nieuw 
onderdeel van de behandelmethode kunnen zijn bij het monitoren van deze kunstmatige 
circulaties vanaf het begin op de IC tot zelfs op de polikliniek. 
 Zodra blijkt dat een patiënt niet in staat is VA-ECMO te ontwennen  en in aanmerking 
komt voor een steunhartimplantatie, ontstaat er een essentiële periode waarin zorgverleners 
de mogelijkheden voor  overbrugging van VA-ECMO naar een lange-termijn oplossing als 
steunhart moeten beoordelen. Mogelijk kan zowel de diagnose als de voorspelling van 
overleving van desbetreffende VA-ECMO-patiënten uitgevoerd worden door directe meting 
van de microcirculatie. Daarom hebben we getracht de waarde van microcirculatiemonitoring 
van hart-longmachine tot aan VA-ECMO uit te zoeken en zelf te onderzoeken (deel 1). Dit 
bracht ons bij de klinische aspecten van korte termijn mechanische circulatieondersteuning bij 
cardiogene shock (deel 2). Vervolgens analyseerden we uitgebreid de klinische kenmerken van 
patiënten met een steunhart. Vooral met aandacht voor diagnostische modaliteiten ter detectie 
van de levensbedreigende complicaties bij deze patiënten (deel 3).  Een gepersonaliseerde 
fysiologische geneeskunde als benadering van deze populatie met kunstmatige circulatie 
heeft continu onze aandacht. Alleen dan zou een op maat gemaakte therapie bij 
patiënten met een tijdelijke en/of permanente mechanische circulatieondersteuning, de 
weefseldoorbloeding en overleving kunnen verbeteren. Door de microcirculatiemetingen in 
de orgaanfunctie te integreren, kunnen alle behandelingsmodaliteiten worden begrepen en 
geoptimaliseerd. De ontwikkeling van de juiste hard- en software voor dagelijks gebruik van 
een microcirculatiecamera in de thuissituatie zou dan in de toekomst verder kunnen worden 
onderzocht.
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DEEL 1 MICROCIRCULATIE IN MECHANISCHE CIRCULATIE-
ONDERSTEUNING.
In Hoofdstuk 2 is de respons van microcirculatie op MCS tijdens kritieke condities 
geassocieerd met pompfalen en verminderde weefselperfusie in alle organen onderzocht. 
Mechanische circulatieondersteuning, met een centrale rol in het verzorgen van de 
weefseloxygenatie tijdens cardiogene shock en gedecompenseerd chronisch hartfalen, mist 
specifieke monitoringparameters. Correctie van globale hemodynamische parameters door 
MCS, levert niet altijd een parallelle verbetering in microcirculatie, perfusie en oxygenatie 
van de orgaansystemen op. Dit wordt gezien als een aandoening die wordt aangeduid als 
een verlies van hemodynamische samenhang (coherentie) tussen macro- en microcirculatie 
(MC). Er is meer studie nodig met behulp van direct in beeld brengen van de microcirculatie 
tijdens MCS van tijdelijke en permanente aard door handmicroscopie aan bed. Bij voorkeur 
moet dit worden uitgevoerd in de vorm van gerandomiseerde, gecontroleerde studies, om 
de aanwezigheid en het klinische belang van hemodynamische coherentie te identificeren. 
Verwacht wordt dat deze verdere onderzoeken het mogelijk zullen maken om patiënten 
die baat zouden kunnen hebben bij behandeling met mechanische hartondersteuning ten 
behoeve van adequate orgaanperfusie, beter te identificeren .
 In Hoofdstuk 3 wordt een overzicht gegeven van de onderzoeken naar aanleiding van 
de microcirculatie tijdens hartchirurgie. Hartchirurgie, geassocieerd met een breed scala aan 
verstoringen in de haarvaten en met verminderde weefseloxygenatie, was de belangrijkste 
focus. Hoewel de macrohemodynamische doelen tijdens hartchirurgie kunnen worden bereikt, 
kan de microcirculatie worden beschadigd en buiten werking blijven. Directe visualisatie van de 
microcirculatie met behulp van handmicroscopie kan de clinicus de fysiologische terugkoppeling 
geven die nodig is voor de vroege herkenning en behandeling van veranderingen in de 
microcirculatie tijdens hartchirurgie. De samenhang tussen de hemodynamische reactie van de 
macrocirculatie en de microcirculatie tijdens operaties lijkt essentieel.
 In Hoofdstuk 4 hebben we de cardiovasculaire reactie op extra zuurstoftoevoer naar 
het lichaam met een VA-ECMO in een klinische studieverband onderzocht. Klinisch gebruik 
van hulpmiddelen, gericht op monitoring van het herstel van eindorganen na het starten 
van een ECMO-behandeling ontbreken nog steeds. Microcirculatie en systemische globale 
hemodynamische waardes werden onderzocht bij 24 patiënten met cardiogene shock onder 
VA-ECMO. Vijftien patiënten overleefden en 9 stierven terwijl ze op VA-ECMO-therapie waren 
ingesteld. Er was geen significant verschil tussen de systemische globale hemodynamische 
variabelen bij de start van VA-ECMO tussen de overlevenden en niet-overlevenden. Er was 
echter een significant verschil in de microcirculatie parameters van zowel kleine als grote 
vaten op alle tijdstippen tussen de overlevenden en niet-overlevenden. Perfused vessel 
density (PVD) bij de start (overlevende versus niet-overlevende, 19,21 versus 13,78 mm/ 
mm2, p = 0,001) was in staat om IC-overleving te voorspellen bij het opstarten van VA-ECMO. 
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De resultaten tonen aan dat PVD van de microcirculatie, gemeten onder de tong bij het 
opstarten van VA-ECMO, kan worden gebruikt om de IC-mortaliteit te voorspellen bij patiënten 
met cardiogene shock. Afgeleide bloedwaardes van weefseldoorbloeding, b.v. gemengd 
veneuze zuurstofverzadiging en lactaat worden nog steeds gebruikt. Directe visualisatie van 
de microcirculatie met behulp van handmicroscopie kan worden beschouwd als de gouden 
standaard voor weefselperfusie omdat de beweging van enkele rode bloedcellen kan worden 
waargenomen en gekwantificeerd. De microcirculatie veranderingen/ reacties op ECMO 
kunnen helpen bij zeer complexe klinische problemen bij deze groeiende populatie van 
patiënten met ondersteunde circulatie.
 In Hoofdstuk 5 hebben we de potentiële waarde van microcirculatieveranderingen 
tijdens het ontwennen van VA-ECMO geëvalueerd. Kenmerken van succesvol ontwennen 
van VA-ECMO zijn nog grotendeels onbekend. Onze hypothese is dat succesvol ontwennen 
geassocieerd is met een aanhoudende microcirculatiefunctie tijdens het verlagen van de 
ECMO-ondersteuning. Daarom probeerden we de bruikbaarheid van beeldvorming van de 
microcirculatie gemeten op dezelfde plek onder de tong te testen, met behulp van Incident 
Dark Field (IDF) beeldvorming bij het beoordelen van al dan niet succesvol ontwennen van 
VA-ECMO en we vergelijken de bevindingen van IDF-beeldvorming met echocardiografische 
parameters. We vonden dat de functionele microcirculatie gemeten onder de tong met behulp 
van IDF-beeldvorming (TVDssF50 en PVDssF50) tijdens pogingen tot ontwennen bij patiënten 
aan VA-ECMO wezenlijke veranderingen toonde binnen 2 minuten en een voorspelling deed 
van hartherstel na cardiogene shock. Dertien patiënten onder VA-ECMO deden mee aan het 
onderzoek. TVDssF50 (21,9 versus 12,9 mm/ mm2, p = 0,001), PVDssF50 (19,7 versus 12,4 
mm / mm2, p = 0,01) en aorta-snelheidstijdintegraal (VTI) bij 50% flowreductie (VTIF50) waren 
hoger bij patiënten met succesvolle versus niet-succesvolle ontwenning. De resultaten zijn 
bemoedigend en benadrukken de rol van dezelfde sublinguale spot-microcirculatiemetingen als 
een nieuwe potentiële waarde voor het voorspellen van succesvol ontwennen van VA-ECMO.
 In Hoofdstuk 6 onderzochten we de effecten van kritieke condities zoals sepsis, 
hoog-risicochirurgie, hartstilstand en longfalen die worden gekenmerkt door verminderde 
weefseloxygenatie, veroorzaakt door falende microcirculatie. Elk veld met verstoorde 
weefseloxygenatie dat onvoldoende werd bewaakt vanwege verlies van hemodynamische 
coherentie, werd onderzocht. Directe monitoring en meting van microcirculatie onder de 
tong met behulp van handmicroscopie kan een meer fysiologische benadering bieden. Het 
evalueren van de samenhang tussen macrocirculatie en microcirculatie als reactie op therapie 
lijkt essentieel te zijn bij het evalueren van de effectiviteit van therapeutische interventies. 
Het verlies van hemodynamische samenhang tussen macrocirculatie en microcirculatie moet 
altijd in gedachten worden gehouden en alle therapeutische benaderingen moeten gericht 
zijn op het corrigeren van hemodynamische incoherentie. Een eenvoudig uit te voeren meting 
van de bloedcirculatie in de haarvaatjes onder de tong kan duidelijkheid verschaffen over 
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de doorbloeding van organen bij een vitaal bedreigde patiënt. Bij een aanhoudend slechte 
doorbloeding zijn de overlevingskansen van een patiënt met hart- of longfalen zeer laag.
DEEL 2 TIJDELIJKE MECHANISCHE ONDERSTEUNING VAN DE 
BLOEDSOMLOOP BIJ CARDIOGENE SHOCK
In deel 2 ligt de focus op korte termijn, oftewel tijdelijke mechanische circulatiesupport 
(MCS) voornamelijk de VA-ECMO welke in toenemende mate wordt gebruikt in ons centrum 
voor hartfalen, op harttransplantatie en op mechanische ondersteuning van de bloedsomloop. 
Cardiogene shock (CS) heeft een hoog sterftecijfer en wordt gedefinieerd als een verstoorde 
doorbloeding van het weefsel, veroorzaakt door falend hartpompen. Veel aandoeningen, zoals 
een acuut myocardinfarct, aangeboren en verworven hartspierziektes in het eindstadium, 
complicaties na een hartoperatie en hartstilstand, kunnen CS veroorzaken. VA-ECMO is 
een effectieve, draagbare en snel inzetbare techniek voor het leveren van mechanische 
circulatieondersteuning aan patiënten in CS. Daarnaast vermindert VA ECMO met succes de tijd 
die nodig is voor het herstellen van het hart. Na deze overbruggingstherapie vereisen sommige 
patiënten  implantatie van een steunhart (LVAD) of een harttransplantatie voor verder herstel 
en overleving. Het kunnen identificeren van hemodynamische variabelen gerelateerd aan 
overleving kan een belangrijk therapeutisch venster zijn voor het optimaliseren van VA-ECMO-
ondersteuning. Momenteel wordt VA-ECMO ook steeds vaker gebruikt tijdens reanimaties na 
hartstilstand binnen en buiten het ziekenhuis (eCPR). Alle in de studies opgenomen patiënten 
waren aangesloten op VA-ECMO met of zonder een ballonpomp (IABP) met als doel het hart te 
overbruggen naar herstel, transplantatie of een kunsthart.
 In Hoofdstuk 7 schetsten we de reactie van het hart- en vaatstelsel op extra 
zuurstoftoevoer middels een geavanceerde hart- longmachine (ECMO) vanaf ontwikkeling 
tot verschillende toepassingsgebieden heden. Hulpmiddelen voor gerichte monitoring 
van het herstel van eindorganen tijdens ECMO ondersteuning ontbreken nog steeds. 
Surrogaten? van weefseldoorbloeding, b.v. gemengde veneuze zuurstofverzadiging en 
lactaat (melkzuur) worden nog steeds gebruikt. Directe visualisatie van de microcirculatie 
met behulp van handmicroscopie kan worden beschouwd als de gouden standaard 
voor weefseldoorbloeding omdat de beweging van enkele rode bloedcellen kan worden 
waargenomen en gekwantificeerd. Een nieuwe generatie microcirculatiecamera’s wordt 
CytoCam-Incident-Dark-Field-beeldvorming genoemd. De microcirculatieveranderingen / 
reacties op ECMO kunnen helpen bij zeer complexe klinische problemen bij de groeiende 
populatie van patiënten met kunstmatige circulatie.
 In Hoofdstuk 8 werd een nieuwe score ontwikkeld om de sterfte op de IC bij patiënten 
met cardiogene shock onder VA-ECMO te voorspellen, uitgebreid door toevoeging van de 
rechter hartfunctie (RVF) aan de bestaande “Sequential Organ Failure score (SOFA-score). 
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Sterfte na VA-ECMO-implantatie blijft hoog bij patiënten met cardiogene shock. RV-falen 
veroorzaakt suboptimale linkerkamer- (LV) vulling, vaak resulterend in biventriculair falen 
waarvoor VA-ECMO-ondersteuning vereist is. In ons centrum   kregen in de periode 2004 
tot 2016 103 patiënten VA-ECMO-therapie. 37 Van hen (36%) stierven op de IC. De mediane 
duur van VA-ECMO-ondersteuning was 7 dagen [IQR 4-11] met een gemiddelde leeftijd van 
49 (± 16 jaar) en 54% man. Door de RV-functie toe te voegen aan de bestaande SOFA-score, 
verbeterden de prestaties van de SOFA-score aanzienlijk. SOFA-RV heeft een AUC van de ROC-
curve van 0,70 en was significant beter dan SOFA alleen (AUC van 0,57). Bovendien waren 
SAVE- en MELD-scores niet in staat de ICU-mortaliteit te voorspellen. Geen van de bestaande 
voorspellingen voor de mortaliteit houdt rekening met rechterhartkamerdisfunctie. Specifieke 
evaluatie van de rechterventrikelfunctie bij patiënten met VA-ECMO wordt daarom ten zeerste 
aanbevolen. Deze studie toont aan dat toevoeging van RV-functie aan de bestaande SOFA-
score de voorspelling van ICU-mortaliteit bij patiënten met VA-ECMO aanzienlijk verbetert. 
Daarom wordt een speciale beoordeling van de rechterventrikelfunctie bij patiënten met VA-
ECMO ten zeerste aanbevolen.
 In Hoofdstuk 9 hebben we de literatuur systematisch beoordeeld en een meta-analyse 
uitgevoerd om de duur en de mate van overbrugging van kortdurende naar permanente 
mechanische circulatiehulpmiddelen tussen 2006 en 2016 te onderzoeken. Negenendertig 
studies, voornamelijk registers van heterogene patiëntenpopulatie ( n = 4151 patiënten), 
werden geïdentificeerd. Afhankelijk van het gebruikte apparaat varieerde de gemiddelde 
ondersteuningsduur (bereik) van 1,6-25 dagen en het gemiddelde aantal tijdelijke MCS-
patiënten dat werd ontslagen was  45-66%. Het gemiddelde aandeel van overbrugging 
naar een permanent steunhart varieerde van  3-30%. Overbrugging naar een  duurzame 
ondersteuning met LVAD werd het meest frequent uitgevoerd bij patiënten met terminale 
cardiomyopathie (22 [12-35]%). We concluderen dat tijdelijke MCS kan worden gebruikt om 
patiënten met cardiogene shock naar een duurzame LVAD te overbruggen. Clinici worden 
aangemoedigd om hun resultaten te delen in een groot register met meerdere centra om de 
optimale apparaatselectie en de beste duur van de ondersteuning te onderzoeken.
DEEL 3 PERMANENTE MECHANISCHE ONDERSTEUNING: STEUNHART 
VOOR LANGDURIGE MECHANISCHE ONDERSTEUNING VAN DE 
BLOEDSOMLOOP BIJ PATIËNTEN MET TERMINAAL HARTFALEN
In deel 3 onderzochten we de meest voorkomende problemen na implantatie van 
steunharten (LVAD’s). Het toenemende gebruik van deze apparaten bij patiënten met 
terminaal hartfalen (HF) als brug naar transplantatie, naar een eventuele harttransplantatie 
of bestemmingstherapie (DT) dwingt ons om te zoeken naar oplossingen die de overleving 
verbeteren. De 1-jaarsoverleving gerapporteerd voor patiënten behandeld met continue 
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flow LVAD was respectievelijk ≈80% en 73% in de interagency-registratie voor mechanische 
bloedsomloopondersteuning (INTERMACS) en de Europese registratie voor patiënten met 
mechanische circulatieondersteuning (EUROMACS).
 In Hoofdstuk 10 beschrijven we de ontwikkeling en validatie van een nieuw rechtszijdig 
hartfalen-(RHF) model na implantatie van een steunhart (LVAD) in het grootste Europese 
register en de risicoscore van rechtszijdig hartfalen ontwikkeld binnen EUROMACS. Post-
LVAD RHF is gerapporteerd tussen 4% en 50% en RHF-geassocieerde 6-maanden mortaliteit 
werd gezien bij 29% van de patiënten die een LVAD kregen. Bovendien heeft RHF een 
grotere impact bij patiënten die LVAD als bestemmingstherapie krijgen, voor wie er geen 
mogelijkheid van een harttransplantatie bestaat. Een risicoscore van 9,5 punten met 5 
variabelen (interagency-register voor klasse met mechanische circulatieondersteuning, 
gebruik van meerdere inotropica , ernstige rechterhartkamerdisfunctie op echocardiografie, 
verhouding van rechter atriale / pulmonale capillaire wigdruk, hemoglobine) werd gecreëerd. 
De gemiddelde scores in de derivatie- en validatiecohorten waren respectievelijk 2,7 ± 1,9 
en 2,6 ± 2,0 (P = 0,32). RHF in het derivatiecohort trad op bij 433 patiënten (21,7%) na 
implantatie van een steunhart en was geassocieerd met een lagere 1-jaars- (53% versus 71%; 
P <0,001) en 2 jaars- (45% versus 58%; P <0,001) overleving vergeleken met patiënten zonder 
RHF. Het RHF-risico varieerde van 11% (lage risicoscore 0-2) tot 43,1% (hoge risicoscore> 
4; P <0,0001). Mediaan intensive care-verblijf was 7 dagen (bereik, 4-15 dagen) versus 24 
dagen (14-38 dagen) bij patiënten zonder versus met RHF, respectievelijk (P <0,001). De 
c-index van de samengestelde score was 0,70 in de derivatie en 0,67 in het validatiecohort. 
De EUROMACS-RHF risicoscore presteerde beter dan (P <0,0001) eerder gepubliceerde 
scores en bekende individuele echocardiografische en hemodynamische markers van RHF. 
Dit nieuwe scoresysteem biedt clinici verbetert  de mogelijkheid om risicobeoordelingen 
op maat te maken vóór, tijdens of na LVAD-implantatie. Die patiënten zouden baat hebben 
bij vroege herkenning in termen van niet alleen minder behoefte aan langdurig ICU-verblijf, 
maar ook, belangrijker, betere overlevingskansen. Die corrigerende maatregelen blijven 
echter speculatief en moeten in prospectieve gerandomiseerde studies worden getest om 
hun nut te bewijzen. Deze nieuwe EUROMACS-RHF-risicoscore presteerde beter dan de 
huidige bekende risicoscores en klinische voorspellers van vroege postoperatieve RHF. Deze 
nieuwe score kan nuttig zijn voor op maat gemaakte, risicogebaseerde klinische beoordeling 
en behandeling van patiënten met gevorderd HF, die zijn geëvalueerd voor therapie met 
mechanische ventriculaire ondersteuning
 In Hoofdstuk 11 analyseerden we de wijze van overlijden na implantatie van LVAD in het 
grootste Europese register. Van 2689 Europese patiënten met LVAD stierven er 1062 (39%) 
tijdens een mediane follow-upduur van 320 [IQR 88-661] dagen, waarvan 487 (46%) van 
de sterfgevallen binnen 90 dagen plaatsvond. Onafhankelijke voorspellers van vroege sterfte 
waren INTERMACS klasse 1 tot 3, bestemmingstherapie, RA tot PCWP> 0,54, pulmonaire 
vasculaire weerstand (PVR)> 4,5 Woods-eenheid en hemoglobine ≤ 10 g / dL. De belangrijkste 
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oorzaken voor overlijden binnen 90 dagen waren MOF (multi orgaan falen 36%), sepsis (28%), 
CPF (hart en long falen = cardiopulmonaal falen 10%), CVA (9%) en rechtszijdig hartfalen (RHF, 
8%). Sepsis (28%), CVA (23%), MOF (14%), bloeding (10%) en CPF (8%) waren de belangrijkste 
oorzaken van overlijden. Bloeding veroorzaakte 19% van de sterfte  op dag 1 en komt na 90 
dagen weer terug  als een belangrijke doodsoorzaak (10%). Evenzo start het risico op een CVA 
op de dag van LVAD-implantatie (11%) en is ook  na 90 dagen opnieuw een belangrijke reden 
van overlijden (23%). Mechanisch falen van een LVAD (5%) als overlijdensoorzaak werd pas 
vanaf  90 dagen na implantatie van een  LVAD waargenomen. Deze studie illustreert  de zeer 
dringende behoefte aan verbetering van pre- en postoperatieve zorg om overlevingskansen 
te verhogen, vroeg na implantatie van LVAD. Van deze wijze van overlijden zijn modificeerbare 
factoren bekend, zoals RHF en anemie, evenals mogelijk beïnvloedbare determinanten van 
vroege sterfte in de hoge INTERMACS-klasse en bij bestemmingstherapie. Vroege sterfte 
wordt voornamelijk gedreven door MOF, in tegenstelling tot CVA in de late periode. Deze 
bevinding kan zorgverleners helpen om de overleving van patiënten te verbeteren door 
middel van een passend en tijdig management van risicofactoren  voor doodsoorzaken zoals 
RHF en anemie vóór LVAD implantatie.
 In Hoofdstuk 12 werd de microcirculatie voor en na LVAD-implantatie onder de tong 
geëvalueerd met behulp van een nieuwe techniek (handmicroscoop) met behulp van 
“Incident Darkfield-Field” beeldvorming (IDF). We includeerden elf patiënten met subklinische 
pericardiale tamponade en twintig zonder. Gemiddelde duur van de microcirculatiemeting 
tot de klinische diagnose van harttamponnade was 24 uur [IQR 0,6- 73]. Beeldvorming van de 
microcirculatie onder de tong voegt een nieuwe dimensie toe aan de klinische monitoring van 
post-cardiale chirurgiepatiënten, inclusief continue flow-LVAD’s als een patiëntvriendelijke 
monitoringtool en kan mogelijk buitengewoon nuttig zijn bij vroege detectie van 
harttamponnade, een anders gemiste levensbedreigende hartcomplicatie met name bij 
patiënten met een niet pulsatiele mechanische ondersteuning. Dagelijkse beoordeling van de 
sublinguale microcirculatie na LVAD-implantatie tot twee weken zou de clinicus ertoe kunnen 
brengen om vroegtijdig gebruik te maken van geavanceerde beeldvormingsinstrumenten, b.v. 
echocardiografie en / of CT-scan voor tijdige detectie van harttamponnade. Microvasculaire 
stroomindex (MFI = microvascular flow index) en een deel van de geperfundeerde vaten (PPV 
= portion of the perfused vessels) zijn veelbelovende microcirculatie parameters die verdere 
validatie vereisen in grotere LVAD-populaties. 
 In Hoofdstuk 13 wordt het probleem van trombo-embolische complicaties / acute 
pomptrombose benadrukt als mogelijk levensbedreigend bij patiënten met continue flow 
steunhart (CF-LVAD). We hebben geprobeerd om vroege tekenen van trombo-embolische 
complicaties / pomptrombose bij patiënten met CF-LVAD te bepalen, wat kan leiden tot 
eerdere interventie. Bij patiënten met een CF-LVAD (HeartMate II) zijn trombo-embolische 
complicaties en / of trombose gepaard gaande met symptomen en tekenen van acute 
hemolyse (bloedafbraak), zoals blijkt uit een hoog lactaat dehydrogenase (LDH), verhoogd 
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pompvermogen en een verlaagde puls index, vooral in de context van een infectie. Deze 
symptomen en verschijnselen kunnen helpen bij de vroege diagnose en tijdige intensivering 
van antitrombotische en / of plaatjes remmende therapie om acute pomptrombose en 
trombo-embolische complicaties, of de noodzaak van pompvervanging te voorkomen.
 In Hoofdstuk 14 wordt onze prospectieve studie beschreven, waarbij 14 ambulante 
patiënten met HeartMate 3 standaard (SE) en met contrast (CE) echocardiografie 
ondergingen. Het doel van deze pilotstudie was om de CE voor de evaluatie van de linker 
hartkamer (LV) te evalueren. Over het algemeen maakte SE visualisatie van 57% van de LV-
segmenten mogelijk (135/238) en CE liet visualisatie toe van 79% LV-segmenten (187/238), 
P <0,001. Routinegebruik van een contrastmiddel lijkt veilig bij patiënten met een nieuwe 
derde generatie steunhart en kan de diagnostische nauwkeurigheid van trans thoracale 
echocardiografie bij deze patiënten verhogen. Bepaling van de LV-dimensies kan vaker 
worden verkregen vanwege een verbeterde LV-visualisatie met behulp van contrastmiddelen.
 In Hoofdstuk 15 worden infecties bij patiënten met steunhart (LVAD) onderzocht, 
vooral de diagnose van LVAD-gerelateerde en LVAD-specifieke infecties worden uitgebreid 
geanalyseerd. Het onderscheid tussen diepe en oppervlakkige infecties is cruciaal in de 
klinische besluitvorming. We gebruikten fluorodeoxyglucose positron emissie tomografie 
/ computertomografie (18F-FDG PET / CT) om verschillende infecties te diagnosticeren. In 
dit hoofdstuk hebben we het huidige bewijsmateriaal in de literatuur besproken en onze 
ervaring beschreven met behulp van 18F-FDG PET / CT voor de diagnose en behandeling van 
LVAD-infecties. Deze studie presenteert negen verschillende LVAD-patiënten die leden aan 
klinisch verdachte of bewezen infecties waarbij 18F-FDG PET / CT-beeldvorming de klinische 
besluitvorming bij LVAD-specifieke en gerelateerde infecties ondersteunde. Deze studie 
betreft de grootste populatie van HMII-patiënten die ooit behandeld zijn dankzij diagnostiek 
met 18F-FDG PET / CT. In de huidige literatuur vonden we slechts 4 studies met casuïstiek 
en series met in totaal 47 patiënten: 2 case reports en 2 case-series met 18F-FDG PET / 
CT werden gepubliceerd tussen 2013 en 2016. 18F-FDG PET / CT beeldvorming verstrekte 
accurate informatie over de lokalisatie en uitgebreidheid van LVAD-specifieke of gerelateerde 
infecties vanaf  3 weken na implantatie. Beoordeling van de huidige literatuur met 2 casussen 
en 2 case-series met een totaal van 47 patiënten wereldwijd, bevestigt de veelbelovende rol 
van deze nieuwe beeldvormingsmodaliteit.
 In Hoofdstuk 16 werd gezocht naar het ontstaan van ventriculaire aritmieën (VA’s) voor 
en na een steunhart-(LVAD) implantatie. We hebben alle volwassen patiënten die een LVAD 
kregen tussen maart 2006 en april 2015 beoordeeld in 2 grote Nederlandse LVAD-centra. 
De primaire uitkomstmaat was het optreden van VA, gedefinieerd als VA dat gedurende > 
30 seconden aanhield of werd behandeld met een implanteerbare cardioverter-defibrillator 
(ICD). Statistiek (Multivariate Cox-regressieanalyse) werd uitgevoerd om voorspellers van 
late (> 30 dagen) VA na operatie te onderzoeken. In totaal ondergingen 204 patiënten LVAD-
implantatie. Vijfentachtig patiënten (41,7%) hadden een voorgeschiedenis van VA vóór 
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implantatie van LVAD. Tijdens een mediane follow-up duur  van 17,3 maanden (interkwartiel 
8,1 - 29,5) ondervonden 62 patiënten (30,4%) post-LVAD VA. Het voorkomen  van VA volgde 
een U-vormige curve, met de hoogste incidentie in de eerste postoperatieve maand, een 
nadir op 15 tot 18 maanden en een stijging na die tijd. VA voor de operatie, de aanwezigheid 
van een ICD, het gebruik van bètablokkers en atriale fibrillatie waren univariate voorspellers 
van late VA na de operatie. In het multivariate Cox-regressiemodel bleef alleen VA voor de 
operatie over als een onafhankelijke voorspeller van late VA na de operatie (aangepaste hazard 
ratio [HR]: 2,13; 95% betrouwbaarheidsinterval [CI]: 1,06 tot 4,27; p = 0,03). De incidentie van 
VA kan worden onderschat wanneer VA-episodes niet goed worden gedocumenteerd, vooral 
niet bij patiënten zonder ICD. Samenvattend volgde de incidentie van VA na de operatie een 
U-vormige curve met een toename in incidentie bij langdurige follow-up. Patiënten met VA 
voor de operatie hadden meer kans op late VA. VA na de implantatie leek de overleving 
of het aantal harttransplantaties (HTx) niet te beïnvloeden. Er was echter spoed-HTx nodig 
bij sommige patiënten met therapieresistente VA. Het is belangrijk om te beseffen dat bij 
bestemmings-therapiepatiënten (DT = destination therapy) met therapieresistente VA, een 
spoed-HTx waarschijnlijk geen goede optie is.
 In Hoofdstuk 17 hebben we 69 patiënten met een steunhart retrospectief onderzocht 
om de incidentie en potentiële voorspellers van mechanisch falen (MDF = mechanical device 
failure) te detecteren. Deze studie toont de snelheid, de bijbehorende factoren, de klinische 
presentatie en de uitkomst van mechanisch falen bij patiënten met een steunhart. MDF 
is een ernstige complicatie met als gevolg dat de resultaten op de lange termijn slechter 
zijn. Patiënten met schijnbaar minder belangrijke, maar cumulatieve technische problemen 
waren na verloop van tijd gevoeliger voor MDF, wat vaak chirurgie en steunhart-vervanging 
vereist. De incidentie van technische problemen neemt met de tijd toe, vergelijkbaar met de 
frequentie van MDF. MDF trad op bij een mediane vervolging van 846 [708-1337] dagen na 
implantatie. De meerderheid van de patiënten met MDF presenteerde zich met rode LVAD-
alarmen en een tijdelijke pompstop. Zeventien procent van de sterfgevallen was te wijten 
aan MDF. Als patiënten echter op tijd in het ziekenhuis zijn, kunnen ze met succes worden 
behandeld. Door een tijdige verbinding met een ongeaarde kabel of door op batterijen te 
blijven, kan verdere elektrische kortsluiting worden voorkomen en kan semi-urgente LVAD-
vervanging of externe reparatie van de aandrijflijn worden uitgevoerd. Kortom, de incidentie 
van defecten aan mechanische apparatuur neemt toe met de tijd en steunhartontvangers 
met een langdurige ondersteuningstijd, een geschiedenis van technische problemen of 
een beschadigde aandrijflijn zijn gevoeliger voor mechanische defecten. Het falen van 
mechanische apparatuur kan met succes worden verholpen als patiënten op tijd in het 
ziekenhuis zijn. We verwachten verbeteringen die de duurzaamheid van steunharten en de 
overlevingskans van patiënten zullen vergroten. Nieuwe technische verbeteringen worden 
gebruikt in de aandrijflijn van de HeartMate III om de levensduur te verbeteren.
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TOEKOMSTPERSPECTIEVEN
Mechanische circulatie ondersteuning (MCS) is een zeer snel evoluerend gebied in de 
behandeling van acuut en chronisch hartfalen. Vanwege het ook nog zo jong gebied worde 
vele klinische aspecten nog opgehelderd en verbeterd. Vanaf het begin van de jaren ‘70 van 
kortstondige / tijdelijke MCS-apparaten tot de voor langdurige / permanente ondersteuning 
van de bloedsomloop, afgelopen een tot twee decennia, is er een duidelijke revolutie in de 
behandeling van ernstig acuut en chronisch hartfalen, die nog steeds snel evolueert.
Twintig jaar geleden werd het helpen van een patiënt met terminaal hartfalen langer dan 
een jaar zonder donorhart beschouwd als een medische prestatie. Tegenwoordig leeft 
de meerderheid van de patiënten gemiddeld twee jaar met een LVAD terwijl ze op een 
transplantatie wachten. Ondanks de groeiende overleving na permanente ondersteuning 
met een verbeterde kwaliteit van leven, zullen deze patiënten toch nog veelvoudige 
ziekenhuisopnames meemaken.
 In dit proefschrift hebben we veel van de huidige klinische, pathofysiologische, en 
logistieke uitdagingen bij korte en lange termijn MCS onderzocht. Nieuwere indicaties die 
MCS voor korte en lange termijn nodig achten, bijvoorbeeld door ECMO ondersteunde 
reanimatie, is een groeiend en bekend fenomeen. In deze en verdere gebieden op MCS 
verwachten we de samenwerking van academische centra met niet-academische hartcentra 
te uitbreiden voor verbetering van de expertise en hierdoor ook de uitkomst van deze 
patiënten. De niet-academische MCS-centra zouden kunnen dienen als perifere hubs waar 
gespecialiseerde cardioloog-intensivisten en intensive care afdelingen die deel zouden 
kunnen uitmaken van het nationale cardiogene shockprogramma geleid door academische 
schokcentra met gespecialiseerde shockteams voor mobiele diensten tussen de hub en de 
perifere hubs. Derhalve is er behoefte aan klinisch en hemodynamisch monitorsysteem in het 
ziekenhuis en op afstand voor deze kunstmatige circulaties. 
 Nieuwe tijdelijke apparaten voor RV en LV falen zullen steeds meer een rol gaan 
spelen in de behandeling van de ernstig zieke patiënten met cardiogene shock die circulatie 
ondersteuning nodig hebben als overbrugging naar herstel of implantatie van een permanente 
MCS-apparaat. Hoogontwikkelde teams kunnen overal worden ingezet en de MCS-apparaten 
zoals ECMO, Impella en IABP zijn nog steeds de hoop op overleving voor veel ernstig zieke 
patiënten. Momenteel wordt ECMO gebruikt voor ernstig hart- en longfalen in alle leeftijden. 
Verder onderzoek is nodig met de nadruk op het verbeteren van antistolling en apparaten, 
het definiëren van indicaties en nieuwe toepassingen zoals septische shock, ECPR en het 
redden van organen voor transplantatie.
 De toekomst van tijdelijke MCS-apparaten hangt grotendeels af van de opkomst van nieuwe 
technologie, waarvan een groot deel al is ontwikkeld of zich in de beginfase van ontwikkeling 
bevindt. Nieuwere MCS-circuits kunnen waarschijnlijk een verdere vereenvoudiging van 
circuits, verhoogde draagbaarheid en automatisering omvatten, wat mogelijk maakt voor 
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meer gebruik in bijzondere omgevingen. Dit soort verbeteringen zou waarschijnlijk gepaard 
gaan met een verdere vermindering van de vereiste antistollingsparameters, verminderde 
ontstekingsreactie en verminderde bewakingsvereisten tegen hogere kosten.
Verbeteringen in het ontwerp van de LVAD’s van de toekomst
Voor duurzame permanente MCS / VAD-apparaten, is de toekomst van miniaturisatie, van 
complete tot gedeeltelijk hemodynamische ondersteuning, minimaal invasief tot percutaan 
in plaats van open sternotomie en kleiner en flexibeler voor individuele patiënten. Ingenieurs 
zetten de volgende grote stap door een kleinere pomp te maken die minder wattage vereist 
- waardoor de batterij volledig kan worden geïmplanteerd en veiliger kan worden opgeladen, 
minder ingrijpende operatie en een grotere patiëntvrijheid - en dat is meer compatibel met 
een hart herstellende van hartfalen. Bovendien zal de ontwikkeling van een apparaat dat 
meer onzichtbaar is voor de patiënt en dat aanpasbaar is aan de unieke fysiologische eisen 
van elke persoon, meer te vergeten zijn. Daarom zouden LVAD’s van de volgende generatie 
(en RVAD’s) volledig implanteerbaar zijn (om het infectierisico te verminderen) aan zowel 
de linker- als de rechterkant van het hart, met meerdere feedbackmechanismen om de 
pompfuncties automatisch te reguleren. Maar op dit moment in de nabije toekomst in de 
acuut gedecompenseerd chronisch hartfalen, is de hamvraag niet een gedeeltelijke versus 
volledige ondersteuning maar eerder een onmiddellijk permanent apparaat versus een tijdelijk 
apparaat als een brug naar herstel- of permanente apparatuur. Meer en meer gedeeltelijke 
ondersteuningsapparaten vroeg in de behandeling van hartfalen zouden een optie zijn. Deze 
apparaten zijn gemakkelijker te implanteren en in het algemeen bij patiënten met een lagere 
NYHA-klasse om verdere hartfalen te voorkomen. Verder is het bediscussiëren van behoefte 
aan univentriculaire versus biventriculaire MCS, het concept van gedeeltelijke versus totale 
ondersteuning van de bloedsomloop is behoorlijk intrigerend. Ervaring met overbrugbare 
patiënten om succesvol te transplanteren met axillaire intra-aortale ballonpompen toont het 
nut aan van gedeeltelijke mechanische ondersteuning voor het falende hart.
 Risicofactoren en strategieën om het rechterventrikel falen na LVAD-implantatie te 
beperken, zijn in de afgelopen vijf jaar uitvoerig beschreven in de literatuur. We hebben een 
risicoscore voor rechtszijdig hartfalen ontwikkeld binnen EUROMACS, wat ons in de nabije 
toekomst zal helpen bij het selecteren van de beste patiënten voor een LVAD-implantatie. 
De juiste selectie en voorspelling van de RV voorafgaand aan de LVAD-implementatie 
blijft echter een diagnostisch raadsel. Veel centra, waaronder de onze, maken gebruik 
van verschillende intra-operatieve manoeuvres om de belasting van de rechterkamer te 
verminderen. Dit moet voor vergelijkbare patiënten wereldwijd uniform worden gemaakt. 
Bij patiënten met levensbedreigend rechtszijdig hartfalen op weg naar LVAD-implantatie, 
konden profylactische nieuwe percutane RVAD’s een veilig antwoord bieden, gemakkelijk te 
implementeren en betrouwbaar voor onmiddellijk macrohemodynamische herstel na LVAD, 
wat acute nierbeschadiging, sepsis en multi-orgaanfalen in veel recente studies voorkomt. 
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Dit apparaat zal waarschijnlijk ook door zijn bekende voordelen helpen bij deze ernstig zieke 
patiënten om in een betere conditie naar de operatiekamer te overbruggen voor een LVAD 
en de periode daarna.
Verbeteringen in het monitoren van de circulatiemiddelen
Verdere studies naar de microcirculatie bij patiënten met cardiogene shock en chronisch 
hartfalen zouden het gebruik van deze unieke methode moeten verbeteren om letterlijk 
te zien wat er met de microcirculatie gebeurt door de macrocirculatie te modificeren. 
Waarschijnlijk, zelfs door de patiënt in zijn eigen omgeving, bewees zelfzorg dat dit instrument 
als bewaking op afstand kan worden gebruikt. Tegenwoordig wordt er een invasieve methode 
gebruikt om gedecompenseerd hartfalen te voorkomen voor en na LVAD-implantatie, die 
nog steeds surrogaat-eindpunten van de bloedsomloop meet. Deze invasief verzamelde 
gegevens zouden kunnen worden toegevoegd aan microcirculatie veranderingen om de 
microfysiologie van de kunstmatige circulaties beter te begrijpen. Deze manier van monitoring 
van de microcirculatie kan ook worden overwogen voor het bewaken van het herstel van 
de systemische circulatieparameters bij cardiogene shockpatiënten, naast de conventionele 
beeldvormingsinstrumenten. 
 In onze focus worden MCS-apparaten zoals VA-ECMO als brug-tot-brug-therapie nog te 
laat gebruikt of geïnitieerd, wat mogelijk leidt tot vermijdbare verslechtering van de patiënt. 
Onderzoek moet zich richten op de ontwikkeling van nieuwe, minder invasieve, linker of rechter 
ventriculaire ondersteuningsapparaten voor tijdelijke en permanente MCS. Mechanische 
circulatiehulpmiddelen op korte en lange termijn hebben een revolutie teweeggebracht in 
de behandelingsmogelijkheden voor patiënten die lijden aan acuut en chronisch hartfalen. 
Naarmate we tegelijkertijd de patiëntenpopulatie uitbreiden die baat kan hebben bij deze 
technologieën en de morbiditeit van implantatie, zullen we aanzienlijke vooruitgang boeken 
bij de behandeling van zeer ernstige kritisch zieke patiënten. We hebben in de afgelopen 
dertig tot vijftig jaar al aanzienlijke vooruitgang geboekt in de therapie en monitoring voor 
deze patiënten en de toekomst is begrijpelijkerwijs  helder voor mechanische ondersteuning 
van de bloedsomloop.
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‘Samenwerking’ is het toverwoord die het ontstaan van dit boek heeft mogelijk gemaakt. Drie 
jaar geleden heb ik mijn opleiding tot intensivist afgerond en ben ik geleidelijk overgegaan 
naar een duaal baan als cardioloog-intensivist en PhD student. Voor de totstandkoming 
van dit boek ben ik alle medewerkers van het Thoraxcentrum en de Intensive Care van het 
Erasmus MC ontzettend dankbaar. Dit boek was niet tot stand gekomen zonder alle hulp en 
ondersteuning die ik van jullie heb mogen ontvangen. Daarom wil ik iedereen bedanken, 
die zowel direct als indirect hieraan heeft bijgedragen. Maar vooral wil ik alle patiënten met 
acuut of chronisch hartfalen, die een mechanische ondersteuning nodig hadden, en hun 
familieleden bedanken voor de toestemming om dit onderzoek mogelijk te maken. Zonder 
hen hebben wij geen bestaansrecht. Verder wil ik mijn promotoren en copromotoren expliciet 
bedanken dat ze mij alle steun hebben gegeven en elk moment met volste vertrouwen achter 
mij hebben gestaan. Waarschijnlijk zal ik ook mensen vergeten te bedanken in dit hoofdstuk, 
maar mijn dank voor diegenen is zeker niet minder.
Professor Zijlstra! Beste Felix, je was gedurende mijn gehele promotietraject op dezelfde 
manier betrokken als tijdens mijn opleiding tot cardioloog (en vooral tijdens mijn cathlabstage): 
zo rustig, kalm en op het juiste moment corrigerend. Jouw kalmte heb ik zowel in de kliniek 
als tijdens wetenschappelijke activiteiten geprobeerd te kopiëren. Hopelijk is het enigszins 
gelukt. Ik zal je altijd dankbaar blijven.
Professor Gommers, beste Diederik, toen ik in opleiding kwam als fellow intensive care 
vertelde je mij dat we meer moesten samenwerken met andere afdelingen en je had 
vertrouwen in mij als cardioloog. Je bent een man met visie en daar heb ik veel baat bij gehad. 
Tijdens dit promotietraject hebben we vele leuke momenten gehad, maar het mooiste was 
dat Feyenoord kampioen werd. Zoals een echte Feyenoorder ben jij ook een man van “Geen 
woorden maar Daden”. Onze ski-weekenden waren legendarisch en jij liet weer zien dat je 
zoals altijd een gewoon mens bent. Wat hebben wij toch gelachen. Bedankt voor alles wat je 
voor me hebt gedaan en je begeleiding van mijn opleiding en aansluitend promotietraject.     
Professor Ince, beste Can, jou naam betekent “het leven” in het Turks en jij hebt de 
microcirculatie, wat de bron van het leven is, leven in geblazen bij mechanische circulatie 
ondersteuning op de intensive care in Nederland en ook internationaal. Jouw gedrevenheid 
en passie voor het onderzoek hebben mij maximaal gestimuleerd. Jouw liefde voor zowel 
het vak als voor je favoriete voetbalclub Beşiktaş is aanstekelijk. Vorig jaar mocht ik in plaats 
van jou een presentatie geven over microcirculatie bevindingen bij mechanische circulatie 
ondersteuning tijdens het anesthesiologie en intensive care congres in Istanbul. Daar zag ik 
nogmaals hoe geliefd je internationaal bent en wat hebben wij die dag toch heerlijk gegeten 
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en gelachen in Istanbul. Konyalilar Restaurant in de wijk Sirkeci zal ik nooit vergeten. Met 
jou een artikel reviseren was altijd dolle pret, want het ging altijd gepaard met lekker eten. 
Bedankt dat je het ook mogelijk maakt dat nog vele promovendi van je mogen genieten de 
komende jaren in het Erasmus MC. Zoals jij altijd zei “Kimse yokken biz vardik” zal ik blijven 
herinneren ook in de toekomst, want zonder microcirculatie geen macrocirculatie. 
Dr Çalışkan, beste Kadir, jouw naam beslaat één van de eigenschappen van “de schepper”. Jij 
hebt de zwaarste taak van je leven op je genomen door mij als PhD student aan te nemen. Al 
maanden probeer ik hier te verwoorden wat ik niet onder woorden kan brengen. De unieke 
impact die jij op mijn leven hebt is eigenlijk ook niet te beschrijven. Zoveel gedachtewisselingen 
(over veel meer dan alleen onderzoek), over goede en minder goede ‘baklava’s’ en met alle 
plannen voor morgen (en overmorgen), kan ik enkel het volgende nog zeggen: “Jouw aandeel 
aan de totstandkoming van dit boek is onbetaalbaar!”. 
Jouw houding om alleen het bereikbare na te streven en niet te zitten jammeren om het 
onbereikbare heeft mij enorm gestimuleerd. Jij zou een geweldige Feyenoorder zijn als je 
niet uit Zaandam kwam. Je bent echt een man van “Geen woorden maar Daden”. Zoals je 
achternaam (Çalışkan) dat ook verklapt, ben jij een harde werker. Jij bent een top cardioloog 
als mens en als clinicus. Je sportieve karakter had ik helemaal niet door totdat je mijn team 
had uitgenodigd naar een volleybaltoernooi waarbij mijn team één na laatste werd, maar 
jouw team in de finale stond. De onderzoekslijnen die we samen bedachten waren maar een 
fractie van wat je allemaal nog erbij deed voor de wetenschap. Ik weet niet hoe vaak ik naast 
jou op die “zwarte plastic camping stoel” heb gezeten op BA-577 van het Thoraxcentrum en 
als ik even geen antwoord had op je vragen, je me een pepermuntje aanreikte. Daar kwam 
al mijn klinische paraatheid vandaan tijdens de diensten op de IC, besefte ik me later. Het 
waren de mooiste didactische momenten. Ik ken geen andere cardioloog die na dr. Balk met 
zoveel passie en zo veel gedrevenheid met de hartfalen patiënten omgaat zoals jij. Niet alleen 
op mijn werk maar ook als mens heb ik veel van je mogen leren. Dat wij samen aan dit boek 
zijn begonnen was geen toeval. Jouw betrokkenheid bij hartfalen patiënten en gedrevenheid 
in de kliniek waren aanstekelijk tijdens mijn hartfalen stage eind 2012. Jouw motivatie om 
uitmuntende resultaten te behalen in de kliniek door onderzoek te doen was ook mijn passie 
geworden. Toen we (Olivier, jij en ik) langs een van jouw transplantatiepatiënten liepen, was 
het duidelijk hoe dankbaar deze mensen je ook waren. Er was zelfs één transplantatiepatiënt 
die als dank je hand wilde kussen! Je bent een voorbeeldpersoon van top tot teen! Het was 
niet gelukt om dit boek af te ronden zonder jouw inspanningen. De top vijf congressen die 
we hebben bezocht, Istanbul, New-Orleans, Washington, Barcelona en Bad Oeynhausen, zijn 
nog steeds onovertrefbaar. ’s Ochtends om 5 uur opstaan, wandelend de stad verkennen 
en al genieten van het congres voordat de dag begon, was geweldig. Heel mijn opleiding 
cardiologie was jij het meest betrokken bij mijn ontwikkeling op het gebied van hartfalen en 
dat gaf mij nog meer het vertrouwen om onderzoek naar de kliniek te vertalen. Sindsdien 
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geldt voor mij één regel “If you understand heart failure, you understand cardiology”. Dank 
je wel!
Professor Bogers wil ik ontzettend bedanken dat ik op een herfstdag in 2006, als net 
afgestudeerde arts, bij hem op de afdeling mocht komen werken en natuurlijk voor het lezen 
en beoordelen van dit proefschrift. Werken bij het Thoraxcentrum is het mooiste wat je als 
arts-assistent kan overkomen. Dankzij u ben ik een goede dokter geworden, heb ik mijn huis 
gekocht en heb ik de overgang kunnen waarmaken naar mij carrière binnen de cardiologie. 
Uw rustgevende betrokkenheid bij de patiëntenzorg tijdens de ochtendoverdrachten en op 
de afdelingen is een zegening voor de hartpatiënten. We hebben jaren later, op de intensive 
care overdrachten weer ontzettend veel plezier gehad en gelachen. Bedankt namens heel 
mijn gezin.   
Professor Boersma, beste Eric, bedankt dat je deel wilde nemen aan de promotiecommissie 
en het secretariswerk op je wilde nemen. Vanaf de opleiding was ik altijd een fan van jouw 
epidemiologie en statistiek lessen. Eindelijk mochten we samen ook aan het grootste artikel 
van dit boek werken en dat gaf enorm veel voldoening en trots. Bedankt voor je begeleiding.
Professor Henriques, beste José, dank voor het beoordelen van het proefschrift. Jouw 
onderzoek naar mechanische circulatie ondersteuning heeft mij altijd geïnteresseerd. Hartelijk 
bedankt voor je deelname in de oppositie. Mocht je betrokkenheid met de Nederlandse 
Antillen bevallen, zou ik graag met je meedenken over een “Caribbean Mechanical Circulatory 
Support Summit”.
Dr. Balk, beste Aggie, allereerst bedankt voor al je vertrouwen in mij tijdens mijn arts-
assistentschap en later als cardioloog en intensivist. Bedankt dat je tijdens mijn hartfalen 
stage mij hebt gestimuleerd om de bevindingen bij patiënten met een LVAD in het 
wetenschappelijke licht te zetten en op te schrijven. Jouw liefde voor het vak is aanstekelijk. 
Het was mijn geluk om jou in de kliniek tijdens mijn opleiding te mogen meemaken. Jouw 
opmerking tijdens mijn hartfalen stage ‘het komt goed he’ vat kort en krachtig samen wat 
ik gedurende mijn cardiologie opleiding heb gepresteerd. Ontzettend bedankt dat je in de 
oppositie wilde deelnemen. 
Professor Deckers, beste Jaap. Vanaf mijn eerste dagen als ANIOS cardiologie heb ik je 
rustgevende houding enorm bewonderd wat me hielp van CCU tot op de polikliniek onder 
jouw supervisie. Als ik terugkijk was jij er altijd bij op belangrijke momenten in mijn carrière. 
Van ANIOS naar AIOS, van cardioloog naar fellow ic en nu bij mijn promotie verdediging. 
Jij hebt ook mijn C-formulier getekend en kreeg toen ook mijn eerste ECMO boek van jou. 
Bedankt dat je ook wilde deelnemen aan de grote commissie.   
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Professor Kappetein, beste AP! Bedankt dat je ook wilde deelnemen aan de grote commissie. 
Van jou heb ik ooit leren skiën, wat verder verfijnd werd door Özcan Birim met één arm 
in mitella, in Ponte di Legno van Milaan. Op de terugweg hadden we met de hele groep 
vertraging door mistbalken op het vliegveld. Hoe je ons in je beste Italiaans weer goed terecht 
liet komen was bezienswaardig. Gedurende mijn carrière in het Erasmus MC heb je mij altijd 
gesteund, waarvoor dank. Zoals jij altijd zei “wie goed doet, goed ontmoet” blijft mijn beste 
geheugensteuntje.  
Professor Tibboel, uw werk en projecten met mechanische circulatie op de kinder IC hebben 
mijn interesse gewekt en zijn een inspiratiebron geweest voor onze onderzoeken op de 
volwassen IC. Hartelijk dank voor uw deelname aan de grote commissie.
Osama Ibrahim Soliman, the king of echo, ik kan je niet genoeg bedanken! Dank voor al je 
begeleiding van zeer moeilijke projecten tijdens mijn opleiding, echo examens in Istanbul, 
opleiding tot intensivist en later bij het vormgeven van dit boek. Je hebt een onuitputtelijke 
energie en tegelijkertijd tolerantie voor slechte vragen. Ooit leerde ik je kennen toen jij PhD 
student was op de afdeling echocardiografie van het Thoraxcentrum. Je kon van één vraag een 
heel project en een boekwerk maken. Als cardioloog maar ook meester in echocardiografie 
ben jij een geschenk aan de geneeskunde. Door jou opgeleide artsen zijn wereldwijd heel 
gerespecteerd en jou zeer erkentelijk wat ik zelf heb ervaren op meerdere internationale 
congressen. Dankzij jouw en onze opleider Dr Folkert ten Cate en jullie lessen en trainingen 
in echocardiografie konden we in 2013, tijdens het congres in Istanbul, twee examens in 
Europese echocardiografie met succes afronden. Ik ben jullie beiden nogmaals zeer dankbaar 
hiervoor. Beste Folkert, nogmaals dank voor je uitgebreide lessen in echocardiografie en de 
gezelligheid in de Kuip tijdens meerdere wedstrijden van Feyenoord. Ook voor je opleidende 
rol tijdens de echo congressen met meest memorabele in Istanbul. Wat hebben we die dagen 
toch gelachen met Kadir, Johannes Schaar, Ken Masdjedi (zonder zijn grappen kwamen 
we niet verder! De olie in de machine!) , Marcel Geleijnse, Sing Yap, Admir Dedic, Cihan 
Simsek, Tuncay Yetgin, Rohit Oemrawsingh, Pietertje Vriesendorp, Christine Pieters, 
Jonathan Lipton, Tineke van den Berg en alle andere arts-assistenten en fellows. 
Onze ABC bijeenkomsten, onder leiding van Marcel Geleijnse en Arend Schinkel, werden 
ook steeds belangrijker voor zowel de echo afdeling als de mechanische circulatie 
geïnteresseerden. Ook hen wil ik bedanken voor deze ABC bijeenkomsten en de projecten 
die we gezamenlijk mochten uitvoeren op de echo afdeling. Er ontstonden zoveel ideeën dat 
er wel per jaar meerdere PhD studenten van onderwerp konden worden voorzien. 
Mijn maten van het clubje “cardiotijgers” Corstiaan den Uil en Jasper Brugts wil ik ontzettend 
bedanken voor hun hulp bij het schrijven van artikelen, de inspirerende houding en de aanzet 
tot wetenschappelijke interesses. De enige hele marathon heb ik met Jasper gelopen in onze 
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geboortestad. Dat was een eitje vergeleken met het afronden van dit boek naast een volledig 
bezet werk en privé leven. Dit boek telt voor wel minstens drie marathons. Corsti met jou 
hebben we enorm goed klinisch en wetenschappelijk werk geleverd op onze intensive care 
van het EMC. Het is een eer om na jou de enige gepromoveerde cardioloog-intensivist te 
worden aan het Erasmus MC. Wat onze aandachtsgebieden betreft, hebben we beiden de 
mechanische circulatie en microcirculatie verder uitgediept. Samen hebben we tijdens onze 
fellowship, maar ook daarna, laten zien dat IC zorg werkelijk een 24-uurs zorg is en geen 
probleem tot de ochtendzon hoeft te wachten. Dank voor de prettige samenwerking. 
Els Forman en Wil van Waardenberg wil ik ontzettend veel bedanken voor hun hulp en tijd 
die ze hebben besteed aan mijn opleiding en later aan de PhD zaken die snel afgehandeld 
moesten worden! Dat was niet gelukt zonder jullie tweeën. Bedankt!
Mijn derde vaderland, Curaçao, is altijd een inspiratiebron geweest vanaf 2004 en tijdens 
mijn gehele promotietraject. “Pero ora bo ta jong bo ta kue mundu ku man!” Het optimaal 
gebruik maken van kleinschaligheid had ik daar voor het eerst in 2004 geleerd. Hier heb ik 
later enorm veel aan gehad tijdens mijn promotieonderzoek. Deze waardevolle mensen die 
mij destijds, en later tijdens het schrijven van dit boek, hebben bijgestaan wil ik met heel 
mijn hart bedanken. Professor Ashley Duits, dr. John John Scnhog, dr. Nouaf Ayubi, Gilda 
Leander, dr. Jeroen Römer, Jane en Oscar Castillo, Karel en de rest van familie Römer en al 
mijn vrienden op het eiland. “Masha masha danki”! 
Dr. Atila Kara, Isik Ocak and Göksel Güven, “The boys from Turkey” . You were my partners 
in research as fellows and PhD students of professor Ince. No matter where you are, your 
impact on the research of the microcirculation workgroup is still persisting. Thank you all 
very much. Atila, I hope that you still play soccer despite the loss of your eyeglasses during 
the Thoraxcenter soccer tournament. Isik, during our last visit to Istanbul you made our trip 
fantastic. Your ideas on improving microcirculatory measurements were excellent. 
Göksel, you will change the history of microcirculation. I believe that the roadmap for 
improvement and clinical use of microcirculatory measurements will come from your 
research! Thanks to your microcirculatory measurements, the cover of my PhD book has 
been very unique! Thank you very much for all your contributions! 
Huwai He, Yasin, Zehra, Philip en Bülen abi! You are all experts on microcirculation. Our 
tour to improve microcirculation is not done yet! We will visit more congresses and research 
meetings on our way to improve monitoring the microcirculation. Huwai, thanks to your 
statistic programs and thanks to Yasins creative images I got a great input for several articles 
in this book. Thank you all very much.  
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Ook wil ik de studenten die hebben bijgedragen aan dit boek, vooral Edon en Yunus, die de 
volgende PhD kandidaten zijn, hartelijk bedanken voor hun hulp in data collectie, analyse en 
verschillende discussies.
Collega cardiologen van het Erasmus MC wil ik allemaal één voor één bedanken voor hun 
steun en vertrouwen in mij gedurende mijn promotietraject. In het bijzonder Tamas Szili-
Törok en Sip Weichers (hiervoor Lara Dabiri en Sophie van Malderen) die als kamergenoten 
van Dr. Caliskan ook tegen mijn grappen en luidruchtige aanwezigheid moesten wennen, maar 
altijd wel in waren voor een grapje en een goed gesprek over mijn PhD traject. In de kliniek 
heb ik ook veel van jullie mogen leren. Tamas, jij bent een top electrofysioloog en ik heb zeer 
prettig met je mogen werken in de diensten als arts-assistent en later ook als collega. Hopelijk 
zal je nog veel assistenten opleiden in het Erasmus MC. Met de NVVC challenge in 2013 heb 
jij de drakenboot met een enorme kracht vooruit gepeddeld. Voor jou speciaal zal ik nog een 
waterpolotoernooi tijdens een NVVC organiseren, dat komt goed! 
Alina en Olivier, jullie hebben altijd achter mij gestaan gedurende mijn opleiding, 
hartfalenstage en PhD traject. Van jullie heb ik ontzettend veel geleerd tijdens mijn opleiding 
en gedurende onze wetenschappelijke activiteiten. Altijd was er bij jullie de gedachte “het 
gaat om jouw proefschrift” die ik met volle vertrouwen in jullie ogen zag ontstaan. Dank jullie 
wel.
Aansluitend op de namen hierboven kan ik niet voorbijgaan aan mijn grootste broertje, 
Ferdi Akca! Jou kan ik niet genoeg bedanken! Wat heb ik toch veel van jou geleerd aan het 
begin van mijn PhD traject, maar ook later als collega op de werkvloer toen jij je stijgende 
lijn bij de thoraxchirurgie al snel te pakken had. Op een gegeven moment was jij klaar met je 
proefschrift en mocht ik je bijstaan als je paranimf samen met de meest geweldige paranimf 
die ik heb mogen meemaken, Ramazan Akca. Het was een fijne ervaring voor mij. Jou heb 
ik als arts-assistent in het thoraxcentrum leren kennen toen jij nog op het VWO zat en als 
leerling de verpleegkundigen hielp met afdelingszaken. Je was altijd liergierig en respectvol 
aanwezig als we een patiënt bij jou op de afdeling moesten beoordelen. Nu is het mijn beurt 
om wat ik van jou heb geleerd te gebruiken om mijn proefschrift af te ronden. Dank je wel 
broertje!   
Graag zou ik al mijn co-auteurs willen bedanken, in het bijzonder Lideke Fröberg voor haar 
tijd, geduld en moeite bij de lessen in PET-CT scans bij patiënten met een LVAD. Verder ook 
de professoren de Jonge, Bakker, Krabatsch, Gummert en Mohacsi voor hun fantastische 
bijdrage aan dit proefschrift.       
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Dear professors Krabatsch, Gummert and Mohacsi. During these thesis our scientific 
collaboration within the EUROMACS registry and during several EUMS was wonderful. Thank 
you for all your support. 
Alle thoraxchirurgen van het Thoraxcentrum met wie ik heb samengewerkt als arts-assistent, 
maar later ook als intensivist, wil ik ontzettend veel bedanken! Professor Ad Bogers, John 
Bol-Raap, Charles Kik, Lex Maat, Peter de Jong, Michael Hartman, Frans Oei, Özcan Birim, 
Wouter van Leeuwen, Edries Mahtab, Margreet Bekker, maar vooral ook Pieter van de 
Woestijne en Jos Bekkers. Jullie hebben mijn directe familieleden geopereerd. Daarvoor ben 
ik jullie in het bijzonder dankbaar. 
Özcan wil ik nogmaals hartelijk bedanken voor al zijn input bij het schrijven van de meeste 
artikelen over LVADs maar natuurlijk ook voor de skilessen. Niet alleen wetenschappelijk maar 
ook in de kliniek ben je zeer betrokken bij de patiënten met een LVAD waarvan ik ontzettend 
veel van heb geleerd. Dank je wel!
Alle cardiologen van de Cardiologen Club Rijnmond wil ik hartelijk bedanken, in het 
bijzonder Madoka Sunamura, Marc van der Linden, Rob van Mechelen en Nico Breuls 
voor hun fantastische congresreizen en gezelligheid. 
Alle medewerkers van de polikliniek cardiologie, Corrie, Memento, Cindy, jullie hebben me 
ontzettend veel geholpen ik ben jullie allemaal dankbaar voor de goede flow op de polikliniek 
met alle LVAD patiënten. 
De echo afdeling van Erasmus MC ben ik zeer erkentelijk voor hun bijdrage tijdens mijn 
opleiding tot cardioloog en onze contrast studies bij LVAD patiënten. Ellen, Linda, Laurus, 
Debbie, Beata, Anja, Saskia, Kwaku, Jackie McGhie en Wim Vletter, bedankt ! Wim 
Vletter en Jackie McGhie nogmaals bedankt voor jullie bijdrage aan mijn opleiding op de 
echocardiografie afdeling. Tijdens onze CEVAD studie hebben jullie mijn fantasievolle ideeën 
tot een reëel kansrijk project gebracht! Net voor jullie pensionering hebben we samen nog 
een mooi project afgeleverd. Ontzettend bedankt hiervoor. 
Kees, Klaas en Hans, bedankt voor de technische oplossingen die jullie boden aan de LVAD 
patiënten. Af en toe moest er gewoon een stofzuiger aan te pas komen! Van jullie kundigheid 
mocht ik genieten tijdens mijn stage op de HTx afdeling en later als intensivist. Dank jullie wel!
Jasmijn, Chantal, Marleen, Marijtje en alle VAD, HTx, Cathlab, EFO en IC verpleegkundigen 
wil ik bedanken. Zonder jullie hulp had ik nooit de structuur van afdeling, poli en echo afdeling 
kunnen coördineren. Iedereen ontzettend bedankt.
Ellen Klaassen, Ymkje, Lara, Lydia, Carol wil ik bedanken voor hun logistieke, energieke en 
emotionele ondersteuning. Jullie steun is en blijft een stevige hoeksteen van dit boek.     
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Wouter de Wilde, Rutger van Til, Linda van der Voort, Michiel Soulié en Anke van 
Steekelenburg. Jullie gedrevenheid en passie voor de circulatie is aanstekelijk. Direct en 
indirect zijn jullie betrokken geraakt bij de totstandkoming van dit boek, mede door jullie 
opleidingen. Bedankt voor de samenwerking gedurende mijn promotieonderzoek en hetgeen 
nog zal volgen. 
Alle intensivisten van het Erasmus MC, prof. dr. Johan Groeneveld, prof. Dr. Jan Bakker, 
Ben, Jelle, Jasper, Djo, Joachim (de wereldburger), Johan, Jeroen, Patricia, Christine, Willy, 
Karen, Hilde, Lucia, Mathieu, Jubi, Eva en Gerrie wil ik één voor één bedanken voor de 
samenwerking gedurende mijn opleiding en later tijdens mijn PhD periode. 
Ditty, Patricia, Alicija, en Erwin Kompanje wil ik enorm bedanken voor hun hulp bij mijn 
promotie. Jullie geduld is oneindig. Erwin heb ik heel vaak zeer vroeg in de ochtend mogen 
lastigvallen met mijn onderzoeksvragen. Jouw “werkethos” is aanstekelijk! Dank je wel voor 
al je hulp en meerdere artikelen die we samen mochten schrijven. 
Nicole Hunfeld wil ik bedanken voor haar dedicated (farmacologische) ondersteuning van 
meerdere researchprotocollen. Het onderzoeksteam van de IC bestaande uit Peter, Paul, 
Loes, Lisa, Ernest, Jeroen, Marjolein, Mo, Esther, Philip en Wim wil ik bedanken voor de 
gezelligheid en de koffie momenten. Mohamud Egal en Esther van der Zee wil ik nogmaals 
bedanken voor hun ontzettend adequate inzet tijdens onze diensten in het Thoraxcentrum. 
Zoran Trogrlic, bedankt voor de samenwerking en de “Zoran criterium”; 20 definitieve 
woorden van het proefschrift per dag op papier zetten, die het onoverzienbare overzienbaar 
maakte voor ieder PhD student. Dank je wel voor je gezelligheid en je motiverende gedachtes. 
Alexandre Augusto Pinto Lima (Alex!) thanks for your lessons on microcirculatory 
measurements and the help to start several studies. My first study in ECMO was based on 
your first protocol, which was very nice to have. Your relaxed behavior in human contact, but 
also with the patients helped us very much. 
Dr. Robert van Thiel, Dinis dos Reis Miranda en Han Meeder als de kern van het ECMO 
team Rotterdam. De nachtritten om patiënten aan de ECMO te leggen / op te halen waren 
onvergetelijk. Als fellow en later als staflid heb ik veel van jullie mogen leren. Dank jullie wel!
Dr. Dinis dos Reis Miranda! Mijn neef! Bedankt voor al je bijdrages in meerdere artikelen die 
we soms tussen al onze druktes in op de IC en soms rustig op je weiland mochten corrigeren. 
Jij bent een geweldig persoon met een enorm hart! Met jou ijverige houding zal de ECMO zorg 
in en rondom Rotterdam alleen maar meer glans krijgen! Dank je wel voor de gezelligheid en 
de onuitputtelijke energie die hebben bijgedragen aan het totstandkoming dit boek!   
Alle arts-assistenten anesthesiologie en intensive care (te veel om een voor een te noemen, 
maar in het bijzonder Omar, Han, Wouter, Samir, Elvira en Geneviève) wil ik bedanken met 
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wie ik als fellow en als intensivist heb samengewerkt. Jullie waren in de kliniek, maar ook bij 
de metingen voor mijn onderzoek aan de patiënten met een VA-ECMO of LVAD onmisbaar. 
Iedereen in het Van Weel-Bethesda ziekenhuis wil ik van harte bedanken en in het bijzonder de 
cardiologen, intensivisten (Servet Duran en Annemieke Dijkstra) en alle verpleegkundigen. 
In de korte periode dat we samen mochten werken hebben jullie ontzettend veel interesse 
getoond in mijn PhD onderzoek. Jullie barmhartige zorg en interesse in de patiënten zal ik 
nooit vergeten. Dank jullie wel!
Intensivisten van het HagaZiekenhuis, wat een geweldig team vormen jullie!!!! Gedurende 
mijn werkzaamheden heb ik van de diversiteit binnen jullie groep enorm mogen leren. Ervaren 
worden en uitrijpen in een gemoedelijke omgeving was een zegening voor mij. Het was zelfs 
tot twee keer weer thuiskomen, waarvoor dank. Ontzettend bedankt Rémon Baak (mijn 
broer cardioloog-intensivist), Tim Jansen, Iwan Meynaar, Ralph Nowitzky, Mirelle Koeman, 
Ilse Purmer, Piet Melief en uiteindelijk Thomas Ottens. Ook wil ik Patricia van Velzen en 
Arthur Nieuwenhof bedanken met wie ik helaas te kort heb gewerkt. Jullie zijn allemaal 
geweldige intensivisten die precies weten wat de vitaal bedreigde patiënten nodig hebben. 
Dank jullie wel voor de heerlijke samenwerking tijdens het ontstaan van dit boek. We zullen 
met mechanische circulatie nog vele patiënten optimaal behandelen op onze intensive care 
in het HagaZiekenhuis. Op menselijk en medisch inhoudelijk gebied heb ik veel mogen leren 
en het is en eer om met jullie samen te werken. Dank jullie wel!
Alle medewerkers van het HagaZiekenhuis, in het bijzonder alle cardiologen en 
cardiothoracale chirurgen wil ik van harte bedanken. Jullie ochtendrondjes langs de IC-
bedden waren hilarisch en leerzaam. De grappen na de rondjes met Ali, Aria, Khalil, Gerard, 
Gabe, Vincent, Joris, Wilco, Matthijs, Ivo, Samer, Carl, Ramon en  Tommy waren genoeg om 
de rest van de dag vol enthousiasme door te komen.
Ron van Domburg, Mattie Lenzen, Wim Rietdijk en Isabella Kardys wil ik enorm bedanken 
voor hun hulp in statistiek bedrijving.
Ibrahim Tasgil (de hersenchirurg) en Paul Cummins wil ik bedanken voor hun taalkundige 
beoordeling van enkele artikelen in het Engels.
Theo de By wil ik ontzettend bedanken voor zijn hulp bij de grootste studies in dit proefschrift. 
Tijdens onze reis door EUROMACS landen hebben we enorm veel gelachen. Het meest 
aangename om jou als reisgenoot te hebben was dat we beiden niet bang waren om te 
verdwalen en we hielden van een stukje wandelen.
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Mijn goede vrienden, vriendinnen, neven, nichten, voetbalmaatjes op maandag-, woensdag 
en ooit ook op vrijdagavonden buiten het ziekenhuis en de onderzoekswereld (o.a. Adnan, 
Aydo, Tony (Bülent), Atabey, Fatih, Jean-Paul, Mustafa, Attila, Adem, Murat, Kemal, Ersen, 
Erhan, Memo, Sabri, Kees, Muhammet, Thao, Hakan….): ondanks dat jullie niets met mijn 
proefschrift te maken hebben gehad, wil ik ook jullie bedanken. Werken in het ziekenhuis en 
het doen van onderzoek tegelijktijdig met een fulltime baan op de intensive care kan je visie 
soms vernauwen. Dank jullie wel voor het onuitputtelijke begrip voor mijn drukte. Momenten 
dat we toch samen konden zijn was altijd genieten, al was het veel te weinig.   
Emile Peters wil ik bedanken voor zijn vrolijkheid tijdens mijn gehele opleiding cardiologie en 
intensive care, maar vooral voor de prachtige foto’s.
Mijn paranimfen, Rahat en Murat, broertje en mijn grote broer! Doctor Muslem, jij hebt 
van dichtbij meegemaakt hoe dit boek letter voor letter in elkaar is gespijkerd. Jij begon met 
jouw promotietraject toen ik in theorie eigenlijk al klaar was met mijn promotietraject. Nu 
ben jij een maand voor mij gepromoveerd wat ik wel begrijp al ik terugkijk hoe hard jij kan 
werken, Dag en Nacht!!! Ongelofelijk veel respect heb ik voor jou doorzettingsvermogen en 
je capaciteiten als teamspeler! Destijds ben jij aan “het TEAM” gekoppeld door Ferdi Akca, 
jouw toenmalige collega etage assistent, die jou ooit daarvoor op de afdeling cardiologie aan 
mij had voorgesteld als de toekomst van cardiologie in het EMC. Jouw bijzondere ideeën niet 
alleen voor meerdere artikelen, presentaties, congressen maar ook restaurants in binnen en 
buitenland (waar we nog even aan een artikel konden werken) hebben ons enorm geholpen. 
Dank je wel dat je ook mijn paranimf wilde worden. 
Murat, mijn broer, met jou had ik genoeg als beste vriend, maat, medevoetballer en 
voetbalcriticus, alles in één dus. Naast jouw drukke werk heb je altijd tijd om mij te helpen 
met de technische zaken in en rondom het huis. Dank je wel dat je altijd voor me klaar staat. 
Als dit boek is afgerond zullen we vaker naar de wedstrijden van Galatasaray in de champions 
league kijken!
Ard Struijs, mijn mentor! Jij beschouwde mij als je vijfde kind! Zonder jouw was ik geen 
intensivist geworden, maar ook helemaal niet begonnen aan dit proefschrift. Al heel vroeg 
op de intensive care van Thoraxchirurgie (november 2006) tot de dag van vandaag heb ik 
je steun gehad. Jij bent een vaderfiguur geweest wanneer ik je nodig had in het ziekenhuis 
maar ook erbuiten. Jij bent mijn grootste steun geweest in zware beslismomenten in mijn 
carrière. Jij bent een man met een enorm groot hart en bedankt dat ik die met je familie heel 
vaak mocht delen. Daarom wil ik ook je vrouw Nel bij deze hartelijk bedanken! Jullie zijn een 
geweldig team samen! Super bedankt!
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Lieve mama en papa, anneciğim babacığım, sizler bana hep dogru olmayi ve cok çalışmayi 
öğrettiniz. Bu kitap kısa zamanda bitti ise sizin eserinizdir. Sizin hakkinizi ödeyemem. 
Babacığım senin dedigin gibi “hayatta en iyi arkadaş ilimdir”. Ik hoop nu meer tijd te hebben 
om vaker jullie kleinkinderen bij jullie langs te brengen! Allah sizden razı olsun! Mijn zussen 
wil ik enorm bedanken voor hun geduld, medeleven en hulp die ze altijd hadden klaarstaan 
niet alleen tijdens mijn geneeskundestudie maar ook bij het schrijven van dit boek. 
Mijn schoonouders Mavis en Mehmet, wil ik van harte bedanken. Zonder jullie steun en hulp 
was dit proefschrift nooit op tijd af. Jullie hulp in ons werk, altijd en overal waar we nodig 
hadden, was onontbeerlijk. Later maakte de liefde en zorg die jullie aan Zülfikar Selim gaven 
ons leven veel makkelijker. Dank jullie wel en zeker ook Ali, Ömer, Melike en Suzan bedankt!
Lieve Melek, mijn engel, “Biricik”, zonder jou was dit nooit gelukt. Jij hebt ons wonderen 
gegeven naast je drukke leven als co-assistent. Je hebt mij een prachtige zoon geschonken. 
Ik heb ontzettend veel geduld van je gevraagd en hiervoor wil ik mijn bewondering naar jou 
toe uiten. Ik hoop dat ik dit nog heel vaak mag vragen. Jouw drukke leven met coschappen, 
kind, familie en een man die vaak diensten had, kon jij vlekkeloos begeleiden. Jij bent een 
perfecte moeder en een geweldige vrouw! Gedurende dit boek zijn we enorm gegroeid en 
de geboorte van Zülfikar Selim heeft ons het mooiste gevoel in ons leven gegeven. Dank je 
wel! Nu kunnen we ons volledig focussen op de grote reis naar Zuid-Amerika, jouw favoriete 
vakantiebestemming. Zodra jij ook klaar bent stappen we in het vliegtuig naar de wervelende 
streken van samba, merengue en tango! Dit keer zal mijn laptop gewoon thuis blijven! Maar 
eerst een babymoon van ons tweede kind naar de zon!
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Name PhD student: S. Akin PhD period: 2015-2018
Erasmus MC Departments Cardiology and Intensive Care Promotoren: F. Zijlstra & D. Gommers
Research School: COEUR Supervisor: E. Boersma
1. PhD training
Year Workload 
(hours)
ECTS
General courses
Erasmus Summer Program: Biostatistics for clinicians 2016 30 1.2
Research Integrity (BROK) 2015 24 0.8
Specific courses
COEUR PhD course and research seminars 2015-2017
Hypertension and microcirculation 2015 12 0.4
Heart Failure 2016 12 0.4
Thrombosis 2017 12 0.4
International conferences and abstract presentations
ELSO congress Atlanta: 1 x oral presentation 2015 14 0.5
European Society of Intensive Care Medicine
1 x oral presentation 2016 28 1.0
European Society of Cardiology: 2 x oral   2017+2018 56 2.0
American Heart Association: 1 x poster 1 x oral 2016 28 1.0
American College of cardiology: 1 x poster 2017 28 1.0
Turkish Society of Cardiology: 1 x oral presentation 2013 14 0.5
Turkish Society of Anesthesiology and Reanimation 2016 12 0.4
1 x oral presentation
Euro ELSO Maastricht: 1 x poster presentation 2017 12 0.4
International Symposium on Intensive Care and Emergency 2018 12 0.4
Medicine: 1 x oral presentation
National conferences and abstract presentations
Nederlandse Vereniging Voor Cardiologie 2013 14 0.5
Topics congress (2x) 2014 28 1.0
Refereeravond regionale intensive care 2015 6 0.2
Refreeravond Rechter ventrikel falen 2016 6 0.2
Werkgroep Educatie Symposium 2018 6 0.2
Didactic skills
Gesprekstechnieken 2018 12 0.4
Advanced Life Support instructor O.S.G. 2015 28 1.0
2. Teaching activities
Lecturing en supervision
Microcirculation Academy AMC Amsterdam 2016 28 2.0
Tutoronderwijs co-assistenten 2016 14 0.5
Advanced Life Support training 2017 14 1.5
Journal Clubs en CCU onderwijs 2017 56 2.0
Klinische lessen verpleegkundigen 2017 120 4.3
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Superviseren van Circulation Practitioner in training 2017 56 2.0
Superviseren van Perfusionist in training 2016 112 4.0
Superviseren van Master studenten 2017 28 1.0
Intensive Care onderwijs over ECMO weaning 2017 3 1.1
Intensive Care onderwijs over rechter ventrikel falen en LVAD 2017 3 0.1
Total 830 32.4
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CURRICULUM VITAE
Şakir Akin was born on 2 April 1981 
in Rotterdam. After his graduation 
in 2000 at the O.S.G. Wolfert 
van Borselen in Rotterdam, he 
studied medicine at the Erasmus 
University of Rotterdam. He 
completed his graduation 
research on ADAMTS13 in relation 
to angiogenesis and coagulation 
in sickle cell patients at the Red 
Cross Blood Bank in Curaçao 
(trainers Prof. A.J. Duits and Dr 
J. Schnog). After graduating in July 2006, he worked for two years as a physician-assistant 
at the Department of Thoracic Surgery and Cardiology at the Erasmus Medical Center in 
Rotterdam. He then started his training as cardiologist at the Erasmus MC in Rotterdam in 
October 2008. (trainers Dr. F.J. ten Cate, Prof. W.J. van der Giessen and Prof. Dr. M.L. Simoons). 
Until October 2011 he followed the preparatory course in Internal Medicine (instructor Dr 
E.F.H. van Bommel) and Cardiology (instructor Dr M.J.M. Kofflard) in the Albert Schweitzer 
hospital in Dordrecht. The cardiology course was completed in October 2014. From April 
2014 until September 2015 he was a fellow at the Intensive Care adult of the Erasmus MC 
(trainers Prof. J. Bakker and Prof. D.A.M.P.J. Gommers). After training as an intensivist, he 
worked as a Cardiologist Intensivist at the Intensive Care adults at Erasmus MC. At the same 
time he worked on his doctoral research (Copromotors Prof. C. Ince and Dr. K. Caliskan) 
together with the departments of Cardiology and Intensive Care, which he carried out for 
two years in addition to his clinical work. The research that led to this thesis was carried out 
in the Cardiology and Intensive Care department (Promoters Prof. F. Zijlstra and Prof. D. A. 
M.P.J. Gommers). Şakir Akin is married to Melek Akin-Ekinci and they have one son together: 
Zülfikar Selim, born 28-01-2018.
351
CHAPTER 20
352
20
CURRICULUM VITAE IN DUTCH
CURRICULUM VITAE IN DUTCH
Şakir Akin is op 2 april 1981 geboren in 
Rotterdam. Na zijn eindexamen in 2000 
aan het O.S.G. Wolfert van Borselen te 
Rotterdam, studeerde hij geneeskunde 
aan de Erasmus Universiteit van 
Rotterdam. Zijn afstudeeronderzoek naar 
ADAMTS13  in relatie tot angiogenese 
en stolling bij sikkelcel patiënten 
heeft hij verricht op de Rode Kruis 
Bloedbank te Curaçao (opleiders prof. 
dr. A.J. Duits en dr. J. Schnog). Na zijn 
afstuderen in juli 2006 heeft hij twee jaar gewerkt als arts-assistent bij achtereenvolgens 
afdeling Thoraxchirurgie en Cardiologie van het Erasmus Medisch Centrum te Rotterdam. 
Aansluitend begon hij in oktober 2008 aan zijn opleiding tot cardioloog in het Erasmus MC te 
Rotterdam (opleiders dr. F.J. ten Cate, prof. dr. W.J. van der Giessen en prof. dr. M.L. Simoons). 
Tot oktober 2011 heeft hij de vooropleiding Interne Geneeskunde (opleider dr. E.F.H. van 
Bommel) en Cardiologie (opleider dr. M.J.M. Kofflard) in het Albert Schweitzer ziekenhuis 
te Dordrecht gevolgd. De opleiding cardiologie werd afgerond in oktober 2014. Vanaf april 
2014 tot september 2015 was hij fellow op de Intensive Care volwassen van het Erasmus MC 
(opleiders prof. dr. J. Bakker en prof. dr. D.A.M.P.J. Gommers). Na opleiding tot intensivist was 
hij werkzaam als Cardioloog-Intensivist op de Intensive Care volwassenen van het Erasmus 
MC. Tegelijkertijd werkte hij aan zijn promotieonderzoek (Copromotoren prof. dr. C. Ince en 
dr. K. Caliskan) samen met de afdelingen Cardiologie en de Intensive Care dat hij gedurende 
twee jaar naast zijn klinische werkzaamheden heeft verricht. Het onderzoek dat geleid heeft 
tot dit proefschrift werd verricht op afdeling Cardiologie en Intensive Care (Promotoren prof 
dr. F. Zijlstra en prof. dr. D.A.M.P.J. Gommers). Şakir Akin is getrouwd met Melek Akin-Ekinci 
en zij hebben samen een zoon: Zülfikar Selim, geboren 28-01-2018.
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CURRICULUM VITAE IN TURKISH 
Şakir Akin, 2 Nisan 1981’de Rotterdam’da 
doğdu. 2000 yılında O.S.G. Wolfert van 
Borselen’den (Rotterdam) mezun olduktan 
sonra Erasmus Universitesi Tıp Fakültesi’nde 
tıp eğitimini tamamladı. Tıp fakültesi 
araştırma tezini, Prof. A. J. Duits ve Dr. J. 
Schnog danışmanlığında ‘Kürasav’daki 
Kızıl Haç Kan Bankası’nda bulunan orak 
hücre anemili hastalarda ADAMTS-13’ün 
anjiogenezis ve koagülasyon ile ilişkisi’ başlıklı 
araştırma ile tamamladı. Temmuz 2006’da tıp 
fakültesinden mezun olduktan sonra 2 yıl süre 
ile Erasmus Üniversitesi Tıp Merkezi Kalp Damar Cerrahisi ve Kardiyoloji Bölümü’nde asistan 
doktor olarak çalıştı. Ekim 2008’de Erasmus Üniversitesi Tıp Merkezi’nde uzman kardiyologi 
ihtisas dalında doktor olarak çalışmaya başlayan Akin, (supervisor Dr. F.J. ten Cate, Prof. W.J. 
van der Giessen ve Prof. Dr. M.L. Simoons) Ekim 2011’e kadar Albert Schweitzer Hastanesi’nde 
(Dordrecht) İç Hastalıkları (supervisor Dr E.F.H. van Bommel) ve Kardiyoloji (supervisor Dr 
M.J.M. Kofflard) hazırlık dersleri gördü. Kardiyoloji eğitimi Ekim 2014’de tamamladı. Nisan 
2014-Eylül 2015 tarihleri arasında Erasmus Universitesi Tıp Merkezi Yoğun Bakım Ünitesi’nde 
fellow asistan olarak çalıştı (Danışmanlar: Prof. Dr. J. Bakker ve Prof. Dr. D.A.M.P.J. Gommers). 
Yoğun bakım eğitimi sonrasında, yine Erasmus Universitesi Tıp Merkezi Yoğun Bakım 
Ünitesi’nde kardiyolog yoğun bakım uzmanı olarak görev yaptı. Ayni dönemde klinik görevi 
yanı sıra, kardiyoloji ve yoğun bakım ünitesinde doktora eğitimine başladı (Danışmanlar: 
Prof. C. Ince ve Dr. K. Çalıskan). Doktora tezini oluşturan araştırmalarını Erasmus Üniversitesi 
Kardiyoloji ve Yoğun Bakım Ünite’sinde gerçekleştirildi (Danışmanlar: Prof. Dr. F. Zijlstra ve 
Prof. Dr. D.A.M.P.J. Gommers). Şakir Akin, Melek Akin-Ekinci ile evli olup Zülfikar Selim Akin 
isminde bir erkek çocuk babasıdır. 
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CURRICULUM VITAE IN PAPIEMENTO
Sakir Akin a nase dia 2 di april 1981 na Rotterdam. 
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Short- and long-term mechanical circulatory 
support devices are increasingly used in acute 
and chronic heart failure. Due to the donor 
shortage, the indicati ons for LVAD therapy have 
been expanded from bridge-to-transplantati on 
to desti nati on therapy. Furthermore, an ICU 
admission of pati ents supported by ECMO 
aft er cardiogenic shock can result in the need 
of LVAD therapy. ECMO therapy is becoming 
a cornerstone in the treatment of acute 
cardiogenic shock, as it can serve as bridge to 
recovery and also as a bridge transplantati on 
or LVAD. During the follow-up of these pati ents 
in the ICU and at the outpati ent clinic it is 
very important to prevent and diagnose 
complicati ons ti mely, thus avoiding devastati ng 
outcomes.
As a consequence of the altered circulatory 
status in pati ents with LVAD and ECMO, 
conventi onal measures such as clinical, 
biochemical, echocardiographic and laboratory 
follow-up is not always suﬃ  cient and ti me 
consuming. Despite advances in hemodynamic 
monitoring techniques complicati ons and 
weaning att empts from ECMO are sti ll lacking in 
monitoring the end-organ functi on. Therefore, 
novel imaging techniques for  microcirculatory 
monitoring in pati ents with mechanical 
circulatory support has been analysed in this 
thesis. We predict that in the near future 
more advanced monitoring techniques will 
be available for monitoring the arti ﬁ cial 
circulati ons for short- and long-term support.
